| Cerovations | NIH awarded $1.5M (SBIR Phase II 5U44NS121557-02, continuation, notice Sep 18, 2026).Evidence (1 event)- Sep 18, 2026 · NIH RePORTER 5U44NS121557-02
Organization: CEROVATIONS, LLC; City/State: Woodbury, MN; Project number: 5U44NS121557-02; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 1499369; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Pilot Clinical Study to Assess Safety and Efficacy of External Ventricular Drainage with Cerebrospinal Fluid Water Removal Osmotherapy for Traumatic Brain Injury-Induced Cerebral Edema; Organization type: Domestic For-Profits
| Sep 18, 2026 | NIH RePORTER 5U44NS121557-02 |
| Autonomous Therapeutics | NIH awarded $977K (SBIR Phase II 5R44AI186871-02, continuation, notice Aug 14, 2026); 2 NIH awards totaling $2.49M in the last 12 months.Evidence (2 events)- Aug 14, 2026 · NIH RePORTER 5R44AI186871-02
Organization: AUTONOMOUS THERAPEUTICS, INC.; City/State: SILVER SPRING, MD; Project number: 5R44AI186871-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 976628; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: AT191: An inhaled & precision RNA therapeutic with pan-variant SARS-CoV-2 efficacy; Organization type: Domestic For-Profits - Dec 10, 2025 · NIH RePORTER 5R01AI180651-03
Organization: AUTONOMOUS THERAPEUTICS, INC.; City/State: SILVER SPRING, MD; Project number: 5R01AI180651-03; Activity code: R01; Fiscal year: 2026; Award notice date: 2025-12-10; FY total cost (award amount): 1510374; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Targeting Feedback Circuitry for Antiviral Therapy; Organization type: Domestic For-Profits
| Aug 14, 2026 | NIH RePORTER 5R44AI186871-02 |
| Transtimulation Research, Inc | NIH awarded $991K (NIH grant 4UH3NS125182-03, extension, notice Apr 9, 2026).Evidence (1 event)- Apr 9, 2026 · NIH RePORTER 4UH3NS125182-03
Organization: TRANSTIMULATION RESEARCH, INC.; City/State: OKLAHOMA CITY, OK; Project number: 4UH3NS125182-03; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-04-09; FY total cost (award amount): 990897; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: AccelBand, a leg-worn transcutaneous neuromodulation device for treating neurogenic bowel dysfunction in individuals with spinal cord injury; Organization type: Domestic For-Profits
| Apr 9, 2026 | NIH RePORTER 4UH3NS125182-03 |
| The Tiny Cargo Company | NIH awarded $1.02M (SBIR Phase II 5R44CA272078-03, continuation, notice Sep 8, 2026); 2 NIH awards totaling $2.01M in the last 12 months.Evidence (2 events)- Sep 8, 2026 · NIH RePORTER 5R44CA272078-03
Organization: TINY CARGO COMPANY, THE; City/State: ROANOKE, VA; Project number: 5R44CA272078-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 1022907; Administering IC: National Cancer Institute; Project title: XoLacta: An Adjuvant Therapy for treatment of Radiation Side effects during HER2-Positive Breast Cancer Treatment; Organization type: Domestic For-Profits - Jun 23, 2026 · NIH RePORTER 1U44TR004958-01A1
Organization: TINY CARGO COMPANY, THE; City/State: ROANOKE, VA; Project number: 1U44TR004958-01A1; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 985974; Administering IC: National Center for Advancing Translational Sciences; Project title: Industrial production of milk extracellular vesicles for dual-use as a systemic radiotherapeutic medical countermeasure and cancer adjuvant therapy; Organization type: Domestic For-Profits
| Sep 8, 2026 | NIH RePORTER 5R44CA272078-03 |
| Molecular Targeting Technologies, Inc. | NIH awarded $638K (NIH grant 1R01CA299133-01, new, notice Aug 24, 2026).Evidence (1 event)- Aug 24, 2026 · NIH RePORTER 1R01CA299133-01
Organization: MOLECULAR TARGETING TECHNOLOGIES, INC.; City/State: WEST CHESTER, PA; Project number: 1R01CA299133-01; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 637529; Administering IC: National Cancer Institute; Project title: Targeted radionuclide therapy for non-small cell lung cancer with Lu-177 EBRGD; Organization type: Domestic For-Profits
| Aug 24, 2026 | NIH RePORTER 1R01CA299133-01 |
| Luna Labs USA LLC | NIH awarded $871K (SBIR Phase II 5R44MH133249-04, continuation, notice Jul 16, 2026).Evidence (1 event)- Jul 16, 2026 · NIH RePORTER 5R44MH133249-04
Organization: LUNA LABS USA, LLC; City/State: CHARLOTTESVILLE, VA; Project number: 5R44MH133249-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 870685; Administering IC: National Institute of Mental Health; Project title: Carbon Nanotube Enabled Delivery of mRNA for an HIV Vaccine Candidate; Organization type: Domestic For-Profits
| Jul 16, 2026 | NIH RePORTER 5R44MH133249-04 |
| Trellis Bioscience | NIH awarded $999K (SBIR Phase II 4U44AI183920-02, extension, notice Aug 12, 2026); 2 NIH awards totaling $2M in the last 12 months.Evidence (2 events)- Aug 12, 2026 · NIH RePORTER 4U44AI183920-02
Organization: TRELLIS BIOSCIENCE, INC.; City/State: Redwood City, CA; Project number: 4U44AI183920-02; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-08-12; FY total cost (award amount): 998879; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Bacterial Pneumonia Therapeutic Antibody Safety Trial; Organization type: Domestic For-Profits - Jul 29, 2026 · NIH RePORTER 1SB1AI191674-01
Organization: TRELLIS BIOSCIENCE, INC.; City/State: Redwood City, CA; Project number: 1SB1AI191674-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-29; FY total cost (award amount): 999759; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Human Antibody for Acute Infection Treatment of RSV; Organization type: Domestic For-Profits
| Aug 12, 2026 | NIH RePORTER 4U44AI183920-02 |
| Virtici | NIH awarded $306K (SBIR Phase I 1R43DE036133-01, new, notice Sep 14, 2026); 6 NIH awards totaling $2.43M in the last 12 months.Evidence (6 events)- Sep 14, 2026 · NIH RePORTER 1R43DE036133-01
Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 1R43DE036133-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 306464; Administering IC: National Institute of Dental and Craniofacial Research; Project title: A Novel Sublingual Vaccine for Preventing andTreating Periodontitis; Organization type: Domestic For-Profits - Sep 2, 2026 · NIH RePORTER 1R43AI188659-01A1
Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 1R43AI188659-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 306500; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Novel Preventative and Treatment for Klebsiella Pneumoniae Infection; Organization type: Domestic For-Profits - Aug 26, 2026 · NIH RePORTER 1R44AR087173-01
Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 1R44AR087173-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 306341; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: A Bioengineered Probiotic for Resetting Immune Function in Rheumatoid Arthritis; Organization type: Domestic For-Profits - Aug 13, 2026 · NIH RePORTER 1R44AI188778-01A1
Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 1R44AI188778-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 300222; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Novel Immune-modulating Probiotic for Treating Rheumatoid Arthritis; Organization type: Domestic For-Profits - Jul 21, 2026 · NIH RePORTER 5R43DE034614-02
Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 5R43DE034614-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-21; FY total cost (award amount): 308096; Administering IC: National Institute of Dental and Craniofacial Research; Project title: A Novel Anti-infective Therapy for Treating Periodontitis; Organization type: Domestic For-Profits - Jun 1, 2026 · NIH RePORTER 5R44HL164202-05
Organization: VIRTICI, LLC; City/State: Seattle, WA; Project number: 5R44HL164202-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-01; FY total cost (award amount): 903600; Administering IC: National Heart Lung and Blood Institute; Project title: A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis; Organization type: Domestic For-Profits
| Sep 14, 2026 | NIH RePORTER 1R43DE036133-01 |
| Sciogen LLC | NIH awarded $314K (SBIR Phase I 1R43AI191860-01, new, notice Aug 21, 2026).Evidence (1 event)- Aug 21, 2026 · NIH RePORTER 1R43AI191860-01
Organization: SCIOGEN, LLC; City/State: San Jose, CA; Project number: 1R43AI191860-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 314363; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Novel respiratory syncytial virus therapeutics targeting G-receptor binding; Organization type: Domestic For-Profits
| Aug 21, 2026 | NIH RePORTER 1R43AI191860-01 |
| Oak Therapeutics Inc. | NIH awarded $899K (SBIR Phase II 2R44AI170237-02A1, competing renewal, notice Aug 5, 2026); 2 NIH awards totaling $1.71M in the last 12 months.Evidence (2 events)- Aug 5, 2026 · NIH RePORTER 2R44AI170237-02A1
Organization: OAK THERAPEUTICS, INC.; City/State: Lawrence, KS; Project number: 2R44AI170237-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 899010; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Novel antiretroviral therapy delivery platform for infants and young children: oral dispensable strips (ODS); Organization type: Domestic For-Profits - Jul 28, 2026 · NIH RePORTER 5R44AI179391-03
Organization: OAK THERAPEUTICS, INC.; City/State: Lawrence, KS; Project number: 5R44AI179391-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 814340; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Oral Dissolvable Strips (ODS) as new pediatric and adult delivery mode of therapy for latent tuberculosis; Organization type: Domestic For-Profits
| Aug 5, 2026 | NIH RePORTER 2R44AI170237-02A1 |
| 3D Molecular Designs, LLC | NIH awarded $1M (SBIR Phase II 2R44GM154526-02, competing renewal, notice Aug 12, 2026); 2 NIH awards totaling $1.27M in the last 12 months.Evidence (2 events)- Aug 12, 2026 · NIH RePORTER 2R44GM154526-02
Organization: 3D MOLECULAR DESIGNS; City/State: MILWAUKEE, WI; Project number: 2R44GM154526-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-12; FY total cost (award amount): 1004963; Administering IC: National Institute of General Medical Sciences; Project title: Harnessing Machine Learning & Object Detection for Automated Evaluation of Student-folded Protein Models; Organization type: Domestic For-Profits - Jun 30, 2026 · NIH RePORTER 5R25GM146236-06
Organization: 3D MOLECULAR DESIGNS; City/State: MILWAUKEE, WI; Project number: 5R25GM146236-06; Activity code: R25; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 270000; Administering IC: National Institute of General Medical Sciences; Project title: Exploring the Molecular Biology of infectious Diseases; Organization type: Domestic For-Profits
| Aug 12, 2026 | NIH RePORTER 2R44GM154526-02 |
| iFIT Prosthetics | NIH awarded $307K (STTR Phase I 1R41HD118857-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R41HD118857-01
Organization: IFIT PROSTHETICS, LLC; City/State: PEWAUKEE, WI; Project number: 1R41HD118857-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 306870; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: ADVANCED CLOSURE SYSTEM FOR ADJUSTABLE , SUBISCHIAL TRANSFEMORAL SOCKETS; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R41HD118857-01 |
| Anvil Diagnostics Inc. | NIH awarded $296K (SBIR Phase I 1R43CK000714-01A1, new, notice Aug 24, 2026).Evidence (1 event)- Aug 24, 2026 · NIH RePORTER 1R43CK000714-01A1
Organization: ANVIL DIAGNOSTICS INC.; City/State: CAMBRIDGE, MA; Project number: 1R43CK000714-01A1; Activity code: R43; Fiscal year: 2025; Award notice date: 2026-08-24; FY total cost (award amount): 296185; Administering IC: National Center for Emerging and Zoonotic Infectious Diseases; Project title: Rapid and Highly Multiplexed Pathogen Detection for Sepsis Patients with Compressed Sensing and Digital PCR; Organization type: Domestic For-Profits
| Aug 24, 2026 | NIH RePORTER 1R43CK000714-01A1 |
| Microsensor Labs, LLC | NIH awarded $307K (SBIR Phase I 1R43CK000713-01A1, new, notice Aug 15, 2026).Evidence (1 event)- Aug 15, 2026 · NIH RePORTER 1R43CK000713-01A1
Organization: MICROSENSOR LABS, LLC; City/State: CHICAGO, IL; Project number: 1R43CK000713-01A1; Activity code: R43; Fiscal year: 2025; Award notice date: 2026-08-15; FY total cost (award amount): 306872; Administering IC: National Center for Emerging and Zoonotic Infectious Diseases; Project title: A High-throughput Automated Platform for Rapid Isolation and Testing of Salmonella; Organization type: Domestic For-Profits
| Aug 15, 2026 | NIH RePORTER 1R43CK000713-01A1 |
| Applied Biotechnology Institute, Inc. | NIH awarded $288K (SBIR Phase I 1R43DK148203-01, new, notice Sep 17, 2026); 2 NIH awards totaling $588K in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 1R43DK148203-01
Organization: APPLIED BIOTECHNOLOGY INSTITUTE; City/State: SAN LUIS OBISPO, CA; Project number: 1R43DK148203-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 288221; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Production in maize of low-cost heat stable forms of GLP-1 and GIP receptor agonists for treatment of diabetes and obesity; Organization type: Domestic For-Profits - Aug 14, 2026 · NIH RePORTER 1R43AI186801-01A1
Organization: APPLIED BIOTECHNOLOGY INSTITUTE; City/State: SAN LUIS OBISPO, CA; Project number: 1R43AI186801-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 299936; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Production of low-cost heat stable forms of adalimumab in maize for treatment of inflammatory bowel disease.; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43DK148203-01 |
| Peak Diagnostic Partners | NIH awarded $1M (SBIR Phase II 1R44AI186802-01A1, new, notice Aug 18, 2026).Evidence (1 event)- Aug 18, 2026 · NIH RePORTER 1R44AI186802-01A1
Organization: PEAK DIAGNOSTIC PARTNERS LLC; City/State: Aurora, CO; Project number: 1R44AI186802-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Multidimensional analysis of biologic treatment failure in uncontrolled asthma; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 1R44AI186802-01A1 |
| Partillion Bioscience | NIH awarded $979K (SBIR Phase II 1R44GM165220-01, new, notice Sep 1, 2026); 3 NIH awards totaling $2.29M in the last 12 months.Evidence (3 events)- Sep 1, 2026 · NIH RePORTER 1R44GM165220-01
Organization: PARTILLION BIOSCIENCE CORPORATION; City/State: LOS ANGELES, CA; Project number: 1R44GM165220-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 979071; Administering IC: National Institute of General Medical Sciences; Project title: Nanovial Kits for Large-Scale Cell-Cell Interaction Sequencing; Organization type: Domestic For-Profits - Jul 16, 2026 · NIH RePORTER 1R43AI186929-01A1
Organization: PARTILLION BIOSCIENCE CORPORATION; City/State: LOS ANGELES, CA; Project number: 1R43AI186929-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 306865; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Multiplexed analysis of antibody secreting cells for enhanced function first antibody discovery; Organization type: Domestic For-Profits - Jun 9, 2026 · NIH RePORTER 5R44AI193415-02
Organization: PARTILLION BIOSCIENCE CORPORATION; City/State: LOS ANGELES, CA; Project number: 5R44AI193415-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Scaling function-first antibody discovery leveraging memory B cells; Organization type: Domestic For-Profits
| Sep 1, 2026 | NIH RePORTER 1R44GM165220-01 |
| Atticus Pharma | NIH awarded $1.01M (SBIR Phase II 1R44AR087266-01A1, new, notice Sep 19, 2026); 2 NIH awards totaling $1.97M in the last 12 months.Evidence (2 events)- Sep 19, 2026 · NIH RePORTER 1R44AR087266-01A1
Organization: ATTICUS PHARMA INC; City/State: GREENVILLE, SC; Project number: 1R44AR087266-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-19; FY total cost (award amount): 1007121; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Phase 2: Development of an endocannabinoid microparticle formulation for the topical treatment of cutaneous manifestations of lupus erythematosus; Organization type: Domestic For-Profits - Aug 13, 2026 · NIH RePORTER 2R44DK129147-02
Organization: ATTICUS PHARMA INC; City/State: GREENVILLE, SC; Project number: 2R44DK129147-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 965708; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Phase II: Optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction; Organization type: Domestic For-Profits
| Sep 19, 2026 | NIH RePORTER 1R44AR087266-01A1 |
| Armor Medical | NIH awarded $1.22M (SBIR Phase II 2R44DP006818-03, competing renewal, notice Aug 15, 2026).Evidence (1 event)- Aug 15, 2026 · NIH RePORTER 2R44DP006818-03
Organization: ARMOR MEDICAL INC.; City/State: SAINT LOUIS, MO; Project number: 2R44DP006818-03; Activity code: R44; Fiscal year: 2025; Award notice date: 2026-08-15; FY total cost (award amount): 1223371; Administering IC: National Center for Chronic Disease Prev and Health Promo; Project title: Early Alerts, Safer Births: A Wearable Device for Real-time Maternal Hemorrhage Monitoring; Organization type: Domestic For-Profits
| Aug 15, 2026 | NIH RePORTER 2R44DP006818-03 |
| ResVita Bio | NIH awarded $1M (SBIR Phase II 2R44AI179327-02A1, competing renewal, notice Jul 30, 2026).Evidence (1 event)- Jul 30, 2026 · NIH RePORTER 2R44AI179327-02A1
Organization: RESVITA BIO, INC.; City/State: Berkeley, CA; Project number: 2R44AI179327-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-30; FY total cost (award amount): 999988; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Skin probiotics to treat atopic dermatitis; Organization type: Domestic For-Profits
| Jul 30, 2026 | NIH RePORTER 2R44AI179327-02A1 |
| Fzata | NIH awarded $2.06M (NIH grant 4UH3NS135350-02, extension, notice Sep 19, 2026); 3 NIH awards totaling $2.74M in the last 12 months.Evidence (3 events)- Sep 19, 2026 · NIH RePORTER 4UH3NS135350-02
Organization: FZATA, INC.; City/State: HALETHORPE, MD; Project number: 4UH3NS135350-02; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-09-19; FY total cost (award amount): 2058422; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome; Organization type: Domestic For-Profits - Sep 17, 2026 · NIH RePORTER 1R44DK146567-01
Organization: FZATA, INC.; City/State: HALETHORPE, MD; Project number: 1R44DK146567-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 372153; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Gut-Targeted IL-10 Delivery via Engineered Saccharomyces boulardii to Prevent Immune Checkpoint Inhibitor Colitis; Organization type: Domestic For-Profits - Sep 11, 2026 · NIH RePORTER 1R44AI197301-01
Organization: FZATA, INC.; City/State: HALETHORPE, MD; Project number: 1R44AI197301-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 313095; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a Dual-Action Oral Immunotherapy for Clostridioides difficile Prevention; Organization type: Domestic For-Profits
| Sep 19, 2026 | NIH RePORTER 4UH3NS135350-02 |
| Exai Bio Inc. | NIH awarded $719K (SBIR Phase II 5R44CA291369-02, continuation, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 5R44CA291369-02
Organization: EXAI BIO, INC.; City/State: PALO ALTO, CA; Project number: 5R44CA291369-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 718994; Administering IC: National Cancer Institute; Project title: Orphan Non-coding RNA-based Test for Detecting Minimal Residual Disease in Resectable Non-small Cell Lung Cancer; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R44CA291369-02 |
| Prokaryotics | NIH awarded $977K (SBIR Phase II 5R44AI165008-03, continuation, notice Jun 3, 2026); 3 NIH awards totaling $1.86M in the last 12 months.Evidence (3 events)- Jun 3, 2026 · NIH RePORTER 5R44AI165008-03
Organization: PROKARYOTICS, INC.; City/State: UNION, NJ; Project number: 5R44AI165008-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 977454; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a mechanistically novel synergistic adjuvant to partner with polymyxin antibiotics; Organization type: Domestic For-Profits - Feb 17, 2026 · NIH RePORTER 5R21AI185171-02
Organization: PROKARYOTICS, INC.; City/State: UNION, NJ; Project number: 5R21AI185171-02; Activity code: R21; Fiscal year: 2026; Award notice date: 2026-02-17; FY total cost (award amount): 204000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Structure-based design of antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) ethanolamine phosphate transferase, Mcd4; Organization type: Domestic For-Profits - Feb 2, 2026 · NIH RePORTER 5R01AI165740-04
Organization: PROKARYOTICS, INC.; City/State: UNION, NJ; Project number: 5R01AI165740-04; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-02-02; FY total cost (award amount): 679600; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide Biogenesis; Organization type: Domestic For-Profits
| Jun 3, 2026 | NIH RePORTER 5R44AI165008-03 |
| Versatope Therapeutics | NIH awarded $1M (SBIR Phase II 5R44AI181242-03, continuation, notice Jun 11, 2026).Evidence (1 event)- Jun 11, 2026 · NIH RePORTER 5R44AI181242-03
Organization: VERSATOPE THERAPEUTICS, INC.; City/State: Lowell, MA; Project number: 5R44AI181242-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 999925; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine; Organization type: Domestic For-Profits
| Jun 11, 2026 | NIH RePORTER 5R44AI181242-03 |
| Molecular Theranostics, LLC | NIH awarded $528K (NIH grant 1R01CA297667-01A1, new, notice Aug 20, 2026).Evidence (1 event)- Aug 20, 2026 · NIH RePORTER 1R01CA297667-01A1
Organization: MOLECULAR THERANOSTICS, LLC; City/State: BEACHWOOD, OH; Project number: 1R01CA297667-01A1; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 528259; Administering IC: National Cancer Institute; Project title: Development of next-generation targeted MRI contrast agents; Organization type: Domestic For-Profits
| Aug 20, 2026 | NIH RePORTER 1R01CA297667-01A1 |
| Virogenomics Biodevelopment, Inc. | NIH awarded $400K (STTR Phase I 1R41DA064189-01, new, notice May 27, 2026); 2 NIH awards totaling $3.7M in the last 12 months.Evidence (2 events)- May 27, 2026 · NIH RePORTER 1R41DA064189-01
Organization: VIROGENOMICS BIODEVELOPMENT, INC.; City/State: Tigard, OR; Project number: 1R41DA064189-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-05-27; FY total cost (award amount): 399889; Administering IC: National Institute on Drug Abuse; Project title: Treatment of CNS damage from non-disordered drug use with DRhQ, a novel regulator of CD74 signaling; Organization type: Domestic For-Profits - Apr 24, 2026 · NIH RePORTER 5UG3DA061709-02
Organization: VIROGENOMICS BIODEVELOPMENT, INC.; City/State: Tigard, OR; Project number: 5UG3DA061709-02; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-04-24; FY total cost (award amount): 3300978; Administering IC: National Institute on Drug Abuse; Project title: IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorder; Organization type: Domestic For-Profits
| May 27, 2026 | NIH RePORTER 1R41DA064189-01 |
| Lifegene- Biomarks, Inc. | NIH awarded $900K (SBIR Phase II 5R44CA281719-03, continuation, notice Jul 7, 2026); 2 NIH awards totaling $1.27M in the last 12 months.Evidence (2 events)- Jul 7, 2026 · NIH RePORTER 5R44CA281719-03
Organization: LIFEGENE-BIOMARKS, INC.; City/State: SAN JUAN, PR; Project number: 5R44CA281719-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 900350; Administering IC: National Cancer Institute; Project title: Precision DNA methylation test to reduce oral cancer disparities in African Americans patients residing in low-resource settings; Organization type: Domestic For-Profits - May 13, 2026 · NIH RePORTER 5R42MD018231-03
Organization: LIFEGENE-BIOMARKS, INC.; City/State: SAN JUAN, PR; Project number: 5R42MD018231-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 366433; Administering IC: National Institute on Minority Health and Health Disparities; Project title: Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas; Organization type: Domestic For-Profits
| Jul 7, 2026 | NIH RePORTER 5R44CA281719-03 |
| Modulo Bio | NIH awarded $848K (SBIR Phase II 1R44NS143633-01A1, new, notice Sep 19, 2026); 2 NIH awards totaling $2.33M in the last 12 months.Evidence (2 events)- Sep 19, 2026 · NIH RePORTER 1R44NS143633-01A1
Organization: MODULO BIO, INC.; City/State: San Diego, CA; Project number: 1R44NS143633-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-19; FY total cost (award amount): 847695; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: The Therapeutic Development of a Clinical NR1H3 Antisense Oligonucleotide to Reprogram Microglia into a Neuroprotective State in ALS and FTD; Organization type: Domestic For-Profits - Feb 25, 2026 · NIH RePORTER 1R61MH143793-01
Organization: MODULO BIO, INC.; City/State: San Diego, CA; Project number: 1R61MH143793-01; Activity code: R61; Fiscal year: 2026; Award notice date: 2026-02-25; FY total cost (award amount): 1479470; Administering IC: National Institute of Mental Health; Project title: Developing an AI-Guided Triculture Platform to Model NeuroHIV specific Microglial States Under ART Suppression with CellPaint/Morphological and Transcriptomic Readouts; Organization type: Domestic For-Profits
| Sep 19, 2026 | NIH RePORTER 1R44NS143633-01A1 |
| Rhaeos, Inc. | NIH awarded $420K (NIH grant 5UH3NS130338-04, continuation, notice Aug 21, 2026); 3 NIH awards totaling $1.49M in the last 12 months.Evidence (3 events)- Aug 21, 2026 · NIH RePORTER 5UH3NS130338-04
Organization: RHAEOS, INC.; City/State: EVANSTON, IL; Project number: 5UH3NS130338-04; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 419724; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of wireless, wearable flow sensors for continuous, long-term tracking of cerebrospinal fluid dynamics in patients with hydrocephalus; Organization type: Domestic For-Profits - Jun 19, 2026 · NIH RePORTER 5R44NS121555-05
Organization: RHAEOS, INC.; City/State: EVANSTON, IL; Project number: 5R44NS121555-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 965691; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Enhancing Healthcare Delivery and Patient Outcomes: Noninvasive Wireless Sensors to Improve Ventricular Shunt Monitoring, Reduce Imaging, and Alleviate the Burden on Providers, Patients, and Families; Organization type: Domestic For-Profits - May 26, 2026 · NIH RePORTER 3UH3NS130338-03S1
Organization: RHAEOS, INC.; City/State: EVANSTON, IL; Project number: 3UH3NS130338-03S1; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 99586; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of wireless, wearable flow sensors for continuous, long-term tracking of cerebrospinal fluid dynamics in patients with hydrocephalus; Organization type: Domestic For-Profits
| Aug 21, 2026 | NIH RePORTER 5UH3NS130338-04 |
| Sanguina, LLC | NIH awarded $962K (SBIR Phase II 5R44HL139250-06, continuation, notice Jul 6, 2026).Evidence (1 event)- Jul 6, 2026 · NIH RePORTER 5R44HL139250-06
Organization: SANGUINA, LLC; City/State: ATLANTA, GA; Project number: 5R44HL139250-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 962375; Administering IC: National Heart Lung and Blood Institute; Project title: Translation of a personalized, non-invasive smartphone app for hemoglobin monitoring for chronic anemia patients; Organization type: Domestic For-Profits
| Jul 6, 2026 | NIH RePORTER 5R44HL139250-06 |
| Synvivia | NIH awarded $856K (SBIR Phase II 5R44GM158472-02, continuation, notice May 7, 2026).Evidence (1 event)- May 7, 2026 · NIH RePORTER 5R44GM158472-02
Organization: SYNVIVIA, INC.; City/State: Emeryville, CA; Project number: 5R44GM158472-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-07; FY total cost (award amount): 856268; Administering IC: National Institute of General Medical Sciences; Project title: Platform for Optimizing Yield and Quality of Therapeutic AAV Vector Manufacturing via Synthetic Helper Genes; Organization type: Domestic For-Profits
| May 7, 2026 | NIH RePORTER 5R44GM158472-02 |
| Precision Biotools Inc. | NIH awarded $1.22M (SBIR Phase II 5R44GM149009-04, continuation, notice Jun 30, 2026).Evidence (1 event)- Jun 30, 2026 · NIH RePORTER 5R44GM149009-04
Organization: PRECISION BIOTOOLS INC; City/State: BRANFORD, CT; Project number: 5R44GM149009-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 1221747; Administering IC: National Institute of General Medical Sciences; Project title: A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D; Organization type: Domestic For-Profits
| Jun 30, 2026 | NIH RePORTER 5R44GM149009-04 |
| Starlight Cardiovascular | NIH awarded $500K (SBIR commercialization 1SB1HL184388-01, new, notice Aug 10, 2026); 3 NIH awards totaling $2.67M in the last 12 months.Evidence (3 events)- Aug 10, 2026 · NIH RePORTER 1SB1HL184388-01
Organization: STARLIGHT CARDIOVASCULAR, INC.; City/State: San Diego, CA; Project number: 1SB1HL184388-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 499952; Administering IC: National Heart Lung and Blood Institute; Project title: Commercialization Readiness of a Pulmonary Flow Restrictor for Hypoplastic Left Heart Syndrome; Organization type: Domestic For-Profits - Aug 3, 2026 · NIH RePORTER 2R44HL162218-04
Organization: STARLIGHT CARDIOVASCULAR, INC.; City/State: San Diego, CA; Project number: 2R44HL162218-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 1166665; Administering IC: National Heart Lung and Blood Institute; Project title: DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME; Organization type: Domestic For-Profits - May 13, 2026 · NIH RePORTER 5R44HL158304-05
Organization: STARLIGHT CARDIOVASCULAR, INC.; City/State: San Diego, CA; Project number: 5R44HL158304-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 999876; Administering IC: National Heart Lung and Blood Institute; Project title: DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY; Organization type: Domestic For-Profits
| Aug 10, 2026 | NIH RePORTER 1SB1HL184388-01 |
| HelixBind | NIH awarded $1M (SBIR Phase II 2R44AI157322-04A1, competing renewal, notice Aug 6, 2026); 5 NIH awards totaling $5.04M in the last 12 months.Evidence (5 events)- Aug 6, 2026 · NIH RePORTER 2R44AI157322-04A1
Organization: HELIXBIND, INC.; City/State: Boxborough, MA; Project number: 2R44AI157322-04A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Direct-from-specimen characterization of bloodstream infections; Organization type: Domestic For-Profits - Jul 16, 2026 · NIH RePORTER 1R44AI197309-01
Organization: HELIXBIND, INC.; City/State: Boxborough, MA; Project number: 1R44AI197309-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 1029859; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Automated system for the direct from blood characterization of bloodstream infections; Organization type: Domestic For-Profits - Jun 30, 2026 · NIH RePORTER 5R44AI186712-03
Organization: HELIXBIND, INC.; City/State: Boxborough, MA; Project number: 5R44AI186712-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 1019702; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: An automated culture-free system for the identification of bloodstream infections direct from blood; Organization type: Domestic For-Profits - Jun 19, 2026 · NIH RePORTER 5R44AI136064-07
Organization: HELIXBIND, INC.; City/State: Boxborough, MA; Project number: 5R44AI136064-07; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 986903; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Direct-from-specimen identification of pathogens common in endocarditis; Organization type: Domestic For-Profits - May 27, 2026 · NIH RePORTER 5SB1AI183963-03
Organization: HELIXBIND, INC.; City/State: Boxborough, MA; Project number: 5SB1AI183963-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-05-27; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Commercialization Readiness Pilot (CRP) program support for: Ultra-sensitive, direct-from-blood, molecular detection of Borrelia infections.; Organization type: Domestic For-Profits
| Aug 6, 2026 | NIH RePORTER 2R44AI157322-04A1 |
| Loki Therapeutics | NIH awarded $727K (STTR Phase II 4R42CA287679-02, extension, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 4R42CA287679-02
Organization: LOKI THERAPEUTICS, INC; City/State: Sa, CA; Project number: 4R42CA287679-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 726592; Administering IC: National Cancer Institute; Project title: Clinical testing of Listeria-TT and Gemcitabine in a Phase I clinical trial with PDAC patients; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 4R42CA287679-02 |
| Viewpoint Molecular Targeting, Inc. | NIH awarded $1.01M (STTR Phase II 4R42CA287696-02, extension, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 4R42CA287696-02
Organization: VIEWPOINT MOLECULAR TARGETING, INC.; City/State: Coralville, IA; Project number: 4R42CA287696-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1006109; Administering IC: National Cancer Institute; Project title: Antibody-based prertargeted alpha particle therapy for ovarian cancer; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 4R42CA287696-02 |
| PhagePro | NIH awarded $1M (SBIR Phase II 5R44AI188855-02, continuation, notice Jun 9, 2026).Evidence (1 event)- Jun 9, 2026 · NIH RePORTER 5R44AI188855-02
Organization: PHAGEPRO, INC.; City/State: Mansfield, MA; Project number: 5R44AI188855-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail; Organization type: Domestic For-Profits
| Jun 9, 2026 | NIH RePORTER 5R44AI188855-02 |
| Microbiotix, Inc. | NIH awarded $299K (STTR Phase I 5R41AI195240-02, continuation, notice Aug 25, 2026); 4 NIH awards totaling $2.23M in the last 12 months.Evidence (4 events)- Aug 25, 2026 · NIH RePORTER 5R41AI195240-02
Organization: MICROBIOTIX, INC; City/State: WORCESTER, MA; Project number: 5R41AI195240-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 299381; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Novel Benzyl-Piperidine antifungal agents to treat intractable Mucorales infections; Organization type: Domestic For-Profits - Aug 3, 2026 · NIH RePORTER 5R43AI188690-02
Organization: MICROBIOTIX, INC; City/State: WORCESTER, MA; Project number: 5R43AI188690-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 289318; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of well tolerated novel Inhibitors of drug resistant CMV; Organization type: Domestic For-Profits - May 19, 2026 · NIH RePORTER 5R42AI165102-04
Organization: MICROBIOTIX, INC; City/State: WORCESTER, MA; Project number: 5R42AI165102-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 969050; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Discovery of Bunyaviral Endonuclease Inhibitors for Anti Viral; Organization type: Domestic For-Profits - Jan 29, 2026 · NIH RePORTER 5R33EY036947-02
Organization: MICROBIOTIX, INC; City/State: WORCESTER, MA; Project number: 5R33EY036947-02; Activity code: R33; Fiscal year: 2026; Award notice date: 2026-01-29; FY total cost (award amount): 669859; Administering IC: National Eye Institute; Project title: Translational studies to advance Filociclovir to IND submission for the treatment of adenoviral conjunctivitis and acute keratoconjunctivitis; Organization type: Domestic For-Profits
| Aug 25, 2026 | NIH RePORTER 5R41AI195240-02 |
| Scanogen Inc. | NIH awarded $972K (SBIR commercialization 5SB1AI192001-02, continuation, notice Sep 18, 2026); 3 NIH awards totaling $2.77M in the last 12 months.Evidence (3 events)- Sep 18, 2026 · NIH RePORTER 5SB1AI192001-02
Organization: SCANOGEN, INC.; City/State: Baltimore, MD; Project number: 5SB1AI192001-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 972243; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Bloodstream infection detection directly on whole blood; Organization type: Domestic For-Profits - Jun 30, 2026 · NIH RePORTER 5R44AI124871-07
Organization: SCANOGEN, INC.; City/State: Baltimore, MD; Project number: 5R44AI124871-07; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Bloodstream infection detection directly on whole blood; Organization type: Domestic For-Profits - Dec 23, 2025 · NIH RePORTER 5R01AI175063-04
Organization: SCANOGEN, INC.; City/State: Baltimore, MD; Project number: 5R01AI175063-04; Activity code: R01; Fiscal year: 2026; Award notice date: 2025-12-23; FY total cost (award amount): 796572; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Rapid ID and AST Directly from Whole Blood Using Single Molecule Detection; Organization type: Domestic For-Profits
| Sep 18, 2026 | NIH RePORTER 5SB1AI192001-02 |
| Vast Therapeutics | NIH awarded $1M (SBIR Phase II 1R44AI191890-01A1, new, notice Sep 14, 2026); 3 NIH awards totaling $2.94M in the last 12 months.Evidence (3 events)- Sep 14, 2026 · NIH RePORTER 1R44AI191890-01A1
Organization: VAST THERAPEUTICS, INC.; City/State: Morrisville, NC; Project number: 1R44AI191890-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Inhaled Nitric-Oxide Releasing Prodrug to Treat Drug Resistant Klebsiella pneumoniae Infections; Organization type: Domestic For-Profits - Aug 14, 2026 · NIH RePORTER 5R44AI186617-02
Organization: VAST THERAPEUTICS, INC.; City/State: Morrisville, NC; Project number: 5R44AI186617-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 950129; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Nebulized ALX1 as a Treatment for Difficult Non-tuberculous Mycobacterial Lung Infections; Organization type: Domestic For-Profits - May 26, 2026 · NIH RePORTER 5R44AI184225-02
Organization: VAST THERAPEUTICS, INC.; City/State: Morrisville, NC; Project number: 5R44AI184225-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 988594; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients; Organization type: Domestic For-Profits
| Sep 14, 2026 | NIH RePORTER 1R44AI191890-01A1 |
| Biological Mimetics | NIH awarded $278K (SBIR Phase I 5R43AI189041-02, continuation, notice May 27, 2026).Evidence (1 event)- May 27, 2026 · NIH RePORTER 5R43AI189041-02
Organization: BIOLOGICAL MIMETICS, INC.; City/State: FREDERICK, MD; Project number: 5R43AI189041-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-05-27; FY total cost (award amount): 277962; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Subunit Vaccine Against Acinetobacter Baumannii; Organization type: Domestic For-Profits
| May 27, 2026 | NIH RePORTER 5R43AI189041-02 |
| Celdara Medical | NIH awarded $356K (SBIR Phase I 1R43DK143897-01A1, new, notice Aug 28, 2026); 6 NIH awards totaling $2.5M in the last 12 months.Evidence (6 events)- Aug 28, 2026 · NIH RePORTER 1R43DK143897-01A1
Organization: CELDARA MEDICAL, LLC; City/State: LEBANON, NH; Project number: 1R43DK143897-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 356328; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a Novel, Allogeneic Cell Therapy for Difficult to Treat IBD; Organization type: Domestic For-Profits - Aug 24, 2026 · NIH RePORTER 1R43AI197698-01
Organization: CELDARA MEDICAL, LLC; City/State: LEBANON, NH; Project number: 1R43AI197698-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 320863; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Precision CAR-NK therapy for VK4-1 autoreactive B cells in autoimmune diseases: advancing treatment with preserved immune function.; Organization type: Domestic For-Profits - Aug 21, 2026 · NIH RePORTER 1R43AI192073-01A1
Organization: CELDARA MEDICAL, LLC; City/State: LEBANON, NH; Project number: 1R43AI192073-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 320863; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of an immunotherapeutic agent for treatment of osteomyelitis; Organization type: Domestic For-Profits - Jun 25, 2026 · NIH RePORTER 5R25AG078135-05
Organization: CELDARA MEDICAL, LLC; City/State: LEBANON, NH; Project number: 5R25AG078135-05; Activity code: R25; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 162000; Administering IC: National Institute on Aging; Project title: Alzheimer's-focused Celdara Medical High-Potential Entrepreneurial Fellowship Program (A-CHEF); Organization type: Domestic For-Profits - Jun 16, 2026 · NIH RePORTER 1R43TR006062-01A1
Organization: CELDARA MEDICAL, LLC; City/State: LEBANON, NH; Project number: 1R43TR006062-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 310564; Administering IC: National Center for Advancing Translational Sciences; Project title: Engineered Tregs as a therapy to Gaucher syndrome; Organization type: Domestic For-Profits - May 26, 2026 · NIH RePORTER 5R44CA298512-02
Organization: CELDARA MEDICAL, LLC; City/State: LEBANON, NH; Project number: 5R44CA298512-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 1024401; Administering IC: National Cancer Institute; Project title: Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma; Organization type: Domestic For-Profits
| Aug 28, 2026 | NIH RePORTER 1R43DK143897-01A1 |
| Dayi Therapeutics, Inc. | NIH awarded $845K (STTR Phase II 5R42HD111138-03, continuation, notice May 11, 2026).Evidence (1 event)- May 11, 2026 · NIH RePORTER 5R42HD111138-03
Organization: DAYI THERAPEUTICS, INC.; City/State: New York, NY; Project number: 5R42HD111138-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-11; FY total cost (award amount): 845187; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Developing RNA therapeutics for rare neurodevelopmental disorders; Organization type: Domestic For-Profits
| May 11, 2026 | NIH RePORTER 5R42HD111138-03 |
| Doty Scientific, Inc. | NIH awarded $994K (SBIR Phase II 2R44GM156167-02, competing renewal, notice Sep 7, 2026); 2 NIH awards totaling $1.94M in the last 12 months.Evidence (2 events)- Sep 7, 2026 · NIH RePORTER 2R44GM156167-02
Organization: DOTY SCIENTIFIC, INC.; City/State: COLUMBIA, SC; Project number: 2R44GM156167-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 994403; Administering IC: National Institute of General Medical Sciences; Project title: Low-loss Bidirectional THz Couplers to Enable Affordable MAS-DNP-NMR; Organization type: Domestic For-Profits - May 11, 2026 · NIH RePORTER 5R44GM148111-03
Organization: DOTY SCIENTIFIC, INC.; City/State: COLUMBIA, SC; Project number: 5R44GM148111-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-11; FY total cost (award amount): 946077; Administering IC: National Institute of General Medical Sciences; Project title: Ultra-low-temperature (6 K) static NMR-DNP for metalloproteins, proteins in cells, and materials; Organization type: Domestic For-Profits
| Sep 7, 2026 | NIH RePORTER 2R44GM156167-02 |
| Sonoran Biosciences | NIH awarded $1.01M (SBIR Phase II 5R44GM145020-03, continuation, notice Jul 9, 2026).Evidence (1 event)- Jul 9, 2026 · NIH RePORTER 5R44GM145020-03
Organization: SONORAN BIOSCIENCES, INC.; City/State: TEMPE, AZ; Project number: 5R44GM145020-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-09; FY total cost (award amount): 1009908; Administering IC: National Institute of General Medical Sciences; Project title: Extended-release injectable gel for multi-day treatment of postoperative pain; Organization type: Domestic For-Profits
| Jul 9, 2026 | NIH RePORTER 5R44GM145020-03 |
| Heligenics, Inc. | NIH awarded $801K (SBIR Phase II 5R44AI188872-02, continuation, notice Jun 11, 2026).Evidence (1 event)- Jun 11, 2026 · NIH RePORTER 5R44AI188872-02
Organization: HELIGENICS INC; City/State: HENDERSON, NV; Project number: 5R44AI188872-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 801133; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: High Content Screening for Bifunctional Chimera Biologics; Organization type: Domestic For-Profits
| Jun 11, 2026 | NIH RePORTER 5R44AI188872-02 |
| Ligo Analytics | NIH awarded $763K (SBIR Phase II 5R44GM148105-03, continuation, notice May 7, 2026).Evidence (1 event)- May 7, 2026 · NIH RePORTER 5R44GM148105-03
Organization: LIGO ANALYTICS, INC.; City/State: DALLAS, TX; Project number: 5R44GM148105-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-07; FY total cost (award amount): 762936; Administering IC: National Institute of General Medical Sciences; Project title: Dynamical Diffraction Analysis for 3D Electron Crystallography; Organization type: Domestic For-Profits
| May 7, 2026 | NIH RePORTER 5R44GM148105-03 |
| Actuated Medical | NIH awarded $1.04M (SBIR Phase II 2R44NS155776-04, competing renewal, notice Sep 17, 2026); 2 NIH awards totaling $1.7M in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 2R44NS155776-04
Organization: ACTUATED MEDICAL, INC.; City/State: BELLEFONTE, PA; Project number: 2R44NS155776-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1040504; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Vibration-integrated Lancing System to Reduce Stress, Pain Response, Heel Damage and Developmental Harm from Recurring Heel Sticks in Neonates; Organization type: Domestic For-Profits - May 18, 2026 · NIH RePORTER 5R44AA030512-04
Organization: ACTUATED MEDICAL, INC.; City/State: BELLEFONTE, PA; Project number: 5R44AA030512-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-18; FY total cost (award amount): 660862; Administering IC: National Institute on Alcohol Abuse and Alcoholism; Project title: Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS Therapy in Alcohol Addiction Treatment; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 2R44NS155776-04 |
| Merlin Biotech Inc. | NIH awarded $400K (SBIR Phase I 1R43DE035421-01, new, notice Sep 11, 2026).Evidence (1 event)- Sep 11, 2026 · NIH RePORTER 1R43DE035421-01
Organization: MERLIN BIOTECH INC; City/State: DOYLESTOWN, PA; Project number: 1R43DE035421-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 400000; Administering IC: National Institute of Dental and Craniofacial Research; Project title: Investigating Enhanced Activity of MER-101 in HPV+ Head and Neck Cancer; Organization type: Domestic For-Profits
| Sep 11, 2026 | NIH RePORTER 1R43DE035421-01 |
| En Solucion Inc | NIH awarded $1.02M (SBIR Phase II 2R44FD008038-02, competing renewal, notice Sep 28, 2026).Evidence (1 event)- Sep 28, 2026 · NIH RePORTER 2R44FD008038-02
Organization: EN SOLUCION, INC.; City/State: WILMINGTON, DE; Project number: 2R44FD008038-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-28; FY total cost (award amount): 1022906; Administering IC: Food and Drug Administration; Project title: Innovative Continuous Sanitization of Fresh Produce Harvesting Equipment; Organization type: Domestic For-Profits
| Sep 28, 2026 | NIH RePORTER 2R44FD008038-02 |
| Capienda Biotech, LLC | NIH awarded $1.4M (SBIR Phase II 2R44TR005335-02A1, competing renewal, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 2R44TR005335-02A1
Organization: CAPIENDA BIOTECH, LLC; City/State: San Diego, CA; Project number: 2R44TR005335-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1401698; Administering IC: National Center for Advancing Translational Sciences; Project title: High-throughput kinetic system for small-molecule drug discovery; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 2R44TR005335-02A1 |
| Exavir Therapeutics | NIH awarded $998K (SBIR Phase II 1R44AI195119-01, new, notice Aug 4, 2026).Evidence (1 event)- Aug 4, 2026 · NIH RePORTER 1R44AI195119-01
Organization: EXAVIR THERAPEUTICS INC.; City/State: San Francisco, CA; Project number: 1R44AI195119-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 998034; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of an Ultra-Long-Acting, Self-Administered, Dolutegravir-Based Treatment Regimen for HIV-1 and HIV-HBV Co-infection; Organization type: Domestic For-Profits
| Aug 4, 2026 | NIH RePORTER 1R44AI195119-01 |
| Praeventix | NIH awarded $355K (SBIR Phase I 1R43DA064569-01, new, notice May 19, 2026).Evidence (1 event)- May 19, 2026 · NIH RePORTER 1R43DA064569-01
Organization: PRAEVENTIX, LLC; City/State: EXTON, PA; Project number: 1R43DA064569-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 355190; Administering IC: National Institute on Drug Abuse; Project title: In Vivo Characterization of 5-HT7 Modulators in Rat Models of Opioid Use Disorder; Organization type: Domestic For-Profits
| May 19, 2026 | NIH RePORTER 1R43DA064569-01 |
| Astrocyte Pharmaceuticals Inc. | NIH awarded $1.5M (SBIR Phase II 5R44NS137896-02, continuation, notice Aug 24, 2026); 2 NIH awards totaling $1.9M in the last 12 months.Evidence (2 events)- Aug 24, 2026 · NIH RePORTER 5R44NS137896-02
Organization: ASTROCYTE PHARMACEUTICALS, INC.; City/State: CAMBRIDGE, MA; Project number: 5R44NS137896-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 1499802; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI); Organization type: Domestic For-Profits - Jul 7, 2026 · NIH RePORTER 1R41DA064479-01
Organization: ASTROCYTE PHARMACEUTICALS, INC.; City/State: CAMBRIDGE, MA; Project number: 1R41DA064479-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 399680; Administering IC: National Institute on Drug Abuse; Project title: Preclinical efficacy of AST-004 as a treatment for substance use disorder; Organization type: Domestic For-Profits
| Aug 24, 2026 | NIH RePORTER 5R44NS137896-02 |
| Sanaria Inc. | NIH awarded $1M (SBIR commercialization 1SB1AI195021-01, new, notice Sep 18, 2026); 2 NIH awards totaling $2M in the last 12 months.Evidence (2 events)- Sep 18, 2026 · NIH RePORTER 1SB1AI195021-01
Organization: SANARIA, INC.; City/State: ROCKVILLE, MD; Project number: 1SB1AI195021-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: New cryovials with integral septum for cryopreservation of PfSPZ vaccine and PfSPZ challenge products.; Organization type: Domestic For-Profits - Sep 17, 2026 · NIH RePORTER 5U44AI124867-08
Organization: SANARIA, INC.; City/State: ROCKVILLE, MD; Project number: 5U44AI124867-08; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Manufacture of aseptic, purified, cryopreserved Plasmodium vivax sporozoites; Organization type: Domestic For-Profits
| Sep 18, 2026 | NIH RePORTER 1SB1AI195021-01 |
| JAN Biotech, Inc. | NIH awarded $999K (SBIR Phase II 5R44AI155075-05, continuation, notice Aug 4, 2026); 2 NIH awards totaling $1.3M in the last 12 months.Evidence (2 events)- Aug 4, 2026 · NIH RePORTER 5R44AI155075-05
Organization: JAN BIOTECH, INC.; City/State: ITHACA, NY; Project number: 5R44AI155075-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 998781; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Sequence-based RNA Fluorescence Assay to Measure Latent HIV Reservoirs; Organization type: Domestic For-Profits - Jul 31, 2026 · NIH RePORTER 1R44AI195231-01
Organization: JAN BIOTECH, INC.; City/State: ITHACA, NY; Project number: 1R44AI195231-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-31; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Clinical Assay to Accurately Profile and Monitor the HIV-1 Reservoir in Chronic-treated Individuals to Guide Treatment Decisions; Organization type: Domestic For-Profits
| Aug 4, 2026 | NIH RePORTER 5R44AI155075-05 |
| Collaborations Pharmaceuticals | NIH awarded $307K (SBIR Phase I 1R43AI191982-01A1, new, notice Aug 27, 2026).Evidence (1 event)- Aug 27, 2026 · NIH RePORTER 1R43AI191982-01A1
Organization: COLLABORATIONS PHARMACEUTICALS, INC.; City/State: FUQUAY VARINA, NC; Project number: 1R43AI191982-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 306870; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Long-term formulation for combination antiviral treatment of HIV; Organization type: Domestic For-Profits
| Aug 27, 2026 | NIH RePORTER 1R43AI191982-01A1 |
| Vincere Biosciences | NIH awarded $1.3M (SBIR Phase II 1R44DK143820-01A1, new, notice Aug 28, 2026).Evidence (1 event)- Aug 28, 2026 · NIH RePORTER 1R44DK143820-01A1
Organization: VINCERE BIOSCIENCES, INC.; City/State: Cambridge, MA; Project number: 1R44DK143820-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 1297479; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: IND-enabling studies of a USP30 inhibitor for acute kidney injury; Organization type: Domestic For-Profits
| Aug 28, 2026 | NIH RePORTER 1R44DK143820-01A1 |
| Kephera Diagnostics | NIH awarded $1.01M (SBIR Phase II 5R44HL180181-02, continuation, notice Sep 4, 2026); 2 NIH awards totaling $1.31M in the last 12 months.Evidence (2 events)- Sep 4, 2026 · NIH RePORTER 5R44HL180181-02
Organization: KEPHERA DIAGNOSTICS, LLC; City/State: Framingham, MA; Project number: 5R44HL180181-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1008567; Administering IC: National Heart Lung and Blood Institute; Project title: Peptide-based ELISA for laboratory diagnosis of sarcoidosis; Organization type: Domestic For-Profits - Aug 24, 2026 · NIH RePORTER 1R43AI186917-01A1
Organization: KEPHERA DIAGNOSTICS, LLC; City/State: Framingham, MA; Project number: 1R43AI186917-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 303250; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Rapid Diagnostic Immunoassay for Strongyloidiasis; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 5R44HL180181-02 |
| Vivid BioInnovations, PBC | NIH awarded $506K (SBIR Phase II 1R44AG102286-01, new, notice Sep 8, 2026); 7 NIH awards totaling $3.76M in the last 12 months.Evidence (7 events)- Sep 8, 2026 · NIH RePORTER 1R44AG102286-01
Organization: VIVID BIOINNOVATIONS, PBC; City/State: San Francisco, CA; Project number: 1R44AG102286-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 506495; Administering IC: National Institute on Aging; Project title: AstroTarget™ Astro-Enrichment Kit: A Microfluidic-Free Platform for High-Throughput Rare-Astrocyte Isolation and Multi-Omic Profiling from Frozen Alzheimer’s Brain; Organization type: Domestic For-Profits - Aug 27, 2026 · NIH RePORTER 4R44AG091101-02
Organization: VIVID BIOINNOVATIONS, PBC; City/State: San Francisco, CA; Project number: 4R44AG091101-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 1012648; Administering IC: National Institute on Aging; Project title: FIND-seq: A Novel Cell Sorting Technology to Enable Investigation of Rare Cells in Primary Human Tissues; Organization type: Domestic For-Profits - Aug 20, 2026 · NIH RePORTER 4R44GM161309-02
Organization: VIVID BIOINNOVATIONS, PBC; City/State: San Francisco, CA; Project number: 4R44GM161309-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 1027505; Administering IC: National Institute of General Medical Sciences; Project title: A Universal Platform for Ultrahigh-Throughput Biocatalyst Evolution With micro-Mass Spectrometry; Organization type: Domestic For-Profits - Aug 19, 2026 · NIH RePORTER 1R44AI195215-01
Organization: VIVID BIOINNOVATIONS, PBC; City/State: San Francisco, CA; Project number: 1R44AI195215-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 307074; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: HIVE-seq: A Novel Omics Technology to Profile Thousands of Single HIV-Positive Cells; Organization type: Domestic For-Profits - Aug 19, 2026 · NIH RePORTER 1R44AI197850-01
Organization: VIVID BIOINNOVATIONS, PBC; City/State: San Francisco, CA; Project number: 1R44AI197850-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 299991; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Spatially Resolved Single-Cell DNA Sequencing: A General Spatial Genomics Platform with Application to HIV Reservoir Mapping; Organization type: Domestic For-Profits - Aug 7, 2026 · NIH RePORTER 1R44CA310740-01
Organization: VIVID BIOINNOVATIONS, PBC; City/State: San Francisco, CA; Project number: 1R44CA310740-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 306872; Administering IC: National Cancer Institute; Project title: Ultrahigh-Throughput Cell Interaction Screening to Advance CAR-T Therapeutic Development; Organization type: Domestic For-Profits - Aug 4, 2026 · NIH RePORTER 1R44GM163514-01
Organization: VIVID BIOINNOVATIONS, PBC; City/State: San Francisco, CA; Project number: 1R44GM163514-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 300001; Administering IC: National Institute of General Medical Sciences; Project title: Integrated High-Throughput Microfluidic-Mass Spectrometry for Enhanced Biomedical Data Generation and AI Model Training; Organization type: Domestic For-Profits
| Sep 8, 2026 | NIH RePORTER 1R44AG102286-01 |
| EicOsis | NIH awarded $2.38M (NIH grant 5UH3DA048767-05, continuation, notice Jan 29, 2026).Evidence (1 event)- Jan 29, 2026 · NIH RePORTER 5UH3DA048767-05
Organization: EICOSIS, LLC; City/State: Davis, CA; Project number: 5UH3DA048767-05; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-01-29; FY total cost (award amount): 2377268; Administering IC: National Institute on Drug Abuse; Project title: Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics; Organization type: Domestic For-Profits
| Jan 29, 2026 | NIH RePORTER 5UH3DA048767-05 |
| Linnaeus Therapeutics | NIH awarded $1M (SBIR Phase II 5R44CA297994-02, continuation, notice May 19, 2026).Evidence (1 event)- May 19, 2026 · NIH RePORTER 5R44CA297994-02
Organization: LINNAEUS THERAPEUTICS INC; City/State: HADDONFIELD, NJ; Project number: 5R44CA297994-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 999960; Administering IC: National Cancer Institute; Project title: Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy; Organization type: Domestic For-Profits
| May 19, 2026 | NIH RePORTER 5R44CA297994-02 |
| Vantis Vascular | NIH awarded $496K (SBIR commercialization 1SB1HL184525-01, new, notice Sep 1, 2026); 2 NIH awards totaling $1.49M in the last 12 months.Evidence (2 events)- Sep 1, 2026 · NIH RePORTER 1SB1HL184525-01
Organization: VANTIS VASCULAR INC; City/State: KALAMAZOO, MI; Project number: 1SB1HL184525-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 496437; Administering IC: National Heart Lung and Blood Institute; Project title: Commercial Readiness of a Catheter for Complex Percutaneous Coronary Intervention; Organization type: Domestic For-Profits - Aug 25, 2026 · NIH RePORTER 5R44HL152835-06
Organization: VANTIS VASCULAR INC; City/State: KALAMAZOO, MI; Project number: 5R44HL152835-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 997212; Administering IC: National Heart Lung and Blood Institute; Project title: Catheter for Complex Percutaneous Coronary Intervention; Organization type: Domestic For-Profits
| Sep 1, 2026 | NIH RePORTER 1SB1HL184525-01 |
| Redbud Labs | NIH awarded $307K (SBIR Phase I 1R43JG000001-01A1, new, notice Aug 18, 2026); 2 NIH awards totaling $1.26M in the last 12 months.Evidence (2 events)- Aug 18, 2026 · NIH RePORTER 1R43JG000001-01A1
Organization: REDBUD LABS, INC.; City/State: Durham, NC; Project number: 1R43JG000001-01A1; Activity code: R43; Fiscal year: 2025; Award notice date: 2026-08-18; FY total cost (award amount): 306872; Administering IC: None; Project title: Development of an automated, compact sample-to-sequencer ready system for extensively/multi drug-resistant TB detection; Organization type: Domestic For-Profits - Jul 22, 2026 · NIH RePORTER 1SB1AI191998-01A1
Organization: REDBUD LABS, INC.; City/State: Durham, NC; Project number: 1SB1AI191998-01A1; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 956224; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Redbud NA1 transfer to manufacturing; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 1R43JG000001-01A1 |
| ReacX Pharmaceuticals | NIH awarded $3.45M (NIH grant 5UH3DA047707-04, continuation, notice Mar 4, 2026).Evidence (1 event)- Mar 4, 2026 · NIH RePORTER 5UH3DA047707-04
Organization: REACX PHARMACEUTICALS, INC.; City/State: SOUTH SAN FRANCISCO, CA; Project number: 5UH3DA047707-04; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-03-04; FY total cost (award amount): 3450000; Administering IC: National Institute on Drug Abuse; Project title: Nalmefene Implant for the Long-Term Treatment of Opioid Use Disorder; Organization type: Domestic For-Profits
| Mar 4, 2026 | NIH RePORTER 5UH3DA047707-04 |
| Rational Vaccines Inc. | NIH awarded $999K (SBIR Phase II 5R44AI170133-03, continuation, notice May 13, 2026).Evidence (1 event)- May 13, 2026 · NIH RePORTER 5R44AI170133-03
Organization: RATIONAL VACCINES, INC.; City/State: WOBURN, MA; Project number: 5R44AI170133-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 999160; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Preclinical Evaluation of a Novel Immunomodulatory Vaccine for Preventing and Treating HSV Infections; Organization type: Domestic For-Profits
| May 13, 2026 | NIH RePORTER 5R44AI170133-03 |
| Quiver Bioscience Inc. | NIH awarded $886K (SBIR Phase II 5R44NS141534-02, continuation, notice May 5, 2026); 2 NIH awards totaling $2.88M in the last 12 months.Evidence (2 events)- May 5, 2026 · NIH RePORTER 5R44NS141534-02
Organization: QUIVER BIOSCIENCE INC.; City/State: CAMBRIDGE, MA; Project number: 5R44NS141534-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-05; FY total cost (award amount): 886042; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide Neurotoxicity; Organization type: Domestic For-Profits - Apr 28, 2026 · NIH RePORTER 1UG3NS146009-01
Organization: QUIVER BIOSCIENCE INC.; City/State: CAMBRIDGE, MA; Project number: 1UG3NS146009-01; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-04-28; FY total cost (award amount): 1993248; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of Nav channel targeting antisense oligonucleotides as chronic pain therapeutics using an integrated platform based on machine learning and optical electrophysiology; Organization type: Domestic For-Profits
| May 5, 2026 | NIH RePORTER 5R44NS141534-02 |
| Cellergy Pharma | NIH awarded $294K (STTR Phase I 5R41AI188995-02, continuation, notice May 28, 2026).Evidence (1 event)- May 28, 2026 · NIH RePORTER 5R41AI188995-02
Organization: CELLERGY PHARMA; City/State: Wilmington, DE; Project number: 5R41AI188995-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-05-28; FY total cost (award amount): 294407; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Bispecific antibody targeting IgE-producing B cells for treating allergic diseases; Organization type: Domestic For-Profits
| May 28, 2026 | NIH RePORTER 5R41AI188995-02 |
| Halcyon Biomedical Inc. | NIH awarded $352K (NIH grant 1R33HL183009-01, new, notice Sep 4, 2026).Evidence (1 event)- Sep 4, 2026 · NIH RePORTER 1R33HL183009-01
Organization: HALCYON BIOMEDICAL, INC.; City/State: FRIENDSWOOD, TX; Project number: 1R33HL183009-01; Activity code: R33; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 351949; Administering IC: National Heart Lung and Blood Institute; Project title: Development and validation of a cell separation platform technology; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 1R33HL183009-01 |
| MDC Studio INC | NIH awarded $310K (NIH grant 1R61HL183026-01, new, notice Sep 1, 2026).Evidence (1 event)- Sep 1, 2026 · NIH RePORTER 1R61HL183026-01
Organization: MDC STUDIO, INC.; City/State: BALTIMORE, MD; Project number: 1R61HL183026-01; Activity code: R61; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 309813; Administering IC: National Heart Lung and Blood Institute; Project title: Automated vascular access device development; Organization type: Domestic For-Profits
| Sep 1, 2026 | NIH RePORTER 1R61HL183026-01 |
| Greenstone Biosciences, Inc. | NIH awarded $626K (NIH grant 1R61HL179715-01A1, new, notice Aug 3, 2026).Evidence (1 event)- Aug 3, 2026 · NIH RePORTER 1R61HL179715-01A1
Organization: GREENSTONE BIOSCIENCES, INC.; City/State: PALO ALTO, CA; Project number: 1R61HL179715-01A1; Activity code: R61; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 625968; Administering IC: National Heart Lung and Blood Institute; Project title: Small Molecule Drug Discovery for Cardiac Fibrosis using AI/ML and iPSC-Derived Organoids; Organization type: Domestic For-Profits
| Aug 3, 2026 | NIH RePORTER 1R61HL179715-01A1 |
| PsychoGenics | NIH awarded $924K (SBIR Phase II 4R44MH138151-03, extension, notice Aug 18, 2026); 2 NIH awards totaling $1.32M in the last 12 months.Evidence (2 events)- Aug 18, 2026 · NIH RePORTER 4R44MH138151-03
Organization: PSYCHOGENICS, INC.; City/State: Paramus, NJ; Project number: 4R44MH138151-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 924001; Administering IC: National Institute of Mental Health; Project title: EEG Signature Analysis for Drug Repurposing for Rare Diseases; Organization type: Domestic For-Profits - Jun 9, 2026 · NIH RePORTER 1R43DA061847-01A1
Organization: PSYCHOGENICS, INC.; City/State: Paramus, NJ; Project number: 1R43DA061847-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 398947; Administering IC: National Institute on Drug Abuse; Project title: TAAR1 Agonists for the Treatment of Stimulant Use Disorder; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 4R44MH138151-03 |
| Arisan Therapeutics, Inc. | NIH awarded $1M (SBIR commercialization 5SB1AI112097-10, continuation, notice May 22, 2026).Evidence (1 event)- May 22, 2026 · NIH RePORTER 5SB1AI112097-10
Organization: ARISAN THERAPEUTICS, INC.; City/State: Carlsbad, CA; Project number: 5SB1AI112097-10; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-05-22; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Initiation of ARN-75039 API and Drug Product NDA Registration Path and Manufacturing of Phase 3 final Drug Product; Organization type: Domestic For-Profits
| May 22, 2026 | NIH RePORTER 5SB1AI112097-10 |
| General Biophysics LLC | NIH awarded $479K (SBIR Phase I 1R43HL184078-01, new, notice Sep 9, 2026).Evidence (1 event)- Sep 9, 2026 · NIH RePORTER 1R43HL184078-01
Organization: GENERAL BIOPHYSICS, LLC; City/State: WAYLAND, MA; Project number: 1R43HL184078-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 479185; Administering IC: National Heart Lung and Blood Institute; Project title: Xenon Gas Preservation of Refrigerated Platelets; Organization type: Domestic For-Profits
| Sep 9, 2026 | NIH RePORTER 1R43HL184078-01 |
| AbVacc | NIH awarded $642K (NIH grant 5R01AI193221-02, continuation, notice Sep 17, 2026); 3 NIH awards totaling $2.34M in the last 12 months.Evidence (3 events)- Sep 17, 2026 · NIH RePORTER 5R01AI193221-02
Organization: ABVACC, INC.; City/State: ROCKVILLE, MD; Project number: 5R01AI193221-02; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 642054; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A multimodal approach for immunotherapy of Staphylococcus aureus bacteremia; Organization type: Domestic For-Profits - May 19, 2026 · NIH RePORTER 5R44AI179371-03
Organization: ABVACC, INC.; City/State: ROCKVILLE, MD; Project number: 5R44AI179371-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease; Organization type: Domestic For-Profits - Feb 19, 2026 · NIH RePORTER 5R01AI111205-10
Organization: ABVACC, INC.; City/State: ROCKVILLE, MD; Project number: 5R01AI111205-10; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-02-19; FY total cost (award amount): 697200; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R01AI193221-02 |
| Boston Immune Technologies and Therapeutics | NIH awarded $990K (SBIR Phase II 5R44AI179385-03, continuation, notice Jun 1, 2026).Evidence (1 event)- Jun 1, 2026 · NIH RePORTER 5R44AI179385-03
Organization: BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC.; City/State: WINCHESTER, MA; Project number: 5R44AI179385-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-01; FY total cost (award amount): 990243; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.; Organization type: Domestic For-Profits
| Jun 1, 2026 | NIH RePORTER 5R44AI179385-03 |
| SKM Instruments, LLC | NIH awarded $314K (SBIR Phase I 1R43DA064718-01, new, notice Jun 19, 2026).Evidence (1 event)- Jun 19, 2026 · NIH RePORTER 1R43DA064718-01
Organization: SKM INSTRUMENTS, LLC; City/State: LARAMIE, WY; Project number: 1R43DA064718-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 314317; Administering IC: National Institute on Drug Abuse; Project title: Low-Cost, User-Friendly SERS Technology for Rapid Detection of Emerging Drug Threats; Organization type: Domestic For-Profits
| Jun 19, 2026 | NIH RePORTER 1R43DA064718-01 |
| Alleviant Medical, Inc. | NIH awarded $996K (SBIR Phase II 5R44HL142440-06, continuation, notice May 13, 2026).Evidence (1 event)- May 13, 2026 · NIH RePORTER 5R44HL142440-06
Organization: ALLEVIANT MEDICAL, INC.; City/State: Austin, TX; Project number: 5R44HL142440-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 996173; Administering IC: National Heart Lung and Blood Institute; Project title: Transcatheter Device for Congestive Heart Failure Treatment Through Left Atrial Decompression; Organization type: Domestic For-Profits
| May 13, 2026 | NIH RePORTER 5R44HL142440-06 |
| Artery Therapeutics, Inc. | NIH awarded $2.27M (SBIR Phase II 1R44AG099463-01, new, notice Sep 17, 2026); 2 NIH awards totaling $4.91M in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 1R44AG099463-01
Organization: ARTERY THERAPEUTICS, INC.; City/State: SAN RAMON, CA; Project number: 1R44AG099463-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 2267403; Administering IC: National Institute on Aging; Project title: Subcutaneous CS6253 9-Month Chronic Toxicology GLP Study in Cynomolgus Monkeys to assess Safety, Tolerability and PK; Organization type: Domestic For-Profits - Mar 3, 2026 · NIH RePORTER 1UG3AG098023-01
Organization: ARTERY THERAPEUTICS, INC.; City/State: SAN RAMON, CA; Project number: 1UG3AG098023-01; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-03-03; FY total cost (award amount): 2644490; Administering IC: National Institute on Aging; Project title: CS6253 Sequential Subcutaneous Pharmacokinetic Study followed by Phase 2A Placebo-Controlled Trial with Three Fixed Doses in APOE4 MCI and AD Patients to assess Safety, PK, and Biomarker Effects; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44AG099463-01 |
| NeuroNexus Technologies | NIH awarded $450K (SBIR Phase I 5R43MH139259-02, continuation, notice May 12, 2026).Evidence (1 event)- May 12, 2026 · NIH RePORTER 5R43MH139259-02
Organization: NEURONEXUS TECHNOLOGIES; City/State: Ann Arbor, MI; Project number: 5R43MH139259-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 449677; Administering IC: National Institute of Mental Health; Project title: Advanced culture and recording system for long-term electrophysiological profiling in human brain organoids; Organization type: Domestic For-Profits
| May 12, 2026 | NIH RePORTER 5R43MH139259-02 |
| BiomeSense | NIH awarded $677K (SBIR Phase II 5R44TR003744-03, continuation, notice Jun 16, 2026).Evidence (1 event)- Jun 16, 2026 · NIH RePORTER 5R44TR003744-03
Organization: BIOMESENSE, INC.; City/State: CHICAGO, IL; Project number: 5R44TR003744-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 676980; Administering IC: National Center for Advancing Translational Sciences; Project title: Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome; Organization type: Domestic For-Profits
| Jun 16, 2026 | NIH RePORTER 5R44TR003744-03 |
| Linshom | NIH awarded $184K (SBIR commercialization 5SB1HL182474-02, continuation, notice Sep 16, 2026); 2 NIH awards totaling $1.32M in the last 12 months.Evidence (2 events)- Sep 16, 2026 · NIH RePORTER 5SB1HL182474-02
Organization: LINSHOM MEDICAL INC; City/State: ELLICOTT CITY, MD; Project number: 5SB1HL182474-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 184164; Administering IC: National Heart Lung and Blood Institute; Project title: Clinical Evaluation of an Alarm Activated Detection System to Enable Early Intervention of Emerging Respiratory Decline with the Linshom Medical Continuous Predictive Respiratory Sensor (CPRS); Organization type: Domestic For-Profits - Sep 4, 2026 · NIH RePORTER 2R44HL164222-04
Organization: LINSHOM MEDICAL INC; City/State: ELLICOTT CITY, MD; Project number: 2R44HL164222-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1133058; Administering IC: National Heart Lung and Blood Institute; Project title: Development and Multi-Site Clinical Evaluation of the Linshom CPRM System - A Wearable, AI Enabled, Wireless Alarm Activated Detection System for Early Intervention of Emerging Respiratory Decline; Organization type: Domestic For-Profits
| Sep 16, 2026 | NIH RePORTER 5SB1HL182474-02 |
| Phenomix Sciences | NIH awarded $348K (SBIR Phase II 5R44DK138619-03, continuation, notice May 7, 2026).Evidence (1 event)- May 7, 2026 · NIH RePORTER 5R44DK138619-03
Organization: PHENOMIX SCIENCES, LLC; City/State: Menlo Park, CA; Project number: 5R44DK138619-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-07; FY total cost (award amount): 348022; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A NOVEL PRECISION MEDICINE APPROACH FOR OBESITY: A RANDOMIZED, MULTI-CENTER TRIAL; Organization type: Domestic For-Profits
| May 7, 2026 | NIH RePORTER 5R44DK138619-03 |
| LASE Innovation | NIH awarded $900K (SBIR Phase II 5R44HG013591-03, continuation, notice Jul 7, 2026).Evidence (1 event)- Jul 7, 2026 · NIH RePORTER 5R44HG013591-03
Organization: LASE INNOVATION INC.; City/State: Waltham, MA; Project number: 5R44HG013591-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 900298; Administering IC: National Human Genome Research Institute; Project title: DNA-optical barcoding technology for spatiotemporal single-cell analysis; Organization type: Domestic For-Profits
| Jul 7, 2026 | NIH RePORTER 5R44HG013591-03 |
| Fox Chase Chemical Diversity Center Inc. | NIH awarded $965K (STTR Phase II 5R42AI162385-05, continuation, notice Jun 30, 2026); 2 NIH awards totaling $2.04M in the last 12 months.Evidence (2 events)- Jun 30, 2026 · NIH RePORTER 5R42AI162385-05
Organization: FOX CHASE CHEMICAL DIVERSITY CENTER, INC; City/State: DOYLESTOWN, PA; Project number: 5R42AI162385-05; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 964562; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum; Organization type: Domestic For-Profits - Feb 17, 2026 · NIH RePORTER 1R01AG098139-01
Organization: FOX CHASE CHEMICAL DIVERSITY CENTER, INC; City/State: DOYLESTOWN, PA; Project number: 1R01AG098139-01; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-02-17; FY total cost (award amount): 1074362; Administering IC: National Institute on Aging; Project title: AI-driven discovery of in vivo chemical probes for understudied targets for the treatment of Alzheimer's disease and related disorders (ADRD); Organization type: Domestic For-Profits
| Jun 30, 2026 | NIH RePORTER 5R42AI162385-05 |
| Cantata Bio | NIH awarded $407K (SBIR Phase I 1R43HG014887-01, new, notice Sep 7, 2026).Evidence (1 event)- Sep 7, 2026 · NIH RePORTER 1R43HG014887-01
Organization: CANTATA BIO LLC; City/State: Worcester, MA; Project number: 1R43HG014887-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 406703; Administering IC: National Human Genome Research Institute; Project title: Pangenome-based Inference of Phased, Inherited Genome from Patient-Derived Sequencing Data; Organization type: Domestic For-Profits
| Sep 7, 2026 | NIH RePORTER 1R43HG014887-01 |
| Instanosis | NIH awarded $1.41M (SBIR Phase II 5R44DA061963-02, continuation, notice May 22, 2026); 3 NIH awards totaling $3.58M in the last 12 months.Evidence (3 events)- May 22, 2026 · NIH RePORTER 5R44DA061963-02
Organization: INSTANOSIS, INC.; City/State: MILFORD, DE; Project number: 5R44DA061963-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-22; FY total cost (award amount): 1414924; Administering IC: National Institute on Drug Abuse; Project title: A Rapid, Sensitive and Instrument-free Oral Fluid Fentanyl Test; Organization type: Domestic For-Profits - May 18, 2026 · NIH RePORTER 5U44DA060264-03
Organization: INSTANOSIS, INC.; City/State: MILFORD, DE; Project number: 5U44DA060264-03; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-05-18; FY total cost (award amount): 760678; Administering IC: National Institute on Drug Abuse; Project title: Addressing Emerging Drug Threats with InstaStrip Rapid Tests; Organization type: Domestic For-Profits - May 12, 2026 · NIH RePORTER 5R44DA060647-03
Organization: INSTANOSIS, INC.; City/State: MILFORD, DE; Project number: 5R44DA060647-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 1399878; Administering IC: National Institute on Drug Abuse; Project title: Rapid, Instrument-free and High Sensitivity Over-the-counter Urine Fentanyl Testing; Organization type: Domestic For-Profits
| May 22, 2026 | NIH RePORTER 5R44DA061963-02 |
| Lebrun Labs LLC | NIH awarded $96K (SBIR commercialization 1SB1ES038803-01, new, notice Jun 23, 2026); 2 NIH awards totaling $1.18M in the last 12 months.Evidence (2 events)- Jun 23, 2026 · NIH RePORTER 1SB1ES038803-01
Organization: LEBRUN LABS, LLC; City/State: ANAHEIM, CA; Project number: 1SB1ES038803-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 95664; Administering IC: National Institute of Environmental Health Sciences; Project title: IVD EIT: A Nonanimal Alternative Method for the Detection of Ocular Irritants; Organization type: Domestic For-Profits - May 18, 2026 · NIH RePORTER 5R44ES036065-03
Organization: LEBRUN LABS, LLC; City/State: ANAHEIM, CA; Project number: 5R44ES036065-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-18; FY total cost (award amount): 1088111; Administering IC: National Institute of Environmental Health Sciences; Project title: An In Chemico Test to Identify Dermal Corrosives; Organization type: Domestic For-Profits
| Jun 23, 2026 | NIH RePORTER 1SB1ES038803-01 |
| Mercator MedSystems, Inc. | NIH awarded $1M (SBIR Phase II 5R44HL102998-06, continuation, notice May 11, 2026).Evidence (1 event)- May 11, 2026 · NIH RePORTER 5R44HL102998-06
Organization: MERCATOR MEDSYSTEMS, INC.; City/State: San Leandro, CA; Project number: 5R44HL102998-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-11; FY total cost (award amount): 1000000; Administering IC: National Heart Lung and Blood Institute; Project title: Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery Disease; Organization type: Domestic For-Profits
| May 11, 2026 | NIH RePORTER 5R44HL102998-06 |
| Dignify Therapeutics | NIH awarded $95K (SBIR Phase II 3U44NS129628-04S1, supplement, notice Sep 3, 2026); 2 NIH awards totaling $294K in the last 12 months.Evidence (2 events)- Sep 3, 2026 · NIH RePORTER 3U44NS129628-04S1
Organization: DIGNIFY THERAPEUTICS, LLC; City/State: RESEARCH TRIANGLE PARK, NC; Project number: 3U44NS129628-04S1; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 94793; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding; Organization type: Domestic For-Profits - May 5, 2026 · NIH RePORTER 5U44NS129628-04
Organization: DIGNIFY THERAPEUTICS, LLC; City/State: RESEARCH TRIANGLE PARK, NC; Project number: 5U44NS129628-04; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-05-05; FY total cost (award amount): 199520; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding; Organization type: Domestic For-Profits
| Sep 3, 2026 | NIH RePORTER 3U44NS129628-04S1 |
| Trace-Ability Inc. | NIH awarded $1M (SBIR Phase II 5R44AI162202-04, continuation, notice May 22, 2026).Evidence (1 event)- May 22, 2026 · NIH RePORTER 5R44AI162202-04
Organization: TRACE-ABILITY, INC.; City/State: VAN NUYS, CA; Project number: 5R44AI162202-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-22; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based HIV imaging PET tracers on a single platform.; Organization type: Domestic For-Profits
| May 22, 2026 | NIH RePORTER 5R44AI162202-04 |
| PAI Life Sciences Inc. | NIH awarded $391K (SBIR Phase I 1R43CA298357-01A1, new, notice Sep 17, 2026); 2 NIH awards totaling $1.11M in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 1R43CA298357-01A1
Organization: PAI LIFE SCIENCES, INC.; City/State: SEATTLE, WA; Project number: 1R43CA298357-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 391300; Administering IC: National Cancer Institute; Project title: LiT4Q TLR4 Agonist Formulation for Mucosal Melanoma; Organization type: Domestic For-Profits - May 19, 2026 · NIH RePORTER 5R44AI140708-07
Organization: PAI LIFE SCIENCES, INC.; City/State: SEATTLE, WA; Project number: 5R44AI140708-07; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 713883; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Vaccine for Lymphatic Filariasis, LFGuard™; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43CA298357-01A1 |
| Proneurogen, Inc | NIH awarded $500K (SBIR Phase I 1R43AG099316-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43AG099316-01
Organization: PRONEUROGEN, INC.; City/State: TUCSON, AZ; Project number: 1R43AG099316-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 499802; Administering IC: National Institute on Aging; Project title: Scale-up GMP Manufacturing of Extended-Release PNA5 for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular Dementia; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43AG099316-01 |
| PEER Technologies PLLC | NIH awarded $1.26M (SBIR Phase II 5R44AR085500-02, continuation, notice Jun 1, 2026).Evidence (1 event)- Jun 1, 2026 · NIH RePORTER 5R44AR085500-02
Organization: PEER TECHNOLOGIES, PLLC; City/State: Washington, DC; Project number: 5R44AR085500-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-01; FY total cost (award amount): 1256846; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Smart Cavity Creator Drill for Lumbar Interbody Fusion: Direct to Phase II; Organization type: Domestic For-Profits
| Jun 1, 2026 | NIH RePORTER 5R44AR085500-02 |
| Taxis Pharmaceuticals Inc | NIH awarded $876K (SBIR Phase II 5R44AI174351-03, continuation, notice Sep 11, 2026); 3 NIH awards totaling $2.17M in the last 12 months.Evidence (3 events)- Sep 11, 2026 · NIH RePORTER 5R44AI174351-03
Organization: TAXIS PHARMACEUTICALS, INC.; City/State: MONMOUTH JUNCTION, NJ; Project number: 5R44AI174351-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 875798; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa; Organization type: Domestic For-Profits - Aug 12, 2026 · NIH RePORTER 1R43AI197297-01
Organization: TAXIS PHARMACEUTICALS, INC.; City/State: MONMOUTH JUNCTION, NJ; Project number: 1R43AI197297-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-12; FY total cost (award amount): 294729; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Lead identification of oral FtsZ inhibitors for the treatment of Clostridioides difficile infections(CDI); Organization type: Domestic For-Profits - May 26, 2026 · NIH RePORTER 5R44AI191886-02
Organization: TAXIS PHARMACEUTICALS, INC.; City/State: MONMOUTH JUNCTION, NJ; Project number: 5R44AI191886-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Lead optimization of oral DHFR inhibitor for the treatment of multidrug-resistant N. gonorrhoeae infections.; Organization type: Domestic For-Profits
| Sep 11, 2026 | NIH RePORTER 5R44AI174351-03 |
| Rise Therapeutics | NIH awarded $740K (SBIR Phase II 1R44CA306440-01A1, new, notice Sep 16, 2026); 5 NIH awards totaling $4.11M in the last 12 months.Evidence (5 events)- Sep 16, 2026 · NIH RePORTER 1R44CA306440-01A1
Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 1R44CA306440-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 740140; Administering IC: National Cancer Institute; Project title: Clinical Validation of a Synthetic Biology-Based Microbial Medicine to Treat Immunotherapy Refractory Solid Tumors; Organization type: Domestic For-Profits - Sep 3, 2026 · NIH RePORTER 1R44DK146369-01
Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 1R44DK146369-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 1042478; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A Novel Immunological-Directed Live Biotherapy Product for Treating Crohn's Disease; Organization type: Domestic For-Profits - Sep 1, 2026 · NIH RePORTER 4UH3DE034134-02
Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 4UH3DE034134-02; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 549833; Administering IC: National Institute of Dental and Craniofacial Research; Project title: A Novel Immunological-Directed Probiotic for the Treatment of Sjögren’s Syndrome; Organization type: Domestic For-Profits - Jul 28, 2026 · NIH RePORTER 5R44AG084484-04
Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 5R44AG084484-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 967715; Administering IC: National Institute on Aging; Project title: A Novel Immunological-Directed Biotherapy for Treating Rheumatoid Arthritis; Organization type: Domestic For-Profits - Jul 16, 2026 · NIH RePORTER 5SB1DK141356-03
Organization: RISE THERAPEUTICS, LLC; City/State: Rockville, MD; Project number: 5SB1DK141356-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 811362; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis; Organization type: Domestic For-Profits
| Sep 16, 2026 | NIH RePORTER 1R44CA306440-01A1 |
| AyuVis Research, Inc. | NIH awarded $360K (SBIR Phase II 5R44HD112276-03, continuation, notice May 25, 2026).Evidence (1 event)- May 25, 2026 · NIH RePORTER 5R44HD112276-03
Organization: AYUVIS RESEARCH, INC.; City/State: FORT WORTH, TX; Project number: 5R44HD112276-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-25; FY total cost (award amount): 359812; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonates; Organization type: Domestic For-Profits
| May 25, 2026 | NIH RePORTER 5R44HD112276-03 |
| Kuria Therapeutics, Inc. | NIH awarded $307K (SBIR Phase I 1R43EY038532-01, new, notice Sep 2, 2026).Evidence (1 event)- Sep 2, 2026 · NIH RePORTER 1R43EY038532-01
Organization: KURIA THERAPEUTICS, INC; City/State: LITTLE ROCK, AR; Project number: 1R43EY038532-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 306805; Administering IC: National Eye Institute; Project title: Testing of SCO-116, an NRF2 activator for Fuchs' Dystrophy, in cultured human corneas; Organization type: Domestic For-Profits
| Sep 2, 2026 | NIH RePORTER 1R43EY038532-01 |
| Cellectgen, Inc. | NIH awarded $936K (SBIR Phase II 2R44DE032549-02A1, competing renewal, notice Sep 4, 2026).Evidence (1 event)- Sep 4, 2026 · NIH RePORTER 2R44DE032549-02A1
Organization: CELLECTGEN, INC.; City/State: PASADENA, CA; Project number: 2R44DE032549-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 935551; Administering IC: National Institute of Dental and Craniofacial Research; Project title: DEVELOPMENT OF A SALIVARY ASSAY FOR MEASURING PERIODONTAL DISEASE ACTIVITY; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 2R44DE032549-02A1 |
| Young Therapeutics, LLC | NIH awarded $1.49M (SBIR Phase II 5R44HL160338-03, continuation, notice Jun 30, 2026).Evidence (1 event)- Jun 30, 2026 · NIH RePORTER 5R44HL160338-03
Organization: YOUNG THERAPEUTICS, LLC; City/State: PHILADELPHIA, PA; Project number: 5R44HL160338-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 1488899; Administering IC: National Heart Lung and Blood Institute; Project title: Minimizing myocardial damage and loss of cardiac function post myocardial infarction using Targeted PKC inhibitors 002 and 004.; Organization type: Domestic For-Profits
| Jun 30, 2026 | NIH RePORTER 5R44HL160338-03 |
| Analytical Diagnostic Solutions Inc. | NIH awarded $312K (SBIR Phase I 1R43DK143768-01A1, new, notice Sep 10, 2026); 3 NIH awards totaling $1.72M in the last 12 months.Evidence (3 events)- Sep 10, 2026 · NIH RePORTER 1R43DK143768-01A1
Organization: ANALYTICAL DIAGNOSTIC SOLUTIONS, INC.; City/State: MOUNT LAUREL, NJ; Project number: 1R43DK143768-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 312453; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A Point of Care-Device for the Determination of Blood Tyrosine (TYR) the "TYR Now"; Organization type: Domestic For-Profits - Sep 2, 2026 · NIH RePORTER 5R44HD114325-03
Organization: ANALYTICAL DIAGNOSTIC SOLUTIONS, INC.; City/State: MOUNT LAUREL, NJ; Project number: 5R44HD114325-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 1095992; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: A point of care-device for the determination of creatinine phosphokinase (CPK), theCPK Now; Organization type: Domestic For-Profits - Aug 5, 2026 · NIH RePORTER 1R43DK146426-01
Organization: ANALYTICAL DIAGNOSTIC SOLUTIONS, INC.; City/State: MOUNT LAUREL, NJ; Project number: 1R43DK146426-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 311172; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A Point of Care Device for Patients with Oxalurias, the Oxalate Now; Organization type: Domestic For-Profits
| Sep 10, 2026 | NIH RePORTER 1R43DK143768-01A1 |
| Amplo Biotechnology | NIH awarded $1.36M (STTR Phase II 5R42NS127713-04, continuation, notice May 12, 2026).Evidence (1 event)- May 12, 2026 · NIH RePORTER 5R42NS127713-04
Organization: AMPLO BIOTECHNOLOGY, INC.; City/State: TOWSON, MD; Project number: 5R42NS127713-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 1357367; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Targeted ColQ gene therapy for Congenital Myasthenic Syndromes; Organization type: Domestic For-Profits
| May 12, 2026 | NIH RePORTER 5R42NS127713-04 |
| Nabgen Inc. | NIH awarded $1.01M (STTR Phase II 5R42TR004338-03, continuation, notice Aug 25, 2026); 2 NIH awards totaling $1.33M in the last 12 months.Evidence (2 events)- Aug 25, 2026 · NIH RePORTER 5R42TR004338-03
Organization: NABGEN, INC.; City/State: DURHAM, NC; Project number: 5R42TR004338-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 1014676; Administering IC: National Center for Advancing Translational Sciences; Project title: Novel strategy to block AAV neutralizing antibody activity; Organization type: Domestic For-Profits - Jul 8, 2026 · NIH RePORTER 1R41TR006064-01
Organization: NABGEN, INC.; City/State: DURHAM, NC; Project number: 1R41TR006064-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-07-08; FY total cost (award amount): 312461; Administering IC: National Center for Advancing Translational Sciences; Project title: Development of a universal approach to block inhibitors for protein replacement therapy; Organization type: Domestic For-Profits
| Aug 25, 2026 | NIH RePORTER 5R42TR004338-03 |
| Bmseed LLC | NIH awarded $701K (SBIR Phase II 2R44NS124469-02, competing renewal, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 2R44NS124469-02
Organization: BMSEED, LLC; City/State: TEMPE, AZ; Project number: 2R44NS124469-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 700518; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: The first adaptable 3D-formfitting microelectrode array for organoid-based models of neurological and neurodegenerative diseases; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 2R44NS124469-02 |
| Scientific Horizons Consulting LLC | NIH awarded $399K (SBIR Phase I 1R43DA065300-01, new, notice Jun 23, 2026).Evidence (1 event)- Jun 23, 2026 · NIH RePORTER 1R43DA065300-01
Organization: SCIENTIFIC HORIZONS CONSULTING LLC; City/State: Irvine, CA; Project number: 1R43DA065300-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 399250; Administering IC: National Institute on Drug Abuse; Project title: Water Inhalable Nicotine (WIN) as An Innovative Orally Inhaled Nicotine Replacement Therapy (NRT) for Smoking Cessation; Organization type: Domestic For-Profits
| Jun 23, 2026 | NIH RePORTER 1R43DA065300-01 |
| Cell Reprogramming & Therapeutics LLC | NIH awarded $422K (SBIR Phase I 1R43GM165021-01, new, notice Aug 18, 2026); 2 NIH awards totaling $845K in the last 12 months.Evidence (2 events)- Aug 18, 2026 · NIH RePORTER 1R43GM165021-01
Organization: CELL REPROGRAMMING AND THERAPEUTICS, LLC; City/State: GREENFIELD, WI; Project number: 1R43GM165021-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 422285; Administering IC: National Institute of General Medical Sciences; Project title: Novel Cell Culture Supplement from Adipocyte-Origin Megakaryocytes and Platelets; Organization type: Domestic For-Profits - Aug 14, 2026 · NIH RePORTER 1R43GM161870-01A1
Organization: CELL REPROGRAMMING AND THERAPEUTICS, LLC; City/State: GREENFIELD, WI; Project number: 1R43GM161870-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 422285; Administering IC: National Institute of General Medical Sciences; Project title: Development of a Novel, Safe, Easily Standardized, and Cost-Effective Cell Growth Supplement for Diverse Cell Culture Applications; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 1R43GM165021-01 |
| Cell Preservation Services Inc. | NIH awarded $314K (SBIR Phase I 1R43CA310739-01, new, notice Sep 16, 2026).Evidence (1 event)- Sep 16, 2026 · NIH RePORTER 1R43CA310739-01
Organization: CELL PRESERVATION SERVICES, INC.; City/State: OWEGO, NY; Project number: 1R43CA310739-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 314400; Administering IC: National Cancer Institute; Project title: Improving Human Hematopoietic Progenitor Cell Cryopreservation using Anti-aging, Nature-inspired and Stress Modulation Formulations; Organization type: Domestic For-Profits
| Sep 16, 2026 | NIH RePORTER 1R43CA310739-01 |
| Keylicon Biosciences | NIH awarded $400K (SBIR Phase I 1R43EB038819-01A1, new, notice Sep 7, 2026); 4 NIH awards totaling $1.43M in the last 12 months.Evidence (4 events)- Sep 7, 2026 · NIH RePORTER 1R43EB038819-01A1
Organization: KEYLICON BIOSCIENCES INC; City/State: BROOKLINE, MA; Project number: 1R43EB038819-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 400000; Administering IC: National Institute of Biomedical Imaging and Bioengineering; Project title: Improving the Stability of saRNA LNP Formulations To Overcome Cold Chain Challenges; Organization type: Domestic For-Profits - Aug 21, 2026 · NIH RePORTER 1R43DK146746-01
Organization: KEYLICON BIOSCIENCES INC; City/State: BROOKLINE, MA; Project number: 1R43DK146746-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 400000; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Extended In Situ Production of Glucocerebrosidase (GCase) for the Treatment of Gaucher Disease; Organization type: Domestic For-Profits - Jul 29, 2026 · NIH RePORTER 1R43AI197306-01
Organization: KEYLICON BIOSCIENCES INC; City/State: BROOKLINE, MA; Project number: 1R43AI197306-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-29; FY total cost (award amount): 314363; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Low Dose Multivalent Influenza Vaccine via Modified Self-Amplifying RNA; Organization type: Domestic For-Profits - Jul 20, 2026 · NIH RePORTER 1R43AI197345-01
Organization: KEYLICON BIOSCIENCES INC; City/State: BROOKLINE, MA; Project number: 1R43AI197345-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 314363; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Multivalent Vaccine Against Lyme Disease via Modified Self-Amplifying RNA; Organization type: Domestic For-Profits
| Sep 7, 2026 | NIH RePORTER 1R43EB038819-01A1 |
| OCULOGENEX | NIH awarded $1.09M (SBIR Phase II 1R44EY038510-01, new, notice Aug 4, 2026).Evidence (1 event)- Aug 4, 2026 · NIH RePORTER 1R44EY038510-01
Organization: OCULOGENEX; City/State: Dallas, TX; Project number: 1R44EY038510-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 1092536; Administering IC: National Eye Institute; Project title: Developing a gene therapy-based solution for early intervention in age related macular degeneration (AMD) to prevent disease progression; Organization type: Domestic For-Profits
| Aug 4, 2026 | NIH RePORTER 1R44EY038510-01 |
| Astero Erado | NIH awarded $306K (SBIR Phase I 1R43AI197270-01, new, notice Aug 11, 2026); 2 NIH awards totaling $1.33M in the last 12 months.Evidence (2 events)- Aug 11, 2026 · NIH RePORTER 1R43AI197270-01
Organization: ASTERO ERADO INC; City/State: COLLEGE STATION, TX; Project number: 1R43AI197270-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 306449; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Severe Autoantibody-Mediated Autoimmune Disease: A New Treatment Approach; Organization type: Domestic For-Profits - May 19, 2026 · NIH RePORTER 5R44AI174502-03
Organization: ASTERO ERADO INC; City/State: COLLEGE STATION, TX; Project number: 5R44AI174502-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 1018916; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Novel approaches for the treatment of autoimmune disease; Organization type: Domestic For-Profits
| Aug 11, 2026 | NIH RePORTER 1R43AI197270-01 |
| 37degrees | NIH awarded $360K (STTR Phase I 1R41GM165131-01, new, notice Aug 6, 2026); 2 NIH awards totaling $817K in the last 12 months.Evidence (2 events)- Aug 6, 2026 · NIH RePORTER 1R41GM165131-01
Organization: 37DEGREES, INC.; City/State: GENEVA, IL; Project number: 1R41GM165131-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 360247; Administering IC: National Institute of General Medical Sciences; Project title: PamON: 3D imaging of live and incubated engineered tissue with photoacoustic microscopy; Organization type: Domestic For-Profits - Aug 3, 2026 · NIH RePORTER 1R43MH139167-01A1
Organization: 37DEGREES, INC.; City/State: GENEVA, IL; Project number: 1R43MH139167-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 456902; Administering IC: National Institute of Mental Health; Project title: InVitreON: A compact and integrated platform for long-term neuronal culture incubation, recording and closed-loop stimulation; Organization type: Domestic For-Profits
| Aug 6, 2026 | NIH RePORTER 1R41GM165131-01 |
| BiaCure Therapies | NIH awarded $1M (SBIR Phase II 5R44AI188772-02, continuation, notice May 22, 2026).Evidence (1 event)- May 22, 2026 · NIH RePORTER 5R44AI188772-02
Organization: BIACURE THERAPIES, INC.; City/State: Waukesha, WI; Project number: 5R44AI188772-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-22; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Using Targeted, Controlled High Frequency Energy for Treatment of Onychomycosis; Organization type: Domestic For-Profits
| May 22, 2026 | NIH RePORTER 5R44AI188772-02 |
| Fibroplate Inc. | NIH awarded $1.16M (SBIR Phase II 1R44AG099306-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44AG099306-01
Organization: FIBROPLATE, INC.; City/State: LAS VEGAS, NV; Project number: 1R44AG099306-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1162390; Administering IC: National Institute on Aging; Project title: Fibrinogen-coated albumin spheres to accelerate bone healing in older adults; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44AG099306-01 |
| EydisBio | NIH awarded $406K (SBIR Phase I 1R43CA310084-01, new, notice Sep 16, 2026).Evidence (1 event)- Sep 16, 2026 · NIH RePORTER 1R43CA310084-01
Organization: EYDIS BIO, INC.; City/State: DURHAM, NC; Project number: 1R43CA310084-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 406496; Administering IC: National Cancer Institute; Project title: Development of a novel, orally bioavailable, TAK1 inhibitor for the treatment of chemotherapy-induced peripheral neuropathy; Organization type: Domestic For-Profits
| Sep 16, 2026 | NIH RePORTER 1R43CA310084-01 |
| Imagenomix | NIH awarded $158K (SBIR Phase I 1R43CA309961-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43CA309961-01
Organization: IMAGENOMIX CORP.; City/State: BROOKLYN, NY; Project number: 1R43CA309961-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 157826; Administering IC: National Cancer Institute; Project title: Analytical Variables and Clinical Utility of AKT1 Mutation Prediction in Breast Cancer Using Deep Learning on Histopathology Images; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43CA309961-01 |
| Mitotherapeutix, LLC | NIH awarded $996K (SBIR Phase II 2R44DK129102-04A1, competing renewal, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 2R44DK129102-04A1
Organization: MITOTHERAPEUTIX, LLC; City/State: CHESHIRE, CT; Project number: 2R44DK129102-04A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 996169; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: cGMP Production, IND-enabling studies, and Phase I Clinical Studies to Test a Novel siRNA drug product for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH); Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 2R44DK129102-04A1 |
| Photothermal Spectroscopy Corp | NIH awarded $307K (SBIR Phase I 1R43GM165235-01, new, notice Aug 27, 2026); 2 NIH awards totaling $1.33M in the last 12 months.Evidence (2 events)- Aug 27, 2026 · NIH RePORTER 1R43GM165235-01
Organization: PHOTOTHERMAL SPECTROSCOPY CORP.; City/State: SANTA BARBARA, CA; Project number: 1R43GM165235-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 306802; Administering IC: National Institute of General Medical Sciences; Project title: High-Speed, High-Content, Label-Free Live-Cell Chemical Imaging in Multiwell Plates Using Photothermal Stimulated Raman Scattering (PT-SRS) Microscopy; Organization type: Domestic For-Profits - Aug 13, 2026 · NIH RePORTER 1R44ES035665-01A1
Organization: PHOTOTHERMAL SPECTROSCOPY CORP.; City/State: SANTA BARBARA, CA; Project number: 1R44ES035665-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 1022908; Administering IC: National Institute of Environmental Health Sciences; Project title: High-Speed Automated Analysis of Sub-20 µm Microplastics by Photothermal Infrared Spectroscopy; Organization type: Domestic For-Profits
| Aug 27, 2026 | NIH RePORTER 1R43GM165235-01 |
| SynCardia Systems | NIH awarded $606K (SBIR Phase I 1R43HL184460-01, new, notice Aug 28, 2026).Evidence (1 event)- Aug 28, 2026 · NIH RePORTER 1R43HL184460-01
Organization: SYNCARDIA SYSTEMS, LLC; City/State: Tucson, AZ; Project number: 1R43HL184460-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 606498; Administering IC: National Heart Lung and Blood Institute; Project title: A wearable, mechanically actuated total artificial heart (Emperor) enabling destination therapy for severe biventricular heart failure patients; Organization type: Domestic For-Profits
| Aug 28, 2026 | NIH RePORTER 1R43HL184460-01 |
| Double Helix Optics, Inc. | NIH awarded $976K (SBIR Phase II 5R44GM151926-03, continuation, notice May 11, 2026).Evidence (1 event)- May 11, 2026 · NIH RePORTER 5R44GM151926-03
Organization: DOUBLE HELIX OPTICS INC.; City/State: BOULDER, CO; Project number: 5R44GM151926-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-11; FY total cost (award amount): 976236; Administering IC: National Institute of General Medical Sciences; Project title: High-resolution extended-depth phase-engineered objectives to accelerate spatial 'omics R&D through computational optics; Organization type: Domestic For-Profits
| May 11, 2026 | NIH RePORTER 5R44GM151926-03 |
| Kovina Therapeutics | NIH awarded $1.14M (SBIR Phase II 1R44CA302154-01A1, new, notice Aug 14, 2026).Evidence (1 event)- Aug 14, 2026 · NIH RePORTER 1R44CA302154-01A1
Organization: KOVINA THERAPEUTICS INC.; City/State: INDIANAPOLIS, IN; Project number: 1R44CA302154-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 1143891; Administering IC: National Cancer Institute; Project title: Novel Therapeutics to Treat HPV-Associated Cancers; Organization type: Domestic For-Profits
| Aug 14, 2026 | NIH RePORTER 1R44CA302154-01A1 |
| Emmune Inc. | NIH awarded $300K (SBIR Phase II 1R44HL184837-01A1, new, notice Aug 24, 2026); 2 NIH awards totaling $599K in the last 12 months.Evidence (2 events)- Aug 24, 2026 · NIH RePORTER 1R44HL184837-01A1
Organization: EMMUNE, INC; City/State: Juno Beach, FL; Project number: 1R44HL184837-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 299664; Administering IC: National Heart Lung and Blood Institute; Project title: Non-viral gene therapy to treat and prevent atherosclerosis; Organization type: Domestic For-Profits - Jul 24, 2026 · NIH RePORTER 1R44AI197364-01
Organization: EMMUNE, INC; City/State: Juno Beach, FL; Project number: 1R44AI197364-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-24; FY total cost (award amount): 299352; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: PK, tolerability, and toxicology studies for eCD4-Ig as a long-acting recombinant protein therapeutic; Organization type: Domestic For-Profits
| Aug 24, 2026 | NIH RePORTER 1R44HL184837-01A1 |
| InBios International | NIH awarded $314K (STTR Phase I 1R41AI197509-01, new, notice Sep 8, 2026); 2 NIH awards totaling $1.29M in the last 12 months; 5 roles open.Evidence (2 events)- Sep 8, 2026 · NIH RePORTER 1R41AI197509-01
Organization: INBIOS INTERNATIONAL, INC.; City/State: Seattle, WA; Project number: 1R41AI197509-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 314363; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a sensitive Point-of-Care immunoassay for tick- borne spotted fever group rickettsioses; Organization type: Domestic For-Profits - Jun 11, 2026 · NIH RePORTER 5R44AI184032-03
Organization: INBIOS INTERNATIONAL, INC.; City/State: Seattle, WA; Project number: 5R44AI184032-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 974356; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of Next-gen Chagas DetectTM Plus Rapid test for sensitive and specific diagnosis of Chagas disease; Organization type: Domestic For-Profits
| Sep 8, 2026 | NIH RePORTER 1R41AI197509-01 |
| Epicypher, Inc. | NIH awarded $1.26M (SBIR Phase II 5R44GM154510-02, continuation, notice Aug 21, 2026); 5 NIH awards totaling $5.62M in the last 12 months.Evidence (5 events)- Aug 21, 2026 · NIH RePORTER 5R44GM154510-02
Organization: EPICYPHER, INC.; City/State: Research Triangle Park, NC; Project number: 5R44GM154510-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 1264176; Administering IC: National Institute of General Medical Sciences; Project title: Asymmetric nucleosome substrates to advance the study of the histone code; Organization type: Domestic For-Profits - Aug 21, 2026 · NIH RePORTER 1R44AI197362-01
Organization: EPICYPHER, INC.; City/State: Research Triangle Park, NC; Project number: 1R44AI197362-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 999268; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Scalable, single-molecule and single-cell chromatin accessibility profiling in primary immune cells; Organization type: Domestic For-Profits - Aug 18, 2026 · NIH RePORTER 1R44TR006068-01A1
Organization: EPICYPHER, INC.; City/State: Research Triangle Park, NC; Project number: 1R44TR006068-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 1062099; Administering IC: National Center for Advancing Translational Sciences; Project title: Genomic profiling of drug-chromatin interactions for accelerated drug development research; Organization type: Domestic For-Profits - Jun 26, 2026 · NIH RePORTER 5R44CA284973-03
Organization: EPICYPHER, INC.; City/State: Research Triangle Park, NC; Project number: 5R44CA284973-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-26; FY total cost (award amount): 1047610; Administering IC: National Cancer Institute; Project title: Epigenomic analysis of cell-free nucleosomes for cancer research; Organization type: Domestic For-Profits - Jun 3, 2026 · NIH RePORTER 5R44AG091990-02
Organization: EPICYPHER, INC.; City/State: Research Triangle Park, NC; Project number: 5R44AG091990-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1249682; Administering IC: National Institute on Aging; Project title: Development of novel epigenetic biomarkers and detection reagents for aging; Organization type: Domestic For-Profits
| Aug 21, 2026 | NIH RePORTER 5R44GM154510-02 |
| MabSwitch | NIH awarded $400K (SBIR Phase I 1R43CA310118-01, new, notice Sep 17, 2026); 2 NIH awards totaling $800K in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 1R43CA310118-01
Organization: MABSWITCH, INC.; City/State: VAN NUYS, CA; Project number: 1R43CA310118-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 399998; Administering IC: National Cancer Institute; Project title: Remote-Controlled PC-CAR T-Cell Therapy for Hard-to-Treat Solid Tumors; Organization type: Domestic For-Profits - Sep 10, 2026 · NIH RePORTER 1R43CA314526-01
Organization: MABSWITCH, INC.; City/State: VAN NUYS, CA; Project number: 1R43CA314526-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 399992; Administering IC: National Cancer Institute; Project title: Affinity-tunable Antibody Drug Conjugate (ADC) against High-Grade Serous Ovarian Cancer; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43CA310118-01 |
| SUS Clinicals Inc. | NIH awarded $400K (STTR Phase II 1R42CA302217-01A1, new, notice Aug 10, 2026).Evidence (1 event)- Aug 10, 2026 · NIH RePORTER 1R42CA302217-01A1
Organization: SUS CLINICALS, INC.; City/State: CINCINNATI, OH; Project number: 1R42CA302217-01A1; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 400001; Administering IC: National Cancer Institute; Project title: Development and Validation of Orthotopic Oncopig Glioma Models for Preclinical Locoregional Therapeutic Evaluation; Organization type: Domestic For-Profits
| Aug 10, 2026 | NIH RePORTER 1R42CA302217-01A1 |
| Kinvard Bio | NIH awarded $314K (SBIR Phase I 1R43AI197431-01, new, notice Aug 3, 2026).Evidence (1 event)- Aug 3, 2026 · NIH RePORTER 1R43AI197431-01
Organization: KINVARD BIO, INC.; City/State: FLOURTOWN, PA; Project number: 1R43AI197431-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 314363; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of oxepanoprolinamide antibiotics for the treatment of complicated urinary tract infections.; Organization type: Domestic For-Profits
| Aug 3, 2026 | NIH RePORTER 1R43AI197431-01 |
| Haima Therapeutics | NIH awarded $500K (SBIR commercialization 1SB1HL184353-01, new, notice Sep 17, 2026); 3 NIH awards totaling $1.53M in the last 12 months.Evidence (3 events)- Sep 17, 2026 · NIH RePORTER 1SB1HL184353-01
Organization: HAIMA THERAPEUTICS, LLC; City/State: CLEVELAND, OH; Project number: 1SB1HL184353-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 499999; Administering IC: National Heart Lung and Blood Institute; Project title: Commercialization Strategy for an Intravenous Hemostatic Nanotechnology for Bleeding Management; Organization type: Domestic For-Profits - Aug 14, 2026 · NIH RePORTER 3R44HL180258-02S1
Organization: HAIMA THERAPEUTICS, LLC; City/State: CLEVELAND, OH; Project number: 3R44HL180258-02S1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 50000; Administering IC: National Heart Lung and Blood Institute; Project title: A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet Agents; Organization type: Domestic For-Profits - Aug 4, 2026 · NIH RePORTER 5R44HL180258-02
Organization: HAIMA THERAPEUTICS, LLC; City/State: CLEVELAND, OH; Project number: 5R44HL180258-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 978218; Administering IC: National Heart Lung and Blood Institute; Project title: A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet Agents; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1SB1HL184353-01 |
| Envisagenics Inc. | NIH awarded $890K (SBIR Phase II 1R44CA310213-01, new, notice Jul 21, 2026).Evidence (1 event)- Jul 21, 2026 · NIH RePORTER 1R44CA310213-01
Organization: ENVISAGENICS, INC.; City/State: Long Island City, NY; Project number: 1R44CA310213-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-21; FY total cost (award amount): 889653; Administering IC: National Cancer Institute; Project title: SpliceDisco: A Machine Learning Tool for the Identification of Alternative Splicing Events Directly Regulated by Pathological Splicing Factors in Cancer; Organization type: Domestic For-Profits
| Jul 21, 2026 | NIH RePORTER 1R44CA310213-01 |
| Alveolus Bio | NIH awarded $273K (SBIR Phase I 1R43AI191900-01A1, new, notice Sep 11, 2026); 2 NIH awards totaling $575K in the last 12 months.Evidence (2 events)- Sep 11, 2026 · NIH RePORTER 1R43AI191900-01A1
Organization: ALVEOLUS BIO, INC.; City/State: BIRMINGHAM, AL; Project number: 1R43AI191900-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 273123; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: An Inhaled Live Biotherapeutic for Influenza Viral Infection; Organization type: Domestic For-Profits - Aug 18, 2026 · NIH RePORTER 1R43AI197548-01
Organization: ALVEOLUS BIO, INC.; City/State: BIRMINGHAM, AL; Project number: 1R43AI197548-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 301768; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Leveraging Live Biotherapeutics for the Treatment of Chronic Rhinosinusitis; Organization type: Domestic For-Profits
| Sep 11, 2026 | NIH RePORTER 1R43AI191900-01A1 |
| Opsin Biotherapeutics Inc. | NIH awarded $1.11M (SBIR Phase II 2R44NS132623-02, competing renewal, notice Sep 21, 2026).Evidence (1 event)- Sep 21, 2026 · NIH RePORTER 2R44NS132623-02
Organization: OPSIN BIOTHERAPEUTICS INC.; City/State: BEDFORD, TX; Project number: 2R44NS132623-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-21; FY total cost (award amount): 1113701; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Optogenetic Neuromodulation for Chronic Pain; Organization type: Domestic For-Profits
| Sep 21, 2026 | NIH RePORTER 2R44NS132623-02 |
| Physical Sciences | NIH awarded $312K (SBIR Phase I 1R43GM164214-01, new, notice Aug 10, 2026); 2 NIH awards totaling $1.36M in the last 12 months.Evidence (2 events)- Aug 10, 2026 · NIH RePORTER 1R43GM164214-01
Organization: PHYSICAL SCIENCES, INC; City/State: ANDOVER, MA; Project number: 1R43GM164214-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 311847; Administering IC: National Institute of General Medical Sciences; Project title: Fluorescence-based Lyobead Assay for Rapid Phage Detection in Bioreactor Systems; Organization type: Domestic For-Profits - Aug 4, 2026 · NIH RePORTER 2R44GM150354-02A1
Organization: PHYSICAL SCIENCES, INC; City/State: ANDOVER, MA; Project number: 2R44GM150354-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 1049845; Administering IC: National Institute of General Medical Sciences; Project title: Metabolic Cytometry for In-line Process Analysis; Organization type: Domestic For-Profits
| Aug 10, 2026 | NIH RePORTER 1R43GM164214-01 |
| Parabon Nanolabs | NIH awarded $295K (SBIR Phase I 1R43AI192177-01A1, new, notice Jun 16, 2026).Evidence (1 event)- Jun 16, 2026 · NIH RePORTER 1R43AI192177-01A1
Organization: PARABON NANOLABS, INC.; City/State: RESTON, VA; Project number: 1R43AI192177-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 295294; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: MetaDx: Rapid Diagnosis of Fungal, Bacterial, and Viral Infections Using Whole Metagenomic Sequencing; Organization type: Domestic For-Profits
| Jun 16, 2026 | NIH RePORTER 1R43AI192177-01A1 |
| TEGA Therapeutics | NIH awarded $498K (SBIR Phase I 1R43HL184653-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43HL184653-01
Organization: TEGA THERAPEUTICS, INC.; City/State: LA JOLLA, CA; Project number: 1R43HL184653-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 498086; Administering IC: National Heart Lung and Blood Institute; Project title: Activities and Biophysical Properties of Heparins, Engineered to Reduce HIT; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43HL184653-01 |
| Nytricx | NIH awarded $314K (SBIR Phase I 1R43HL184590-01, new, notice Jul 22, 2026).Evidence (1 event)- Jul 22, 2026 · NIH RePORTER 1R43HL184590-01
Organization: NYTRICX INC.; City/State: ATHENS, GA; Project number: 1R43HL184590-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 314337; Administering IC: National Heart Lung and Blood Institute; Project title: Engineering Nitric Oxide Releasing Intravascular Catheters with Solid Slippery Surfaces to Combat Infection and Thrombosis; Organization type: Domestic For-Profits
| Jul 22, 2026 | NIH RePORTER 1R43HL184590-01 |
| Luna Bioscience, Inc. | NIH awarded $300K (STTR Phase I 5R41AI188742-02, continuation, notice Sep 2, 2026); 2 NIH awards totaling $601K in the last 12 months.Evidence (2 events)- Sep 2, 2026 · NIH RePORTER 5R41AI188742-02
Organization: LUNA BIOSCIENCE, INC.; City/State: WESTPORT, CT; Project number: 5R41AI188742-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 300435; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Antibody Detection for Diagnosis of Acute Leptospirosis; Organization type: Domestic For-Profits - Jul 14, 2026 · NIH RePORTER 1R41AI197598-01
Organization: LUNA BIOSCIENCE, INC.; City/State: WESTPORT, CT; Project number: 1R41AI197598-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 300239; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of Surrogate Biomarkers for Supporting Clinical Trials of Human Leptospirosis Vaccines; Organization type: Domestic For-Profits
| Sep 2, 2026 | NIH RePORTER 5R41AI188742-02 |
| CellFE | NIH awarded $1.05M (SBIR Phase II 1R44CA310250-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44CA310250-01
Organization: CELLFE INC.; City/State: ATLANTA, GA; Project number: 1R44CA310250-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1052108; Administering IC: National Cancer Institute; Project title: High throughput, high efficiency, rapid mechanical transfection for CAR T-cell therapeutics; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44CA310250-01 |
| Panorama Research Incorporated | NIH awarded $387K (SBIR Phase I 1R43CA310345-01, new, notice Sep 18, 2026).Evidence (1 event)- Sep 18, 2026 · NIH RePORTER 1R43CA310345-01
Organization: PANORAMA RESEARCH, INC.; City/State: SUNNYVALE, CA; Project number: 1R43CA310345-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 387240; Administering IC: National Cancer Institute; Project title: Novel macrophage repolarization therapy for colorectal cancer; Organization type: Domestic For-Profits
| Sep 18, 2026 | NIH RePORTER 1R43CA310345-01 |
| Arkayli Biopharma | NIH awarded $1M (SBIR Phase II 1R44HL184627-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44HL184627-01
Organization: ARKAYLI BIOPHARMA, INC.; City/State: Tracys Landing, MD; Project number: 1R44HL184627-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 999904; Administering IC: National Heart Lung and Blood Institute; Project title: Clinical Development of ARK001 Formulation as a Targeted Therapeutic for InfantileHemangioma; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44HL184627-01 |
| Potomac Affinity Protein LLC | NIH awarded $378K (SBIR Phase I 1R43GM159468-01A1, new, notice Jun 23, 2026); 2 NIH awards totaling $1.49M in the last 12 months.Evidence (2 events)- Jun 23, 2026 · NIH RePORTER 1R43GM159468-01A1
Organization: POTOMAC AFFINITY PROTEINS, LLC; City/State: NORTH POTOMAC, MD; Project number: 1R43GM159468-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 377602; Administering IC: National Institute of General Medical Sciences; Project title: Self-amplifying protease chain reactions for simple, sensitive, and quantitative detection; Organization type: Domestic For-Profits - Jun 9, 2026 · NIH RePORTER 2R44GM140633-02A1
Organization: POTOMAC AFFINITY PROTEINS, LLC; City/State: NORTH POTOMAC, MD; Project number: 2R44GM140633-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 1109087; Administering IC: National Institute of General Medical Sciences; Project title: Selection system for identifying protein-specific folding tags that enable purification of native cytokines from E. coli; Organization type: Domestic For-Profits
| Jun 23, 2026 | NIH RePORTER 1R43GM159468-01A1 |
| Athna Biotech Inc. | NIH awarded $937K (STTR Phase II 2R42CA262399-02, competing renewal, notice Sep 10, 2026); 2 NIH awards totaling $2.04M in the last 12 months.Evidence (2 events)- Sep 10, 2026 · NIH RePORTER 2R42CA262399-02
Organization: ATHNA BIOTECH, INC.; City/State: Athens, GA; Project number: 2R42CA262399-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 937492; Administering IC: National Cancer Institute; Project title: Development of a salt-based nanomedicine for non-muscle invasive bladder cancer; Organization type: Domestic For-Profits - Sep 7, 2026 · NIH RePORTER 5R42CA257584-03
Organization: ATHNA BIOTECH, INC.; City/State: Athens, GA; Project number: 5R42CA257584-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 1098560; Administering IC: National Cancer Institute; Project title: Development of a radiation-activatable nanoparticle for lung cancer therapy; Organization type: Domestic For-Profits
| Sep 10, 2026 | NIH RePORTER 2R42CA262399-02 |
| CMTX Biotech Inc. | NIH awarded $296K (STTR Phase I 1R41AI197642-01, new, notice Sep 1, 2026); 3 NIH awards totaling $1.01M in the last 12 months.Evidence (3 events)- Sep 1, 2026 · NIH RePORTER 1R41AI197642-01
Organization: CMTX BIOTECH, INC.; City/State: KINGS PARK, NY; Project number: 1R41AI197642-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 296470; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Drug Repurposing for the Treatment of Staphylococcus aureus Bacteremia; Organization type: Domestic For-Profits - Aug 28, 2026 · NIH RePORTER 1R41HL184801-01A1
Organization: CMTX BIOTECH, INC.; City/State: KINGS PARK, NY; Project number: 1R41HL184801-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 367988; Administering IC: National Heart Lung and Blood Institute; Project title: A Lung-Specific, Sulfonium Lipid Nanoparticle (sLNP) Formulation of Incyclinide for the Treatment of ALI/ARDS; Organization type: Domestic For-Profits - Jun 23, 2026 · NIH RePORTER 1R41DK143771-01A1
Organization: CMTX BIOTECH, INC.; City/State: KINGS PARK, NY; Project number: 1R41DK143771-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 349687; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Novel Small Molecule for the Prevention of Hemorrhagic Cystitis; Organization type: Domestic For-Profits
| Sep 1, 2026 | NIH RePORTER 1R41AI197642-01 |
| Claria Medical, Inc. | NIH awarded $1.68M (SBIR Phase II 1R44HD121300-01, new, notice Sep 17, 2026); 2 NIH awards totaling $1.78M in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 1R44HD121300-01
Organization: CLARIA MEDICAL, INC.; City/State: Mountain View, CA; Project number: 1R44HD121300-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1675722; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: A Multicenter Randomized Controlled Trial of a Safer and Faster Contained Tissue Extraction System for Laparoscopic Hysterectomy; Organization type: Domestic For-Profits - Sep 2, 2026 · NIH RePORTER 5R44HD105575-04
Organization: CLARIA MEDICAL, INC.; City/State: Mountain View, CA; Project number: 5R44HD105575-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 107203; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: A Safe, Fast, and Cost-Effective System for Tissue Removal in Laparoscopic Hysterectomy and Other Minimally Invasive Surgery; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44HD121300-01 |
| Foli Bio | NIH awarded $400K (SBIR Phase I 1R43HG014430-01A1, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43HG014430-01A1
Organization: FOLI BIO INC.; City/State: NEW YORK, NY; Project number: 1R43HG014430-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 399875; Administering IC: National Human Genome Research Institute; Project title: Development of fecal exfoliome sequencing as a multi-omics approach for gut health management; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43HG014430-01A1 |
| Tango Biosciences | NIH awarded $1.15M (SBIR Phase II 2R44GM146514-02, competing renewal, notice Sep 1, 2026); 2 NIH awards totaling $1.48M in the last 12 months.Evidence (2 events)- Sep 1, 2026 · NIH RePORTER 2R44GM146514-02
Organization: TANGO BIOSCIENCES, INC.; City/State: CHICAGO, IL; Project number: 2R44GM146514-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 1150462; Administering IC: National Institute of General Medical Sciences; Project title: Generating phosphobodies to activated protein kinases; Organization type: Domestic For-Profits - Aug 24, 2026 · NIH RePORTER 1R43GM165191-01
Organization: TANGO BIOSCIENCES, INC.; City/State: CHICAGO, IL; Project number: 1R43GM165191-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 332917; Administering IC: National Institute of General Medical Sciences; Project title: Peptide Glues; Organization type: Domestic For-Profits
| Sep 1, 2026 | NIH RePORTER 2R44GM146514-02 |
| Medosome Biotec | NIH awarded $356K (SBIR Phase I 1R43DK146558-01, new, notice Jul 14, 2026).Evidence (1 event)- Jul 14, 2026 · NIH RePORTER 1R43DK146558-01
Organization: MEDOSOME BIOTEC, LLC; City/State: Alachua, FL; Project number: 1R43DK146558-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 356251; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Developing GLP-1 Producing Genetically Engineered Probiotics for Treatment of Metabolic Diseases; Organization type: Domestic For-Profits
| Jul 14, 2026 | NIH RePORTER 1R43DK146558-01 |
| Allied Innovative Systems | NIH awarded $371K (SBIR Phase I 1R43HL184623-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43HL184623-01
Organization: ALLIED INNOVATIVE SYSTEMS, LLC; City/State: Chatham, NJ; Project number: 1R43HL184623-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 371226; Administering IC: National Heart Lung and Blood Institute; Project title: A new method for the determination of alloantibody titer; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43HL184623-01 |
| Retham Technologies LLC | NIH awarded $1.69M (SBIR Phase II 5R44HL147734-05, continuation, notice Jun 16, 2026).Evidence (1 event)- Jun 16, 2026 · NIH RePORTER 5R44HL147734-05
Organization: RETHAM TECHNOLOGIES, INC.; City/State: Wauwatosa, WI; Project number: 5R44HL147734-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 1693897; Administering IC: National Heart Lung and Blood Institute; Project title: An in vitro diagnostic assay for the early and accurate detection of platelet-activating antibodies associated with Heparin-inducedThrombocytopenia; Organization type: Domestic For-Profits
| Jun 16, 2026 | NIH RePORTER 5R44HL147734-05 |
| Annoviant | NIH awarded $895K (SBIR Phase II 5R44HL147771-06, continuation, notice May 12, 2026).Evidence (1 event)- May 12, 2026 · NIH RePORTER 5R44HL147771-06
Organization: ANNOVIANT, INC; City/State: ALPHARETTA, GA; Project number: 5R44HL147771-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 895062; Administering IC: National Heart Lung and Blood Institute; Project title: Pulmonary Valved Graft with Regeneration Potential for Pediatric Patients; Organization type: Domestic For-Profits
| May 12, 2026 | NIH RePORTER 5R44HL147771-06 |
| SignaBlok, Inc. | NIH awarded $353K (SBIR Phase I 1R43DK148026-01, new, notice Sep 4, 2026); 2 NIH awards totaling $1.18M in the last 12 months.Evidence (2 events)- Sep 4, 2026 · NIH RePORTER 1R43DK148026-01
Organization: SIGNABLOK, INC.; City/State: WORCESTER, MA; Project number: 1R43DK148026-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 353264; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: New TREM-1 therapy for inflammatory bowel disease; Organization type: Domestic For-Profits - May 13, 2026 · NIH RePORTER 5R44EY034015-03
Organization: SIGNABLOK, INC.; City/State: WORCESTER, MA; Project number: 5R44EY034015-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 830491; Administering IC: National Eye Institute; Project title: First-in-class TREM-1 inhibitors for neovascular retinal diseases; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 1R43DK148026-01 |
| PASCALL Systems, Incorporated | NIH awarded $1.07M (SBIR Phase II 5R44AG090247-03, continuation, notice Jul 10, 2026); 6 NIH awards totaling $7M in the last 12 months.Evidence (6 events)- Jul 10, 2026 · NIH RePORTER 5R44AG090247-03
Organization: PASCALL SYSTEMS, INCORPORATED; City/State: Boston, MA; Project number: 5R44AG090247-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 1069722; Administering IC: National Institute on Aging; Project title: Developing an Elderly Patient-Specific, Accurate, Intuitive and Highly Interpretable System for Unconsciousness Management in General Anesthesia Using PASCALL FDA-Cleared Intraoperative EEG Monitor; Organization type: Domestic For-Profits - Jul 1, 2026 · NIH RePORTER 1SB1NS147475-01
Organization: PASCALL SYSTEMS, INCORPORATED; City/State: Boston, MA; Project number: 1SB1NS147475-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-01; FY total cost (award amount): 199806; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Embedded Entrepreneur to Commercialize Active Stimulation/Monitoring Technologies to Optimize Pain and Nociception Management During Regional Anesthesia, General Anesthesia, and Post-Operative Care; Organization type: Domestic For-Profits - Jun 25, 2026 · NIH RePORTER 5R42AG084399-03
Organization: PASCALL SYSTEMS, INCORPORATED; City/State: Boston, MA; Project number: 5R42AG084399-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 999317; Administering IC: National Institute on Aging; Project title: Developing a novel system combining cognitive assessment with PASCALL FDA-cleared intraoperative anesthesia EEG brain monitor to prevent postoperative neurocognitive disorders in aging patients; Organization type: Domestic For-Profits - Jun 3, 2026 · NIH RePORTER 5SB1AG097192-02
Organization: PASCALL SYSTEMS, INCORPORATED; City/State: Boston, MA; Project number: 5SB1AG097192-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1998482; Administering IC: National Institute on Aging; Project title: Commercialization Readiness of an Intraoperative EEG-Guided Precision Anesthesia Management System to Prevent Postoperative Delirium in Elderly and Patients at Risk for Alzheimer's & Related Dementia; Organization type: Domestic For-Profits - Jun 3, 2026 · NIH RePORTER 5R44AG066325-05
Organization: PASCALL SYSTEMS, INCORPORATED; City/State: Boston, MA; Project number: 5R44AG066325-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1499986; Administering IC: National Institute on Aging; Project title: Developing an Intraoperative EEG-Guided Precision Anesthesia Management System to Prevent Postoperative Delirium in Elderly and Patients at Risk for Alzheimer's & Related Dementias; Organization type: Domestic For-Profits - Jun 3, 2026 · NIH RePORTER 5R44AG087872-03
Organization: PASCALL SYSTEMS, INCORPORATED; City/State: Boston, MA; Project number: 5R44AG087872-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1236964; Administering IC: National Institute on Aging; Project title: Developing an Integrated Brain State Monitor for Personalized Anesthesia Decision Support: Preventing Postoperative Delirium in Elderly and Patients At Risk for Alzheimer's or Related Dementias; Organization type: Domestic For-Profits
| Jul 10, 2026 | NIH RePORTER 5R44AG090247-03 |
| Via Therapeutics, LLC | NIH awarded $277K (SBIR Phase I 1R43EY038569-01, new, notice Sep 18, 2026); 5 NIH awards totaling $2.54M in the last 12 months.Evidence (5 events)- Sep 18, 2026 · NIH RePORTER 1R43EY038569-01
Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 1R43EY038569-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 277143; Administering IC: National Eye Institute; Project title: Novel Ocular Aerosol Drug Delivery Device for the Treatment Optimization of Glaucoma.; Organization type: Domestic For-Profits - Sep 17, 2026 · NIH RePORTER 2R44CA257783-02A1
Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 2R44CA257783-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 660779; Administering IC: National Cancer Institute; Project title: Development of dermal targeting formulations for squamous cell carcinoma; Organization type: Domestic For-Profits - Sep 9, 2026 · NIH RePORTER 1R43AI197715-01
Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 1R43AI197715-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 313674; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of Macrophage Targeting Inhaled Tigecycline Dry Powder Formulation for Treating Non-Tuberculous Mycobacterial (NTM) Infections; Organization type: Domestic For-Profits - Aug 28, 2026 · NIH RePORTER 1R41HL186958-01
Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 1R41HL186958-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 315082; Administering IC: National Heart Lung and Blood Institute; Project title: Dry powders of whole blood prepared by thin-film freeze-drying; Organization type: Domestic For-Profits - Jul 10, 2026 · NIH RePORTER 5R44AI174337-03
Organization: VIA THERAPEUTICS, LLC; City/State: AUSTIN, TX; Project number: 5R44AI174337-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 971316; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza; Organization type: Domestic For-Profits
| Sep 18, 2026 | NIH RePORTER 1R43EY038569-01 |
| Riptide Bioscience | NIH awarded $1M (SBIR Phase II 1R44AI197713-01, new, notice Aug 1, 2026).Evidence (1 event)- Aug 1, 2026 · NIH RePORTER 1R44AI197713-01
Organization: RIPTIDE BIOSCIENCE, INC.; City/State: VALLEJO, CA; Project number: 1R44AI197713-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-01; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Designed Host Defense Peptide to Prevent Burn Infections; Organization type: Domestic For-Profits
| Aug 1, 2026 | NIH RePORTER 1R44AI197713-01 |
| Xleratehealth, LLC | NIH awarded $1.25M (SBIR Phase II 2R44GM148083-04, competing renewal, notice Jun 19, 2026).Evidence (1 event)- Jun 19, 2026 · NIH RePORTER 2R44GM148083-04
Organization: XLERATEHEALTH, LLC; City/State: LOUISVILLE, KY; Project number: 2R44GM148083-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 1250177; Administering IC: National Institute of General Medical Sciences; Project title: XLerator Network - From Lab to Market: Scaling Academic Innovation for Commercial Success; Organization type: Domestic For-Profits
| Jun 19, 2026 | NIH RePORTER 2R44GM148083-04 |
| Inherent Biosciences | NIH awarded $1.17M (SBIR Phase II 1R44HD121294-01, new, notice Aug 21, 2026).Evidence (1 event)- Aug 21, 2026 · NIH RePORTER 1R44HD121294-01
Organization: INHERENT BIOSCIENCES, INC.; City/State: Salt Lake City, UT; Project number: 1R44HD121294-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 1167156; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Epigenetic Diagnostic for Severe Spermatogenic Failure and Associated Malignancy Risks; Organization type: Domestic For-Profits
| Aug 21, 2026 | NIH RePORTER 1R44HD121294-01 |
| Phoenix Nest | NIH awarded $1.49M (SBIR Phase II 1R44NS147802-01, new, notice Jul 14, 2026).Evidence (1 event)- Jul 14, 2026 · NIH RePORTER 1R44NS147802-01
Organization: PHOENIX NEST, INC.; City/State: BROOKLYN, NY; Project number: 1R44NS147802-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 1492329; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Manufacturing and Analytical Development for JLK-247 Gene Therapy; Organization type: Domestic For-Profits
| Jul 14, 2026 | NIH RePORTER 1R44NS147802-01 |
| Ividence Inc. | NIH awarded $315K (SBIR Phase I 1R43MH143510-01, new, notice Aug 7, 2026).Evidence (1 event)- Aug 7, 2026 · NIH RePORTER 1R43MH143510-01
Organization: IVIDENCE INC; City/State: HOCKESSIN, DE; Project number: 1R43MH143510-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 315276; Administering IC: National Institute of Mental Health; Project title: Repurposing Glucagon-Like Peptide-1 Receptor Agonists for Mental Health Outcomes via Federated Causal Inference; Organization type: Domestic For-Profits
| Aug 7, 2026 | NIH RePORTER 1R43MH143510-01 |
| Amelia Technologies LLC | NIH awarded $1.04M (SBIR Phase II 1R44ES038434-01, new, notice Jun 23, 2026).Evidence (1 event)- Jun 23, 2026 · NIH RePORTER 1R44ES038434-01
Organization: AMELIA TECHNOLOGIES, LLC; City/State: WASHINGTON, DC; Project number: 1R44ES038434-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 1037876; Administering IC: National Institute of Environmental Health Sciences; Project title: EcoWell: Smart Incubation Technology for Next-Generation Environmental Science Labs; Organization type: Domestic For-Profits
| Jun 23, 2026 | NIH RePORTER 1R44ES038434-01 |
| Nephropathology Associates, PLC | NIH awarded $267K (SBIR Phase I 1R43AI197708-01, new, notice Aug 12, 2026).Evidence (1 event)- Aug 12, 2026 · NIH RePORTER 1R43AI197708-01
Organization: NEPHROPATHOLOGY ASSOCIATES; City/State: LITTLE ROCK, AR; Project number: 1R43AI197708-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-12; FY total cost (award amount): 266613; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Precision Diagnostics in T-cell Mediated Rejection: Predicting Treatment Resistance at Time of Diagnosis; Organization type: Domestic For-Profits
| Aug 12, 2026 | NIH RePORTER 1R43AI197708-01 |
| Vasoptic Medical | NIH awarded $948K (SBIR Phase II 1R44AG099581-01, new, notice Sep 17, 2026); 2 NIH awards totaling $1.95M in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 1R44AG099581-01
Organization: VASOPTIC MEDICAL, INC.; City/State: BALTIMORE, MD; Project number: 1R44AG099581-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 947679; Administering IC: National Institute on Aging; Project title: Noninvasive assessment of neurovascular coupling for early diagnosis of cognitive impairment; Organization type: Domestic For-Profits - Aug 19, 2026 · NIH RePORTER 2R44EY032847-02A1
Organization: VASOPTIC MEDICAL, INC.; City/State: BALTIMORE, MD; Project number: 2R44EY032847-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 999883; Administering IC: National Eye Institute; Project title: Imaging of episcleral venous blood flow for assessment of micro-invasive glaucoma surgery; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44AG099581-01 |
| North Shore Therapeutics, Inc. | NIH awarded $450K (STTR Phase I 1R41MH140642-01A1, new, notice Aug 26, 2026).Evidence (1 event)- Aug 26, 2026 · NIH RePORTER 1R41MH140642-01A1
Organization: NORTH SHORE THERAPEUTICS, INC.; City/State: Rochester, MN; Project number: 1R41MH140642-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 450020; Administering IC: National Institute of Mental Health; Project title: NST-SPARK: Developing an Augmented Reality (AR) Digital Health Intervention for Negative Symptoms in Schizophrenia; Organization type: Domestic For-Profits
| Aug 26, 2026 | NIH RePORTER 1R41MH140642-01A1 |
| Mucommune | NIH awarded $1.16M (SBIR Phase II 1R44HD121291-01, new, notice Sep 17, 2026); 14 NIH awards totaling $11.08M in the last 12 months.Evidence (14 events)- Sep 17, 2026 · NIH RePORTER 1R44HD121291-01
Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1R44HD121291-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1163587; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: IND-enabling development of MM012, an antibody-based non-hormonal contraceptive intravaginal ring; Organization type: Domestic For-Profits - Sep 11, 2026 · NIH RePORTER 1R44AI197810-01
Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1R44AI197810-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 1006467; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: SBIR: In vivo engineering of dual CD19/CD138 CAR-T cells for treatment of Systemic Lupus Erythematosus; Organization type: Domestic For-Profits - Sep 7, 2026 · NIH RePORTER 1P50HD123737-01
Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1P50HD123737-01; Activity code: P50; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 1860006; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Preclinical and clinical development of on-demand and sustained non-hormonal contraceptives based on highly multivalent contraceptive antibody; Organization type: Domestic For-Profits - Sep 7, 2026 · NIH RePORTER 1P50HD123737-01
Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1P50HD123737-01; Activity code: P50; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 1441607; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Clinical development of MM011, an instantly dissolving vaginal tablet releasing HCMA for on-demand non-hormonal contraception; Organization type: Domestic For-Profits - Sep 7, 2026 · NIH RePORTER 1P50HD123737-01
Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1P50HD123737-01; Activity code: P50; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 208837; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Establishing a rhesus macaque post-coital test model to predict clinical efficacy of HCMA contraceptives; Organization type: Domestic For-Profits - Sep 7, 2026 · NIH RePORTER 1P50HD123737-01
Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1P50HD123737-01; Activity code: P50; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 95436; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Biospecimen Core supporting the preclinical and clinical development of highly multivalent contraceptive antibody (HMCA); Organization type: Domestic For-Profits - Sep 7, 2026 · NIH RePORTER 1P50HD123737-01
Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1P50HD123737-01; Activity code: P50; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 82731; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: HMCA-CDRC: Administrative Core; Organization type: Domestic For-Profits - Sep 7, 2026 · NIH RePORTER 1P50HD123737-01
Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 1P50HD123737-01; Activity code: P50; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 31395; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Clinical development of MM012, a vaginal ring releasing HCMA for month-long non-hormonal contraception; Organization type: Domestic For-Profits - Sep 4, 2026 · NIH RePORTER 5R44HD118898-02
Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 5R44HD118898-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1168977; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Fast Dissolving MM008 Tablet for Instant On-Demand Non-Hormonal Contraception; Organization type: Domestic For-Profits - Aug 26, 2026 · NIH RePORTER 5R44CA306674-02
Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 5R44CA306674-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 1025819; Administering IC: National Cancer Institute; Project title: SBIR: In vivo engineering of B7-H3.CAR-T cells for ovarian cancer therapy; Organization type: Domestic For-Profits - Aug 13, 2026 · NIH RePORTER 5R44CA310402-02
Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 5R44CA310402-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 1146083; Administering IC: National Cancer Institute; Project title: SBIR: In vivo engineering of multifaceted B7H3.CAR-T cells for cellular immunotherapy of pancreatic ductal adenocarcinoma; Organization type: Domestic For-Profits - Aug 5, 2026 · NIH RePORTER 5R43AI189008-02
Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 5R43AI189008-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 309210; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Engineering a physiologically-tuned reservoir intravaginal ring releasing lactic acid for the treatment and prevention of bacterial vaginosis; Organization type: Domestic For-Profits - May 26, 2026 · NIH RePORTER 5R44AI192170-02
Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 5R44AI192170-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 992780; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: IND-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic acid release to treat and prevent bacterial vaginosis; Organization type: Domestic For-Profits - Mar 4, 2026 · NIH RePORTER 4R33HD117428-02
Organization: MUCOMMUNE, LLC; City/State: Morrisville, NC; Project number: 4R33HD117428-02; Activity code: R33; Fiscal year: 2026; Award notice date: 2026-03-04; FY total cost (award amount): 550000; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Development of an ultrapotent anti-sperm antibody construct for non-hormonal contraception; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44HD121291-01 |
| TrAMPoline Pharma | NIH awarded $398K (SBIR Phase I 1R43CA310292-01, new, notice Sep 10, 2026).Evidence (1 event)- Sep 10, 2026 · NIH RePORTER 1R43CA310292-01
Organization: TRAMPOLINE PHARMA, INC.; City/State: AURORA, CO; Project number: 1R43CA310292-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 398039; Administering IC: National Cancer Institute; Project title: Development of a Universal Next Generation T Cell Receptor Cancer Therapy: Preclinical Proof-of-Concept and Optimization; Organization type: Domestic For-Profits
| Sep 10, 2026 | NIH RePORTER 1R43CA310292-01 |
| Iaso Therapeutics | NIH awarded $300K (SBIR Phase I 1R43AI197624-01, new, notice Jul 1, 2026).Evidence (1 event)- Jul 1, 2026 · NIH RePORTER 1R43AI197624-01
Organization: IASO THERAPEUTICS, INC.; City/State: EAST LANSING, MI; Project number: 1R43AI197624-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-01; FY total cost (award amount): 299999; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Next generation multi-antigen Staphylococcus aureus vaccine enabled by proprietary mutant bacteriophage Qbeta; Organization type: Domestic For-Profits
| Jul 1, 2026 | NIH RePORTER 1R43AI197624-01 |
| Merakris Therapeutics | NIH awarded $1.11M (SBIR Phase II 1R44DK146625-01, new, notice Jul 17, 2026).Evidence (1 event)- Jul 17, 2026 · NIH RePORTER 1R44DK146625-01
Organization: MERAKRIS THERAPEUTICS INC; City/State: HILLSBOROUGH, NC; Project number: 1R44DK146625-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 1109504; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Evaluation of Efficacy and Safety of MTX-001 in Diabetic Foot Ulcers; Organization type: Domestic For-Profits
| Jul 17, 2026 | NIH RePORTER 1R44DK146625-01 |
| Ramona Optics Inc. | NIH awarded $745K (SBIR Phase II 2R44MH133521-03, competing renewal, notice Sep 4, 2026); 2 NIH awards totaling $1.75M in the last 12 months.Evidence (2 events)- Sep 4, 2026 · NIH RePORTER 2R44MH133521-03
Organization: RAMONA OPTICS, INC.; City/State: DURHAM, NC; Project number: 2R44MH133521-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 745337; Administering IC: National Institute of Mental Health; Project title: A parallelized imaging platform for accurate and efficient long-term assessment of brain organoid development; Organization type: Domestic For-Profits - Jul 14, 2026 · NIH RePORTER 5R44CA285197-03
Organization: RAMONA OPTICS, INC.; City/State: DURHAM, NC; Project number: 5R44CA285197-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 1000000; Administering IC: National Cancer Institute; Project title: A parallelized computational microscope platform for high-throughput live imaging of patient-derived organoids; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 2R44MH133521-03 |
| Triangle Biotechnology | NIH awarded $1M (SBIR commercialization 1SB1AI197360-01, new, notice Jul 20, 2026).Evidence (1 event)- Jul 20, 2026 · NIH RePORTER 1SB1AI197360-01
Organization: TRIANGLE BIOTECHNOLOGY, INC.; City/State: Chapel Hill, NC; Project number: 1SB1AI197360-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Commercializing nanodroplet technology to improve diagnostic sensitivity for difficult-to-lyse microbial samples; Organization type: Domestic For-Profits
| Jul 20, 2026 | NIH RePORTER 1SB1AI197360-01 |
| Neurexis Therapeutics, Inc. | NIH awarded $485K (SBIR Phase I 1R43AG094353-01A1, new, notice Sep 17, 2026); 2 NIH awards totaling $723K in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 1R43AG094353-01A1
Organization: NEUREXIS THERAPEUTICS, INC.; City/State: AURORA, CO; Project number: 1R43AG094353-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 484929; Administering IC: National Institute on Aging; Project title: Restoring AD-related neuronal dysfunction with a neuroprotective peptide; Organization type: Domestic For-Profits - Aug 27, 2026 · NIH RePORTER 5R44NS120427-04
Organization: NEUREXIS THERAPEUTICS, INC.; City/State: AURORA, CO; Project number: 5R44NS120427-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 238126; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: IND-enabling studies for a potent and efficient neuroprotective drug; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43AG094353-01A1 |
| Prenosis | NIH awarded $1.22M (SBIR Phase II 1R44HL180159-01A1, new, notice Aug 21, 2026).Evidence (1 event)- Aug 21, 2026 · NIH RePORTER 1R44HL180159-01A1
Organization: PRENOSIS, INC.; City/State: CHAMPAIGN, IL; Project number: 1R44HL180159-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 1218102; Administering IC: National Heart Lung and Blood Institute; Project title: Derivation and Validation of the Heart Failure CardioScore: an AI Diagnostic for HeartFailure using Novel Biomarkers and Clinical Data; Organization type: Domestic For-Profits
| Aug 21, 2026 | NIH RePORTER 1R44HL180159-01A1 |
| Giner Inc. | NIH awarded $591K (SBIR Phase I 1R43HL184803-01, new, notice Sep 1, 2026); 2 NIH awards totaling $1.6M in the last 12 months.Evidence (2 events)- Sep 1, 2026 · NIH RePORTER 1R43HL184803-01
Organization: GINER, INC.; City/State: NEWTON, MA; Project number: 1R43HL184803-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 591499; Administering IC: National Heart Lung and Blood Institute; Project title: Asthma Management by Monitoring Nitric Oxide (NO) Levels in Exhaled Breath; Organization type: Domestic For-Profits - Aug 31, 2026 · NIH RePORTER 5R44ES033890-03
Organization: GINER, INC.; City/State: NEWTON, MA; Project number: 5R44ES033890-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 1003898; Administering IC: National Institute of Environmental Health Sciences; Project title: Low-Cost Amperometric Ozone Monitor for Communities Affected by Wildfires; Organization type: Domestic For-Profits
| Sep 1, 2026 | NIH RePORTER 1R43HL184803-01 |
| Limax Biosciences | NIH awarded $1.05M (SBIR Phase II 1R44HL184761-01, new, notice Sep 9, 2026).Evidence (1 event)- Sep 9, 2026 · NIH RePORTER 1R44HL184761-01
Organization: LIMAX BIOSCIENCES INC; City/State: SOMERVILLE, MA; Project number: 1R44HL184761-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 1047908; Administering IC: National Heart Lung and Blood Institute; Project title: Advanced Hemostatic Adhesive Hydrogel System for Postpartum Hemorrhage Control; Organization type: Domestic For-Profits
| Sep 9, 2026 | NIH RePORTER 1R44HL184761-01 |
| Innovative Design Labs Inc. | NIH awarded $1.05M (SBIR Phase II 5R44GM161237-02, continuation, notice Aug 31, 2026); 6 NIH awards totaling $5.9M in the last 12 months.Evidence (6 events)- Aug 31, 2026 · NIH RePORTER 5R44GM161237-02
Organization: INNOVATIVE DESIGN LABS, INC.; City/State: MINNEAPOLIS, MN; Project number: 5R44GM161237-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 1047458; Administering IC: National Institute of General Medical Sciences; Project title: PhysioSim: Innovative Physiology Simulation Education Kits for Pre-College Students and Teachers; Organization type: Domestic For-Profits - Aug 21, 2026 · NIH RePORTER 1R44HL186085-01
Organization: INNOVATIVE DESIGN LABS, INC.; City/State: MINNEAPOLIS, MN; Project number: 1R44HL186085-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 1020633; Administering IC: National Heart Lung and Blood Institute; Project title: Improving the Training of CPR and AED Interventions to Real World Characteristics; Organization type: Domestic For-Profits - Aug 18, 2026 · NIH RePORTER 1R43AI197687-01
Organization: INNOVATIVE DESIGN LABS, INC.; City/State: MINNEAPOLIS, MN; Project number: 1R43AI197687-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 313110; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Automated Skill Assessment of Sterile Procedures; Organization type: Domestic For-Profits - Jul 10, 2026 · NIH RePORTER 5R44AG060779-05
Organization: INNOVATIVE DESIGN LABS, INC.; City/State: MINNEAPOLIS, MN; Project number: 5R44AG060779-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 1508825; Administering IC: National Institute on Aging; Project title: Non-Contact Point of Care Device for Sleep Studies; Organization type: Domestic For-Profits - Jul 10, 2026 · NIH RePORTER 5R44AG063679-04
Organization: INNOVATIVE DESIGN LABS, INC.; City/State: MINNEAPOLIS, MN; Project number: 5R44AG063679-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 962408; Administering IC: National Institute on Aging; Project title: A Gait and Path Tortuosity System for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD); Organization type: Domestic For-Profits - Jun 12, 2026 · NIH RePORTER 5R44MD020606-02
Organization: INNOVATIVE DESIGN LABS, INC.; City/State: MINNEAPOLIS, MN; Project number: 5R44MD020606-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-12; FY total cost (award amount): 1048499; Administering IC: National Institute on Minority Health and Health Disparities; Project title: Addressing Challenges in Peripheral Intravenous Catheter Education; Organization type: Domestic For-Profits
| Aug 31, 2026 | NIH RePORTER 5R44GM161237-02 |
| Stem Pharm | NIH awarded $971K (SBIR Phase II 2R44AG082625-02, competing renewal, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 2R44AG082625-02
Organization: STEM PHARM, INC.; City/State: MADISON, WI; Project number: 2R44AG082625-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 971368; Administering IC: National Institute on Aging; Project title: Alzheimer's Disease Drug Discovery Using a Human Organoid Model of Neuroinflammation; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 2R44AG082625-02 |
| Abterra Biosciences | NIH awarded $307K (SBIR Phase I 1R43AI197772-01, new, notice Aug 17, 2026).Evidence (1 event)- Aug 17, 2026 · NIH RePORTER 1R43AI197772-01
Organization: ABTERRA BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 1R43AI197772-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-17; FY total cost (award amount): 306555; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A platform for serum antibody repertoire analysis for autoimmune disease diagnosis; Organization type: Domestic For-Profits
| Aug 17, 2026 | NIH RePORTER 1R43AI197772-01 |
| Proteovista | NIH awarded $286K (SBIR Phase I 1R43GM165210-01, new, notice Sep 16, 2026); 2 NIH awards totaling $592K in the last 12 months.Evidence (2 events)- Sep 16, 2026 · NIH RePORTER 1R43GM165210-01
Organization: PROTEOVISTA, LLC; City/State: MADISON, WI; Project number: 1R43GM165210-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 286118; Administering IC: National Institute of General Medical Sciences; Project title: Development of the High-Density SNAP-Dimer Microarray for Functional Analysis of Dimeric Protein Complexes; Organization type: Domestic For-Profits - Jun 5, 2026 · NIH RePORTER 1R43GM163471-01
Organization: PROTEOVISTA, LLC; City/State: MADISON, WI; Project number: 1R43GM163471-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-05; FY total cost (award amount): 306151; Administering IC: National Institute of General Medical Sciences; Project title: Development of ClusterBuild to Synthesize Biosynthetic Gene Clusters; Organization type: Domestic For-Profits
| Sep 16, 2026 | NIH RePORTER 1R43GM165210-01 |
| Creosalus Inc. | NIH awarded $314K (STTR Phase I 1R41EB038861-01, new, notice Aug 18, 2026).Evidence (1 event)- Aug 18, 2026 · NIH RePORTER 1R41EB038861-01
Organization: CREOSALUS, INC.; City/State: LOUISVILLE, KY; Project number: 1R41EB038861-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 314359; Administering IC: National Institute of Biomedical Imaging and Bioengineering; Project title: Point of Care Differential Scanning Calorimetry; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 1R41EB038861-01 |
| Hesperos | NIH awarded $1M (SBIR Phase II 1R44AI197758-01, new, notice Aug 28, 2026); 3 NIH awards totaling $3.22M in the last 12 months.Evidence (3 events)- Aug 28, 2026 · NIH RePORTER 1R44AI197758-01
Organization: HESPEROS, INC; City/State: ORLANDO, FL; Project number: 1R44AI197758-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Expanded implementation of a human-based Malaria-on-a-Chip phenotypic disease model for the evaluation of therapeutic efficacy and off-target toxicity; Organization type: Domestic For-Profits - Jul 21, 2026 · NIH RePORTER 2R44TR004811-03
Organization: HESPEROS, INC; City/State: ORLANDO, FL; Project number: 2R44TR004811-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-21; FY total cost (award amount): 720882; Administering IC: National Center for Advancing Translational Sciences; Project title: Human Neuromuscular Junction Platform to Evaluate Botulinum Toxin Potency; Organization type: Domestic For-Profits - May 12, 2026 · NIH RePORTER 5R44AG071386-04
Organization: HESPEROS, INC; City/State: ORLANDO, FL; Project number: 5R44AG071386-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 1499996; Administering IC: National Institute on Aging; Project title: Modulatory Role of Blood-Brain-Barrier and Enzymatic Activity in an Innovative Human Model of Anticholinergic Drug Induced Dementia; Organization type: Domestic For-Profits
| Aug 28, 2026 | NIH RePORTER 1R44AI197758-01 |
| Javelin Biotech Inc. | NIH awarded $350K (SBIR Phase I 1R43TR005374-01A1, new, notice Jun 16, 2026).Evidence (1 event)- Jun 16, 2026 · NIH RePORTER 1R43TR005374-01A1
Organization: JAVELIN BIOTECH; City/State: Billerica, MA; Project number: 1R43TR005374-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 349677; Administering IC: National Center for Advancing Translational Sciences; Project title: Investigating the Impact of Metabolic Disease States on the Pharmacodynamics and Toxicity of FDA-Approved Antisense Oligonucleotides Using an Integrated Liver-Kidney Model; Organization type: Domestic For-Profits
| Jun 16, 2026 | NIH RePORTER 1R43TR005374-01A1 |
| Amissa Inc. | NIH awarded $313K (SBIR Phase I 1R43AG099614-01, new, notice Sep 17, 2026); 2 NIH awards totaling $817K in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 1R43AG099614-01
Organization: AMISSA, INC.; City/State: Charlotte, NC; Project number: 1R43AG099614-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 313211; Administering IC: National Institute on Aging; Project title: SMART-HRT: Smartwatch-Based Monitoring and Real-Time Tracking for Optimizing Hormone Replacement Therapy Efficacy in Menopause.; Organization type: Domestic For-Profits - Aug 19, 2026 · NIH RePORTER 1R43MD021449-01
Organization: AMISSA, INC.; City/State: Charlotte, NC; Project number: 1R43MD021449-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 504222; Administering IC: National Institute on Minority Health and Health Disparities; Project title: HERMOSA: Understanding the Perimenopausal Health Experience of Latina Women Using Digital Biomarkers from Apple Watch.; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43AG099614-01 |
| Xyone Therapeutics | NIH awarded $396K (SBIR Phase I 1R43AG099628-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43AG099628-01
Organization: XYONE THERAPEUTICS INC.; City/State: WESTON, MA; Project number: 1R43AG099628-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 396322; Administering IC: National Institute on Aging; Project title: Development and Performance Evaluation of a TruE2 Diagnostic Algorithm for Free Estradiol; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43AG099628-01 |
| Trace Biosciences | NIH awarded $449K (SBIR Phase II 1R44NS147800-01, new, notice Sep 3, 2026).Evidence (1 event)- Sep 3, 2026 · NIH RePORTER 1R44NS147800-01
Organization: TRACE BIOSCIENCES INC; City/State: Beaverton, OR; Project number: 1R44NS147800-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 448711; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Molecular Imaging of Peripheral and Central Nervous System Myelin; Organization type: Domestic For-Profits
| Sep 3, 2026 | NIH RePORTER 1R44NS147800-01 |
| Aldatu Biosciences | NIH awarded $997K (SBIR Phase II 2R44AI172551-04, competing renewal, notice Sep 2, 2026); 2 NIH awards totaling $1.96M in the last 12 months.Evidence (2 events)- Sep 2, 2026 · NIH RePORTER 2R44AI172551-04
Organization: ALDATU BIOSCIENCES, INC.; City/State: Watertown, MA; Project number: 2R44AI172551-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 996962; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.; Organization type: Domestic For-Profits - Jul 30, 2026 · NIH RePORTER 5R44AI157650-05
Organization: ALDATU BIOSCIENCES, INC.; City/State: Watertown, MA; Project number: 5R44AI157650-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-30; FY total cost (award amount): 960045; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus.; Organization type: Domestic For-Profits
| Sep 2, 2026 | NIH RePORTER 2R44AI172551-04 |
| Sinopia Biosciences | NIH awarded $1.48M (SBIR Phase II 2R44GM154585-02, competing renewal, notice Sep 10, 2026); 3 NIH awards totaling $4.59M in the last 12 months.Evidence (3 events)- Sep 10, 2026 · NIH RePORTER 2R44GM154585-02
Organization: SINOPIA BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 2R44GM154585-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 1477110; Administering IC: National Institute of General Medical Sciences; Project title: Development and Validation of Data Standards and Computational Methods for Large Scale Metabolomics Data Analysis for Data Driven Drug Discovery; Organization type: Domestic For-Profits - Sep 7, 2026 · NIH RePORTER 2R44NS124398-04A1
Organization: SINOPIA BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 2R44NS124398-04A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 3000000; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Preclinical development of a novel therapeutic for Parkinson's disease; Organization type: Domestic For-Profits - Aug 10, 2026 · NIH RePORTER 5R43CA295316-02
Organization: SINOPIA BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 5R43CA295316-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 114274; Administering IC: National Cancer Institute; Project title: Development of a metabolomics enabled AI/ML platform for discovery of new treatments to enhance drug sensitivity in cancer; Organization type: Domestic For-Profits
| Sep 10, 2026 | NIH RePORTER 2R44GM154585-02 |
| Cellchorus Inc. | NIH awarded $999K (SBIR commercialization 1SB1GM163323-01, new, notice Sep 14, 2026); 3 NIH awards totaling $3.05M in the last 12 months.Evidence (3 events)- Sep 14, 2026 · NIH RePORTER 1SB1GM163323-01
Organization: CELLCHORUS INC.; City/State: Houston, TX; Project number: 1SB1GM163323-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 998873; Administering IC: National Institute of General Medical Sciences; Project title: Dynamic single-cell analysis instrument commercial readiness (CRP); Organization type: Domestic For-Profits - Jul 21, 2026 · NIH RePORTER 5R42TR005299-03
Organization: CELLCHORUS INC.; City/State: Houston, TX; Project number: 5R42TR005299-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-07-21; FY total cost (award amount): 1021147; Administering IC: National Center for Advancing Translational Sciences; Project title: LF-TIMING: Large-scale label-free profiling of cell-cell interactions; Organization type: Domestic For-Profits - Jun 8, 2026 · NIH RePORTER 5R44TR005137-03
Organization: CELLCHORUS INC.; City/State: Houston, TX; Project number: 5R44TR005137-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-08; FY total cost (award amount): 1034752; Administering IC: National Center for Advancing Translational Sciences; Project title: Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing; Organization type: Domestic For-Profits
| Sep 14, 2026 | NIH RePORTER 1SB1GM163323-01 |
| Infixion Bioscience Inc. | NIH awarded $479K (SBIR Phase I 1R43NS147645-01, new, notice Aug 26, 2026).Evidence (1 event)- Aug 26, 2026 · NIH RePORTER 1R43NS147645-01
Organization: INFIXION BIOSCIENCE, INC.; City/State: ESCONDIDO, CA; Project number: 1R43NS147645-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 478799; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Selection of a Lead Candidate for the Development of an ASO Therapeutic for NF1 Cognitive and Social Deficits; Organization type: Domestic For-Profits
| Aug 26, 2026 | NIH RePORTER 1R43NS147645-01 |
| PopCheck Technologies | NIH awarded $391K (SBIR Phase I 1R43HL184749-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43HL184749-01
Organization: POPCHECK TECHNOLOGIES INC; City/State: MEMPHIS, TN; Project number: 1R43HL184749-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 390966; Administering IC: National Heart Lung and Blood Institute; Project title: A Non-invasive Wearable Device for Monitoring and Predicting the Development of Venous Clots; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43HL184749-01 |
| Integrated Medical Sensors | NIH awarded $923K (SBIR Phase II 1R44DK146647-01, new, notice Aug 25, 2026).Evidence (1 event)- Aug 25, 2026 · NIH RePORTER 1R44DK146647-01
Organization: INTEGRATED MEDICAL SENSORS; City/State: IRVINE, CA; Project number: 1R44DK146647-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 922875; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A Miniaturized and Flexible Continuous Glucose Monitoring Platform using Scalable Semiconductor Manufacturing; Organization type: Domestic For-Profits
| Aug 25, 2026 | NIH RePORTER 1R44DK146647-01 |
| Monod Bio | NIH awarded $377K (SBIR Phase II 1R44GM161195-01A1, new, notice Aug 3, 2026); 2 NIH awards totaling $708K in the last 12 months.Evidence (2 events)- Aug 3, 2026 · NIH RePORTER 1R44GM161195-01A1
Organization: MONOD BIO, INC.; City/State: SEATTLE, WA; Project number: 1R44GM161195-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 377260; Administering IC: National Institute of General Medical Sciences; Project title: Design of rapid and quantitative biosensors with computational protein design; Organization type: Domestic For-Profits - Jul 23, 2026 · NIH RePORTER 1R43GM163512-01
Organization: MONOD BIO, INC.; City/State: SEATTLE, WA; Project number: 1R43GM163512-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-23; FY total cost (award amount): 330955; Administering IC: National Institute of General Medical Sciences; Project title: Computational Protein Design of Robust and Scalable Recombinant HRP and Poly-HRP Reagents; Organization type: Domestic For-Profits
| Aug 3, 2026 | NIH RePORTER 1R44GM161195-01A1 |
| Unandup, LLC | NIH awarded $406K (SBIR Phase I 1R43CA310649-01, new, notice Sep 1, 2026); 2 NIH awards totaling $695K in the last 12 months.Evidence (2 events)- Sep 1, 2026 · NIH RePORTER 1R43CA310649-01
Organization: UNANDUP, LLC; City/State: SAINT LOUIS, MO; Project number: 1R43CA310649-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 405753; Administering IC: National Cancer Institute; Project title: Improved Magnetomotive Embolization for Hepatocellular Carcinoma; Organization type: Domestic For-Profits - May 12, 2026 · NIH RePORTER 5R43HL178364-02
Organization: UNANDUP, LLC; City/State: SAINT LOUIS, MO; Project number: 5R43HL178364-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 289177; Administering IC: National Heart Lung and Blood Institute; Project title: Magnetic Rotational Platform for Coronary Lesions; Organization type: Domestic For-Profits
| Sep 1, 2026 | NIH RePORTER 1R43CA310649-01 |
| Primrose Bio | NIH awarded $952K (SBIR Phase II 1R44TR006096-01, new, notice Jul 8, 2026).Evidence (1 event)- Jul 8, 2026 · NIH RePORTER 1R44TR006096-01
Organization: PRIMROSE BIO, INC.; City/State: SAN DIEGO, CA; Project number: 1R44TR006096-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-08; FY total cost (award amount): 951630; Administering IC: National Center for Advancing Translational Sciences; Project title: Enhanced nucleic acid therapeutics: synthetic sequence elements for boosting protein expression in genetic medicines; Organization type: Domestic For-Profits
| Jul 8, 2026 | NIH RePORTER 1R44TR006096-01 |
| Makani Science | NIH awarded $363K (NIH grant 5R61HL177500-02, continuation, notice May 7, 2026).Evidence (1 event)- May 7, 2026 · NIH RePORTER 5R61HL177500-02
Organization: MAKANI SCIENCE, INC.; City/State: IRVINE, CA; Project number: 5R61HL177500-02; Activity code: R61; Fiscal year: 2026; Award notice date: 2026-05-07; FY total cost (award amount): 362934; Administering IC: National Heart Lung and Blood Institute; Project title: Continuous Respiratory Monitoring Platform for Classifying Apnea of Prematurity; Organization type: Domestic For-Profits
| May 7, 2026 | NIH RePORTER 5R61HL177500-02 |
| Accelevir Diagnostics LLC | NIH awarded $532K (NIH grant 3R24AI143502-07S1, supplement, notice Sep 17, 2026); 2 NIH awards totaling $1.3M in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 3R24AI143502-07S1
Organization: ACCELEVIR DIAGNOSTICS, LLC; City/State: BALTIMORE, MD; Project number: 3R24AI143502-07S1; Activity code: R24; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 531874; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Centralized Resource to Accurately Quantify Latent and Expressed HIVReservoirs; Organization type: Domestic For-Profits - May 14, 2026 · NIH RePORTER 5R24AI143502-07
Organization: ACCELEVIR DIAGNOSTICS, LLC; City/State: BALTIMORE, MD; Project number: 5R24AI143502-07; Activity code: R24; Fiscal year: 2026; Award notice date: 2026-05-14; FY total cost (award amount): 764899; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Centralized Resource to Accurately Quantify Latent and Expressed HIVReservoirs; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 3R24AI143502-07S1 |
| Link Biosystems Inc. | NIH awarded $781K (SBIR Phase II 5R44CA281356-03, continuation, notice Jul 7, 2026).Evidence (1 event)- Jul 7, 2026 · NIH RePORTER 5R44CA281356-03
Organization: LINK BIOSYSTEMS INC.; City/State: IRVINGTON, NY; Project number: 5R44CA281356-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 780952; Administering IC: National Cancer Institute; Project title: CELL EXPANSION BIOREACTORS FOR ASSAY-READY IMMUNOCOMPETENT PATIENT MODELS; Organization type: Domestic For-Profits
| Jul 7, 2026 | NIH RePORTER 5R44CA281356-03 |
| Endomet Biosciences, Inc. | NIH awarded $2.05M (SBIR commercialization 5SB1HD118921-02, continuation, notice May 12, 2026).Evidence (1 event)- May 12, 2026 · NIH RePORTER 5SB1HD118921-02
Organization: ENDOMET BIOSCIENCES, INC; City/State: Irvine, CA; Project number: 5SB1HD118921-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 2045762; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Novel, Non-hormonal Therapeutic for Endometriosis; Organization type: Domestic For-Profits
| May 12, 2026 | NIH RePORTER 5SB1HD118921-02 |
| Biosensing Instrument Inc. | NIH awarded $921K (STTR Phase II 5R42GM154550-03, continuation, notice Jul 22, 2026); 2 NIH awards totaling $1.73M in the last 12 months.Evidence (2 events)- Jul 22, 2026 · NIH RePORTER 5R42GM154550-03
Organization: BIOSENSING INSTRUMENT, INC.; City/State: TEMPE, AZ; Project number: 5R42GM154550-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 920788; Administering IC: National Institute of General Medical Sciences; Project title: Plasmonic Scattering Microscopy for high-throughput in-situ quantification of molecular binding kinetics on single cells; Organization type: Domestic For-Profits - Jul 20, 2026 · NIH RePORTER 4R42GM157918-02
Organization: BIOSENSING INSTRUMENT, INC.; City/State: TEMPE, AZ; Project number: 4R42GM157918-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 807496; Administering IC: National Institute of General Medical Sciences; Project title: Spotting-free Nano-Oscillator Array for Quantification of Virion Displayed Membrane Protein Binding Kinetics; Organization type: Domestic For-Profits
| Jul 22, 2026 | NIH RePORTER 5R42GM154550-03 |
| IRIS Media Inc | NIH awarded $789K (SBIR Phase II 5R44HD111084-03, continuation, notice May 25, 2026).Evidence (1 event)- May 25, 2026 · NIH RePORTER 5R44HD111084-03
Organization: IRIS MEDIA, INC.; City/State: EUGENE, OR; Project number: 5R44HD111084-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-25; FY total cost (award amount): 789175; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Promoting Parallel Parenting: Putting Children First during High-Conflict Divorce and Separation (PCF); Organization type: Domestic For-Profits
| May 25, 2026 | NIH RePORTER 5R44HD111084-03 |
| Allander Biotechnologies | NIH awarded $1.21M (SBIR Phase II 1R44DE034643-01A1, new, notice Sep 17, 2026); 2 NIH awards totaling $2.28M in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 1R44DE034643-01A1
Organization: ALLANDER BIOTECHNOLOGIES, INC.; City/State: AURORA, CO; Project number: 1R44DE034643-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1210798; Administering IC: National Institute of Dental and Craniofacial Research; Project title: cGMP manufacturing the clinical batch of oral gel drug for treating oral mucositis in cancer patients; Organization type: Domestic For-Profits - Sep 14, 2026 · NIH RePORTER 5R44CA310522-02
Organization: ALLANDER BIOTECHNOLOGIES, INC.; City/State: AURORA, CO; Project number: 5R44CA310522-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1066148; Administering IC: National Cancer Institute; Project title: First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44DE034643-01A1 |
| Nextgenjane Inc. | NIH awarded $714K (SBIR Phase II 5R44HD118899-02, continuation, notice May 12, 2026).Evidence (1 event)- May 12, 2026 · NIH RePORTER 5R44HD118899-02
Organization: NEXTGENJANE, INC.; City/State: Oakland, CA; Project number: 5R44HD118899-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 714095; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Performance evaluation of a non-invasive menstrual test for endometriosis in infertility patients; Organization type: Domestic For-Profits
| May 12, 2026 | NIH RePORTER 5R44HD118899-02 |
| Sensydia | NIH awarded $816K (STTR Phase II 5R42HL167342-03, continuation, notice May 13, 2026).Evidence (1 event)- May 13, 2026 · NIH RePORTER 5R42HL167342-03
Organization: SENSYDIA CORPORATION; City/State: LOS ANGELES, CA; Project number: 5R42HL167342-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 816106; Administering IC: National Heart Lung and Blood Institute; Project title: A non-invasive, automated platform for hemodynamic assessment of patients at risk of heart failure or pulmonary hypertension; Organization type: Domestic For-Profits
| May 13, 2026 | NIH RePORTER 5R42HL167342-03 |
| Covira Surgical | NIH awarded $1M (STTR Phase II 5R42AI174369-03, continuation, notice May 26, 2026).Evidence (1 event)- May 26, 2026 · NIH RePORTER 5R42AI174369-03
Organization: COVIRA SURGICAL; City/State: NORTH CHICAGO, IL; Project number: 5R42AI174369-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection; Organization type: Domestic For-Profits
| May 26, 2026 | NIH RePORTER 5R42AI174369-03 |
| Akyso Therapeutics | NIH awarded $2.93M (NIH grant 5UG3DA062511-02, continuation, notice Aug 4, 2026); 2 NIH awards totaling $5.65M in the last 12 months.Evidence (2 events)- Aug 4, 2026 · NIH RePORTER 5UG3DA062511-02
Organization: AKYSO THERAPEUTICS, LLC; City/State: SALISBURY, MD; Project number: 5UG3DA062511-02; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 2932500; Administering IC: National Institute on Drug Abuse; Project title: Development of a bioabsorbable, subcutaneous, extended-release buprenorphine implant for opioid use disorder; Organization type: Domestic For-Profits - Jun 11, 2026 · NIH RePORTER 5UH3DA048338-05
Organization: AKYSO THERAPEUTICS, LLC; City/State: SALISBURY, MD; Project number: 5UH3DA048338-05; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 2715203; Administering IC: National Institute on Drug Abuse; Project title: A Long-Acting Bioabsorbable Naltrexone Subcutaneous Implant for Opioid Use Disorder; Organization type: Domestic For-Profits
| Aug 4, 2026 | NIH RePORTER 5UG3DA062511-02 |
| ProThera Biologics | NIH awarded $954K (SBIR Phase II 5R44AI141283-06, continuation, notice May 13, 2026).Evidence (1 event)- May 13, 2026 · NIH RePORTER 5R44AI141283-06
Organization: PROTHERA BIOLOGICS, LLC; City/State: PROVIDENCE, RI; Project number: 5R44AI141283-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 954189; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Rapid Test to Assist Therapy in Neonatal Sepsis and Necrotizing Enterocolitis; Organization type: Domestic For-Profits
| May 13, 2026 | NIH RePORTER 5R44AI141283-06 |
| Nanoscope Technologies | NIH awarded $786K (NIH grant 5U01EY035026-03, continuation, notice May 13, 2026).Evidence (1 event)- May 13, 2026 · NIH RePORTER 5U01EY035026-03
Organization: NANOSCOPE TECHNOLOGIES, LLC; City/State: ARLINGTON, TX; Project number: 5U01EY035026-03; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 785718; Administering IC: National Eye Institute; Project title: Sonogenetic Restoration of Vision for Retinitis Pigmentosa; Organization type: Domestic For-Profits
| May 13, 2026 | NIH RePORTER 5U01EY035026-03 |
| Progentec Diagnostics | NIH awarded $895K (SBIR commercialization 5SB1AI184309-03, continuation, notice Jun 12, 2026).Evidence (1 event)- Jun 12, 2026 · NIH RePORTER 5SB1AI184309-03
Organization: PROGENTEC DIAGNOSTICS, INC.; City/State: Oklahoma City, OK; Project number: 5SB1AI184309-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-06-12; FY total cost (award amount): 895140; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Commercialization Readiness of Immune Mediator Based Blood Tests that Inform Concurrent and Future Clinical Disease Activity in Systemic Lupus Erythematosus (SLE); Organization type: Domestic For-Profits
| Jun 12, 2026 | NIH RePORTER 5SB1AI184309-03 |
| GMJ Technologies, Inc. | NIH awarded $902K (SBIR Phase II 5R44GM156142-03, continuation, notice May 12, 2026).Evidence (1 event)- May 12, 2026 · NIH RePORTER 5R44GM156142-03
Organization: GMJ TECHNOLOGIES, INC.; City/State: EVERETT, WA; Project number: 5R44GM156142-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 902099; Administering IC: National Institute of General Medical Sciences; Project title: High-Resolution Native Capillary Zone Electrophoresis with Inline UV and Native Mass Spectrometry for Characterizing Charge Variants in Biologics; Organization type: Domestic For-Profits
| May 12, 2026 | NIH RePORTER 5R44GM156142-03 |
| Thymmune Therapeutics | NIH awarded $1M (SBIR Phase II 5R44AI170266-05, continuation, notice Jun 5, 2026).Evidence (1 event)- Jun 5, 2026 · NIH RePORTER 5R44AI170266-05
Organization: THYMMUNE THERAPEUTICS, INC; City/State: CAMBRIDGE, MA; Project number: 5R44AI170266-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-05; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a stem-cell derived thymic cell therapy to treat patients with athymia; Organization type: Domestic For-Profits
| Jun 5, 2026 | NIH RePORTER 5R44AI170266-05 |
| Axonova Medical | NIH awarded $903K (SBIR Phase II 5R44NS125892-04, continuation, notice Jun 11, 2026).Evidence (1 event)- Jun 11, 2026 · NIH RePORTER 5R44NS125892-04
Organization: AXONOVA MEDICAL, LLC; City/State: PHILADELPHIA, PA; Project number: 5R44NS125892-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 902542; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of Tissue Engineered Neuromuscular Interfaces from GalSafe Neurons; Organization type: Domestic For-Profits
| Jun 11, 2026 | NIH RePORTER 5R44NS125892-04 |
| Moonlight Therapeutics, Inc. | NIH awarded $1M (SBIR Phase II 5U44AI165328-03, continuation, notice Jun 8, 2026); 2 NIH awards totaling $2M in the last 12 months.Evidence (2 events)- Jun 8, 2026 · NIH RePORTER 5U44AI165328-03
Organization: MOONLIGHT THERAPEUTICS, INC.; City/State: Marietta, GA; Project number: 5U44AI165328-03; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-06-08; FY total cost (award amount): 999927; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy; Organization type: Domestic For-Profits - May 28, 2026 · NIH RePORTER 5SB1AI184000-03
Organization: MOONLIGHT THERAPEUTICS, INC.; City/State: Marietta, GA; Project number: 5SB1AI184000-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-05-28; FY total cost (award amount): 999380; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Scale-up manufacturing of microneedle stamp for peanut allergen immunotherapy; Organization type: Domestic For-Profits
| Jun 8, 2026 | NIH RePORTER 5U44AI165328-03 |
| Jacaranda Biosciences, Inc. | NIH awarded $1.44M (SBIR Phase II 5R44DC020069-03, continuation, notice Jul 16, 2026).Evidence (1 event)- Jul 16, 2026 · NIH RePORTER 5R44DC020069-03
Organization: JACARANDA BIOSCIENCES, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44DC020069-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 1436795; Administering IC: National Institute on Deafness and Other Communication Disorders; Project title: eiF2B Activators to Treat Noise-Induced Hearing Loss; Organization type: Domestic For-Profits
| Jul 16, 2026 | NIH RePORTER 5R44DC020069-03 |
| 3DT Holdings, LLC | NIH awarded $1.05M (SBIR Phase II 5R44HL169034-03, continuation, notice Jun 9, 2026).Evidence (1 event)- Jun 9, 2026 · NIH RePORTER 5R44HL169034-03
Organization: 3DT HOLDINGS, LLC; City/State: SAN DIEGO, CA; Project number: 5R44HL169034-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 1050048; Administering IC: National Heart Lung and Blood Institute; Project title: Software-guided Operative Planning of MitraClip Placement; Organization type: Domestic For-Profits
| Jun 9, 2026 | NIH RePORTER 5R44HL169034-03 |
| Insilica LLC | NIH awarded $1.01M (SBIR Phase II 5R44ES035359-03, continuation, notice May 11, 2026).Evidence (1 event)- May 11, 2026 · NIH RePORTER 5R44ES035359-03
Organization: INSILICA, LLC; City/State: Bethesda, MD; Project number: 5R44ES035359-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-11; FY total cost (award amount): 1005398; Administering IC: National Institute of Environmental Health Sciences; Project title: srvc-EHSR: Sysrev Version Control - Environmental and Health Related Systematic Reviews; Organization type: Domestic For-Profits
| May 11, 2026 | NIH RePORTER 5R44ES035359-03 |
| Microsurgical Innovations Inc | NIH awarded $1.01M (STTR Phase II 5R42NS112066-03, continuation, notice May 19, 2026).Evidence (1 event)- May 19, 2026 · NIH RePORTER 5R42NS112066-03
Organization: MICROSURGICAL INNOVATIONS, INC.; City/State: SALT LAKE CITY, UT; Project number: 5R42NS112066-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 1005546; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Tacrolimus-eluting nerve guidance conduit for enhanced regeneration in critical-sized peripheral nerve injuries; Organization type: Domestic For-Profits
| May 19, 2026 | NIH RePORTER 5R42NS112066-03 |
| MicroCures Inc. | NIH awarded $236K (STTR Phase I 5R41NS137941-02, continuation, notice May 18, 2026).Evidence (1 event)- May 18, 2026 · NIH RePORTER 5R41NS137941-02
Organization: MICROCURES, INC.; City/State: SANTA CRUZ, CA; Project number: 5R41NS137941-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-05-18; FY total cost (award amount): 235898; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Promoting tissue repair and functional recovery after spinal cord injury by targeting the microtubule regulatory protein Fidgetin-like 2.; Organization type: Domestic For-Profits
| May 18, 2026 | NIH RePORTER 5R41NS137941-02 |
| Hepatx Corporation | NIH awarded $149K (SBIR Phase I 5R43DK139879-02, continuation, notice Jun 23, 2026).Evidence (1 event)- Jun 23, 2026 · NIH RePORTER 5R43DK139879-02
Organization: HEPATX CORPORATION; City/State: PALO ALTO, CA; Project number: 5R43DK139879-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 149068; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a proteomic assay for monitoring transplanted cells and tissues; Organization type: Domestic For-Profits
| Jun 23, 2026 | NIH RePORTER 5R43DK139879-02 |
| Belay Diagnostics, LLC | NIH awarded $919K (STTR Phase II 5R42NS135834-03, continuation, notice Jul 15, 2026); 1 role open.Evidence (1 event)- Jul 15, 2026 · NIH RePORTER 5R42NS135834-03
Organization: BELAY DIAGNOSTICS, LLC; City/State: Chicago, IL; Project number: 5R42NS135834-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-07-15; FY total cost (award amount): 919093; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Multi-omic CSF Assay for the Diagnosis of Brain Cancers; Organization type: Domestic For-Profits
| Jul 15, 2026 | NIH RePORTER 5R42NS135834-03 |
| POP Biotechnologies Inc. | NIH awarded $310K (STTR Phase I 1R41HL184798-01A1, new, notice Jul 31, 2026); 3 NIH awards totaling $2.08M in the last 12 months.Evidence (3 events)- Jul 31, 2026 · NIH RePORTER 1R41HL184798-01A1
Organization: POP BIOTECHNOLOGIES, INC; City/State: BUFFALO, NY; Project number: 1R41HL184798-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-07-31; FY total cost (award amount): 309794; Administering IC: National Heart Lung and Blood Institute; Project title: Liposome-displayed ApoB fragment for active immunotherapy against atherosclerosis; Organization type: Domestic For-Profits - Jun 26, 2026 · NIH RePORTER 5R44AI181479-03
Organization: POP BIOTECHNOLOGIES, INC; City/State: BUFFALO, NY; Project number: 5R44AI181479-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-26; FY total cost (award amount): 948983; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment; Organization type: Domestic For-Profits - Jun 25, 2026 · NIH RePORTER 5R42AG082620-04
Organization: POP BIOTECHNOLOGIES, INC; City/State: BUFFALO, NY; Project number: 5R42AG082620-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 822289; Administering IC: National Institute on Aging; Project title: Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes; Organization type: Domestic For-Profits
| Jul 31, 2026 | NIH RePORTER 1R41HL184798-01A1 |
| Noctrix Health, Inc. | NIH awarded $1.32M (SBIR Phase II 5R44NS117294-05, continuation, notice May 19, 2026); since then posted 11 roles.Evidence (1 event)- May 19, 2026 · NIH RePORTER 5R44NS117294-05
Organization: NOCTRIX HEALTH, INC; City/State: Pleasanton, CA; Project number: 5R44NS117294-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 1324304; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Developing closed-loop tonic motor activation therapy for treatment of refractory restless legs syndrome; Organization type: Domestic For-Profits
| May 19, 2026 | NIH RePORTER 5R44NS117294-05 |
| Turing Medical | NIH awarded $1.25M (SBIR Phase II 4R44AG097349-02, extension, notice Aug 27, 2026); 2 NIH awards totaling $2.59M in the last 12 months.Evidence (2 events)- Aug 27, 2026 · NIH RePORTER 4R44AG097349-02
Organization: TURING MEDICAL TECHNOLOGIES INC; City/State: SAINT LOUIS, MO; Project number: 4R44AG097349-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 1245404; Administering IC: National Institute on Aging; Project title: Real-time head motion monitoring for all clinical MR sequences using Universal FIRMM; Organization type: Domestic For-Profits - Jun 9, 2026 · NIH RePORTER 5SB1MH135555-03
Organization: TURING MEDICAL TECHNOLOGIES INC; City/State: SAINT LOUIS, MO; Project number: 5SB1MH135555-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 1346397; Administering IC: National Institute of Mental Health; Project title: Commercialization readiness of motion-robust brain MRI for pediatric healthcare; Organization type: Domestic For-Profits
| Aug 27, 2026 | NIH RePORTER 4R44AG097349-02 |
| Spike Neuro LLC | NIH awarded $1.69M (SBIR Phase II 1R44NS145912-01A1, new, notice Sep 18, 2026); 2 NIH awards totaling $1.87M in the last 12 months.Evidence (2 events)- Sep 18, 2026 · NIH RePORTER 1R44NS145912-01A1
Organization: SPIKE NEURO LLC; City/State: ANN ARBOR, MI; Project number: 1R44NS145912-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 1693866; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Advancing High-Density Carbon Fiber Electrode Arrays for Commercial Neurotechnology Applications; Organization type: Domestic For-Profits - Aug 18, 2026 · NIH RePORTER 5R41MH141906-02
Organization: SPIKE NEURO LLC; City/State: ANN ARBOR, MI; Project number: 5R41MH141906-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 173801; Administering IC: National Institute of Mental Health; Project title: The development of a flexible carbon fiber penetrating nerve cuff and cortical array for neural recording, stimulation, and neurochemical detection; Organization type: Domestic For-Profits
| Sep 18, 2026 | NIH RePORTER 1R44NS145912-01A1 |
| MyoGene Bio | NIH awarded $498K (SBIR commercialization 5SB1AR084953-02, continuation, notice Jul 9, 2026); 2 NIH awards totaling $1.48M in the last 12 months.Evidence (2 events)- Jul 9, 2026 · NIH RePORTER 5SB1AR084953-02
Organization: MYOGENE BIO, LLC; City/State: San Diego, CA; Project number: 5SB1AR084953-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-09; FY total cost (award amount): 498365; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Advancing manufacturing and release testing of a gene editing therapy for Duchenne muscular dystrophy; Organization type: Domestic For-Profits - May 13, 2026 · NIH RePORTER 5R44NS141438-05
Organization: MYOGENE BIO, LLC; City/State: San Diego, CA; Project number: 5R44NS141438-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-13; FY total cost (award amount): 978397; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy; Organization type: Domestic For-Profits
| Jul 9, 2026 | NIH RePORTER 5SB1AR084953-02 |
| Sur180 Therapeutics, Inc. | NIH awarded $1.14M (SBIR Phase II 5R44HD109055-03, continuation, notice Jun 3, 2026).Evidence (1 event)- Jun 3, 2026 · NIH RePORTER 5R44HD109055-03
Organization: SUR180 THERAPEUTICS, LLC; City/State: MCALLEN, TX; Project number: 5R44HD109055-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1140501; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Phase II- Repurposing CRH antagonists for the treatment of endometriosis; Organization type: Domestic For-Profits
| Jun 3, 2026 | NIH RePORTER 5R44HD109055-03 |
| RareCyte | NIH awarded $658K (SBIR Phase II 5R44CA298064-02, continuation, notice Jul 17, 2026).Evidence (1 event)- Jul 17, 2026 · NIH RePORTER 5R44CA298064-02
Organization: RARECYTE, INC.; City/State: SEATTLE, WA; Project number: 5R44CA298064-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 658336; Administering IC: National Cancer Institute; Project title: Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis; Organization type: Domestic For-Profits
| Jul 17, 2026 | NIH RePORTER 5R44CA298064-02 |
| Allvivo Vascular | NIH awarded $1M (SBIR Phase II 5R44AI136195-06, continuation, notice Jul 16, 2026).Evidence (1 event)- Jul 16, 2026 · NIH RePORTER 5R44AI136195-06
Organization: ALLVIVO VASCULAR, INC.; City/State: LAKE FOREST, CA; Project number: 5R44AI136195-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 999999; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Antimicrobial Treatment to Combat Wound Biofilm; Organization type: Domestic For-Profits
| Jul 16, 2026 | NIH RePORTER 5R44AI136195-06 |
| Stress Therapeutics, Inc. | NIH awarded $995K (SBIR Phase I 5U43AA032129-02, continuation, notice May 18, 2026).Evidence (1 event)- May 18, 2026 · NIH RePORTER 5U43AA032129-02
Organization: STRESS THERAPEUTICS, INC.; City/State: SAN DIEGO, CA; Project number: 5U43AA032129-02; Activity code: U43; Fiscal year: 2026; Award notice date: 2026-05-18; FY total cost (award amount): 995447; Administering IC: National Institute on Alcohol Abuse and Alcoholism; Project title: Investigational New Drug (IND)-enabling Study for a New Therapeutic for Alcohol Use Disorder (AUD); Organization type: Domestic For-Profits
| May 18, 2026 | NIH RePORTER 5U43AA032129-02 |
| Synapticure Inc. | NIH awarded $1.25M (SBIR Phase II 5R44NS143521-02, continuation, notice May 26, 2026).Evidence (1 event)- May 26, 2026 · NIH RePORTER 5R44NS143521-02
Organization: SYNAPTICURE, INC.; City/State: KENILWORTH, IL; Project number: 5R44NS143521-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 1246192; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: 3D in vitro model of genetic and sporadic FTD: accelerating novel therapeutic development; Organization type: Domestic For-Profits
| May 26, 2026 | NIH RePORTER 5R44NS143521-02 |
| MiNK Therapeutics | NIH awarded $307K (STTR Phase I 5R41AI192061-02, continuation, notice May 22, 2026).Evidence (1 event)- May 22, 2026 · NIH RePORTER 5R41AI192061-02
Organization: MINK THERAPEUTICS INC; City/State: NEW YORK, NY; Project number: 5R41AI192061-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-05-22; FY total cost (award amount): 306500; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Developing allogeneic iNKT cell adoptive therapy to improve outcomes for HSCT indications; Organization type: Domestic For-Profits
| May 22, 2026 | NIH RePORTER 5R41AI192061-02 |
| Northstar Genomics, LLC | NIH awarded $98K (STTR Phase I 5R41AR086049-02, continuation, notice Aug 17, 2026); 2 NIH awards totaling $368K in the last 12 months.Evidence (2 events)- Aug 17, 2026 · NIH RePORTER 5R41AR086049-02
Organization: NORTHSTAR GENOMICS, LLC; City/State: EAGAN, MN; Project number: 5R41AR086049-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-17; FY total cost (award amount): 98483; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Novel approaches to humanized skeletal muscle in pig; Organization type: Domestic For-Profits - Jun 16, 2026 · NIH RePORTER 5R41HL174447-02
Organization: NORTHSTAR GENOMICS, LLC; City/State: EAGAN, MN; Project number: 5R41HL174447-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 269750; Administering IC: National Heart Lung and Blood Institute; Project title: Bioengineering strategies for exogenic organ production; Organization type: Domestic For-Profits
| Aug 17, 2026 | NIH RePORTER 5R41AR086049-02 |
| Syntis Bio Inc. | NIH awarded $917K (SBIR Phase II 5R44DK141341-03, continuation, notice Aug 10, 2026); 2 NIH awards totaling $2.11M in the last 12 months.Evidence (2 events)- Aug 10, 2026 · NIH RePORTER 5R44DK141341-03
Organization: SYNTIS BIO INC; City/State: Boston, MA; Project number: 5R44DK141341-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 916664; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of an Oral Pill to Mimic the Effects of Gastric Bypass Surgery; Organization type: Domestic For-Profits - May 26, 2026 · NIH RePORTER 5R44DK138869-03
Organization: SYNTIS BIO INC; City/State: Boston, MA; Project number: 5R44DK138869-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 1190375; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Polymer Epithelial Lining for the Oral Delivery of Macromolecules; Organization type: Domestic For-Profits
| Aug 10, 2026 | NIH RePORTER 5R44DK141341-03 |
| TissueVision | NIH awarded $1.44M (SBIR Phase II 5R44MH129132-04, continuation, notice Jul 20, 2026).Evidence (1 event)- Jul 20, 2026 · NIH RePORTER 5R44MH129132-04
Organization: TISSUEVISION, INC.; City/State: Newton, MA; Project number: 5R44MH129132-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 1438419; Administering IC: National Institute of Mental Health; Project title: The Development of Tabletop Brain-Mapping Platform; Organization type: Domestic For-Profits
| Jul 20, 2026 | NIH RePORTER 5R44MH129132-04 |
| DoseOptics LLC | NIH awarded $999K (SBIR Phase II 5R44CA232879-06, continuation, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 5R44CA232879-06
Organization: DOSEOPTICS, LLC; City/State: LEBANON, NH; Project number: 5R44CA232879-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 998974; Administering IC: National Cancer Institute; Project title: DoseRT™ : A Non-Contact Optical Patient and Beam Dosimetry System for Continuous in vivo Radiotherapy Verification; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R44CA232879-06 |
| Spatial Genomics, Inc. | NIH awarded $1.24M (SBIR Phase II 5R44MH140731-02, continuation, notice May 22, 2026).Evidence (1 event)- May 22, 2026 · NIH RePORTER 5R44MH140731-02
Organization: SPATIAL GENOMICS, INC.; City/State: Pasadena, CA; Project number: 5R44MH140731-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-22; FY total cost (award amount): 1244076; Administering IC: National Institute of Mental Health; Project title: Next generation spatial genomics tools for the human brain; Organization type: Domestic For-Profits
| May 22, 2026 | NIH RePORTER 5R44MH140731-02 |
| CG Scientific | NIH awarded $765K (SBIR Phase II 5R44GM139391-03, continuation, notice Jun 3, 2026).Evidence (1 event)- Jun 3, 2026 · NIH RePORTER 5R44GM139391-03
Organization: CG SCIENTIFIC, INC.; City/State: WORCESTER, MA; Project number: 5R44GM139391-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 765267; Administering IC: National Institute of General Medical Sciences; Project title: Low-Cost Platform Technology for Rapid Isolation of Peripheral Blood Mononuclear Cells; Organization type: Domestic For-Profits
| Jun 3, 2026 | NIH RePORTER 5R44GM139391-03 |
| SimplusDx, Inc. | NIH awarded $532K (NIH grant 1R01CA310960-01, new, notice Jun 18, 2026).Evidence (1 event)- Jun 18, 2026 · NIH RePORTER 1R01CA310960-01
Organization: SIMPLUSDX, INC.; City/State: DURHAM, NC; Project number: 1R01CA310960-01; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-06-18; FY total cost (award amount): 532105; Administering IC: National Cancer Institute; Project title: Development and validation of a point-of-need screening test for hepatocellular carcinoma; Organization type: Domestic For-Profits
| Jun 18, 2026 | NIH RePORTER 1R01CA310960-01 |
| Electronic Biosciences, Inc. | NIH awarded $466K (NIH grant 1R21GM165253-01, new, notice Sep 14, 2026); 3 NIH awards totaling $1.36M in the last 12 months.Evidence (3 events)- Sep 14, 2026 · NIH RePORTER 1R21GM165253-01
Organization: ELECTRONIC BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 1R21GM165253-01; Activity code: R21; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 466291; Administering IC: National Institute of General Medical Sciences; Project title: Enabling Protein Sequencing Through Friction-Mediated Nanopore Transport; Organization type: Domestic For-Profits - Sep 10, 2026 · NIH RePORTER 1R21HD121871-01
Organization: ELECTRONIC BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 1R21HD121871-01; Activity code: R21; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 472706; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: High-Fidelity Nanopore Sequencing of CGG Repeats and Methylation in the FMR1 Gene; Organization type: Domestic For-Profits - Jun 9, 2026 · NIH RePORTER 1R21CA304932-01A1
Organization: ELECTRONIC BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 1R21CA304932-01A1; Activity code: R21; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 418854; Administering IC: National Cancer Institute; Project title: Next-Generation Oncoproteomic Sequencing and Precision Profiling; Organization type: Domestic For-Profits
| Sep 14, 2026 | NIH RePORTER 1R21GM165253-01 |
| Velorum Therapeutics | NIH awarded $1.26M (SBIR Phase II 5R44CA291444-02, continuation, notice Aug 6, 2026).Evidence (1 event)- Aug 6, 2026 · NIH RePORTER 5R44CA291444-02
Organization: VELORUM THERAPEUTICS INC.; City/State: PLANO, TX; Project number: 5R44CA291444-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 1258345; Administering IC: National Cancer Institute; Project title: VEL-03: IND-enabling development of a novel therapeutic approach for treatment of non-small cell lung cancer and other solid tumors; Organization type: Domestic For-Profits
| Aug 6, 2026 | NIH RePORTER 5R44CA291444-02 |
| Cortechs Labs, Inc. | NIH awarded $933K (SBIR Phase II 5R44AG079694-03, continuation, notice May 7, 2026).Evidence (1 event)- May 7, 2026 · NIH RePORTER 5R44AG079694-03
Organization: CORTECHS LABS, INC.; City/State: San Diego, CA; Project number: 5R44AG079694-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-07; FY total cost (award amount): 932694; Administering IC: National Institute on Aging; Project title: Quantification of ARIA During the Treatment of Alzheimer's Patients; Organization type: Domestic For-Profits
| May 7, 2026 | NIH RePORTER 5R44AG079694-03 |
| Conifer Point Pharmaceuticals LLC | NIH awarded $1M (SBIR Phase II 5R44GM109549-05, continuation, notice Jun 23, 2026).Evidence (1 event)- Jun 23, 2026 · NIH RePORTER 5R44GM109549-05
Organization: CONIFER POINT PHARMACEUTICALS, LLC; City/State: DOYLESTOWN, PA; Project number: 5R44GM109549-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 1000000; Administering IC: National Institute of General Medical Sciences; Project title: An Open Web Service For Fragment-based Design of Small Molecule Inhibitors; Organization type: Domestic For-Profits
| Jun 23, 2026 | NIH RePORTER 5R44GM109549-05 |
| Kathera Bioscience Inc. | NIH awarded $995K (SBIR Phase II 5R44AI181163-03, continuation, notice May 25, 2026).Evidence (1 event)- May 25, 2026 · NIH RePORTER 5R44AI181163-03
Organization: KATHERA BIOSCIENCE INC.; City/State: UNION, NJ; Project number: 5R44AI181163-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-25; FY total cost (award amount): 995100; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Novel Broad Spectrum Inhibitors of Dihydrofolate Reductase (DHFR) for Treatment of Infections from High Threat Fungal Pathogens; Organization type: Domestic For-Profits
| May 25, 2026 | NIH RePORTER 5R44AI181163-03 |
| Salimetrics, LLC | NIH awarded $214K (SBIR Phase I 1R43MD021487-01, new, notice Aug 10, 2026).Evidence (1 event)- Aug 10, 2026 · NIH RePORTER 1R43MD021487-01
Organization: SALIMETRICS, LLC; City/State: STATE COLLEGE, PA; Project number: 1R43MD021487-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 213640; Administering IC: National Institute on Minority Health and Health Disparities; Project title: An At Home Dried Saliva Spot (DSS) Test to Determine Insulin Resistance: A Scalable Tool for Early Detection in Underserved Communities; Organization type: Domestic For-Profits
| Aug 10, 2026 | NIH RePORTER 1R43MD021487-01 |
| Media REZ LLC | NIH awarded $696K (SBIR Phase II 5R44CA254637-03, continuation, notice Jun 9, 2026).Evidence (1 event)- Jun 9, 2026 · NIH RePORTER 5R44CA254637-03
Organization: MEDIA REZ, LLC; City/State: WASHINGTON, DC; Project number: 5R44CA254637-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 696092; Administering IC: National Cancer Institute; Project title: Intervention for Chronic Insufficient Sleep in Young Adult Cancer Patients and Survivors; Organization type: Domestic For-Profits
| Jun 9, 2026 | NIH RePORTER 5R44CA254637-03 |
| Altis Biosystems, Inc. | NIH awarded $1M (SBIR Phase II 5R44DK130708-03, continuation, notice May 19, 2026).Evidence (1 event)- May 19, 2026 · NIH RePORTER 5R44DK130708-03
Organization: ALTIS BIOSYSTEMS, INC.; City/State: Durham, NC; Project number: 5R44DK130708-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 1001183; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Mucus and ALI Models of the Human Intestine; Organization type: Domestic For-Profits
| May 19, 2026 | NIH RePORTER 5R44DK130708-03 |
| Kinea Bio, Inc. | NIH awarded $1.02M (SBIR Phase II 4R44AR084978-02, extension, notice Sep 23, 2026); 3 NIH awards totaling $2.42M in the last 12 months.Evidence (3 events)- Sep 23, 2026 · NIH RePORTER 4R44AR084978-02
Organization: KINEA BIO, INC.; City/State: Mukilteo, WA; Project number: 4R44AR084978-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-23; FY total cost (award amount): 1021458; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Scalable Non-viral Gene Delivery for Neuromuscular Diseases; Organization type: Domestic For-Profits - Aug 28, 2026 · NIH RePORTER 1R44HL182563-01A1
Organization: KINEA BIO, INC.; City/State: Mukilteo, WA; Project number: 1R44HL182563-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 599669; Administering IC: National Heart Lung and Blood Institute; Project title: Split-Intein Protein Ligation: Enabling AAV Delivery of Large Genes for Clinical Translation in Genetic Cardiac Diseases; Organization type: Domestic For-Profits - Jun 16, 2026 · NIH RePORTER 5R44AR083801-03
Organization: KINEA BIO, INC.; City/State: Mukilteo, WA; Project number: 5R44AR083801-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 796218; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Development of novel genetic medicine approaches to treat orphan diseases; Organization type: Domestic For-Profits
| Sep 23, 2026 | NIH RePORTER 4R44AR084978-02 |
| InnoTech Precision Medicine, Inc | NIH awarded $365K (SBIR Phase I 1R43DE035900-01, new, notice Sep 4, 2026); 2 NIH awards totaling $1.43M in the last 12 months.Evidence (2 events)- Sep 4, 2026 · NIH RePORTER 1R43DE035900-01
Organization: INNOTECH PRECISION MEDICINE, INC; City/State: BOSTON, MA; Project number: 1R43DE035900-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 365004; Administering IC: National Institute of Dental and Craniofacial Research; Project title: Integrated Multiomics Diagnostics at the Point of Care for Healthy Living; Organization type: Domestic For-Profits - Aug 20, 2026 · NIH RePORTER 5R44DE033312-03
Organization: INNOTECH PRECISION MEDICINE, INC; City/State: BOSTON, MA; Project number: 5R44DE033312-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 1069047; Administering IC: National Institute of Dental and Craniofacial Research; Project title: Point of Care Detection of HPV and P16 in Saliva; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 1R43DE035900-01 |
| Ensysce Biosciences | NIH awarded $5.28M (NIH grant 5U01DA059791-03, continuation, notice Jul 14, 2026).Evidence (1 event)- Jul 14, 2026 · NIH RePORTER 5U01DA059791-03
Organization: ENSYSCE BIOSCIENCES, INC.; City/State: LA JOLLA, CA; Project number: 5U01DA059791-03; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 5279389; Administering IC: National Institute on Drug Abuse; Project title: PF614-MPAR: clinical development of opioid with oral overdose protection; Organization type: Domestic For-Profits
| Jul 14, 2026 | NIH RePORTER 5U01DA059791-03 |
| Plakous Therapeutics | NIH awarded $827K (SBIR Phase II 5R44HD100243-06, continuation, notice Jun 9, 2026).Evidence (1 event)- Jun 9, 2026 · NIH RePORTER 5R44HD100243-06
Organization: PLAKOUS THERAPEUTICS, INC.; City/State: PFAFFTOWN, NC; Project number: 5R44HD100243-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 826522; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: IND Enabling Studies and Manufacturing Scale Up of Human Placental Extract to Prevent Surgical Necrotizing Enterocolitis; Organization type: Domestic For-Profits
| Jun 9, 2026 | NIH RePORTER 5R44HD100243-06 |
| Xylyx Bio | NIH awarded $957K (SBIR Phase II 5R44DK139877-03, continuation, notice Sep 10, 2026); 3 NIH awards totaling $3.44M in the last 12 months.Evidence (3 events)- Sep 10, 2026 · NIH RePORTER 5R44DK139877-03
Organization: XYLYX BIO, INC.; City/State: BROOKLYN, NY; Project number: 5R44DK139877-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 956566; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development; Organization type: Domestic For-Profits - Aug 7, 2026 · NIH RePORTER 5R44HL182545-02
Organization: XYLYX BIO, INC.; City/State: BROOKLYN, NY; Project number: 5R44HL182545-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 1483340; Administering IC: National Heart Lung and Blood Institute; Project title: Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantation; Organization type: Domestic For-Profits - Jul 23, 2026 · NIH RePORTER 5R44CA287881-03
Organization: XYLYX BIO, INC.; City/State: BROOKLYN, NY; Project number: 5R44CA287881-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-23; FY total cost (award amount): 1003395; Administering IC: National Cancer Institute; Project title: Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development; Organization type: Domestic For-Profits
| Sep 10, 2026 | NIH RePORTER 5R44DK139877-03 |
| Biolinq Inc. | NIH awarded $862K (SBIR Phase II 5R44DK129875-05, continuation, notice Jun 11, 2026).Evidence (1 event)- Jun 11, 2026 · NIH RePORTER 5R44DK129875-05
Organization: BIOLINQ INCORPORATED; City/State: San Diego, CA; Project number: 5R44DK129875-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 861567; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes; Organization type: Domestic For-Profits
| Jun 11, 2026 | NIH RePORTER 5R44DK129875-05 |
| Aquinnah Pharmaceuticals | NIH awarded $1.5M (SBIR Phase II 5R44NS141531-02, continuation, notice Sep 2, 2026); 2 NIH awards totaling $2.5M in the last 12 months.Evidence (2 events)- Sep 2, 2026 · NIH RePORTER 5R44NS141531-02
Organization: AQUINNAH PHARMACEUTICALS, INC.; City/State: NEWTON, MA; Project number: 5R44NS141531-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 1499529; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of a novel oral brain penetrant therapeutic for ALS disease; Organization type: Domestic For-Profits - Aug 26, 2026 · NIH RePORTER 5R44AG060843-06
Organization: AQUINNAH PHARMACEUTICALS, INC.; City/State: NEWTON, MA; Project number: 5R44AG060843-06; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 997942; Administering IC: National Institute on Aging; Project title: Development of a novel Alzheimer's disease therapeutic targeting tau; Organization type: Domestic For-Profits
| Sep 2, 2026 | NIH RePORTER 5R44NS141531-02 |
| Gel4Med | NIH awarded $1M (SBIR Phase II 5R44AI143079-03, continuation, notice Jun 25, 2026).Evidence (1 event)- Jun 25, 2026 · NIH RePORTER 5R44AI143079-03
Organization: GEL4MED, INC.; City/State: BRIGHTON, MA; Project number: 5R44AI143079-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Novel dermal templates for prevention and treatment of biofilms in cutaneous wounds; Organization type: Domestic For-Profits
| Jun 25, 2026 | NIH RePORTER 5R44AI143079-03 |
| 3D BioAnalytiX, Inc. | NIH awarded $421K (NIH grant 1R33HL185603-01, new, notice Jun 25, 2026).Evidence (1 event)- Jun 25, 2026 · NIH RePORTER 1R33HL185603-01
Organization: 3D BIOANALYTIX, INC.; City/State: SAN DIEGO, CA; Project number: 1R33HL185603-01; Activity code: R33; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 421400; Administering IC: National Heart Lung and Blood Institute; Project title: A Transformative Structural Proteomics Platform for Early Detection of Misfolding-Driven Cardiovascular Diseases; Organization type: Domestic For-Profits
| Jun 25, 2026 | NIH RePORTER 1R33HL185603-01 |
| Chemia Biosciences, Inc. | NIH awarded $958K (SBIR Phase II 2R44GM154504-02, competing renewal, notice Aug 7, 2026); 2 NIH awards totaling $1.73M in the last 12 months.Evidence (2 events)- Aug 7, 2026 · NIH RePORTER 2R44GM154504-02
Organization: CHEMIA BIOSCIENCES, INC.; City/State: PITTSBURGH, PA; Project number: 2R44GM154504-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 958339; Administering IC: National Institute of General Medical Sciences; Project title: Discovering novel natural products from fungal species; Organization type: Domestic For-Profits - Jun 26, 2026 · NIH RePORTER 5R44GM159545-02
Organization: CHEMIA BIOSCIENCES, INC.; City/State: PITTSBURGH, PA; Project number: 5R44GM159545-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-26; FY total cost (award amount): 767806; Administering IC: National Institute of General Medical Sciences; Project title: A novel platform for nonribosomal peptide discovery; Organization type: Domestic For-Profits
| Aug 7, 2026 | NIH RePORTER 2R44GM154504-02 |
| Advertent Biotherapeutics, Inc. | NIH awarded $750K (SBIR Phase II 5R44AR081168-03, continuation, notice Jul 14, 2026).Evidence (1 event)- Jul 14, 2026 · NIH RePORTER 5R44AR081168-03
Organization: ADVERTENT BIOTHERAPEUTICS, INC.; City/State: EAST LANSING, MI; Project number: 5R44AR081168-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 750221; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: A novel agent for preventing fatty degeneration of muscles in LGMD2B; Organization type: Domestic For-Profits
| Jul 14, 2026 | NIH RePORTER 5R44AR081168-03 |
| Privo Technologies | NIH awarded $1.17M (SBIR Phase II 5R44CA281020-09, continuation, notice Jun 18, 2026).Evidence (1 event)- Jun 18, 2026 · NIH RePORTER 5R44CA281020-09
Organization: PRIVO TECHNOLOGIES, LLC; City/State: PEABODY, MA; Project number: 5R44CA281020-09; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-18; FY total cost (award amount): 1170285; Administering IC: National Cancer Institute; Project title: Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer); Organization type: Domestic For-Profits
| Jun 18, 2026 | NIH RePORTER 5R44CA281020-09 |
| Innovative Biotherapies, Inc. | NIH awarded $797K (SBIR Phase II 5R44HL170779-03, continuation, notice Jun 9, 2026).Evidence (1 event)- Jun 9, 2026 · NIH RePORTER 5R44HL170779-03
Organization: INNOVATIVE BIOTHERAPIES, INC.; City/State: ANN ARBOR, MI; Project number: 5R44HL170779-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 797411; Administering IC: National Heart Lung and Blood Institute; Project title: Cell Directed Immunomodulation Therapy as a Bridge to Left Ventricular Device Implantation in Chronic Heart Failure Patients; Organization type: Domestic For-Profits
| Jun 9, 2026 | NIH RePORTER 5R44HL170779-03 |
| Sparian Biosciences, Inc | NIH awarded $3.08M (NIH grant 5UG3DA064392-02, continuation, notice Jun 16, 2026).Evidence (1 event)- Jun 16, 2026 · NIH RePORTER 5UG3DA064392-02
Organization: SPARIAN BIOSCIENCES, INC.; City/State: NEW YORK CITY, NY; Project number: 5UG3DA064392-02; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 3084524; Administering IC: National Institute on Drug Abuse; Project title: Clinical Development of SBS-147: First-in-class Oral Arylepoxamide Agonist for Pain; Organization type: Domestic For-Profits
| Jun 16, 2026 | NIH RePORTER 5UG3DA064392-02 |
| WAVi | NIH awarded $1.21M (SBIR Phase II 4R44DA058431-02, extension, notice Sep 3, 2026).Evidence (1 event)- Sep 3, 2026 · NIH RePORTER 4R44DA058431-02
Organization: WAVI COMPANY; City/State: Englewood, CO; Project number: 4R44DA058431-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 1208000; Administering IC: National Institute on Drug Abuse; Project title: Development of an AI-empowered device that utilizes multimodal data-visualization to aid in the diagnosis, and treatment, of OUD; Organization type: Domestic For-Profits
| Sep 3, 2026 | NIH RePORTER 4R44DA058431-02 |
| Cerulean Scientific | NIH awarded $1.07M (SBIR Phase II 5R44HL172473-03, continuation, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 5R44HL172473-03
Organization: CERULEAN SCIENTIFIC INC.; City/State: LANCASTER, PA; Project number: 5R44HL172473-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1072347; Administering IC: National Heart Lung and Blood Institute; Project title: Slippery, Omniphobic Coating to Prevent Thrombosis and Biofilm Formation on Peripheral Vascular Grafts; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R44HL172473-03 |
| Evrys Bio | NIH awarded $962K (SBIR Phase II 5R44AI157725-04, continuation, notice Sep 10, 2026).Evidence (1 event)- Sep 10, 2026 · NIH RePORTER 5R44AI157725-04
Organization: EVRYS BIO, INC.; City/State: DOYLESTOWN, PA; Project number: 5R44AI157725-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 961797; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure; Organization type: Domestic For-Profits
| Sep 10, 2026 | NIH RePORTER 5R44AI157725-04 |
| Voxel Healthcare LLC | NIH awarded $665K (SBIR Phase II 5R44CA281709-03, continuation, notice Jul 7, 2026).Evidence (1 event)- Jul 7, 2026 · NIH RePORTER 5R44CA281709-03
Organization: VOXEL HEALTHCARE, LLC; City/State: Pasadena, CA; Project number: 5R44CA281709-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 665400; Administering IC: National Cancer Institute; Project title: Long term radiation treatment planning in brain tumors in the pediatric population; Organization type: Domestic For-Profits
| Jul 7, 2026 | NIH RePORTER 5R44CA281709-03 |
| Pinnacle Technology, Inc. | NIH awarded $984K (SBIR Phase II 5R44MH134669-03, continuation, notice Aug 13, 2026).Evidence (1 event)- Aug 13, 2026 · NIH RePORTER 5R44MH134669-03
Organization: PINNACLE TECHNOLOGY, INC; City/State: LAWRENCE, KS; Project number: 5R44MH134669-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 984425; Administering IC: National Institute of Mental Health; Project title: Functionalized Multi-Modal Tetrode Arrays for Real-Time, Site-Specific Neurochemical Monitoring; Organization type: Domestic For-Profits
| Aug 13, 2026 | NIH RePORTER 5R44MH134669-03 |
| Salus Discovery LLC | NIH awarded $1M (SBIR Phase II 5R44AI184104-03, continuation, notice Aug 26, 2026); 2 NIH awards totaling $1.91M in the last 12 months.Evidence (2 events)- Aug 26, 2026 · NIH RePORTER 5R44AI184104-03
Organization: SALUS DISCOVERY, LLC; City/State: Madison, WI; Project number: 5R44AI184104-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 999991; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Flow Direct: Next Generation Urine LFA for TB Diagnosis in Point-of-Care Settings; Organization type: Domestic For-Profits - Jul 1, 2026 · NIH RePORTER 5R44AI179588-03
Organization: SALUS DISCOVERY, LLC; City/State: Madison, WI; Project number: 5R44AI179588-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-01; FY total cost (award amount): 913705; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: 3STEP: A swab-seal-read assay for tuberculosis and RIF resistance enabled by autonomous extraction technology; Organization type: Domestic For-Profits
| Aug 26, 2026 | NIH RePORTER 5R44AI184104-03 |
| The DNA Medicine Institute, Inc. | NIH awarded $50K (SBIR Phase II 3R44HL151147-05S1, supplement, notice Jul 16, 2026); 2 NIH awards totaling $1.05M in the last 12 months.Evidence (2 events)- Jul 16, 2026 · NIH RePORTER 3R44HL151147-05S1
Organization: DNA MEDICINE INSTITUTE; City/State: Cambridge, MA; Project number: 3R44HL151147-05S1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-16; FY total cost (award amount): 50000; Administering IC: National Heart Lung and Blood Institute; Project title: TABA Supplement for Hemophilia Point-of-Care Device; Organization type: Domestic For-Profits - Jul 6, 2026 · NIH RePORTER 5R44HL151147-05
Organization: DNA MEDICINE INSTITUTE; City/State: Cambridge, MA; Project number: 5R44HL151147-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 1000000; Administering IC: National Heart Lung and Blood Institute; Project title: Hemophilia Point-of-Care Monitoring Device and App; Organization type: Domestic For-Profits
| Jul 16, 2026 | NIH RePORTER 3R44HL151147-05S1 |
| ODMR Technologies, Inc | NIH awarded $984K (STTR Phase II 5R42GM145129-03, continuation, notice Jul 1, 2026).Evidence (1 event)- Jul 1, 2026 · NIH RePORTER 5R42GM145129-03
Organization: ODMR TECHNOLOGIES, INC.; City/State: EL CERRITO, CA; Project number: 5R42GM145129-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-07-01; FY total cost (award amount): 984215; Administering IC: National Institute of General Medical Sciences; Project title: Diamond NMR spectrometer for microfluidic metabolite profiling; Organization type: Domestic For-Profits
| Jul 1, 2026 | NIH RePORTER 5R42GM145129-03 |
| Autonomous Healthcare Inc. | NIH awarded $306K (SBIR Phase I 1R43HL187059-01, new, notice Aug 18, 2026); 2 NIH awards totaling $1.19M in the last 12 months.Evidence (2 events)- Aug 18, 2026 · NIH RePORTER 1R43HL187059-01
Organization: AUTONOMOUS HEALTHCARE, INC.; City/State: SANTA CLARA, CA; Project number: 1R43HL187059-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 305999; Administering IC: National Heart Lung and Blood Institute; Project title: A Feasibility Study for a Clinical Decision Support System to Assist with Vasopressor Titration; Organization type: Domestic For-Profits - Jul 20, 2026 · NIH RePORTER 5R44DA058470-03
Organization: AUTONOMOUS HEALTHCARE, INC.; City/State: SANTA CLARA, CA; Project number: 5R44DA058470-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 886573; Administering IC: National Institute on Drug Abuse; Project title: Noncontact Monitoring for the Detection of Opioid-Induced Respiratory Depression; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 1R43HL187059-01 |
| NeuroGT | NIH awarded $1.48M (SBIR Phase II 5R44NS143501-02, continuation, notice Sep 14, 2026); 3 NIH awards totaling $3.17M in the last 12 months.Evidence (3 events)- Sep 14, 2026 · NIH RePORTER 5R44NS143501-02
Organization: NEUROGT, INC.; City/State: Chapel Hill, NC; Project number: 5R44NS143501-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1484525; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS I; Organization type: Domestic For-Profits - Sep 14, 2026 · NIH RePORTER 5R44NS135667-03
Organization: NEUROGT, INC.; City/State: Chapel Hill, NC; Project number: 5R44NS135667-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1341983; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of gene therapy product for treating MPS IIIB; Organization type: Domestic For-Profits - May 12, 2026 · NIH RePORTER 5R41NS143578-02
Organization: NEUROGT, INC.; City/State: Chapel Hill, NC; Project number: 5R41NS143578-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 342740; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC; Organization type: Domestic For-Profits
| Sep 14, 2026 | NIH RePORTER 5R44NS143501-02 |
| Syracuse Biolabs, Inc. | NIH awarded $534K (STTR Phase II 5R42GM140530-03, continuation, notice Jun 30, 2026).Evidence (1 event)- Jun 30, 2026 · NIH RePORTER 5R42GM140530-03
Organization: SYRACUSE BIOLABS, INC.; City/State: CAMILLUS, NY; Project number: 5R42GM140530-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 534278; Administering IC: National Institute of General Medical Sciences; Project title: Commercialization of a phylogenetic cell separation method for downstream purification of nucleic acids; Organization type: Domestic For-Profits
| Jun 30, 2026 | NIH RePORTER 5R42GM140530-03 |
| Vivreon Biosciences | NIH awarded $1.95M (SBIR commercialization 5SB1AG087756-02, continuation, notice May 12, 2026).Evidence (1 event)- May 12, 2026 · NIH RePORTER 5SB1AG087756-02
Organization: VIVREON BIOSCIENCES, LLC; City/State: San Diego, CA; Project number: 5SB1AG087756-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-05-12; FY total cost (award amount): 1948898; Administering IC: National Institute on Aging; Project title: Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease; Organization type: Domestic For-Profits
| May 12, 2026 | NIH RePORTER 5SB1AG087756-02 |
| Rivanna Medical | NIH awarded $1.1M (SBIR Phase II 5R44CA302033-02, continuation, notice Jul 14, 2026); 1 role open.Evidence (1 event)- Jul 14, 2026 · NIH RePORTER 5R44CA302033-02
Organization: RIVANNA MEDICAL, INC.; City/State: CHARLOTTESVILLE, VA; Project number: 5R44CA302033-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 1104515; Administering IC: National Cancer Institute; Project title: Reduced Traumatic Lumbar Puncture Rates in Pediatric Oncology Patients Through Development of an AI-Assisted, Ultrasound-Based Interventional Guidance Platform; Organization type: Domestic For-Profits
| Jul 14, 2026 | NIH RePORTER 5R44CA302033-02 |
| March Biosciences | NIH awarded $399K (SBIR Phase II 1R44CA314963-01, new, notice Sep 17, 2026); 2 NIH awards totaling $1.52M in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 1R44CA314963-01
Organization: MARCH BIOSCIENCES INC; City/State: HOUSTON, TX; Project number: 1R44CA314963-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 399003; Administering IC: National Cancer Institute; Project title: Overcoming Immune Evasion in Hepatocellular Carcinoma with Engineered T-Cell Therapy; Organization type: Domestic For-Profits - Aug 31, 2026 · NIH RePORTER 5R44CA302357-02
Organization: MARCH BIOSCIENCES INC; City/State: HOUSTON, TX; Project number: 5R44CA302357-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 1124607; Administering IC: National Cancer Institute; Project title: A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphoma; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44CA314963-01 |
| SurgiVance | NIH awarded $1.27M (SBIR Phase II 5R44CA302122-02, continuation, notice Jun 3, 2026).Evidence (1 event)- Jun 3, 2026 · NIH RePORTER 5R44CA302122-02
Organization: SURGIVANCE, INC.; City/State: Portland, OR; Project number: 5R44CA302122-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1271776; Administering IC: National Cancer Institute; Project title: Rapid 3D POC digital cancer pathology by unique confocal microscopy instrumentation and downstream AI: a simple, efficient, robust direct-to-digital approach to meet market demand; Organization type: Domestic For-Profits
| Jun 3, 2026 | NIH RePORTER 5R44CA302122-02 |
| NE Scientific INC | NIH awarded $689K (SBIR Phase II 5R44CA287803-03, continuation, notice May 14, 2026).Evidence (1 event)- May 14, 2026 · NIH RePORTER 5R44CA287803-03
Organization: NE SCIENTIFIC, INC.; City/State: BURLINGTON, MA; Project number: 5R44CA287803-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-14; FY total cost (award amount): 689478; Administering IC: National Cancer Institute; Project title: Computer Guided Microwave Liver Ablation; Organization type: Domestic For-Profits
| May 14, 2026 | NIH RePORTER 5R44CA287803-03 |
| Kinetic River Corp. | NIH awarded $1M (SBIR commercialization 5SB1GM157775-02, continuation, notice May 7, 2026).Evidence (1 event)- May 7, 2026 · NIH RePORTER 5SB1GM157775-02
Organization: KINETIC RIVER CORPORATION; City/State: MOUNTAIN VIEW, CA; Project number: 5SB1GM157775-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-05-07; FY total cost (award amount): 999993; Administering IC: National Institute of General Medical Sciences; Project title: Compensation-Free Flow Cytometer with Expanded Reagent Choices and Reduced Manufacturing Costs; Organization type: Domestic For-Profits
| May 7, 2026 | NIH RePORTER 5SB1GM157775-02 |
| Outlier Technology, LLC | NIH awarded $1.15M (SBIR Phase II 5R44AG081111-03, continuation, notice Jul 28, 2026).Evidence (1 event)- Jul 28, 2026 · NIH RePORTER 5R44AG081111-03
Organization: OUTLIER TECHNOLOGY, LLC; City/State: GAINESVILLE, FL; Project number: 5R44AG081111-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 1152435; Administering IC: National Institute on Aging; Project title: NeuroSync: a data-driven, music-based augmented reality neurorehabilitation platform of games & puzzles to stimulate neuroplasticity and prolong functional independence in Alzheimer's Disease patients; Organization type: Domestic For-Profits
| Jul 28, 2026 | NIH RePORTER 5R44AG081111-03 |
| NovoPedics | NIH awarded $1.02M (SBIR Phase II 5R44AR081745-03, continuation, notice Jun 11, 2026).Evidence (1 event)- Jun 11, 2026 · NIH RePORTER 5R44AR081745-03
Organization: NOVOPEDICS, INC.; City/State: Princeton, NJ; Project number: 5R44AR081745-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-11; FY total cost (award amount): 1016692; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Efficacy of MeniscoFix for Sub-Total Meniscal Replacement: A Comprehensive Approach in Cadaver Knees and an Ovine Surgical Model; Organization type: Domestic For-Profits
| Jun 11, 2026 | NIH RePORTER 5R44AR081745-03 |
| Marker Therapeutics, Inc. | NIH awarded $645K (NIH grant 1R01FD008756-01, new, notice Sep 24, 2026); 2 NIH awards totaling $1.31M in the last 12 months.Evidence (2 events)- Sep 24, 2026 · NIH RePORTER 1R01FD008756-01
Organization: MARKER THERAPEUTICS, INC.; City/State: HOUSTON, TX; Project number: 1R01FD008756-01; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-09-24; FY total cost (award amount): 645493; Administering IC: Food and Drug Administration; Project title: Safety and Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in Pancreatic Cancer Patients; Organization type: Domestic For-Profits - Jul 20, 2026 · NIH RePORTER 5R44CA291521-03
Organization: MARKER THERAPEUTICS, INC.; City/State: HOUSTON, TX; Project number: 5R44CA291521-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 665000; Administering IC: National Cancer Institute; Project title: A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma; Organization type: Domestic For-Profits
| Sep 24, 2026 | NIH RePORTER 1R01FD008756-01 |
| Genetivision Corporation | NIH awarded $984K (SBIR Phase II 5R44GM161181-02, continuation, notice Jun 26, 2026).Evidence (1 event)- Jun 26, 2026 · NIH RePORTER 5R44GM161181-02
Organization: GENETIVISION CORPORATION; City/State: Stafford, TX; Project number: 5R44GM161181-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-26; FY total cost (award amount): 984472; Administering IC: National Institute of General Medical Sciences; Project title: A Precisely Controllable Loss-of-Function Mutation Collection in Drosophila; Organization type: Domestic For-Profits
| Jun 26, 2026 | NIH RePORTER 5R44GM161181-02 |
| VeriSIM Life, Inc. | NIH awarded $513K (STTR Phase II 5R42DA056084-03, continuation, notice Aug 14, 2026).Evidence (1 event)- Aug 14, 2026 · NIH RePORTER 5R42DA056084-03
Organization: VERISIM LIFE, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R42DA056084-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 512644; Administering IC: National Institute on Drug Abuse; Project title: Development of therapeutic candidates for stimulant use disorder using AI-driven platform for focused drug discovery and accelerated development; Organization type: Domestic For-Profits
| Aug 14, 2026 | NIH RePORTER 5R42DA056084-03 |
| Doxy.me Inc. | NIH awarded $704K (SBIR Phase II 5R44MH129065-04, continuation, notice Aug 13, 2026); 3 roles open.Evidence (1 event)- Aug 13, 2026 · NIH RePORTER 5R44MH129065-04
Organization: DOXY.ME, LLC; City/State: Charleston, SC; Project number: 5R44MH129065-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 704454; Administering IC: National Institute of Mental Health; Project title: Doxy.me VR: A scalable virtual reality app to facilitate evidence-based immersive telemental health; Organization type: Domestic For-Profits
| Aug 13, 2026 | NIH RePORTER 5R44MH129065-04 |
| Aronora | NIH awarded $1.07M (SBIR Phase II 5R44HL170881-03, continuation, notice Jun 1, 2026).Evidence (1 event)- Jun 1, 2026 · NIH RePORTER 5R44HL170881-03
Organization: ARONORA, INC.; City/State: Portland, OR; Project number: 5R44HL170881-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-01; FY total cost (award amount): 1069527; Administering IC: National Heart Lung and Blood Institute; Project title: Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis; Organization type: Domestic For-Profits
| Jun 1, 2026 | NIH RePORTER 5R44HL170881-03 |
| Ortholevo, Inc. | NIH awarded $490K (SBIR commercialization 5SB1AR084380-03, continuation, notice Jul 14, 2026).Evidence (1 event)- Jul 14, 2026 · NIH RePORTER 5SB1AR084380-03
Organization: ORTHOLEVO, INC.; City/State: Lynnfield, MA; Project number: 5SB1AR084380-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 490333; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Late Stage Development of Sustained-release Relaxin for Treating Joint Contracture; Organization type: Domestic For-Profits
| Jul 14, 2026 | NIH RePORTER 5SB1AR084380-03 |
| Briteseed | NIH awarded $1M (SBIR Phase II 5R44EB036417-03, continuation, notice Jul 6, 2026).Evidence (1 event)- Jul 6, 2026 · NIH RePORTER 5R44EB036417-03
Organization: BRITESEED, LLC; City/State: CHICAGO, IL; Project number: 5R44EB036417-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 1000469; Administering IC: National Institute of Biomedical Imaging and Bioengineering; Project title: Development of a Multispectral Kerrison Rongeur for Dura and Nerve Root Detection; Organization type: Domestic For-Profits
| Jul 6, 2026 | NIH RePORTER 5R44EB036417-03 |
| AbbraTech Inc. | NIH awarded $301K (SBIR Phase II 5R44GM156476-03, continuation, notice Aug 25, 2026).Evidence (1 event)- Aug 25, 2026 · NIH RePORTER 5R44GM156476-03
Organization: ABBRATECH, INC.; City/State: Branford, CT; Project number: 5R44GM156476-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 301174; Administering IC: National Institute of General Medical Sciences; Project title: DIRECTED DISCOVERY AND VALIDATION OF ANTI-SPLICE-JUNCTION SITE Abs; Organization type: Domestic For-Profits
| Aug 25, 2026 | NIH RePORTER 5R44GM156476-03 |
| Fimbrion Therapeutics | NIH awarded $300K (SBIR Phase I 5R43AI192175-02, continuation, notice Sep 3, 2026); 3 NIH awards totaling $900K in the last 12 months.Evidence (3 events)- Sep 3, 2026 · NIH RePORTER 5R43AI192175-02
Organization: FIMBRION THERAPEUTICS, INC.; City/State: SAINT LOUIS, MO; Project number: 5R43AI192175-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Thiazolino-Pyridone Compounds as Novel Antimycobacterial Drugs for Tuberculosis; Organization type: Domestic For-Profits - Aug 6, 2026 · NIH RePORTER 5R43AI192169-02
Organization: FIMBRION THERAPEUTICS, INC.; City/State: SAINT LOUIS, MO; Project number: 5R43AI192169-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Small Molecule Glycoside Inhibitors of LecB for the Treatment of Pseudomonas Infections; Organization type: Domestic For-Profits - Jul 29, 2026 · NIH RePORTER 5R43AI188991-02
Organization: FIMBRION THERAPEUTICS, INC.; City/State: SAINT LOUIS, MO; Project number: 5R43AI188991-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-29; FY total cost (award amount): 300001; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous Mycobacteria; Organization type: Domestic For-Profits
| Sep 3, 2026 | NIH RePORTER 5R43AI192175-02 |
| Emmyon, Inc. | NIH awarded $1.02M (SBIR Phase II 5R44DK142200-02, continuation, notice Jul 23, 2026).Evidence (1 event)- Jul 23, 2026 · NIH RePORTER 5R44DK142200-02
Organization: EMMYON, INC.; City/State: Rochester, MN; Project number: 5R44DK142200-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-23; FY total cost (award amount): 1021719; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of novel therapeutics for obesity and type 2 diabetes; Organization type: Domestic For-Profits
| Jul 23, 2026 | NIH RePORTER 5R44DK142200-02 |
| BrightSpec | NIH awarded $819K (SBIR Phase II 5R44GM157779-02, continuation, notice Jul 22, 2026).Evidence (1 event)- Jul 22, 2026 · NIH RePORTER 5R44GM157779-02
Organization: BRIGHTSPEC, INC.; City/State: CHARLOTTESVILLE, VA; Project number: 5R44GM157779-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 819002; Administering IC: National Institute of General Medical Sciences; Project title: MR^3: Development of a Molecular Rotational Resonance Ratiometer; Organization type: Domestic For-Profits
| Jul 22, 2026 | NIH RePORTER 5R44GM157779-02 |
| Litron Laboratories | NIH awarded $645K (SBIR Phase II 5R44ES036902-03, continuation, notice Aug 14, 2026); 2 NIH awards totaling $1.49M in the last 12 months.Evidence (2 events)- Aug 14, 2026 · NIH RePORTER 5R44ES036902-03
Organization: LITRON LABORATORIES, LTD.; City/State: ROCHESTER, NY; Project number: 5R44ES036902-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 645357; Administering IC: National Institute of Environmental Health Sciences; Project title: Development of a Comprehensive Hen's Egg Model for Genotoxicity Testing; Organization type: Domestic For-Profits - Aug 10, 2026 · NIH RePORTER 5R44ES035550-03
Organization: LITRON LABORATORIES, LTD.; City/State: ROCHESTER, NY; Project number: 5R44ES035550-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 843789; Administering IC: National Institute of Environmental Health Sciences; Project title: Modeling the Responsiveness of Sensitive Populations to Genotoxic Agents Using DNA Repair Inhibitors; Organization type: Domestic For-Profits
| Aug 14, 2026 | NIH RePORTER 5R44ES036902-03 |
| DemeRx | NIH awarded $796K (SBIR Phase I 5R43AA032127-02, continuation, notice Jul 23, 2026).Evidence (1 event)- Jul 23, 2026 · NIH RePORTER 5R43AA032127-02
Organization: DEMERX, INC.; City/State: MIAMI, FL; Project number: 5R43AA032127-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-23; FY total cost (award amount): 796298; Administering IC: National Institute on Alcohol Abuse and Alcoholism; Project title: Investigational New Drug Development of Noribogaine for Alcohol Use Disorder; Organization type: Domestic For-Profits
| Jul 23, 2026 | NIH RePORTER 5R43AA032127-02 |
| Solaris Vaccines, Inc. | NIH awarded $274K (STTR Phase I 5R41AI186746-02, continuation, notice Aug 14, 2026).Evidence (1 event)- Aug 14, 2026 · NIH RePORTER 5R41AI186746-02
Organization: SOLARIS VACCINES, INC.; City/State: FORT COLLINS, CO; Project number: 5R41AI186746-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 274002; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A whole-cell inactivated vaccine for improved protection against tuberculosis; Organization type: Domestic For-Profits
| Aug 14, 2026 | NIH RePORTER 5R41AI186746-02 |
| Pearl Diagnostics, Inc. | NIH awarded $977K (SBIR commercialization 5SB1AI186689-02, continuation, notice Jun 30, 2026).Evidence (1 event)- Jun 30, 2026 · NIH RePORTER 5SB1AI186689-02
Organization: PEARL DIAGNOSTICS, INC.; City/State: BALTIMORE, MD; Project number: 5SB1AI186689-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 977071; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Point of Care Urine Test to Aid Diagnosis of Aspergillosis; Organization type: Domestic For-Profits
| Jun 30, 2026 | NIH RePORTER 5SB1AI186689-02 |
| Ometa Labs LLC | NIH awarded $702K (SBIR Phase II 5R44GM162107-02, continuation, notice Jul 11, 2026).Evidence (1 event)- Jul 11, 2026 · NIH RePORTER 5R44GM162107-02
Organization: OMETA LABS LLC; City/State: CARLSBAD, CA; Project number: 5R44GM162107-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-11; FY total cost (award amount): 702348; Administering IC: National Institute of General Medical Sciences; Project title: Bioinformatics platform for large scale untargeted metabolomics analysis; Organization type: Domestic For-Profits
| Jul 11, 2026 | NIH RePORTER 5R44GM162107-02 |
| Ting Therapeutics | NIH awarded $524K (SBIR Phase II 5R44DC019065-05, continuation, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 5R44DC019065-05
Organization: TING THERAPEUTICS, INC.; City/State: San Diego, CA; Project number: 5R44DC019065-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 524299; Administering IC: National Institute on Deafness and Other Communication Disorders; Project title: Therapeutics to prevent aminoglycoside-induced hearing loss; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R44DC019065-05 |
| Cognition Therapeutics | NIH awarded $16.49M (NIH grant 5R01AG065248-05, continuation, notice Aug 25, 2026).Evidence (1 event)- Aug 25, 2026 · NIH RePORTER 5R01AG065248-05
Organization: COGNITION THERAPEUTICS, INC.; City/State: PITTSBURGH, PA; Project number: 5R01AG065248-05; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 16494670; Administering IC: National Institute on Aging; Project title: Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months; Organization type: Domestic For-Profits
| Aug 25, 2026 | NIH RePORTER 5R01AG065248-05 |
| Owic Technologies Inc. | NIH awarded $1.23M (SBIR Phase II 4R44GM161182-02, extension, notice Aug 21, 2026).Evidence (1 event)- Aug 21, 2026 · NIH RePORTER 4R44GM161182-02
Organization: OWIC TECHNOLOGIES INC; City/State: ITHACA, NY; Project number: 4R44GM161182-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 1228929; Administering IC: National Institute of General Medical Sciences; Project title: High throughput electrosynthesis for enhanced drug discovery via light-powered smart microelectronics; Organization type: Domestic For-Profits
| Aug 21, 2026 | NIH RePORTER 4R44GM161182-02 |
| NanoNewron | NIH awarded $1.52M (STTR Phase II 5R42AG080864-03, continuation, notice Jun 3, 2026).Evidence (1 event)- Jun 3, 2026 · NIH RePORTER 5R42AG080864-03
Organization: NANONEWRON LLC; City/State: Union, NJ; Project number: 5R42AG080864-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1519969; Administering IC: National Institute on Aging; Project title: Development of a therapeutic nanobody targeting brain TNFa for the treatment of Alzheimer Disease; Organization type: Domestic For-Profits
| Jun 3, 2026 | NIH RePORTER 5R42AG080864-03 |
| Topaz Biosciences, Inc. | NIH awarded $576K (SBIR Phase II 5R44AR082722-03, continuation, notice Jul 17, 2026).Evidence (1 event)- Jul 17, 2026 · NIH RePORTER 5R44AR082722-03
Organization: TOPAZ BIOSCIENCES, INC.; City/State: EMERYVILLE, CA; Project number: 5R44AR082722-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 576499; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Development of novel endolysins targeting Cutibacterium acnes to treat acne vulgaris; Organization type: Domestic For-Profits
| Jul 17, 2026 | NIH RePORTER 5R44AR082722-03 |
| Vasarya Therapeutics, Inc. | NIH awarded $1.13M (SBIR Phase II 5R44HL170936-03, continuation, notice Sep 4, 2026).Evidence (1 event)- Sep 4, 2026 · NIH RePORTER 5R44HL170936-03
Organization: VASARYA THERAPEUTICS, INC.; City/State: CAMDEN, DE; Project number: 5R44HL170936-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1126840; Administering IC: National Heart Lung and Blood Institute; Project title: Translating a Novel Therapeutic Approach to the Treatment for Idiopathic Pulmonary Fibrosis; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 5R44HL170936-03 |
| Molecular Intelligence LLC | NIH awarded $88K (SBIR Phase I 5R43GM161135-02, continuation, notice Sep 8, 2026).Evidence (1 event)- Sep 8, 2026 · NIH RePORTER 5R43GM161135-02
Organization: MOLECULAR INTELLIGENCE LLC; City/State: WEST LAFAYETTE, IN; Project number: 5R43GM161135-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 87668; Administering IC: National Institute of General Medical Sciences; Project title: Modeling Receptor-ligand interactions for Drug Discoveryfrom Cryo-EM data using AI; Organization type: Domestic For-Profits
| Sep 8, 2026 | NIH RePORTER 5R43GM161135-02 |
| Celestial Therapeutics Inc. | NIH awarded $643K (SBIR Phase II 5R44AI177056-03, continuation, notice Jul 30, 2026).Evidence (1 event)- Jul 30, 2026 · NIH RePORTER 5R44AI177056-03
Organization: CELESTIAL THERAPEUTICS INC.; City/State: IRVINE, CA; Project number: 5R44AI177056-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-30; FY total cost (award amount): 643140; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a dry powder inhalation product against Respiratory Syncytial Virus based on an endogenous anionic pulmonary surfactant lipid; Organization type: Domestic For-Profits
| Jul 30, 2026 | NIH RePORTER 5R44AI177056-03 |
| INSIGHTFIL | NIH awarded $598K (SBIR Phase II 5R44TR003071-04, continuation, notice Aug 14, 2026).Evidence (1 event)- Aug 14, 2026 · NIH RePORTER 5R44TR003071-04
Organization: INSIGHTFIL; City/State: BOSTON, MA; Project number: 5R44TR003071-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 598106; Administering IC: National Center for Advancing Translational Sciences; Project title: Personalized multi-medication packaging with integrated real-time instrumentation to improve adherence; Organization type: Domestic For-Profits
| Aug 14, 2026 | NIH RePORTER 5R44TR003071-04 |
| Killer Snails LLC | NIH awarded $1.3M (SBIR Phase II 4R44GM161184-02, extension, notice Jul 27, 2026).Evidence (1 event)- Jul 27, 2026 · NIH RePORTER 4R44GM161184-02
Organization: KILLER SNAILS LLC; City/State: BROOKLYN, NY; Project number: 4R44GM161184-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-27; FY total cost (award amount): 1299019; Administering IC: National Institute of General Medical Sciences; Project title: Flu Finders: Data Literacy through Wastewater Monitoring; Organization type: Domestic For-Profits
| Jul 27, 2026 | NIH RePORTER 4R44GM161184-02 |
| Plumeria Therapeutics, Inc. | NIH awarded $1.5M (SBIR Phase II 5R44NS120617-03, continuation, notice May 26, 2026).Evidence (1 event)- May 26, 2026 · NIH RePORTER 5R44NS120617-03
Organization: PLUMERIA THERAPEUTICS, INC.; City/State: Plainsboro, NJ; Project number: 5R44NS120617-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-26; FY total cost (award amount): 1499999; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Laboratory Developed Test (LDT) to Support Clinical Evaluation of a Drug for Painful Diabetic Neuropathy; Organization type: Domestic For-Profits
| May 26, 2026 | NIH RePORTER 5R44NS120617-03 |
| Shift Pharmaceuticals Holdings, Inc. | NIH awarded $37K (STTR Phase I 5R41EY036319-02, continuation, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 5R41EY036319-02
Organization: SHIFT PHARMACEUTICALS HOLDINGS, INC.; City/State: COLUMBIA, MO; Project number: 5R41EY036319-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 37074; Administering IC: National Eye Institute; Project title: Anti-sense oligonucleotide inhibitors of retinoic acid signaling and reversion of retinal remodeling for mitigating vision loss; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R41EY036319-02 |
| Gateway Bio, Inc. | NIH awarded $735K (SBIR Phase II 5R44TR003255-04, continuation, notice Jul 20, 2026).Evidence (1 event)- Jul 20, 2026 · NIH RePORTER 5R44TR003255-04
Organization: GATEWAY BIO, INC.; City/State: DURHAM, NC; Project number: 5R44TR003255-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 735254; Administering IC: National Center for Advancing Translational Sciences; Project title: Scale-up and Toxicity Studies of POEGMA-Uricase; Organization type: Domestic For-Profits
| Jul 20, 2026 | NIH RePORTER 5R44TR003255-04 |
| CYTORUM | NIH awarded $843K (SBIR Phase II 5R44GM146557-03, continuation, notice Aug 31, 2026).Evidence (1 event)- Aug 31, 2026 · NIH RePORTER 5R44GM146557-03
Organization: CYTORUM, INC.; City/State: Santa Clara, CA; Project number: 5R44GM146557-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 843224; Administering IC: National Institute of General Medical Sciences; Project title: Xbeads: A Platform for Flow Cytometry Sample QC and Harmonization; Organization type: Domestic For-Profits
| Aug 31, 2026 | NIH RePORTER 5R44GM146557-03 |
| HDT Bio Corp. | NIH awarded $1.06M (NIH grant 5R01AI180195-03, continuation, notice Jul 24, 2026).Evidence (1 event)- Jul 24, 2026 · NIH RePORTER 5R01AI180195-03
Organization: HDT BIO CORPORATION; City/State: SEATTLE, WA; Project number: 5R01AI180195-03; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-07-24; FY total cost (award amount): 1063126; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Immunological mechanism of muscle-localizing self-replicating RNA vaccines; Organization type: Domestic For-Profits
| Jul 24, 2026 | NIH RePORTER 5R01AI180195-03 |
| IN Vivo Analytics, Inc. | NIH awarded $907K (SBIR Phase II 5R44MH140129-03, continuation, notice Aug 19, 2026).Evidence (1 event)- Aug 19, 2026 · NIH RePORTER 5R44MH140129-03
Organization: IN VIVO ANALYTICS, INC.; City/State: NEW YORK, NY; Project number: 5R44MH140129-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 907050; Administering IC: National Institute of Mental Health; Project title: A modular bioluminescence imaging platform using a novel multi-aperture method; Organization type: Domestic For-Profits
| Aug 19, 2026 | NIH RePORTER 5R44MH140129-03 |
| Epoulosis Therapeutics, Inc. | NIH awarded $1.01M (SBIR Phase II 5R44DK141401-02, continuation, notice Jul 22, 2026).Evidence (1 event)- Jul 22, 2026 · NIH RePORTER 5R44DK141401-02
Organization: EPOULOSIS THERAPEUTICS, INC.; City/State: NEWTON, MA; Project number: 5R44DK141401-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 1012588; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Metrifonate local application for DFU treatment; Organization type: Domestic For-Profits
| Jul 22, 2026 | NIH RePORTER 5R44DK141401-02 |
| Onc.AI, Inc. | NIH awarded $314K (SBIR Phase II 5R44CA302212-02, continuation, notice Jul 22, 2026).Evidence (1 event)- Jul 22, 2026 · NIH RePORTER 5R44CA302212-02
Organization: ONC.AI, INC.; City/State: SAN CARLOS, CA; Project number: 5R44CA302212-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 313742; Administering IC: National Cancer Institute; Project title: Deep Learning Serial Radiomics for Improved Cancer Therapy Response Assessment.; Organization type: Domestic For-Profits
| Jul 22, 2026 | NIH RePORTER 5R44CA302212-02 |
| Spikegadgets, Inc. | NIH awarded $861K (SBIR Phase II 5R44MH142264-02, continuation, notice Jul 17, 2026).Evidence (1 event)- Jul 17, 2026 · NIH RePORTER 5R44MH142264-02
Organization: SPIKEGADGETS, LLC; City/State: San Francisco, CA; Project number: 5R44MH142264-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 860666; Administering IC: National Institute of Mental Health; Project title: A Commercial Platform for High-Volume Behavior and Electrophysiology Research; Organization type: Domestic For-Profits
| Jul 17, 2026 | NIH RePORTER 5R44MH142264-02 |
| Tymora Analytical Operations LLC | NIH awarded $747K (SBIR Phase II 5R44AG063589-04, continuation, notice Jul 10, 2026).Evidence (1 event)- Jul 10, 2026 · NIH RePORTER 5R44AG063589-04
Organization: TYMORA ANALYTICAL OPERATIONS, LLC; City/State: WEST LAFAYETTE, IN; Project number: 5R44AG063589-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 747422; Administering IC: National Institute on Aging; Project title: Validation and clinicaldevelopment of plasma EV protein biomarkers for minimally-invasive detection of Alzheimersdisease; Organization type: Domestic For-Profits
| Jul 10, 2026 | NIH RePORTER 5R44AG063589-04 |
| Siolta Therapeutics, Inc. | NIH awarded $935K (SBIR Phase II 5R44AI195248-02, continuation, notice Jul 14, 2026).Evidence (1 event)- Jul 14, 2026 · NIH RePORTER 5R44AI195248-02
Organization: SIOLTA THERAPEUTICS, INC.; City/State: SAN CARLOS, CA; Project number: 5R44AI195248-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 935435; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a multispecies live biotherapeutic product for the prevention of recurrent bacterial vaginosis; Organization type: Domestic For-Profits
| Jul 14, 2026 | NIH RePORTER 5R44AI195248-02 |
| Zymo Research Corp. | NIH awarded $908K (STTR Phase II 5R42NS098918-06, continuation, notice Aug 11, 2026).Evidence (1 event)- Aug 11, 2026 · NIH RePORTER 5R42NS098918-06
Organization: ZYMO RESEARCH CORPORATION; City/State: IRVINE, CA; Project number: 5R42NS098918-06; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 907735; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: A Novel Xenon Delivery Platform for Cerebroprotection During Stroke; Organization type: Domestic For-Profits
| Aug 11, 2026 | NIH RePORTER 5R42NS098918-06 |
| Myosin Therapeutics Inc. | NIH awarded $2.24M (SBIR Phase II 5R44CA278293-05, continuation, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 5R44CA278293-05
Organization: MYOSIN THERAPEUTICS INC.; City/State: JUPITER, FL; Project number: 5R44CA278293-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 2241448; Administering IC: National Cancer Institute; Project title: Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R44CA278293-05 |
| Westat | NIH awarded $3.52M (NIH grant 5U54DA046060-09, continuation, notice Sep 11, 2026); 20 NIH awards totaling $86.82M in the last 12 months.Evidence (20 events)- Sep 11, 2026 · NIH RePORTER 5U54DA046060-09
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5U54DA046060-09; Activity code: U54; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 3517105; Administering IC: National Institute on Drug Abuse; Project title: Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science; Organization type: Domestic For-Profits - Sep 11, 2026 · NIH RePORTER 5U54DA046060-09
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5U54DA046060-09; Activity code: U54; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 879278; Administering IC: National Institute on Drug Abuse; Project title: Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science - Leadership and Logistics Core; Organization type: Domestic For-Profits - Sep 11, 2026 · NIH RePORTER 5U54DA046060-09
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5U54DA046060-09; Activity code: U54; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 879277; Administering IC: National Institute on Drug Abuse; Project title: Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science - Analysis and Rapid Response Core; Organization type: Domestic For-Profits - Sep 11, 2026 · NIH RePORTER 5U54DA046060-09
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5U54DA046060-09; Activity code: U54; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 879275; Administering IC: National Institute on Drug Abuse; Project title: Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science - Career Enhancement Core; Organization type: Domestic For-Profits - Sep 11, 2026 · NIH RePORTER 5U54DA046060-09
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5U54DA046060-09; Activity code: U54; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 879275; Administering IC: National Institute on Drug Abuse; Project title: Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science - Dissemination Core; Organization type: Domestic For-Profits - Sep 3, 2026 · NIH RePORTER 5U24MH139129-02
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5U24MH139129-02; Activity code: U24; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 1891124; Administering IC: National Institute of Mental Health; Project title: Early Psychosis Intervention Network (EPINET) Data Coordinating Center; Organization type: Domestic For-Profits - Aug 28, 2026 · NIH RePORTER 4OT2HL158287-02
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 4OT2HL158287-02; Activity code: OT2; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 41085453; Administering IC: National Heart Lung and Blood Institute; Project title: NHLBI Community Engagement Technical Assistance Center (CETAC); Organization type: Domestic For-Profits - Jul 20, 2026 · NIH RePORTER 3U54DA046060-08S1
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 3U54DA046060-08S1; Activity code: U54; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 127945; Administering IC: National Institute on Drug Abuse; Project title: Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science; Organization type: Domestic For-Profits - Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 7732236; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits - Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 4439439; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Operations and Collaborations Center - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits - Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 463713; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: St. Jude Children's Research Hospital - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits - Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 447573; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Fenway Community Health Center, Inc., Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits - Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 408234; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Children's Hospital Los Angeles Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits - Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 349649; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: The Hektoen Institute of Medical Research Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits - Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 348214; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Children's National Hospital Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits - Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 329106; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: The Administrators of the Tulane Educational Fund dba TUHSC Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Tri; Organization type: Domestic For-Profits - Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 321882; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Johns Hopkins University Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits - Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 320315; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Baylor College of Medicine Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits - Jun 25, 2026 · NIH RePORTER 5UM2HD111076-05
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 5UM2HD111076-05; Activity code: UM2; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 304111; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: University of South Florida Site Consortium - Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) Operations and Collaborations Center (UM2 Clinical Trial Optional); Organization type: Domestic For-Profits - Jan 30, 2026 · NIH RePORTER 3OT2HL158287-01SG
Organization: WESTAT, INC.; City/State: Bethesda, MD; Project number: 3OT2HL158287-01SG; Activity code: OT2; Fiscal year: 2026; Award notice date: 2026-01-30; FY total cost (award amount): 21218938; Administering IC: National Heart Lung and Blood Institute; Project title: NHLBI Community Engagement Technical Assistance Center (CETAC); Organization type: Domestic For-Profits
| Sep 11, 2026 | NIH RePORTER 5U54DA046060-09 |
| Attagene, Inc. | NIH awarded $50K (SBIR Phase II 3R44ES038062-02S1, supplement, notice Aug 31, 2026); 2 NIH awards totaling $1.15M in the last 12 months.Evidence (2 events)- Aug 31, 2026 · NIH RePORTER 3R44ES038062-02S1
Organization: ATTAGENE, INC.; City/State: RESEARCH TRIANGLE PARK, NC; Project number: 3R44ES038062-02S1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 50000; Administering IC: National Institute of Environmental Health Sciences; Project title: A Two-Tier Effect-Based Water Bioactivity Surveillance System.; Organization type: Domestic For-Profits - Aug 19, 2026 · NIH RePORTER 5R44ES038062-02
Organization: ATTAGENE, INC.; City/State: RESEARCH TRIANGLE PARK, NC; Project number: 5R44ES038062-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 1095747; Administering IC: National Institute of Environmental Health Sciences; Project title: A Two-Tier Effect-Based Water Bioactivity Surveillance System.; Organization type: Domestic For-Profits
| Aug 31, 2026 | NIH RePORTER 3R44ES038062-02S1 |
| Trethera | NIH awarded $897K (STTR Phase II 5R42DK138578-03, continuation, notice Sep 17, 2026); 3 NIH awards totaling $3.04M in the last 12 months.Evidence (3 events)- Sep 17, 2026 · NIH RePORTER 5R42DK138578-03
Organization: TRETHERA CORPORATION; City/State: SHERMAN OAKS, CA; Project number: 5R42DK138578-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 897265; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease; Organization type: Domestic For-Profits - Aug 11, 2026 · NIH RePORTER 5R44AI188587-02
Organization: TRETHERA CORPORATION; City/State: SHERMAN OAKS, CA; Project number: 5R44AI188587-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 994978; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus; Organization type: Domestic For-Profits - Aug 5, 2026 · NIH RePORTER 5R44CA302066-02
Organization: TRETHERA CORPORATION; City/State: SHERMAN OAKS, CA; Project number: 5R44CA302066-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 1150000; Administering IC: National Cancer Institute; Project title: Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R42DK138578-03 |
| Alcamena Stem Cell Therapeutics | NIH awarded $1.5M (SBIR Phase II 5R44NS145934-02, continuation, notice Sep 4, 2026).Evidence (1 event)- Sep 4, 2026 · NIH RePORTER 5R44NS145934-02
Organization: ALCAMENA STEM CELL THERAPEUTICS, LLC; City/State: Baltimore, MD; Project number: 5R44NS145934-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1500000; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: FDA Phase 1 Development of a Novel Nonopioid Cell and Tissue Permeable Peptide Therapeutic for Epigenetic Reprogramming of Neuropathic Pain; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 5R44NS145934-02 |
| Faknostics, LLC | NIH awarded $663K (STTR Phase II 5R42HL162392-04, continuation, notice Sep 4, 2026); 2 NIH awards totaling $1.33M in the last 12 months.Evidence (2 events)- Sep 4, 2026 · NIH RePORTER 5R42HL162392-04
Organization: FAKNOSTICS, LLC; City/State: PHOENIX, AZ; Project number: 5R42HL162392-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 662561; Administering IC: National Heart Lung and Blood Institute; Project title: Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis; Organization type: Domestic For-Profits - Aug 3, 2026 · NIH RePORTER 5R42DK141379-03
Organization: FAKNOSTICS, LLC; City/State: PHOENIX, AZ; Project number: 5R42DK141379-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 669464; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 5R42HL162392-04 |
| IVOS Medical, Inc. | NIH awarded $145K (SBIR Phase II 5R44HL164325-04, continuation, notice Sep 16, 2026).Evidence (1 event)- Sep 16, 2026 · NIH RePORTER 5R44HL164325-04
Organization: IVOS MEDICAL, INC.; City/State: DANA POINT, CA; Project number: 5R44HL164325-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 144919; Administering IC: National Heart Lung and Blood Institute; Project title: IVOS Medical: Intubation, Optimized.; Organization type: Domestic For-Profits
| Sep 16, 2026 | NIH RePORTER 5R44HL164325-04 |
| Arbor Medical Innovations LLC | NIH awarded $1.33M (SBIR Phase II 5U44NS122002-05, continuation, notice Aug 21, 2026).Evidence (1 event)- Aug 21, 2026 · NIH RePORTER 5U44NS122002-05
Organization: ARBOR MEDICAL INNOVATIONS, LLC; City/State: YPSILANTI, MI; Project number: 5U44NS122002-05; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 1327568; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Actigraphy Enhanced Clinical Chronic Lower Back Pain Management; Organization type: Domestic For-Profits
| Aug 21, 2026 | NIH RePORTER 5U44NS122002-05 |
| ZetrOZ Systems | NIH awarded $2.15M (SBIR Phase II 5R44AG061985-08, continuation, notice Aug 17, 2026).Evidence (1 event)- Aug 17, 2026 · NIH RePORTER 5R44AG061985-08
Organization: ZETROZ SYSTEMS, LLC; City/State: TRUMBULL, CT; Project number: 5R44AG061985-08; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-17; FY total cost (award amount): 2154078; Administering IC: National Institute on Aging; Project title: Daily & Localized NSAID Sonophoresis for Symptomatic Treatment of Knee Osteoarthritis; Organization type: Domestic For-Profits
| Aug 17, 2026 | NIH RePORTER 5R44AG061985-08 |
| PleoPharma | NIH awarded $2.2M (NIH grant 1U01DA066079-01, new, notice Aug 12, 2026).Evidence (1 event)- Aug 12, 2026 · NIH RePORTER 1U01DA066079-01
Organization: PLEOPHARMA, INC.; City/State: MALVERN, PA; Project number: 1U01DA066079-01; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-08-12; FY total cost (award amount): 2199962; Administering IC: National Institute on Drug Abuse; Project title: Phase 3 Trial of PP-01 for Mitigation of Cannabis Withdrawal in CUD; Organization type: Domestic For-Profits
| Aug 12, 2026 | NIH RePORTER 1U01DA066079-01 |
| Newleos Therapeutics, Inc. | NIH awarded $3.1M (NIH grant 1UG3DA066264-01, new, notice Sep 8, 2026).Evidence (1 event)- Sep 8, 2026 · NIH RePORTER 1UG3DA066264-01
Organization: NEWLEOS THERAPEUTICS, INC.; City/State: HOPKINTON, MA; Project number: 1UG3DA066264-01; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 3097247; Administering IC: National Institute on Drug Abuse; Project title: NTX-2001, a trace amine-associated receptor 1 (TAAR1) partial agonist, for the treatment of Cocaine Use Disorder; Organization type: Domestic For-Profits
| Sep 8, 2026 | NIH RePORTER 1UG3DA066264-01 |
| TwoStep Therapeutics | NIH awarded $1.3M (SBIR Phase II 1R44CA306597-01A1, new, notice Sep 4, 2026); 1 role open.Evidence (1 event)- Sep 4, 2026 · NIH RePORTER 1R44CA306597-01A1
Organization: TWOSTEP THERAPEUTICS, INC.; City/State: SAN CARLOS, CA; Project number: 1R44CA306597-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1303289; Administering IC: National Cancer Institute; Project title: Developing a broadly applicable targeted peptide-drug conjugate for the treatment of solid tumors; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 1R44CA306597-01A1 |
| Curza Inc | NIH awarded $1M (SBIR Phase II 5R44AI186898-03, continuation, notice Jun 26, 2026).Evidence (1 event)- Jun 26, 2026 · NIH RePORTER 5R44AI186898-03
Organization: CURZA INC; City/State: Salt Lake City, UT; Project number: 5R44AI186898-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-26; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: New oral antibiotics focused on treating MDR Gram-negative infections; Organization type: Domestic For-Profits
| Jun 26, 2026 | NIH RePORTER 5R44AI186898-03 |
| Clear Scientific, Inc. | NIH awarded $3M (NIH grant 1U01DA066075-01, new, notice Jul 20, 2026).Evidence (1 event)- Jul 20, 2026 · NIH RePORTER 1U01DA066075-01
Organization: CLEAR SCIENTIFIC, LLC; City/State: CAMBRIDGE, MA; Project number: 1U01DA066075-01; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-07-20; FY total cost (award amount): 3000030; Administering IC: National Institute on Drug Abuse; Project title: A Phase 2a clinical study to evaluate the safety and efficacy of CS-1103, a therapeutic agent to treat methamphetamine intoxication; Organization type: Domestic For-Profits
| Jul 20, 2026 | NIH RePORTER 1U01DA066075-01 |
| Newomics | NIH awarded $1M (SBIR Phase II 5R44GM161156-02, continuation, notice Aug 31, 2026).Evidence (1 event)- Aug 31, 2026 · NIH RePORTER 5R44GM161156-02
Organization: NEWOMICS, INC; City/State: Berkeley, CA; Project number: 5R44GM161156-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 1000000; Administering IC: National Institute of General Medical Sciences; Project title: Multispray Technology for Studying Biomolecular Interactions; Organization type: Domestic For-Profits
| Aug 31, 2026 | NIH RePORTER 5R44GM161156-02 |
| atai Therapeutics, Inc. | NIH awarded $2.73M (NIH grant 5UG3DA064403-02, continuation, notice Jul 6, 2026).Evidence (1 event)- Jul 6, 2026 · NIH RePORTER 5UG3DA064403-02
Organization: ATAI THERAPEUTICS, INC.; City/State: NEW YORK, NY; Project number: 5UG3DA064403-02; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 2733774; Administering IC: National Institute on Drug Abuse; Project title: Optimization and Development of Non-Hallucinogenic 5-HT2A/2C Agonists as Opioid Use Disorder Therapeutics; Organization type: Domestic For-Profits
| Jul 6, 2026 | NIH RePORTER 5UG3DA064403-02 |
| Alida Biosciences Inc. | NIH awarded $1.15M (SBIR Phase II 5R44GM159469-02, continuation, notice Jul 17, 2026).Evidence (1 event)- Jul 17, 2026 · NIH RePORTER 5R44GM159469-02
Organization: ALIDA BIOSCIENCES, INC.; City/State: SAN DIEGO, CA; Project number: 5R44GM159469-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 1146785; Administering IC: National Institute of General Medical Sciences; Project title: Pseudouridine detection with single-base resolution in a multiplexed epitranscriptomics assay; Organization type: Domestic For-Profits
| Jul 17, 2026 | NIH RePORTER 5R44GM159469-02 |
| Mirecule Inc. | NIH awarded $609K (SBIR Phase II 5R44NS119147-05, continuation, notice Sep 4, 2026).Evidence (1 event)- Sep 4, 2026 · NIH RePORTER 5R44NS119147-05
Organization: MIRECULE, INC.; City/State: Gaithersburg, MD; Project number: 5R44NS119147-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 608751; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 5R44NS119147-05 |
| Stingray Therapeutics Inc. | NIH awarded $1.46M (SBIR Phase II 5R44CA278144-04, continuation, notice Sep 16, 2026).Evidence (1 event)- Sep 16, 2026 · NIH RePORTER 5R44CA278144-04
Organization: STINGRAY THERAPEUTICS, INC.; City/State: HOUSTON, TX; Project number: 5R44CA278144-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 1460952; Administering IC: National Cancer Institute; Project title: A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab; Organization type: Domestic For-Profits
| Sep 16, 2026 | NIH RePORTER 5R44CA278144-04 |
| Tendel Therapies Inc. | NIH awarded $1M (SBIR Phase II 5R44AI192249-02, continuation, notice Aug 4, 2026).Evidence (1 event)- Aug 4, 2026 · NIH RePORTER 5R44AI192249-02
Organization: TENDEL THERAPIES INC.; City/State: KENSINGTON, CA; Project number: 5R44AI192249-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-04; FY total cost (award amount): 999990; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Optimizing SIV reservoir depletion by Tendel bsAb-98; Organization type: Domestic For-Profits
| Aug 4, 2026 | NIH RePORTER 5R44AI192249-02 |
| Arcascope | NIH awarded $598K (STTR Phase II 5R42HL163783-04, continuation, notice Sep 2, 2026).Evidence (1 event)- Sep 2, 2026 · NIH RePORTER 5R42HL163783-04
Organization: ARCASCOPE, INC; City/State: CHANTILLY, VA; Project number: 5R42HL163783-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 598418; Administering IC: National Heart Lung and Blood Institute; Project title: Real-world translation of a dynamic and personalized intervention for shift workers; Organization type: Domestic For-Profits
| Sep 2, 2026 | NIH RePORTER 5R42HL163783-04 |
| Revel Pharmaceuticals | NIH awarded $924K (SBIR Phase II 5R44AG084351-03, continuation, notice Jul 10, 2026).Evidence (1 event)- Jul 10, 2026 · NIH RePORTER 5R44AG084351-03
Organization: REVEL PHARMACEUTICALS INC.; City/State: San Francisco, CA; Project number: 5R44AG084351-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 923550; Administering IC: National Institute on Aging; Project title: Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts; Organization type: Domestic For-Profits
| Jul 10, 2026 | NIH RePORTER 5R44AG084351-03 |
| Scarab Genomics LLC | NIH awarded $852K (SBIR Phase II 5R44GM156147-03, continuation, notice Sep 4, 2026); 2 NIH awards totaling $1.77M in the last 12 months.Evidence (2 events)- Sep 4, 2026 · NIH RePORTER 5R44GM156147-03
Organization: SCARAB GENOMICS, LLC; City/State: MADISON, WI; Project number: 5R44GM156147-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 851745; Administering IC: National Institute of General Medical Sciences; Project title: An improved low-endotoxin Clean Genome E. coli strain for production of biological products; Organization type: Domestic For-Profits - Sep 2, 2026 · NIH RePORTER 5R44GM161364-02
Organization: SCARAB GENOMICS, LLC; City/State: MADISON, WI; Project number: 5R44GM161364-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 917119; Administering IC: National Institute of General Medical Sciences; Project title: Development of a continuous microbial fermentation system using reduced genome E. coli that undergo programmed autolysis and generate nuclease post-production for the manufacture of biopharmaceuticals; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 5R44GM156147-03 |
| Toi Labs, Inc. | NIH awarded $1.09M (SBIR Phase II 5R44AG074812-03, continuation, notice Jul 10, 2026).Evidence (1 event)- Jul 10, 2026 · NIH RePORTER 5R44AG074812-03
Organization: TOI LABS, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44AG074812-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 1089746; Administering IC: National Institute on Aging; Project title: Use of a Novel Toilet Seat to Passively Collect Digital Biomarkers in Assisted Living Settings; Organization type: Domestic For-Profits
| Jul 10, 2026 | NIH RePORTER 5R44AG074812-03 |
| Lighthouse Pharmaceuticals | NIH awarded $12.59M (NIH grant 5R01AG088524-02, continuation, notice Aug 18, 2026).Evidence (1 event)- Aug 18, 2026 · NIH RePORTER 5R01AG088524-02
Organization: LIGHTHOUSE PHARMACEUTICALS, INC.; City/State: Novato, CA; Project number: 5R01AG088524-02; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 12591952; Administering IC: National Institute on Aging; Project title: A Randomized, Double-Blind, Placebo-Controlled Study of LHP588 in Subjects with P. gingivalis-Positive Alzheimer's Disease; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 5R01AG088524-02 |
| GentiBio, Inc | NIH awarded $1.06M (SBIR Phase II 1R44DK148134-01, new, notice Sep 17, 2026); 4 NIH awards totaling $3.6M in the last 12 months.Evidence (4 events)- Sep 17, 2026 · NIH RePORTER 1R44DK148134-01
Organization: GENTIBIO, INC.; City/State: CAMBRIDGE, MA; Project number: 1R44DK148134-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1061227; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: An allogeneic and gut specific Engineered T regulatory cell therapy for the treatment of Inflammatory Bowel Disease; Organization type: Domestic For-Profits - Sep 7, 2026 · NIH RePORTER 1R43NS149828-01
Organization: GENTIBIO, INC.; City/State: CAMBRIDGE, MA; Project number: 1R43NS149828-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 320037; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Engineered Tissue Treg Therapy for the Treatment of ALS; Organization type: Domestic For-Profits - Aug 24, 2026 · NIH RePORTER 1R44DK148168-01
Organization: GENTIBIO, INC.; City/State: CAMBRIDGE, MA; Project number: 1R44DK148168-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 1066332; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: GNTI-148: an allogeneic islet-specific engineered Treg for treating T1D; Organization type: Domestic For-Profits - Jul 8, 2026 · NIH RePORTER 5R44NS145848-02
Organization: GENTIBIO, INC.; City/State: CAMBRIDGE, MA; Project number: 5R44NS145848-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-08; FY total cost (award amount): 1150749; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of Tissue Engineered Tregs as a Treatment for Acute Ischemic Stroke; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44DK148134-01 |
| Zymtronix Catalytic Systems, Inc. | NIH awarded $202K (SBIR Phase II 5R44GM134847-04, continuation, notice Jul 22, 2026).Evidence (1 event)- Jul 22, 2026 · NIH RePORTER 5R44GM134847-04
Organization: ZYMTRONIX CATALYTIC SYSTEMS, INC.; City/State: Durham, NC; Project number: 5R44GM134847-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 201770; Administering IC: National Institute of General Medical Sciences; Project title: Scaling-up flow processes for the chemoenzymatic synthesis of a sialylated glycan; Organization type: Domestic For-Profits
| Jul 22, 2026 | NIH RePORTER 5R44GM134847-04 |
| Integral Molecular | NIH awarded $879K (SBIR commercialization 5SB1GM156044-03, continuation, notice Sep 8, 2026); 3 NIH awards totaling $2.05M in the last 12 months; since then posted 2 roles.Evidence (3 events)- Sep 8, 2026 · NIH RePORTER 5SB1GM156044-03
Organization: INTEGRAL MOLECULAR; City/State: PHILADELPHIA, PA; Project number: 5SB1GM156044-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 879255; Administering IC: National Institute of General Medical Sciences; Project title: Specificity Screening Drug Development Tool for Biotherapeutic Safety; Organization type: Domestic For-Profits - Jul 30, 2026 · NIH RePORTER 5R44GM150317-03
Organization: INTEGRAL MOLECULAR; City/State: PHILADELPHIA, PA; Project number: 5R44GM150317-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-30; FY total cost (award amount): 631033; Administering IC: National Institute of General Medical Sciences; Project title: High-throughput Discovery of Antibodies against Understudied Membrane Proteins using mRNA; Organization type: Domestic For-Profits - Jun 19, 2026 · NIH RePORTER 5U24AI189369-02
Organization: INTEGRAL MOLECULAR; City/State: PHILADELPHIA, PA; Project number: 5U24AI189369-02; Activity code: U24; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 541852; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Generation of Pan-reactive Antibody and Cytokine Reagents for Immunologic Analysis of Bats; Organization type: Domestic For-Profits
| Sep 8, 2026 | NIH RePORTER 5SB1GM156044-03 |
| Expanse Bio LLC | NIH awarded $983K (SBIR Phase II 5R44AI186974-04, continuation, notice Jul 15, 2026).Evidence (1 event)- Jul 15, 2026 · NIH RePORTER 5R44AI186974-04
Organization: EXPANSE BIO LLC; City/State: NORTH CHARLESTON, SC; Project number: 5R44AI186974-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-15; FY total cost (award amount): 983076; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Neonatal and Young Pediatric Kidney Preservation through Nanowarming and Vitrification; Organization type: Domestic For-Profits
| Jul 15, 2026 | NIH RePORTER 5R44AI186974-04 |
| Immunova | NIH awarded $460K (SBIR Phase I 1R43AG102094-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43AG102094-01
Organization: IMMUNOVA, LLC; City/State: GAINESVILLE, FL; Project number: 1R43AG102094-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 459616; Administering IC: National Institute on Aging; Project title: Mitigating Age-Related Cognitive Decline through a First-in-Class Lipid Neurogenic Therapy; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43AG102094-01 |
| Highland Instruments Inc. | NIH awarded $1.5M (SBIR Phase II 2R44NS110237-04, competing renewal, notice Aug 6, 2026); 2 NIH awards totaling $3.41M in the last 12 months.Evidence (2 events)- Aug 6, 2026 · NIH RePORTER 2R44NS110237-04
Organization: HIGHLAND INSTRUMENTS, INC.; City/State: CAMBRIDGE, MA; Project number: 2R44NS110237-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 1496687; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: ESStim for the Treatment of Postural Instability in Patients with Parkinson's Disease - Phase IIB; Organization type: Domestic For-Profits - Jun 3, 2026 · NIH RePORTER 5SB1AG091887-02
Organization: HIGHLAND INSTRUMENTS, INC.; City/State: CAMBRIDGE, MA; Project number: 5SB1AG091887-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1916568; Administering IC: National Institute on Aging; Project title: CRP: Noninvasive brain stimulation for chronic pain treatment; Organization type: Domestic For-Profits
| Aug 6, 2026 | NIH RePORTER 2R44NS110237-04 |
| Corami Biotech | NIH awarded $1.16M (STTR Phase II 5R42HL149495-03, continuation, notice Sep 9, 2026).Evidence (1 event)- Sep 9, 2026 · NIH RePORTER 5R42HL149495-03
Organization: CORAMI BIOTECH INC.; City/State: MEMPHIS, TN; Project number: 5R42HL149495-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 1164977; Administering IC: National Heart Lung and Blood Institute; Project title: Minimally Invasive Local Delivery of Cardiac Gene Therapy; Organization type: Domestic For-Profits
| Sep 9, 2026 | NIH RePORTER 5R42HL149495-03 |
| Light Research Inc. | NIH awarded $477K (SBIR Phase II 5R44DE033307-03, continuation, notice Aug 20, 2026).Evidence (1 event)- Aug 20, 2026 · NIH RePORTER 5R44DE033307-03
Organization: LIGHT RESEARCH, INC.; City/State: TUCSON, AZ; Project number: 5R44DE033307-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 477217; Administering IC: National Institute of Dental and Craniofacial Research; Project title: Multimodal intraoral camera; Organization type: Domestic For-Profits
| Aug 20, 2026 | NIH RePORTER 5R44DE033307-03 |
| BEAM Diagnostics, Inc. | NIH awarded $1.75M (SBIR commercialization 5SB1AA032146-02, continuation, notice Aug 13, 2026).Evidence (1 event)- Aug 13, 2026 · NIH RePORTER 5SB1AA032146-02
Organization: BEAM DIAGNOSTICS, INC.; City/State: Roanoke, VA; Project number: 5SB1AA032146-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 1749353; Administering IC: National Institute on Alcohol Abuse and Alcoholism; Project title: Achieving FDA Approval & Commercial Readiness for Beacon-AUD: A Digital Diagnostic Medical Device for Alcohol Use Disorder; Organization type: Domestic For-Profits
| Aug 13, 2026 | NIH RePORTER 5SB1AA032146-02 |
| Paratechs Corp. | NIH awarded $535K (SBIR Phase II 5R44OD032088-03, continuation, notice Aug 25, 2026).Evidence (1 event)- Aug 25, 2026 · NIH RePORTER 5R44OD032088-03
Organization: PARATECHS CORP.; City/State: LEXINGTON, KY; Project number: 5R44OD032088-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 535088; Administering IC: NIH Office of the Director; Project title: A novel rat sperm cryopreservation and artificial insemination system; Organization type: Domestic For-Profits
| Aug 25, 2026 | NIH RePORTER 5R44OD032088-03 |
| Harlingene Life Sciences LLC | NIH awarded $1M (STTR Phase II 5R42AI177204-04, continuation, notice Aug 18, 2026).Evidence (1 event)- Aug 18, 2026 · NIH RePORTER 5R42AI177204-04
Organization: HARLINGENE LIFE SCIENCES LLC; City/State: DOYLESTOWN, PA; Project number: 5R42AI177204-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Hepatoselective Dihydrozuinolizone (HS-DHQ) Molecules for Treatment and Prevention of Hepatitis A Virus (HAV) Infection; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 5R42AI177204-04 |
| Tezcat Biosciences | NIH awarded $929K (SBIR Phase II 5R44CA265512-03, continuation, notice Aug 27, 2026); 2 NIH awards totaling $1.33M in the last 12 months.Evidence (2 events)- Aug 27, 2026 · NIH RePORTER 5R44CA265512-03
Organization: TEZCAT BIOSCIENCES, INC.; City/State: NEW HAVEN, CT; Project number: 5R44CA265512-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 928698; Administering IC: National Cancer Institute; Project title: A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.; Organization type: Domestic For-Profits - Aug 18, 2026 · NIH RePORTER 1R41CA306696-01A1
Organization: TEZCAT BIOSCIENCES, INC.; City/State: NEW HAVEN, CT; Project number: 1R41CA306696-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 399855; Administering IC: National Cancer Institute; Project title: Tumor-targeted delivery of radio/chemotherapy in pancreatic cancer.; Organization type: Domestic For-Profits
| Aug 27, 2026 | NIH RePORTER 5R44CA265512-03 |
| EvoDenovo Inc. | NIH awarded $687K (SBIR Phase II 5R44DA053844-04, continuation, notice Aug 24, 2026).Evidence (1 event)- Aug 24, 2026 · NIH RePORTER 5R44DA053844-04
Organization: EVODENOVO, INC.; City/State: andover, MA; Project number: 5R44DA053844-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 687310; Administering IC: National Institute on Drug Abuse; Project title: Development of small molecule therapeutics for mitigating opioid withdrawal syndrome; Organization type: Domestic For-Profits
| Aug 24, 2026 | NIH RePORTER 5R44DA053844-04 |
| Great Lakes NeuroTechnologies Inc. | NIH awarded $949K (SBIR Phase II 2R44MD013767-04A1, competing renewal, notice Aug 25, 2026); 2 NIH awards totaling $1.88M in the last 12 months.Evidence (2 events)- Aug 25, 2026 · NIH RePORTER 2R44MD013767-04A1
Organization: GREAT LAKES NEUROTECHNOLOGIES; City/State: Independence, OH; Project number: 2R44MD013767-04A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 949447; Administering IC: National Institute on Minority Health and Health Disparities; Project title: DiSCERN: Advanced PD Therapy Candidacy and Evaluation System; Organization type: Domestic For-Profits - Jun 19, 2026 · NIH RePORTER 5R44NS143484-02
Organization: GREAT LAKES NEUROTECHNOLOGIES; City/State: Independence, OH; Project number: 5R44NS143484-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 926671; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: DBS-Expert Pro: Automated Deep Brain Stimulation Programming Using Functional Mapping; Organization type: Domestic For-Profits
| Aug 25, 2026 | NIH RePORTER 2R44MD013767-04A1 |
| Ship of Theseus LLC | NIH awarded $50K (SBIR Phase II 3R44HL158313-03S1, supplement, notice Aug 13, 2026); 2 NIH awards totaling $375K in the last 12 months.Evidence (2 events)- Aug 13, 2026 · NIH RePORTER 3R44HL158313-03S1
Organization: SHIP OF THESEUS, LLC; City/State: Eagleville, PA; Project number: 3R44HL158313-03S1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 50000; Administering IC: National Heart Lung and Blood Institute; Project title: Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant; Organization type: Domestic For-Profits - Jul 22, 2026 · NIH RePORTER 5R44HL158313-03
Organization: SHIP OF THESEUS, LLC; City/State: Eagleville, PA; Project number: 5R44HL158313-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 324853; Administering IC: National Heart Lung and Blood Institute; Project title: Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant; Organization type: Domestic For-Profits
| Aug 13, 2026 | NIH RePORTER 3R44HL158313-03S1 |
| BriaCell Therapeutics | NIH awarded $948K (SBIR Phase II 5R44CA281555-03, continuation, notice Sep 9, 2026).Evidence (1 event)- Sep 9, 2026 · NIH RePORTER 5R44CA281555-03
Organization: BRIACELL THERAPEUTICS CORP; City/State: PHILADELPHIA, PA; Project number: 5R44CA281555-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 947870; Administering IC: National Cancer Institute; Project title: An Off-the-Shelf tumor cell vaccine with HLA-matching alleles for personalized treatment of advanced metastatic prostate cancer.; Organization type: Domestic For-Profits
| Sep 9, 2026 | NIH RePORTER 5R44CA281555-03 |
| Optimeos Life Sciences, Inc. | NIH awarded $300K (SBIR Phase I 5R43AI188970-02, continuation, notice Jul 23, 2026).Evidence (1 event)- Jul 23, 2026 · NIH RePORTER 5R43AI188970-02
Organization: OPTIMEOS LIFE SCIENCES, INC.; City/State: Princeton, NJ; Project number: 5R43AI188970-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-23; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: In vivo targeted delivery of nucleic acids to hematopoietic stem cells for treating primary immunodeficiencies; Organization type: Domestic For-Profits
| Jul 23, 2026 | NIH RePORTER 5R43AI188970-02 |
| Nurelm, Inc. | NIH awarded $588K (SBIR Phase II 5R44MH138145-03, continuation, notice Jul 15, 2026).Evidence (1 event)- Jul 15, 2026 · NIH RePORTER 5R44MH138145-03
Organization: NURELM E-BUSINESS SOFTWARE; City/State: PITTSBURGH, PA; Project number: 5R44MH138145-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-15; FY total cost (award amount): 587897; Administering IC: National Institute of Mental Health; Project title: Using Machine Learning and Sensing to Contextualize Hyperactivity Measurement on Wearable Devices; Organization type: Domestic For-Profits
| Jul 15, 2026 | NIH RePORTER 5R44MH138145-03 |
| Circumvent Pharmaceuticals | NIH awarded $1.22M (SBIR Phase II 5R44NS120360-04, continuation, notice Aug 3, 2026).Evidence (1 event)- Aug 3, 2026 · NIH RePORTER 5R44NS120360-04
Organization: CIRCUMVENT PHARMACEUTICALS, INC.; City/State: PORTLAND, CA; Project number: 5R44NS120360-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 1219273; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a Therapeutic Agent for Treating CLN1 Batten Disease; Organization type: Domestic For-Profits
| Aug 3, 2026 | NIH RePORTER 5R44NS120360-04 |
| Attogene Corporation | NIH awarded $421K (SBIR Phase II 2R44ES034301-02A1, competing renewal, notice Jul 28, 2026).Evidence (1 event)- Jul 28, 2026 · NIH RePORTER 2R44ES034301-02A1
Organization: ATTOGENE; City/State: AUSTIN, TX; Project number: 2R44ES034301-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 421018; Administering IC: National Institute of Environmental Health Sciences; Project title: Development of a portable, rapid, easy-to-use, quantitative dihydroanatoxin-a detection system; Organization type: Domestic For-Profits
| Jul 28, 2026 | NIH RePORTER 2R44ES034301-02A1 |
| RealSeq Biosciences | NIH awarded $383K (SBIR Phase I 1R43CA314894-01, new, notice Aug 20, 2026); 2 NIH awards totaling $1.4M in the last 12 months.Evidence (2 events)- Aug 20, 2026 · NIH RePORTER 1R43CA314894-01
Organization: REALSEQ BIOSCIENCES, INC.; City/State: SANTA CRUZ, CA; Project number: 1R43CA314894-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 382518; Administering IC: National Cancer Institute; Project title: Advanced approach for target small RNAs enrichment from biological samples and sequencing library preparation (TSR-Seq); Organization type: Domestic For-Profits - Aug 7, 2026 · NIH RePORTER 5R44HG013284-03
Organization: REALSEQ BIOSCIENCES, INC.; City/State: SANTA CRUZ, CA; Project number: 5R44HG013284-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 1020220; Administering IC: National Human Genome Research Institute; Project title: Preparation of sequencing libraries for multi-analyte analysis of RNAs; Organization type: Domestic For-Profits
| Aug 20, 2026 | NIH RePORTER 1R43CA314894-01 |
| Sylvatica Biotech Inc. | NIH awarded $972K (SBIR Phase II 5R44DK136457-03, continuation, notice Aug 7, 2026).Evidence (1 event)- Aug 7, 2026 · NIH RePORTER 5R44DK136457-03
Organization: SYLVATICA BIOTECH, INC.; City/State: NORTH CHARLESTON, SC; Project number: 5R44DK136457-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 972116; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Enhanced supercooling for extending non-freezing preservation in preclinical porcine and human donor livers; Organization type: Domestic For-Profits
| Aug 7, 2026 | NIH RePORTER 5R44DK136457-03 |
| Evidation Health, Inc. | NIH awarded $2.02M (SBIR Phase II 4R44DA062284-02, extension, notice Jun 23, 2026).Evidence (1 event)- Jun 23, 2026 · NIH RePORTER 4R44DA062284-02
Organization: EVIDATION HEALTH, INC.; City/State: MENLO PARK, CA; Project number: 4R44DA062284-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-23; FY total cost (award amount): 2023761; Administering IC: National Institute on Drug Abuse; Project title: Research and Engagement on Substance use Harnessing Awareness and Personalized Education (RESHAPE); Organization type: Domestic For-Profits
| Jun 23, 2026 | NIH RePORTER 4R44DA062284-02 |
| Merlin Therapeutics | NIH awarded $1.5M (SBIR Phase II 5R44NS145814-02, continuation, notice Aug 14, 2026).Evidence (1 event)- Aug 14, 2026 · NIH RePORTER 5R44NS145814-02
Organization: MERLIN THERAPEUTICS INC; City/State: KING OF PRUSSIA, PA; Project number: 5R44NS145814-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 1500000; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: AAV-mediated delivery of the inflammasome adapter protein, ASC, as a pro-apoptotic gene therapy for schwannoma; Organization type: Domestic For-Profits
| Aug 14, 2026 | NIH RePORTER 5R44NS145814-02 |
| CND Life Sciences | NIH awarded $1.01M (SBIR Phase II 5R44NS143486-02, continuation, notice Sep 7, 2026).Evidence (1 event)- Sep 7, 2026 · NIH RePORTER 5R44NS143486-02
Organization: CND LIFE SCIENCES, INC.; City/State: Scottsdale, AZ; Project number: 5R44NS143486-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 1012800; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Analysis of Cutaneous Phosphorylated alpha-Synuclein to Identify Patients at Risk of Progressing from Essential Tremor to Parkinson's Disease; Organization type: Domestic For-Profits
| Sep 7, 2026 | NIH RePORTER 5R44NS143486-02 |
| BacStitch DNA | NIH awarded $1.08M (SBIR Phase II 1R44HG014736-01A1, new, notice Sep 3, 2026).Evidence (1 event)- Sep 3, 2026 · NIH RePORTER 1R44HG014736-01A1
Organization: BACSTITCH DNA INC.; City/State: Los Altos, CA; Project number: 1R44HG014736-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 1077022; Administering IC: National Human Genome Research Institute; Project title: Hierarchical in vivo assembly for rapid and high-throughput construction of long DNA sequences; Organization type: Domestic For-Profits
| Sep 3, 2026 | NIH RePORTER 1R44HG014736-01A1 |
| MitoChem Therapeutics | NIH awarded $321K (SBIR Phase I 1R43EY037591-01A1, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43EY037591-01A1
Organization: MITOCHEM THERAPEUTICS INC.; City/State: CHARLESTON, SC; Project number: 1R43EY037591-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 320790; Administering IC: National Eye Institute; Project title: Novel gene mutation agnostic small molecule to treat retinitis pigmentosa; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43EY037591-01A1 |
| SFC Fluidics | NIH awarded $250K (SBIR Phase I 1R43DK146368-01A1, new, notice Aug 31, 2026).Evidence (1 event)- Aug 31, 2026 · NIH RePORTER 1R43DK146368-01A1
Organization: SFC FLUIDICS, LLC; City/State: FAYETTEVILLE, AR; Project number: 1R43DK146368-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 250000; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a Phenolics Depletion Chip (PDC) for Use in Insulin Delivery Patch Pumps; Organization type: Domestic For-Profits
| Aug 31, 2026 | NIH RePORTER 1R43DK146368-01A1 |
| Simulations Plus Inc. | NIH awarded $115K (NIH grant 5U01FD008388-03, continuation, notice Sep 8, 2026).Evidence (1 event)- Sep 8, 2026 · NIH RePORTER 5U01FD008388-03
Organization: SIMULATIONS PLUS, INC.; City/State: LANCASTER, CA; Project number: 5U01FD008388-03; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 114912; Administering IC: Food and Drug Administration; Project title: From Bench to Bioequivalence: In Vitro Mechanistic Understanding of ASD Drug Products in Simulated Gastrointestinal Conditions; Organization type: Domestic For-Profits
| Sep 8, 2026 | NIH RePORTER 5U01FD008388-03 |
| Blotting Innovations | NIH awarded $1.03M (SBIR Phase II 5R44GM148112-03, continuation, notice Aug 7, 2026).Evidence (1 event)- Aug 7, 2026 · NIH RePORTER 5R44GM148112-03
Organization: BLOTTING INNOVATIONS, INC; City/State: CENTRAL, SC; Project number: 5R44GM148112-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 1026555; Administering IC: National Institute of General Medical Sciences; Project title: High-Throughput Western Blotting; Organization type: Domestic For-Profits
| Aug 7, 2026 | NIH RePORTER 5R44GM148112-03 |
| NephroDi Therapeutics | NIH awarded $999K (SBIR Phase II 5R44DK127798-03, continuation, notice Jul 27, 2026).Evidence (1 event)- Jul 27, 2026 · NIH RePORTER 5R44DK127798-03
Organization: NEPHRODI THERAPEUTICS, INC.; City/State: Seattle, WA; Project number: 5R44DK127798-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-27; FY total cost (award amount): 998617; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Novel AMPK activator for treatment of congenital X-linked nephrogenic diabetes insipidus in pediatric patients; Organization type: Domestic For-Profits
| Jul 27, 2026 | NIH RePORTER 5R44DK127798-03 |
| Myolex | NIH awarded $137K (SBIR Phase I 5R43CA306431-02, continuation, notice Sep 1, 2026).Evidence (1 event)- Sep 1, 2026 · NIH RePORTER 5R43CA306431-02
Organization: MYOLEX, INC.; City/State: Brookline, MA; Project number: 5R43CA306431-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 136944; Administering IC: National Cancer Institute; Project title: Electrical impedance myography (EIM) to detect and track cancer cachexia; Organization type: Domestic For-Profits
| Sep 1, 2026 | NIH RePORTER 5R43CA306431-02 |
| iVeena Delivery Systems, Inc. | NIH awarded $1.11M (SBIR Phase II 5R44EY034770-03, continuation, notice Sep 11, 2026).Evidence (1 event)- Sep 11, 2026 · NIH RePORTER 5R44EY034770-03
Organization: IVEENA DELIVERY SYSTEMS, INC.; City/State: SALT LAKE CITY, UT; Project number: 5R44EY034770-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 1111998; Administering IC: National Eye Institute; Project title: Topical Eyedrops Increasing Lysyl Oxidase and Dopamine Activity to Control Myopia; Organization type: Domestic For-Profits
| Sep 11, 2026 | NIH RePORTER 5R44EY034770-03 |
| Oncotherapy Solutions | NIH awarded $400K (SBIR Phase I 1R43CA306418-01A1, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43CA306418-01A1
Organization: ONCOTHERAPY SOLUTIONS, LLC; City/State: Seattle, WA; Project number: 1R43CA306418-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 400000; Administering IC: National Cancer Institute; Project title: Stable, highly potent and safe lead peptide drug conjugate for the treatment of triple-negative breast cancer.; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43CA306418-01A1 |
| Remedy Plan Therapeutics | NIH awarded $1.18M (SBIR Phase II 1R44CA314487-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44CA314487-01
Organization: REMEDY PLAN; City/State: GAITHERSBURG, MD; Project number: 1R44CA314487-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1181436; Administering IC: National Cancer Institute; Project title: Preclinical validation of NAMPT and PARP inhibitor combinations for breast cancer to support clinical studies; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44CA314487-01 |
| Enyx Therapeutics LLC | NIH awarded $792K (STTR Phase II 5R42AA028465-03, continuation, notice Aug 13, 2026).Evidence (1 event)- Aug 13, 2026 · NIH RePORTER 5R42AA028465-03
Organization: ENYX THERAPEUTICS, LLC; City/State: NEW YORK, NY; Project number: 5R42AA028465-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 791929; Administering IC: National Institute on Alcohol Abuse and Alcoholism; Project title: Gene Therapy to Treat Ethanol-induced Osteoporosis Associated with Aldehyde Dehydrogenase 2 Deficiency in Post-menopausal East Asian Women; Organization type: Domestic For-Profits
| Aug 13, 2026 | NIH RePORTER 5R42AA028465-03 |
| IHP Therapeutics | NIH awarded $433K (NIH grant 5UH3NS134781-03, continuation, notice Sep 7, 2026).Evidence (1 event)- Sep 7, 2026 · NIH RePORTER 5UH3NS134781-03
Organization: IHP THERAPEUTICS, INC.; City/State: San Carlos, CA; Project number: 5UH3NS134781-03; Activity code: UH3; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 433322; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease; Organization type: Domestic For-Profits
| Sep 7, 2026 | NIH RePORTER 5UH3NS134781-03 |
| SHY Therapeutics | NIH awarded $287K (SBIR Phase I 5R43AI186577-02, continuation, notice Sep 10, 2026).Evidence (1 event)- Sep 10, 2026 · NIH RePORTER 5R43AI186577-02
Organization: SHY THERAPEUTICS, LLC; City/State: HARRISON, NY; Project number: 5R43AI186577-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 286724; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a Novel Class of Antifungal Therapy; Organization type: Domestic For-Profits
| Sep 10, 2026 | NIH RePORTER 5R43AI186577-02 |
| Palvella Therapeutics | NIH awarded $484K (NIH grant 5R01FD008196-03, continuation, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 5R01FD008196-03
Organization: PALVELLA THERAPEUTICS, INC.; City/State: WAYNE, PA; Project number: 5R01FD008196-03; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 484481; Administering IC: Food and Drug Administration; Project title: SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R01FD008196-03 |
| AivoCode | NIH awarded $500K (SBIR Phase I 1R43AG099485-01A1, new, notice Sep 16, 2026); 2 NIH awards totaling $1.74M in the last 12 months.Evidence (2 events)- Sep 16, 2026 · NIH RePORTER 1R43AG099485-01A1
Organization: AIVOCODE, LLP; City/State: Encinitas, CA; Project number: 1R43AG099485-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 499880; Administering IC: National Institute on Aging; Project title: Early Detection of Alzheimer’s Disease Using a Novel ImmunoPET Conjugate; Organization type: Domestic For-Profits - Jun 3, 2026 · NIH RePORTER 5R44AG097127-02
Organization: AIVOCODE, LLP; City/State: Encinitas, CA; Project number: 5R44AG097127-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1237522; Administering IC: National Institute on Aging; Project title: Single domain antibody development for improving vascular dysfunction in Alzheimer’s disease; Organization type: Domestic For-Profits
| Sep 16, 2026 | NIH RePORTER 1R43AG099485-01A1 |
| Theia Imaging LLC | NIH awarded $61K (SBIR Phase II 3R44EY033604-03S2, supplement, notice Sep 21, 2026); 2 NIH awards totaling $1.09M in the last 12 months.Evidence (2 events)- Sep 21, 2026 · NIH RePORTER 3R44EY033604-03S2
Organization: THEIA IMAGING LLC; City/State: CHAPEL HILL, NC; Project number: 3R44EY033604-03S2; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-21; FY total cost (award amount): 60860; Administering IC: National Eye Institute; Project title: A Widefield, Handheld OCT system for Patients who are Unable to Cooperate; Organization type: Domestic For-Profits - Jul 17, 2026 · NIH RePORTER 2R44EY034418-02A1
Organization: THEIA IMAGING LLC; City/State: CHAPEL HILL, NC; Project number: 2R44EY034418-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 1031041; Administering IC: National Eye Institute; Project title: Ultrahigh Speed, Widefield OCT Angiography System for Patients who are Unable to Cooperate; Organization type: Domestic For-Profits
| Sep 21, 2026 | NIH RePORTER 3R44EY033604-03S2 |
| Max Biopharma, Inc. | NIH awarded $365K (SBIR Phase I 1R43HL184363-01A1, new, notice Sep 9, 2026).Evidence (1 event)- Sep 9, 2026 · NIH RePORTER 1R43HL184363-01A1
Organization: MAX BIOPHARMA, INC.; City/State: LOS ANGELES, CA; Project number: 1R43HL184363-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 364853; Administering IC: National Heart Lung and Blood Institute; Project title: Examination of anti-fibrotic and immune modulatory effects of Oxy210 for targeting cystic fibrosis; Organization type: Domestic For-Profits
| Sep 9, 2026 | NIH RePORTER 1R43HL184363-01A1 |
| YourChoice Therapeutics | NIH awarded $994K (SBIR Phase II 1R44HD120117-01A1, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44HD120117-01A1
Organization: YOURCHOICE THERAPEUTICS, INC.; City/State: Berkeley, CA; Project number: 1R44HD120117-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 994056; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Tablet development and relative bioavailability study in men for ongoing clinical development of YCT-529 as an oral non-hormonal male contraceptive; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44HD120117-01A1 |
| Allinaire Therapeutics | NIH awarded $1.5M (SBIR Phase II 1R44HL186831-01, new, notice Sep 9, 2026).Evidence (1 event)- Sep 9, 2026 · NIH RePORTER 1R44HL186831-01
Organization: ALLINAIRE THERAPEUTICS, LLC; City/State: CLEVELAND, OH; Project number: 1R44HL186831-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 1498892; Administering IC: National Heart Lung and Blood Institute; Project title: An anti-EMAP II monoclonal antibody as a first-in-class treatment for Group III pulmonary hypertension patients with chronic obstructive pulmonary disease; Organization type: Domestic For-Profits
| Sep 9, 2026 | NIH RePORTER 1R44HL186831-01 |
| Cessation Therapeutics | NIH awarded $2.09M (NIH grant 5U01DA063352-02, continuation, notice Aug 25, 2026).Evidence (1 event)- Aug 25, 2026 · NIH RePORTER 5U01DA063352-02
Organization: CESSATION THERAPEUTICS, LLC; City/State: SAN JOSE, CA; Project number: 5U01DA063352-02; Activity code: U01; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 2089891; Administering IC: National Institute on Drug Abuse; Project title: Development of the anti-fentanyl monoclonal antibody, CSX-1004, for prophylaxis against fentanyl and fentanyl analog overdose; Organization type: Domestic For-Profits
| Aug 25, 2026 | NIH RePORTER 5U01DA063352-02 |
| Panome Bio | NIH awarded $1.16M (SBIR Phase II 5R44CA295318-02, continuation, notice Aug 25, 2026).Evidence (1 event)- Aug 25, 2026 · NIH RePORTER 5R44CA295318-02
Organization: PANOME BIO INC; City/State: SAINT LOUIS, MO; Project number: 5R44CA295318-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 1164167; Administering IC: National Cancer Institute; Project title: Biomarker discovery in colon cancer through next-generation metabolomics; Organization type: Domestic For-Profits
| Aug 25, 2026 | NIH RePORTER 5R44CA295318-02 |
| Ossium Health Inc. | NIH awarded $580K (SBIR Phase II 5R44AI183961-03, continuation, notice Aug 11, 2026); since then posted 4 roles.Evidence (1 event)- Aug 11, 2026 · NIH RePORTER 5R44AI183961-03
Organization: OSSIUM HEALTH, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44AI183961-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 579970; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury; Organization type: Domestic For-Profits
| Aug 11, 2026 | NIH RePORTER 5R44AI183961-03 |
| Framergy Inc. | NIH awarded $400K (SBIR Phase I 1R43CA314462-01, new, notice Aug 27, 2026).Evidence (1 event)- Aug 27, 2026 · NIH RePORTER 1R43CA314462-01
Organization: FRAMERGY, INC.; City/State: Wilmington, DE; Project number: 1R43CA314462-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 400000; Administering IC: National Cancer Institute; Project title: A Novel Sunscreen Formulation, Broad Spectrum UV Protection for Cancer Prevention Featuring Photoreactivation to Repair Existing Sun Damage; Organization type: Domestic For-Profits
| Aug 27, 2026 | NIH RePORTER 1R43CA314462-01 |
| OncoTAb | NIH awarded $1.13M (SBIR Phase II 1R44CA306447-01A1, new, notice Jul 17, 2026).Evidence (1 event)- Jul 17, 2026 · NIH RePORTER 1R44CA306447-01A1
Organization: ONCOTAB, INC; City/State: CHARLOTTE, NC; Project number: 1R44CA306447-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 1130587; Administering IC: National Cancer Institute; Project title: Combination Therapy of T-Cell Engager and Chemotherapy for Pancreatic Cancer Treatment; Organization type: Domestic For-Profits
| Jul 17, 2026 | NIH RePORTER 1R44CA306447-01A1 |
| Noveome Biotherapeutics | NIH awarded $265K (STTR Phase I 1R41AG099399-01A1, new, notice Sep 7, 2026).Evidence (1 event)- Sep 7, 2026 · NIH RePORTER 1R41AG099399-01A1
Organization: NOVEOME BIOTHERAPEUTICS, INC.; City/State: PITTSBURGH, PA; Project number: 1R41AG099399-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 265064; Administering IC: National Institute on Aging; Project title: Intranasal ST266 Treatment of the Intracerebroventricular Streptozotocin Rat Model of Cognitive Impairment; Organization type: Domestic For-Profits
| Sep 7, 2026 | NIH RePORTER 1R41AG099399-01A1 |
| Ef Therapeutics LLC | NIH awarded $1.06M (SBIR Phase II 5R44CA298522-02, continuation, notice Aug 28, 2026).Evidence (1 event)- Aug 28, 2026 · NIH RePORTER 5R44CA298522-02
Organization: EF THERAPEUTICS CORP.; City/State: TAMPA, FL; Project number: 5R44CA298522-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 1060745; Administering IC: National Cancer Institute; Project title: IntellipulseTM Platform Technology for Effective Delivery of Therapeutic Agents; Organization type: Domestic For-Profits
| Aug 28, 2026 | NIH RePORTER 5R44CA298522-02 |
| Immunoshield Therapeutics | NIH awarded $935K (SBIR Phase II 5R44DK136496-03, continuation, notice Jul 30, 2026).Evidence (1 event)- Jul 30, 2026 · NIH RePORTER 5R44DK136496-03
Organization: IMMUNOSHIELD THERAPEUTICS INC.; City/State: CHANDLER, AZ; Project number: 5R44DK136496-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-30; FY total cost (award amount): 935197; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Hydrogel injection molded islet macroencapsulation devices to treat diabetes in a non-human primate model; Organization type: Domestic For-Profits
| Jul 30, 2026 | NIH RePORTER 5R44DK136496-03 |
| Kano Therapeutics | NIH awarded $984K (SBIR Phase II 4R44GM159495-02, extension, notice Aug 18, 2026).Evidence (1 event)- Aug 18, 2026 · NIH RePORTER 4R44GM159495-02
Organization: KANO THERAPEUTICS INC; City/State: CAMBRIDGE, MA; Project number: 4R44GM159495-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 984281; Administering IC: National Institute of General Medical Sciences; Project title: Active non-viral nuclear delivery of DNA templates independent of mitosis; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 4R44GM159495-02 |
| Opus Genetics Inc | NIH awarded $1M (SBIR Phase II 1R44EY038152-01A1, new, notice Sep 19, 2026); 2 NIH awards totaling $2.02M in the last 12 months.Evidence (2 events)- Sep 19, 2026 · NIH RePORTER 1R44EY038152-01A1
Organization: OPUS GENETICS INC.; City/State: RALEIGH, NC; Project number: 1R44EY038152-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-19; FY total cost (award amount): 1004925; Administering IC: National Eye Institute; Project title: Development of OPGx-RDH12 as a gene therapy for RDH12 deficiency associated Leber congenital amaurosis (LCA); Organization type: Domestic For-Profits - Sep 17, 2026 · NIH RePORTER 1R44EY038149-01A1
Organization: OPUS GENETICS INC.; City/State: RALEIGH, NC; Project number: 1R44EY038149-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1012469; Administering IC: National Eye Institute; Project title: Development of OPGx-NMNAT1 as a gene therapy for NMNAT1 associated LCA.; Organization type: Domestic For-Profits
| Sep 19, 2026 | NIH RePORTER 1R44EY038152-01A1 |
| Enzyme by Design | NIH awarded $400K (SBIR Phase I 1R43CA306391-01A1, new, notice Sep 16, 2026).Evidence (1 event)- Sep 16, 2026 · NIH RePORTER 1R43CA306391-01A1
Organization: ENZYME BY DESIGN, INC.; City/State: CHICAGO, IL; Project number: 1R43CA306391-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 400000; Administering IC: National Cancer Institute; Project title: Validating the reduced immunogenicity of novel human-like asparaginases to de-risk clinical development; Organization type: Domestic For-Profits
| Sep 16, 2026 | NIH RePORTER 1R43CA306391-01A1 |
| Apex Biomedical Company, LLC | NIH awarded $504K (SBIR commercialization 1SB1AR087897-01, new, notice Sep 11, 2026).Evidence (1 event)- Sep 11, 2026 · NIH RePORTER 1SB1AR087897-01
Organization: APEX BIOMEDICAL COMPANY, LLC; City/State: Wilsonville, OR; Project number: 1SB1AR087897-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 504235; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Improving Fracture Healing with Active Plating Technology; Organization type: Domestic For-Profits
| Sep 11, 2026 | NIH RePORTER 1SB1AR087897-01 |
| X-Therma | NIH awarded $1.1M (SBIR Phase II 2R44DK136396-03, competing renewal, notice Jul 7, 2026).Evidence (1 event)- Jul 7, 2026 · NIH RePORTER 2R44DK136396-03
Organization: X-THERMA INC.; City/State: Hercules, CA; Project number: 2R44DK136396-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 1100001; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Phase IIB - Greatly Extended Subzero Ischemic Storage of Renal Allografts Using Novel Bio-inspired Next Generation Cryoprotectants; Organization type: Domestic For-Profits
| Jul 7, 2026 | NIH RePORTER 2R44DK136396-03 |
| Ridgeline Therapeutics | NIH awarded $2.12M (SBIR Phase II 1R44AG102216-01, new, notice Sep 17, 2026); 2 NIH awards totaling $3.02M in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 1R44AG102216-01
Organization: RIDGELINE THERAPEUTICS, INC.; City/State: Houston, TX; Project number: 1R44AG102216-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 2117233; Administering IC: National Institute on Aging; Project title: Cardiovascular Safety and Scalable Manufacturing for Investigational New Drug Filing of a Novel Oral Drug to Accelerate Musculoskeletal Recovery in Older Adults; Organization type: Domestic For-Profits - Jul 28, 2026 · NIH RePORTER 5R44AG092210-02
Organization: RIDGELINE THERAPEUTICS, INC.; City/State: Houston, TX; Project number: 5R44AG092210-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 904811; Administering IC: National Institute on Aging; Project title: Preclinical validation of a novel adjunct small molecule drug to prevent muscle loss and enhance weight loss in older adults; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44AG102216-01 |
| Sano Healthcare Consultants, LLC | NIH awarded $1.06M (SBIR Phase II 2R44DA061387-02, competing renewal, notice Aug 5, 2026).Evidence (1 event)- Aug 5, 2026 · NIH RePORTER 2R44DA061387-02
Organization: SANO HEALTHCARE CONSULTANTS, LLC; City/State: Ontario, CA; Project number: 2R44DA061387-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 1055180; Administering IC: National Institute on Drug Abuse; Project title: Secure Remote Dispensing of Liquid Methadone with Home Monitoring: Environmental Interactive Devices Support Sustainable Economic and Expansive Clinical Treatment of Opioid Use Disorder Treatment; Organization type: Domestic For-Profits
| Aug 5, 2026 | NIH RePORTER 2R44DA061387-02 |
| Serinus Biosciences | NIH awarded $349K (SBIR Phase II 1R44GM165171-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44GM165171-01
Organization: SERINUS BIOSCIENCES INC; City/State: NEW YORK, NY; Project number: 1R44GM165171-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 349090; Administering IC: National Institute of General Medical Sciences; Project title: A massively parallel cell-based platform for the rational discovery of molecular glues; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44GM165171-01 |
| HydroGene Therapeutics | NIH awarded $1.03M (SBIR Phase II 1R44HL187020-01, new, notice Sep 16, 2026); 2 NIH awards totaling $2.12M in the last 12 months.Evidence (2 events)- Sep 16, 2026 · NIH RePORTER 1R44HL187020-01
Organization: HYDROGENE THERAPEUTICS INC; City/State: HOUSTON, TX; Project number: 1R44HL187020-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 1027445; Administering IC: National Heart Lung and Blood Institute; Project title: Non-viral hydrodynamic gene therapy for life-long correction of hemophilia; Organization type: Domestic For-Profits - Sep 10, 2026 · NIH RePORTER 1R44DK148200-01
Organization: HYDROGENE THERAPEUTICS INC; City/State: HOUSTON, TX; Project number: 1R44DK148200-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 1097036; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Developing Hydrodynamic Injection through Biliary System for the Treatment of Wilson's Disease; Organization type: Domestic For-Profits
| Sep 16, 2026 | NIH RePORTER 1R44HL187020-01 |
| Enigma Biomedical | NIH awarded $897K (SBIR Phase II 1R44AG102186-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44AG102186-01
Organization: ENIGMA BIOMEDICAL USA, INC; City/State: KNOXVILLE, TN; Project number: 1R44AG102186-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 896719; Administering IC: National Institute on Aging; Project title: Clinical Evaluation of a Novel [18F] Positron Emission Tomography (PET) Tracer for Differential Diagnosis and Staging of 4R Tauopathies; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44AG102186-01 |
| Paulex Bio | NIH awarded $350K (STTR Phase II 1R42DK148220-01, new, notice Sep 10, 2026).Evidence (1 event)- Sep 10, 2026 · NIH RePORTER 1R42DK148220-01
Organization: PAULEX BIO INC.; City/State: LA JOLLA, CA; Project number: 1R42DK148220-01; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 350000; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Preclinical Development of Paulex-4 for Human Trials for Beta Cell Regeneration to treat Diabetes; Organization type: Domestic For-Profits
| Sep 10, 2026 | NIH RePORTER 1R42DK148220-01 |
| Switch Therapeutics | NIH awarded $1.61M (SBIR Phase II 1R44AG102082-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44AG102082-01
Organization: SWITCH THERAPEUTICS INC.; City/State: SOUTH SAN FRANCISCO, CA; Project number: 1R44AG102082-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1609473; Administering IC: National Institute on Aging; Project title: Liver-Sparing APOE Inhibitor for the Treatment of Alzheimer's Disease in APOE4 Homozygotes; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44AG102082-01 |
| Bessor Pharma | NIH awarded $1.1M (SBIR Phase II 5R44DK111251-05, continuation, notice Jul 28, 2026).Evidence (1 event)- Jul 28, 2026 · NIH RePORTER 5R44DK111251-05
Organization: BESSOR PHARMA, LLC; City/State: FRAMINGHAM, MA; Project number: 5R44DK111251-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 1099995; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a novel renalase agonist for the treatment of acute pancreatitis; Organization type: Domestic For-Profits
| Jul 28, 2026 | NIH RePORTER 5R44DK111251-05 |
| Constantiam Biosciences | NIH awarded $1.25M (SBIR Phase II 2R44AG084431-02, competing renewal, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 2R44AG084431-02
Organization: CONSTANTIAM BIOSCIENCES INC.; City/State: KATY, TX; Project number: 2R44AG084431-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1252240; Administering IC: National Institute on Aging; Project title: Leveraging high-throughput functional data for assessment of Alzheimer's risk; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 2R44AG084431-02 |
| Persista Bio | NIH awarded $1.01M (SBIR Phase II 5R44DK142496-02, continuation, notice Jul 31, 2026).Evidence (1 event)- Jul 31, 2026 · NIH RePORTER 5R44DK142496-02
Organization: PERSISTA BIO INC; City/State: ITHACA, NY; Project number: 5R44DK142496-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-31; FY total cost (award amount): 1006033; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Advanced Pre-Clinical Development of O2LineTM System for Type 1 Diabetes Cell Therapy; Organization type: Domestic For-Profits
| Jul 31, 2026 | NIH RePORTER 5R44DK142496-02 |
| Nanohmics Inc. | NIH awarded $1.02M (SBIR Phase II 5R44CK000679-03, continuation, notice Aug 24, 2026); 2 NIH awards totaling $1.34M in the last 12 months.Evidence (2 events)- Aug 24, 2026 · NIH RePORTER 5R44CK000679-03
Organization: NANOHMICS, INC.; City/State: AUSTIN, TX; Project number: 5R44CK000679-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 1022797; Administering IC: National Center for Emerging and Zoonotic Infectious Diseases; Project title: Lateral Flow-Electrochemiluminescent (LF-ECL) Test Strips and Portable Reader for Ultrasensitive Foodborne Pathogen Detection; Organization type: Domestic For-Profits - Jul 23, 2026 · NIH RePORTER 1R43ES038796-01
Organization: NANOHMICS, INC.; City/State: AUSTIN, TX; Project number: 1R43ES038796-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-23; FY total cost (award amount): 313365; Administering IC: National Institute of Environmental Health Sciences; Project title: Handheld Fluorescent Lysosomal Yeast (FLY) Biosensor for Toxic Metal Ions andOrganic Pollutants in Water; Organization type: Domestic For-Profits
| Aug 24, 2026 | NIH RePORTER 5R44CK000679-03 |
| MindImmune Therapeutics | NIH awarded $496K (SBIR Phase I 1R43AG102103-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43AG102103-01
Organization: MINDIMMUNE THERAPEUTICS, INC.; City/State: KINGSTON, RI; Project number: 1R43AG102103-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 496415; Administering IC: National Institute on Aging; Project title: Targeting CD11c immune cells to alleviate cerebral amyloid angiopathy and amyloid-related imaging abnormality in patients with Alzheimer's disease; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43AG102103-01 |
| KaliVir Immunotherapeutics | NIH awarded $307K (SBIR Phase II 1R44CA314562-01, new, notice Sep 3, 2026).Evidence (1 event)- Sep 3, 2026 · NIH RePORTER 1R44CA314562-01
Organization: KALIVIR IMMUNOTHERAPEUTICS, INC; City/State: PITTSBURGH, PA; Project number: 1R44CA314562-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 306756; Administering IC: National Cancer Institute; Project title: Translation of the novel oncolytic immunotherapy VET6-PDI; Organization type: Domestic For-Profits
| Sep 3, 2026 | NIH RePORTER 1R44CA314562-01 |
| Perception Dynamics Institute | NIH awarded $1.01M (SBIR Phase II 2R44NS132718-03, competing renewal, notice Sep 7, 2026).Evidence (1 event)- Sep 7, 2026 · NIH RePORTER 2R44NS132718-03
Organization: PERCEPTION DYNAMICS INSTITUTE; City/State: Encinitas, CA; Project number: 2R44NS132718-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-07; FY total cost (award amount): 1005434; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Retraining neural pathways improves cognitive skills after a mild traumatic brain injury; Organization type: Domestic For-Profits
| Sep 7, 2026 | NIH RePORTER 2R44NS132718-03 |
| RyTek Medical Inc. | NIH awarded $472K (STTR Phase I 1R41NS143559-01A1, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R41NS143559-01A1
Organization: RYTEK MEDICAL, INC.; City/State: LEBANON, NH; Project number: 1R41NS143559-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 472228; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: PulmoZ: A wearable bioimpedance-sensing patch for remote pulmonary function assessment in ALS; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R41NS143559-01A1 |
| Thetis Pharmaceuticals LLC | NIH awarded $670K (SBIR commercialization 1SB1DK145287-01A1, new, notice Sep 17, 2026); 2 NIH awards totaling $941K in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 1SB1DK145287-01A1
Organization: THETIS PHARMACEUTICALS, LLC; City/State: DEEP RIVER, CT; Project number: 1SB1DK145287-01A1; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 669925; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of TP-317 for Ulcerative Colitis; Organization type: Domestic For-Profits - Jul 6, 2026 · NIH RePORTER 5R44CA278026-03
Organization: THETIS PHARMACEUTICALS, LLC; City/State: DEEP RIVER, CT; Project number: 5R44CA278026-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 271378; Administering IC: National Cancer Institute; Project title: Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1SB1DK145287-01A1 |
| Glyphic Biotechnologies, Inc. | NIH awarded $1.6M (SBIR Phase II 2R44GM151897-02A1, competing renewal, notice Jul 24, 2026); 5 roles open.Evidence (1 event)- Jul 24, 2026 · NIH RePORTER 2R44GM151897-02A1
Organization: GLYPHIC BIOTECHNOLOGIES, INC.; City/State: MENLO PARK, CA; Project number: 2R44GM151897-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-24; FY total cost (award amount): 1599463; Administering IC: National Institute of General Medical Sciences; Project title: Single-molecule protein sequencing: resolving individual amino acids via commercially accessible nanopores; Organization type: Domestic For-Profits
| Jul 24, 2026 | NIH RePORTER 2R44GM151897-02A1 |
| Tempo Therapeutics Inc | NIH awarded $1.42M (SBIR Phase II 1R44CA314892-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44CA314892-01
Organization: TEMPO THERAPEUTICS, INC.; City/State: San Diego, CA; Project number: 1R44CA314892-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1423186; Administering IC: National Cancer Institute; Project title: MOSAIC II: A Randomized Clinical Study of the MAP Wound Matrix to Reduce Time to Graft-Readiness after Non-Melanoma Skin Cancer Resection; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44CA314892-01 |
| Bridgesource Medical, Corp. | NIH awarded $1.51M (SBIR commercialization 1SB1AG102150-01, new, notice Sep 17, 2026); 2 NIH awards totaling $1.83M in the last 12 months.Evidence (2 events)- Sep 17, 2026 · NIH RePORTER 1SB1AG102150-01
Organization: BRIDGESOURCE MEDICAL CORPORATION; City/State: AUSTIN, TX; Project number: 1SB1AG102150-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1511003; Administering IC: National Institute on Aging; Project title: Medical Device Identifier to Improve Emergency Triage; Organization type: Domestic For-Profits - Aug 24, 2026 · NIH RePORTER 1R43HL182792-01A1
Organization: BRIDGESOURCE MEDICAL CORPORATION; City/State: AUSTIN, TX; Project number: 1R43HL182792-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 320727; Administering IC: National Heart Lung and Blood Institute; Project title: A Right Heart Catheter for Pressure-Volume Loop Risk Stratification for Percutaneous Valve Repair in Tricuspid Regurgitation; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1SB1AG102150-01 |
| Andson Biotech | NIH awarded $1.4M (SBIR Phase II 1R44GM165164-01, new, notice Sep 3, 2026).Evidence (1 event)- Sep 3, 2026 · NIH RePORTER 1R44GM165164-01
Organization: ANDSON BIOTECH INC.; City/State: ATLANTA, GA; Project number: 1R44GM165164-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 1403671; Administering IC: National Institute of General Medical Sciences; Project title: Development of an Automated Sample Preparation Platform for High Throughput Mass Spectrometry Characterization of Biotherapeutics; Organization type: Domestic For-Profits
| Sep 3, 2026 | NIH RePORTER 1R44GM165164-01 |
| XCellAssay | NIH awarded $1.14M (SBIR Phase II 2R44ES036049-02, competing renewal, notice Jul 10, 2026).Evidence (1 event)- Jul 10, 2026 · NIH RePORTER 2R44ES036049-02
Organization: XCELLASSAY, INC.; City/State: SAN FRANCISCO, CA; Project number: 2R44ES036049-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 1135244; Administering IC: National Institute of Environmental Health Sciences; Project title: Multiplexed Nuclear Receptor BioAssay platform to inexpensively and broadly survey the nation's water supply for contamination by endocrine disrupting chemicals; Organization type: Domestic For-Profits
| Jul 10, 2026 | NIH RePORTER 2R44ES036049-02 |
| Cognixion | NIH awarded $1.26M (SBIR Phase II 1R44DC023888-01A1, new, notice Jul 22, 2026).Evidence (1 event)- Jul 22, 2026 · NIH RePORTER 1R44DC023888-01A1
Organization: COGNIXION CORPORATION; City/State: SANTA BARBARA, CA; Project number: 1R44DC023888-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 1258551; Administering IC: National Institute on Deafness and Other Communication Disorders; Project title: BCI and Hybrid BCI Wearable Agency Device for ALS.; Organization type: Domestic For-Profits
| Jul 22, 2026 | NIH RePORTER 1R44DC023888-01A1 |
| Enfuego Therapeutics, Inc. | NIH awarded $312K (SBIR Phase II 1R44CA314597-01, new, notice Sep 14, 2026).Evidence (1 event)- Sep 14, 2026 · NIH RePORTER 1R44CA314597-01
Organization: ENFUEGO THERAPEUTICS INC.; City/State: PITTSBORO, NC; Project number: 1R44CA314597-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 311734; Administering IC: National Cancer Institute; Project title: Overcoming Adaptive KRAS Inhibitor Resistance with Ligand-Directed KRAS G12V-panTEAD Chimeras; Organization type: Domestic For-Profits
| Sep 14, 2026 | NIH RePORTER 1R44CA314597-01 |
| N.P. Photonics, Inc. | NIH awarded $307K (SBIR Phase I 1R43GM165163-01, new, notice Sep 1, 2026).Evidence (1 event)- Sep 1, 2026 · NIH RePORTER 1R43GM165163-01
Organization: NP PHOTONICS, INC.; City/State: TUCSON, AZ; Project number: 1R43GM165163-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 306873; Administering IC: National Institute of General Medical Sciences; Project title: Low-cost robust compact 900 nm femtosecond laser source for two-photon microscopy; Organization type: Domestic For-Profits
| Sep 1, 2026 | NIH RePORTER 1R43GM165163-01 |
| Origin Endoscopy | NIH awarded $1.21M (SBIR Phase II 1R44DK145328-01A1, new, notice Sep 14, 2026).Evidence (1 event)- Sep 14, 2026 · NIH RePORTER 1R44DK145328-01A1
Organization: ORIGIN ENDOSCOPY INC.; City/State: BALTIMORE, MD; Project number: 1R44DK145328-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1212289; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of EpiMAX, a first-in-class injectable hemostatic agent for long-acting hemostasis of gastrointestinal bleeding; Organization type: Domestic For-Profits
| Sep 14, 2026 | NIH RePORTER 1R44DK145328-01A1 |
| Dauntless Biotherapeutics, Inc. | NIH awarded $400K (SBIR Phase I 1R43CA306683-01A1, new, notice Aug 11, 2026).Evidence (1 event)- Aug 11, 2026 · NIH RePORTER 1R43CA306683-01A1
Organization: DAUNTLESS BIOTHERAPEUTICS, INC.; City/State: San Diego, CA; Project number: 1R43CA306683-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 400000; Administering IC: National Cancer Institute; Project title: Overcoming Breast Cancer Resistance with a Dual-Function Antibody Therapeutic; Organization type: Domestic For-Profits
| Aug 11, 2026 | NIH RePORTER 1R43CA306683-01A1 |
| Equator Therapeutics | NIH awarded $423K (SBIR Phase I 1R43DK146576-01A1, new, notice Aug 27, 2026).Evidence (1 event)- Aug 27, 2026 · NIH RePORTER 1R43DK146576-01A1
Organization: EQUATOR THERAPEUTICS, INC.; City/State: Saint Louis, MO; Project number: 1R43DK146576-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 422785; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Partial Agonism of Mitochondrial Thermogenesis for the Safe Stimulation of Energy Expenditure; Organization type: Domestic For-Profits
| Aug 27, 2026 | NIH RePORTER 1R43DK146576-01A1 |
| JiLLiON Therapeutics Inc. | NIH awarded $1.12M (SBIR Phase II 2R44AG085856-02, competing renewal, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 2R44AG085856-02
Organization: JILLION THERAPEUTICS INC.; City/State: BROOKLYN, NY; Project number: 2R44AG085856-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1118025; Administering IC: National Institute on Aging; Project title: Advancing DEL-derived Small Molecule Inhibitors of Pathological Tau Toward Preclinical Development for Alzheimer’s Disease and Tauopathies; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 2R44AG085856-02 |
| AiM Medical Robotics | NIH awarded $1.01M (SBIR Phase II 1R44CA314728-01, new, notice Aug 25, 2026).Evidence (1 event)- Aug 25, 2026 · NIH RePORTER 1R44CA314728-01
Organization: AIM MEDICAL ROBOTICS INC; City/State: WORCESTER, MA; Project number: 1R44CA314728-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 1008660; Administering IC: National Cancer Institute; Project title: Intraoperative MRI-Guided Neurosurgery Robot for Enhancing Ablative Treatment of Brain Cancer; Organization type: Domestic For-Profits
| Aug 25, 2026 | NIH RePORTER 1R44CA314728-01 |
| Cellular Vehicles Inc. | NIH awarded $1.02M (SBIR Phase II 2R44TR005112-02, competing renewal, notice Jun 16, 2026).Evidence (1 event)- Jun 16, 2026 · NIH RePORTER 2R44TR005112-02
Organization: CELLULAR VEHICLES INC.; City/State: SAN MATEO, CA; Project number: 2R44TR005112-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 1022611; Administering IC: National Center for Advancing Translational Sciences; Project title: Development of a novel tool that standardizes and automates the formulation of cell-laden hydrogels; Organization type: Domestic For-Profits
| Jun 16, 2026 | NIH RePORTER 2R44TR005112-02 |
| Airway Therapeutics | NIH awarded $1.91M (SBIR Phase II 1R44HL186892-01, new, notice Sep 10, 2026).Evidence (1 event)- Sep 10, 2026 · NIH RePORTER 1R44HL186892-01
Organization: AIRWAY THERAPEUTICS, INC.; City/State: Atlanta, GA; Project number: 1R44HL186892-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 1906253; Administering IC: National Heart Lung and Blood Institute; Project title: A Randomized,Phase 2b/3 Study to Evaluate the Efficacy and Safety of Zelpultide Alfa in Preventing BPD in High-Risk Preterm Neonates Compared to Standard of Care.; Organization type: Domestic For-Profits
| Sep 10, 2026 | NIH RePORTER 1R44HL186892-01 |
| Claret Bioscience | NIH awarded $386K (SBIR Phase I 1R43CA314763-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43CA314763-01
Organization: CLARET BIOSCIENCE, LLC; City/State: BIRMINGHAM, MI; Project number: 1R43CA314763-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 385919; Administering IC: National Cancer Institute; Project title: A cfDNA methylo-fragmentomic assay for prediction of risk-progression in Prostate Cancer; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43CA314763-01 |
| Expression Therapeutics, LLC | NIH awarded $1.13M (SBIR Phase II 2R44CA281633-02A1, competing renewal, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 2R44CA281633-02A1
Organization: EXPRESSION THERAPEUTICS; City/State: TUCKER, GA; Project number: 2R44CA281633-02A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1131730; Administering IC: National Cancer Institute; Project title: ADEPT-STAR therapy for high risk neuroblastoma; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 2R44CA281633-02A1 |
| Intus Biosciences | NIH awarded $404K (SBIR Phase II 1R44CA314644-01, new, notice Aug 18, 2026).Evidence (1 event)- Aug 18, 2026 · NIH RePORTER 1R44CA314644-01
Organization: INTUS BIOSCIENCES LLC; City/State: FARMINGTON, CT; Project number: 1R44CA314644-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 404338; Administering IC: National Cancer Institute; Project title: Non-Invasive, Bacterial-Based Early-Onset Colorectal Screen; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 1R44CA314644-01 |
| NextStep Robotics Inc. | NIH awarded $307K (STTR Phase I 1R41AG102361-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R41AG102361-01
Organization: NEXTSTEP ROBOTICS, LLC; City/State: BALTIMORE, MD; Project number: 1R41AG102361-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 306884; Administering IC: National Institute on Aging; Project title: A Modular Overground Balance Walkway for Task-Specific Perturbation-based Fall Prevention Assessment and Training; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R41AG102361-01 |
| AlphaRose Therapeutics | NIH awarded $313K (SBIR Phase II 1R44HD122555-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44HD122555-01
Organization: ALPHAROSE THERAPEUTICS INC.; City/State: Leander, TX; Project number: 1R44HD122555-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 313208; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Anti-Sense Oligonucleotide Therapy for HNRNPH2 Neurodevelopmental Disorder.; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44HD122555-01 |
| Migra-Therapeutics | NIH awarded $315K (SBIR Phase I 1R43CA310425-01A1, new, notice Sep 14, 2026).Evidence (1 event)- Sep 14, 2026 · NIH RePORTER 1R43CA310425-01A1
Organization: MIGRA-THERAPEUTICS, LLC; City/State: Atlanta, GA; Project number: 1R43CA310425-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 314896; Administering IC: National Cancer Institute; Project title: Development of tumor targeting and stroma penetrating toxin for pancreatic cancer treatment; Organization type: Domestic For-Profits
| Sep 14, 2026 | NIH RePORTER 1R43CA310425-01A1 |
| Tiba Biotech LLC | NIH awarded $397K (SBIR Phase I 1R43HL184887-01A1, new, notice Aug 3, 2026).Evidence (1 event)- Aug 3, 2026 · NIH RePORTER 1R43HL184887-01A1
Organization: TIBA BIOTECH, LLC; City/State: CAMBRIDGE, MA; Project number: 1R43HL184887-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 396805; Administering IC: National Heart Lung and Blood Institute; Project title: Lung-targeting delivery of small interfering RNA for pulmonary therapeutics; Organization type: Domestic For-Profits
| Aug 3, 2026 | NIH RePORTER 1R43HL184887-01A1 |
| Cascade Biocatalysts Inc. | NIH awarded $307K (SBIR Phase I 1R43TR006332-01, new, notice Aug 5, 2026).Evidence (1 event)- Aug 5, 2026 · NIH RePORTER 1R43TR006332-01
Organization: CASCADE BIOCATALYSTS INC.; City/State: DENVER, CO; Project number: 1R43TR006332-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 306871; Administering IC: National Center for Advancing Translational Sciences; Project title: Immobilized Cofactor Regeneration Systems to Accelerate Enzymatic API Manufacturing; Organization type: Domestic For-Profits
| Aug 5, 2026 | NIH RePORTER 1R43TR006332-01 |
| Midwest Bioprocessing Center | NIH awarded $314K (SBIR Phase I 1R43GM165183-01, new, notice Aug 24, 2026); 2 NIH awards totaling $628K in the last 12 months.Evidence (2 events)- Aug 24, 2026 · NIH RePORTER 1R43GM165183-01
Organization: MIDWEST BIOPROCESSING CENTER, INC.; City/State: Peoria, IL; Project number: 1R43GM165183-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 313770; Administering IC: National Institute of General Medical Sciences; Project title: Production of Pseudaminic Acids and Their CMP-activated Derivatives; Organization type: Domestic For-Profits - Aug 13, 2026 · NIH RePORTER 1R43GM165201-01
Organization: MIDWEST BIOPROCESSING CENTER, INC.; City/State: Peoria, IL; Project number: 1R43GM165201-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 313957; Administering IC: National Institute of General Medical Sciences; Project title: Chemoenzymatic Production of Bioorthogonal Carbohydrates for Glycan Research Applications; Organization type: Domestic For-Profits
| Aug 24, 2026 | NIH RePORTER 1R43GM165183-01 |
| ISA Associates, Inc. | NIH awarded $305K (SBIR Phase I 1R43HL186938-01, new, notice Jul 31, 2026).Evidence (1 event)- Jul 31, 2026 · NIH RePORTER 1R43HL186938-01
Organization: ISA ASSOCIATES, INC.; City/State: Arlington, VA; Project number: 1R43HL186938-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-31; FY total cost (award amount): 305471; Administering IC: National Heart Lung and Blood Institute; Project title: Reducing Hypertension Among Men in Manual and Trade Labor: A Mobile Stress Management and Medication Adherence Intervention; Organization type: Domestic For-Profits
| Jul 31, 2026 | NIH RePORTER 1R43HL186938-01 |
| Catena Biosciences | NIH awarded $1.07M (SBIR Phase II 1R44CA314761-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44CA314761-01
Organization: CATENA BIOSCIENCES, INC.; City/State: EL CERRITO, CA; Project number: 1R44CA314761-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1072102; Administering IC: National Cancer Institute; Project title: Advancing Site-Selective Multi-Payload HER2-Targeted Conjugates to Overcome Resistance and Boost Survival in Breast and Gastric Cancers; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44CA314761-01 |
| Zaiput Flow Technologies LLC | NIH awarded $306K (SBIR Phase I 1R43TR006372-01, new, notice Aug 10, 2026).Evidence (1 event)- Aug 10, 2026 · NIH RePORTER 1R43TR006372-01
Organization: ZAIPUT FLOW TECHNOLOGIES LLC; City/State: Waltham, MA; Project number: 1R43TR006372-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 306301; Administering IC: National Center for Advancing Translational Sciences; Project title: Continuous, Scalable, Safe Hydrogenation for Pharmaceutical Manufacturing; Organization type: Domestic For-Profits
| Aug 10, 2026 | NIH RePORTER 1R43TR006372-01 |
| Intero Biosystems Inc. | NIH awarded $350K (SBIR Phase I 1R43TR006331-01, new, notice Jul 14, 2026); 2 NIH awards totaling $1.4M in the last 12 months.Evidence (2 events)- Jul 14, 2026 · NIH RePORTER 1R43TR006331-01
Organization: INTERO BIOSYSTEMS INC.; City/State: Aurora, CO; Project number: 1R43TR006331-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-14; FY total cost (award amount): 349824; Administering IC: National Center for Advancing Translational Sciences; Project title: A Novel Human Intestinal Organoid Platform with Peristaltic Function for Drug Discovery and Pre-Clinical Testing in GI Motility Disorders; Organization type: Domestic For-Profits - Jul 7, 2026 · NIH RePORTER 2R44TR005379-02
Organization: INTERO BIOSYSTEMS INC.; City/State: Aurora, CO; Project number: 2R44TR005379-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-07; FY total cost (award amount): 1046897; Administering IC: National Center for Advancing Translational Sciences; Project title: A Novel Multi-Lineage Human Intestinal Organoid Screening Platform for Drug Discovery and Preclinical Testing; Organization type: Domestic For-Profits
| Jul 14, 2026 | NIH RePORTER 1R43TR006331-01 |
| Hummingbird Precision Machine Co. | NIH awarded $313K (SBIR Phase I 1R43GM165185-01, new, notice Jul 8, 2026).Evidence (1 event)- Jul 8, 2026 · NIH RePORTER 1R43GM165185-01
Organization: HUMMINGBIRD PRECISION MACHINE COMPANY; City/State: LACEY, WA; Project number: 1R43GM165185-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-08; FY total cost (award amount): 313383; Administering IC: National Institute of General Medical Sciences; Project title: Integrated Mixing and Inkjet Deposition for Time Resolved Cryo-EM Sample Preparation; Organization type: Domestic For-Profits
| Jul 8, 2026 | NIH RePORTER 1R43GM165185-01 |
| SonALAsense, Inc. | NIH awarded $497K (SBIR Phase II 5R44CA275508-03, continuation, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 5R44CA275508-03
Organization: SONALASENSE INC; City/State: San Carlos, CA; Project number: 5R44CA275508-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 497384; Administering IC: National Cancer Institute; Project title: Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R44CA275508-03 |
| GSNO Therapeutics | NIH awarded $303K (SBIR Phase I 1R43EY039156-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43EY039156-01
Organization: GSNO THERAPEUTICS, INC.; City/State: SHELTON, WA; Project number: 1R43EY039156-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 303035; Administering IC: National Eye Institute; Project title: Inhibition of Optic Nerve Degeneration; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43EY039156-01 |
| Quantum Simulation Technologies Inc. | NIH awarded $1.02M (SBIR Phase II 2R44GM152994-02, competing renewal, notice Sep 1, 2026).Evidence (1 event)- Sep 1, 2026 · NIH RePORTER 2R44GM152994-02
Organization: QUANTUM SIMULATION TECHNOLOGIES, INC.; City/State: Boston, MA; Project number: 2R44GM152994-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 1022908; Administering IC: National Institute of General Medical Sciences; Project title: Binding free energy predictions for peptide drugs: A novel machine learning-based peptide simulation model for high-throughput computational lead optimization with quantum mechanical accuracy.; Organization type: Domestic For-Profits
| Sep 1, 2026 | NIH RePORTER 2R44GM152994-02 |
| DUB Therapeutics Inc. | NIH awarded $1.01M (SBIR Phase II 5R44EY038138-02, continuation, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 5R44EY038138-02
Organization: DUB THERAPEUTICS INC.; City/State: SYRACUSE, NY; Project number: 5R44EY038138-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1009284; Administering IC: National Eye Institute; Project title: A novel siRNA therapeutic to prevent scarring and bleb failure after trabeculectomy; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R44EY038138-02 |
| Koronis Biomedical Technologies | NIH awarded $1.1M (SBIR Phase II 5R44DK127631-05, continuation, notice Aug 11, 2026).Evidence (1 event)- Aug 11, 2026 · NIH RePORTER 5R44DK127631-05
Organization: KORONIS BIOMEDICAL TECHNOLOGIES CORPORAT; City/State: Minneapolis, MN; Project number: 5R44DK127631-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 1099700; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Kidney Support in Pediatric Patients using an Ultrafiltration Device; Organization type: Domestic For-Profits
| Aug 11, 2026 | NIH RePORTER 5R44DK127631-05 |
| AgonOx, Inc. | NIH awarded $978K (SBIR Phase II 1R44CA314796-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44CA314796-01
Organization: AGONOX, INC.; City/State: PORTLAND, OR; Project number: 1R44CA314796-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 977639; Administering IC: National Cancer Institute; Project title: Enriching and expanding tumor-reactive CD8 T-cells to treat breast cancer; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44CA314796-01 |
| NeuroTherapia | NIH awarded $1.21M (SBIR Phase II 1R44AG102269-01, new, notice Sep 8, 2026).Evidence (1 event)- Sep 8, 2026 · NIH RePORTER 1R44AG102269-01
Organization: NEUROTHERAPIA, INC.; City/State: CLEVELAND, OH; Project number: 1R44AG102269-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 1213723; Administering IC: National Institute on Aging; Project title: Preclinical toxicology in animals to prove the safety of a novel Alzheimer's Disease treatment; Organization type: Domestic For-Profits
| Sep 8, 2026 | NIH RePORTER 1R44AG102269-01 |
| Virtus Therapeutics Corporation | NIH awarded $1M (SBIR Phase II 2R44NS127740-03A1, competing renewal, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 2R44NS127740-03A1
Organization: VIRTUS THERAPEUTICS CORPORATION; City/State: Groton, CT; Project number: 2R44NS127740-03A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 999841; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: PanK Activators for the Treatment of Pantothenate Kinase-Associated Neurodegeneration; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 2R44NS127740-03A1 |
| Ora Biomedical, Inc. | NIH awarded $300K (SBIR Phase I 1R43AG102309-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43AG102309-01
Organization: ORA BIOMEDICAL, INC.; City/State: TUKWILA, WA; Project number: 1R43AG102309-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 299783; Administering IC: National Institute on Aging; Project title: RadBot: Next-Generation Drug Discovery for Environmental Stress Resistance Using Longevity Biology; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43AG102309-01 |
| Goeppert LLC | NIH awarded $350K (SBIR Phase I 1R43TR006093-01A1, new, notice Jun 26, 2026).Evidence (1 event)- Jun 26, 2026 · NIH RePORTER 1R43TR006093-01A1
Organization: GOEPPERT, LLC; City/State: PHILADELPHIA, PA; Project number: 1R43TR006093-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-26; FY total cost (award amount): 350000; Administering IC: National Center for Advancing Translational Sciences; Project title: NANO-PAVE: A Nanopore-Based Method for AAV Capsid Quality Assessment; Organization type: Domestic For-Profits
| Jun 26, 2026 | NIH RePORTER 1R43TR006093-01A1 |
| AnelleO | NIH awarded $500K (SBIR commercialization 1SB1HD120142-01A1, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1SB1HD120142-01A1
Organization: ANELLEO, INC.; City/State: CHAPEL HILL, NC; Project number: 1SB1HD120142-01A1; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 499604; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: CRP - Innovative 3D Printed Intravaginal Ring AnelleO-PRO, the first Single Administration of Progesterone for Infertility; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1SB1HD120142-01A1 |
| Cansera Inc. | NIH awarded $291K (STTR Phase II 1R42CA314789-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R42CA314789-01
Organization: CANSERA, INC.; City/State: LOS ANGELES, CA; Project number: 1R42CA314789-01; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 290828; Administering IC: National Cancer Institute; Project title: CellLogic: Deep Learning Identification and Characterization of Rare Events in Fluorescent Whole Slide Imaging; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R42CA314789-01 |
| Lucier Pharmaceuticals Inc. | NIH awarded $606K (STTR Phase I 1R41HL184579-01A1, new, notice Sep 11, 2026).Evidence (1 event)- Sep 11, 2026 · NIH RePORTER 1R41HL184579-01A1
Organization: LUCIER PHARMACEUTICALS INC; City/State: CYPRESS, TX; Project number: 1R41HL184579-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 606311; Administering IC: National Heart Lung and Blood Institute; Project title: Diagnostic and Therapeutic Potential of LU-1001 for Coronary Microvascular Dysfunction; Organization type: Domestic For-Profits
| Sep 11, 2026 | NIH RePORTER 1R41HL184579-01A1 |
| Nirrin Technologies Inc. | NIH awarded $1.16M (SBIR Phase II 1R44GM165281-01, new, notice Aug 10, 2026).Evidence (1 event)- Aug 10, 2026 · NIH RePORTER 1R44GM165281-01
Organization: NIRRIN TECHNOLOGIES INC; City/State: BILLERICA, MA; Project number: 1R44GM165281-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 1156172; Administering IC: National Institute of General Medical Sciences; Project title: Integration of High-Precision Tunable Laser Spectroscopy (HPTLS) into Liquid Chromatography for Quantitative Bioformulation Analysis; Organization type: Domestic For-Profits
| Aug 10, 2026 | NIH RePORTER 1R44GM165281-01 |
| Diorasis Therapeutics | NIH awarded $759K (SBIR Phase II 1R44EY039191-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44EY039191-01
Organization: DIORASIS THERAPEUTICS CORPORATION; City/State: Watertown, MA; Project number: 1R44EY039191-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 758533; Administering IC: National Eye Institute; Project title: Gene therapy to normalize intraocular pressure for the treatment of juvenile open angle glaucoma; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44EY039191-01 |
| Virtuoso Surgical | NIH awarded $1.09M (SBIR Phase II 1R44EB038843-01A1, new, notice Sep 1, 2026).Evidence (1 event)- Sep 1, 2026 · NIH RePORTER 1R44EB038843-01A1
Organization: VIRTUOSO SURGICAL, INC.; City/State: NASHVILLE, TN; Project number: 1R44EB038843-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 1094485; Administering IC: National Institute of Biomedical Imaging and Bioengineering; Project title: A Robot to Enable Broad Deployment of the Least Invasive Uterine Fibroid Surgical Intervention; Organization type: Domestic For-Profits
| Sep 1, 2026 | NIH RePORTER 1R44EB038843-01A1 |
| Arsenal Medical, Inc. | NIH awarded $2.24M (SBIR commercialization 1SB1AG102149-01, new, notice Sep 18, 2026).Evidence (1 event)- Sep 18, 2026 · NIH RePORTER 1SB1AG102149-01
Organization: ARSENAL MEDICAL, INC.; City/State: Waltham, MA; Project number: 1SB1AG102149-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 2238626; Administering IC: National Institute on Aging; Project title: RADIANT: A Pivotal Clinical Study of a Next-Generation Embolic for Chronic Subdural Hematoma; Organization type: Domestic For-Profits
| Sep 18, 2026 | NIH RePORTER 1SB1AG102149-01 |
| Levee Medical | NIH awarded $912K (SBIR Phase II 1R44CA314945-01, new, notice Jul 29, 2026).Evidence (1 event)- Jul 29, 2026 · NIH RePORTER 1R44CA314945-01
Organization: LEVEE MEDICAL INC; City/State: RALEIGH, NC; Project number: 1R44CA314945-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-29; FY total cost (award amount): 912125; Administering IC: National Cancer Institute; Project title: Novel Scaffold for Mitigating Post-Prostatectomy Urinary Incontinence; Organization type: Domestic For-Profits
| Jul 29, 2026 | NIH RePORTER 1R44CA314945-01 |
| Junipero Therapeutics, Inc. | NIH awarded $307K (STTR Phase I 1R41NS150094-01, new, notice Sep 8, 2026).Evidence (1 event)- Sep 8, 2026 · NIH RePORTER 1R41NS150094-01
Organization: JUNIPERO THERAPEUTICS, INC.; City/State: KANNAPOLIS, NC; Project number: 1R41NS150094-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 306872; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Epigenetic Silencing of VCP via an ASO-Conjugate Based Induced Proximity System for the Treatment of FTD-ALS in VCP Disease; Organization type: Domestic For-Profits
| Sep 8, 2026 | NIH RePORTER 1R41NS150094-01 |
| L2 Diagnostics | NIH awarded $323K (STTR Phase I 1R41AR087258-01A1, new, notice Sep 19, 2026); 4 NIH awards totaling $1.2M in the last 12 months.Evidence (4 events)- Sep 19, 2026 · NIH RePORTER 1R41AR087258-01A1
Organization: L2 DIAGNOSTICS, LLC; City/State: NEW HAVEN, CT; Project number: 1R41AR087258-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-19; FY total cost (award amount): 323090; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: A novel therapeutic, L2ASOCLE, for treating cutaneous lupus erythematosus (CLE); Organization type: Domestic For-Profits - Aug 28, 2026 · NIH RePORTER 5R41AI195230-02
Organization: L2 DIAGNOSTICS, LLC; City/State: NEW HAVEN, CT; Project number: 5R41AI195230-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: PfAg, a multivalent peptide vaccine against malaria; Organization type: Domestic For-Profits - Aug 19, 2026 · NIH RePORTER 5R43AI188960-02
Organization: L2 DIAGNOSTICS, LLC; City/State: NEW HAVEN, CT; Project number: 5R43AI188960-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 274710; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Point of Care Test for Babesia microti; Organization type: Domestic For-Profits - Aug 14, 2026 · NIH RePORTER 5R41AI195232-02
Organization: L2 DIAGNOSTICS, LLC; City/State: NEW HAVEN, CT; Project number: 5R41AI195232-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 300065; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A vaccine targeting mosquito metabolic pathways to eradicate malaria; Organization type: Domestic For-Profits
| Sep 19, 2026 | NIH RePORTER 1R41AR087258-01A1 |
| Signature Diagnostics | NIH awarded $307K (STTR Phase I 1R41HD122600-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R41HD122600-01
Organization: SIGNATURE DIAGNOSTICS INC; City/State: PITTSBURGH, PA; Project number: 1R41HD122600-01; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 306510; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Development of a Stool-Based Screening Method for the Early Detection of Necrotizing Enterocolitis in Premature Neonates; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R41HD122600-01 |
| Alphyn Biologics | NIH awarded $1.1M (SBIR Phase II 1R44AT013899-01, new, notice Sep 16, 2026).Evidence (1 event)- Sep 16, 2026 · NIH RePORTER 1R44AT013899-01
Organization: ALPHYN BIOLOGICS, INC.; City/State: ANNAPOLIS, MD; Project number: 1R44AT013899-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 1100000; Administering IC: National Center for Complementary and Integrative Health; Project title: AB-101: A Multi-Target Botanical Hydrogel for Combating Antimicrobial Resistance in Atopic Dermatitis; Organization type: Domestic For-Profits
| Sep 16, 2026 | NIH RePORTER 1R44AT013899-01 |
| Acomhal Research | NIH awarded $400K (STTR Phase I 1R41CA306619-01A1, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R41CA306619-01A1
Organization: ACOMHAL RESEARCH, INC.; City/State: ROANOKE, VA; Project number: 1R41CA306619-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 400000; Administering IC: National Cancer Institute; Project title: Alphavirus vector-mediated expression of a connexin43 mimetic peptide in glioblastoma therapy; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R41CA306619-01A1 |
| MiTeGen | NIH awarded $1M (SBIR Phase II 2R44GM156169-02, competing renewal, notice Aug 14, 2026).Evidence (1 event)- Aug 14, 2026 · NIH RePORTER 2R44GM156169-02
Organization: MITEGEN, LLC; City/State: ITHACA, NY; Project number: 2R44GM156169-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 999741; Administering IC: National Institute of General Medical Sciences; Project title: Improving cryopreservation outcomes of small biological samples through ultra-fast convective cooling and warming; Organization type: Domestic For-Profits
| Aug 14, 2026 | NIH RePORTER 2R44GM156169-02 |
| ProDa BioTech, LLC | NIH awarded $1.14M (SBIR Phase II 1R44CA314813-01, new, notice Sep 4, 2026).Evidence (1 event)- Sep 4, 2026 · NIH RePORTER 1R44CA314813-01
Organization: PRODA BIOTECH, LLC; City/State: MARIETTA, GA; Project number: 1R44CA314813-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1139113; Administering IC: National Cancer Institute; Project title: Development of a new combination therapy for pancreatic ductal adenocarcinoma treatment; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 1R44CA314813-01 |
| Artificial Axon Labs | NIH awarded $1.48M (SBIR Phase II 2R44NS135867-02, competing renewal, notice Aug 6, 2026).Evidence (1 event)- Aug 6, 2026 · NIH RePORTER 2R44NS135867-02
Organization: ARTIFICIAL AXON LABS INC.; City/State: TOPSFIELD, MA; Project number: 2R44NS135867-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 1478216; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: In vitro myelination assay modeling the environment of MS lesions for predictive discovery of remyelinating therapies; Organization type: Domestic For-Profits
| Aug 6, 2026 | NIH RePORTER 2R44NS135867-02 |
| Rejuvenation Technologies Inc. | NIH awarded $1.07M (SBIR Phase II 3R44TR005328-02S1, supplement, notice Aug 5, 2026); 2 NIH awards totaling $3.13M in the last 12 months.Evidence (2 events)- Aug 5, 2026 · NIH RePORTER 3R44TR005328-02S1
Organization: REJUVENATION TECHNOLOGIES, INC.; City/State: Mountain View, CA; Project number: 3R44TR005328-02S1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 1065587; Administering IC: National Center for Advancing Translational Sciences; Project title: Advanced tools for translation of intravenously-infused RNA LNP therapeutics to the clinic; Organization type: Domestic For-Profits - Jul 1, 2026 · NIH RePORTER 1SB1AA033292-01
Organization: REJUVENATION TECHNOLOGIES, INC.; City/State: Mountain View, CA; Project number: 1SB1AA033292-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-07-01; FY total cost (award amount): 2063303; Administering IC: National Institute on Alcohol Abuse and Alcoholism; Project title: Advancing a telomere extension biologic to treat alcohol-associated liver damage to IND; Organization type: Domestic For-Profits
| Aug 5, 2026 | NIH RePORTER 3R44TR005328-02S1 |
| Micro-Leads | NIH awarded $1.49M (SBIR Phase II 1R44DC023860-01, new, notice Jul 23, 2026).Evidence (1 event)- Jul 23, 2026 · NIH RePORTER 1R44DC023860-01
Organization: MICRO-LEADS, INC.; City/State: Somerville, MA; Project number: 1R44DC023860-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-23; FY total cost (award amount): 1486972; Administering IC: National Institute on Deafness and Other Communication Disorders; Project title: Closed-Loop Stimulation to Restore Voice and Swallowing by Reanimating Paralyzed Vocal Folds; Organization type: Domestic For-Profits
| Jul 23, 2026 | NIH RePORTER 1R44DC023860-01 |
| Inomagen Therapeutics | NIH awarded $1.41M (SBIR Phase II 1R44HL187127-01, new, notice Aug 28, 2026).Evidence (1 event)- Aug 28, 2026 · NIH RePORTER 1R44HL187127-01
Organization: INOMAGEN THERAPEUTICS, INC; City/State: CHICAGO, IL; Project number: 1R44HL187127-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 1412149; Administering IC: National Heart Lung and Blood Institute; Project title: A New and Disruptive Gene Based Therapy for Atrial Fibrillation; Organization type: Domestic For-Profits
| Aug 28, 2026 | NIH RePORTER 1R44HL187127-01 |
| eXoZymes | NIH awarded $1.03M (SBIR Phase II 2R44GM159516-05A1, competing renewal, notice Jun 19, 2026).Evidence (1 event)- Jun 19, 2026 · NIH RePORTER 2R44GM159516-05A1
Organization: INVIZYNE TECHNOLOGIES, INC.; City/State: Monrovia, CA; Project number: 2R44GM159516-05A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 1034289; Administering IC: National Institute of General Medical Sciences; Project title: SimplePath IIB: Pre-clinical development of Cannabinoid analogs; Organization type: Domestic For-Profits
| Jun 19, 2026 | NIH RePORTER 2R44GM159516-05A1 |
| OpenCell Technologies | NIH awarded $287K (SBIR Phase I 1R43CA310210-01A1, new, notice Sep 15, 2026).Evidence (1 event)- Sep 15, 2026 · NIH RePORTER 1R43CA310210-01A1
Organization: OPENCELL TECHNOLOGIES, INC.; City/State: SAINT LOUIS, MO; Project number: 1R43CA310210-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-15; FY total cost (award amount): 287125; Administering IC: National Cancer Institute; Project title: Enhancing NK Cell Engineering Through Optimized SoftPoration(TM) for Cell-Based Therapeutics; Organization type: Domestic For-Profits
| Sep 15, 2026 | NIH RePORTER 1R43CA310210-01A1 |
| InSight Surgical Technologies LLC | NIH awarded $982K (SBIR Phase II 1R44CA314780-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44CA314780-01
Organization: INSIGHT SURGICAL TECHNOLOGIES INC.; City/State: Lebanon, NH; Project number: 1R44CA314780-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 982300; Administering IC: National Cancer Institute; Project title: Advanced Surgical Guidance with Image Updating; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44CA314780-01 |
| Saros Therapeutics Inc. | NIH awarded $1.16M (SBIR Phase II 1R44CA306545-01A1, new, notice Sep 1, 2026).Evidence (1 event)- Sep 1, 2026 · NIH RePORTER 1R44CA306545-01A1
Organization: SAROS THERAPEUTICS INC; City/State: CHICAGO, IL; Project number: 1R44CA306545-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 1164203; Administering IC: National Cancer Institute; Project title: Demonstrating safety and combination therapy potential of a novel nanoparticle delivery system; Organization type: Domestic For-Profits
| Sep 1, 2026 | NIH RePORTER 1R44CA306545-01A1 |
| Blacksmith Medicines | NIH awarded $400K (SBIR Phase I 1R43CA309911-01A1, new, notice Sep 11, 2026).Evidence (1 event)- Sep 11, 2026 · NIH RePORTER 1R43CA309911-01A1
Organization: BLACKSMITH MEDICINES, INC.; City/State: SAN DIEGO, CA; Project number: 1R43CA309911-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 399915; Administering IC: National Cancer Institute; Project title: Combination of a novel selective FEN1 metallonuclease inhibitor with Olaparib for the treatment of PARP-resistant ovarian cancers; Organization type: Domestic For-Profits
| Sep 11, 2026 | NIH RePORTER 1R43CA309911-01A1 |
| Assayquant Technologies, Inc. | NIH awarded $1.31M (SBIR Phase II 1R44AG102290-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44AG102290-01
Organization: ASSAYQUANT TECHNOLOGIES, INC.; City/State: MARLBOROUGH, MA; Project number: 1R44AG102290-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1312010; Administering IC: National Institute on Aging; Project title: Selective Sensor Peptides for High-throughput, Kinetic Biomarker Assays of Kinase Activity in Neurodegeneration and Related Disorders; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44AG102290-01 |
| Auritec Pharmaceuticals | NIH awarded $1.03M (SBIR Phase II 1R44AG102256-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R44AG102256-01
Organization: AURITEC PHARMACEUTICALS, INC.; City/State: PASADENA, CA; Project number: 1R44AG102256-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1029519; Administering IC: National Institute on Aging; Project title: Long-acting Injectable Brexpiprazole for Agitation in Alzheimer's Dementia; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R44AG102256-01 |
| Matregenix Inc. | NIH awarded $314K (STTR Phase I 1R41HL184685-01A1, new, notice Aug 21, 2026); 2 NIH awards totaling $1.43M in the last 12 months.Evidence (2 events)- Aug 21, 2026 · NIH RePORTER 1R41HL184685-01A1
Organization: MATREGENIX; City/State: BOSTON, MA; Project number: 1R41HL184685-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 314211; Administering IC: National Heart Lung and Blood Institute; Project title: Sustained 9-cis Retinoic Acid-Eluting Nanofiber Scaffolds for Enhanced Lymphatic Regeneration and Lymphedema Treatment; Organization type: Domestic For-Profits - Jun 19, 2026 · NIH RePORTER 5R44DE035026-02
Organization: MATREGENIX; City/State: BOSTON, MA; Project number: 5R44DE035026-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 1119000; Administering IC: National Institute of Dental and Craniofacial Research; Project title: Enhancing Dental and Craniomaxillofacial Surgery Outcomes with Cost-Effective and Scalable Animal-Free Amino Acid-Based Membranes for Guided Bone Regeneration; Organization type: Domestic For-Profits
| Aug 21, 2026 | NIH RePORTER 1R41HL184685-01A1 |
| Talus Bioscience | NIH awarded $1.04M (SBIR Phase II 1R44TR005930-01A1, new, notice Jun 19, 2026).Evidence (1 event)- Jun 19, 2026 · NIH RePORTER 1R44TR005930-01A1
Organization: TALUS BIOSCIENCE, INC.; City/State: Seattle, WA; Project number: 1R44TR005930-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 1035634; Administering IC: National Center for Advancing Translational Sciences; Project title: Deployment of an AI platform to accelerate transcription factor drug development; Organization type: Domestic For-Profits
| Jun 19, 2026 | NIH RePORTER 1R44TR005930-01A1 |
| Orlucent | NIH awarded $1.56M (SBIR Phase II 1R44CA306680-01A1, new, notice Sep 3, 2026).Evidence (1 event)- Sep 3, 2026 · NIH RePORTER 1R44CA306680-01A1
Organization: ORLUCENT, INC.; City/State: Los Gatos, CA; Project number: 1R44CA306680-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 1556529; Administering IC: National Cancer Institute; Project title: Development of Manufacturing Controls for ORL1: A Fluorescent Imaging Agent for In Vivo Molecular Imaging of Melanomas; Organization type: Domestic For-Profits
| Sep 3, 2026 | NIH RePORTER 1R44CA306680-01A1 |
| Xosomix LLC | NIH awarded $349K (SBIR Phase I 1R43AG102280-01, new, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 1R43AG102280-01
Organization: XOSOMIX LLC; City/State: SAN DIEGO, CA; Project number: 1R43AG102280-01; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 349359; Administering IC: National Institute on Aging; Project title: Extracellular Vesicle encapsulated Adeno-associated virus (EV-AAV)-mediated delivery of Neurotrophic factor-α1(NF- α1)/Carboxypeptidase E (CPE) gene (EV-AAV-CPE) as a therapy for Alzheimer's Disease.; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 1R43AG102280-01 |
| Vizlitics Inc. | NIH awarded $1.15M (SBIR Phase II 5R44CA281547-03, continuation, notice Sep 11, 2026).Evidence (1 event)- Sep 11, 2026 · NIH RePORTER 5R44CA281547-03
Organization: VIZLITICS INC.; City/State: CHAPPAQUA, NY; Project number: 5R44CA281547-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 1145004; Administering IC: National Cancer Institute; Project title: VIPCare: Virtual Predictive Care workflow with EHR integrated surveillance for optimalfollow-up care management for Cancer Patients; Organization type: Domestic For-Profits
| Sep 11, 2026 | NIH RePORTER 5R44CA281547-03 |
| MAIA Biotechnology | NIH awarded $770K (SBIR Phase II 5R44CA309843-02, continuation, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 5R44CA309843-02
Organization: MAIA BIOTECHNOLOGY, INC.; City/State: CHICAGO, IL; Project number: 5R44CA309843-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 770168; Administering IC: National Cancer Institute; Project title: Novel Telomere-Targeting Therapy for Advanced Non-Small Cell Lung Cancer; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R44CA309843-02 |
| Rithim Biologics Inc. | NIH awarded $769K (SBIR Phase II 5R44HL172541-03, continuation, notice Sep 14, 2026).Evidence (1 event)- Sep 14, 2026 · NIH RePORTER 5R44HL172541-03
Organization: RITHIM BIOLOGICS, INC.; City/State: WOODBINE, MD; Project number: 5R44HL172541-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 768857; Administering IC: National Heart Lung and Blood Institute; Project title: Novel Gene Therapy, Techniques, and Devices to Prevent Ventricular Tachycardia; Organization type: Domestic For-Profits
| Sep 14, 2026 | NIH RePORTER 5R44HL172541-03 |
| Gradient Medical, Inc. | NIH awarded $1.15M (STTR Phase II 5R42CA275587-03, continuation, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 5R42CA275587-03
Organization: GRADIENT MEDICAL, INC.; City/State: Raleigh, NC; Project number: 5R42CA275587-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1150000; Administering IC: National Cancer Institute; Project title: Commercialization of Algorithmic Non-thermal Ablation Technology for the Treatment of Inoperable Tumors; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R42CA275587-03 |
| Contraline | NIH awarded $829K (SBIR Phase II 5R44HD115509-03, continuation, notice Sep 2, 2026).Evidence (1 event)- Sep 2, 2026 · NIH RePORTER 5R44HD115509-03
Organization: CONTRALINE, INC.; City/State: CHARLOTTESVILLE, VA; Project number: 5R44HD115509-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 829377; Administering IC: Eunice Kennedy Shriver National Institute of Child Health and Human Development; Project title: Development of ADAM Air: A Non-Hormonal Vas Occlusive Contraceptive Device; Organization type: Domestic For-Profits
| Sep 2, 2026 | NIH RePORTER 5R44HD115509-03 |
| Exhalix, LLC | NIH awarded $117K (SBIR Phase I 5R43DK143762-02, continuation, notice Aug 28, 2026).Evidence (1 event)- Aug 28, 2026 · NIH RePORTER 5R43DK143762-02
Organization: EXHALIX, LLC; City/State: Albuquerque, NM; Project number: 5R43DK143762-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 116757; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: A Hydrogen Sulfide Delivery Technology for Organ Preservation Therapy; Organization type: Domestic For-Profits
| Aug 28, 2026 | NIH RePORTER 5R43DK143762-02 |
| Cambium Oncology LLC | NIH awarded $1.05M (SBIR Phase II 5R44CA285206-03, continuation, notice Jul 17, 2026).Evidence (1 event)- Jul 17, 2026 · NIH RePORTER 5R44CA285206-03
Organization: CAMBIUM ONCOLOGY LLC; City/State: ATLANTA, GA; Project number: 5R44CA285206-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 1050003; Administering IC: National Cancer Institute; Project title: Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia; Organization type: Domestic For-Profits
| Jul 17, 2026 | NIH RePORTER 5R44CA285206-03 |
| Amydis Diagnostics | NIH awarded $1.11M (SBIR Phase II 5R44AG078075-03, continuation, notice Jul 10, 2026).Evidence (1 event)- Jul 10, 2026 · NIH RePORTER 5R44AG078075-03
Organization: AMYDIS DIAGNOSTICS, INC.; City/State: La Jolla, CA; Project number: 5R44AG078075-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 1107817; Administering IC: National Institute on Aging; Project title: Development of a topical tracer to detect TDP43 in ALS, LATE and FTD retinas for AI-powered disease insights; Organization type: Domestic For-Profits
| Jul 10, 2026 | NIH RePORTER 5R44AG078075-03 |
| Immunyx Pharma USA Inc. | NIH awarded $982K (SBIR Phase II 5R44DK145292-02, continuation, notice Aug 5, 2026).Evidence (1 event)- Aug 5, 2026 · NIH RePORTER 5R44DK145292-02
Organization: IMMUNYX PHARMA USA INC.; City/State: NEW YORK, NY; Project number: 5R44DK145292-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 981715; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of IMYX-3 for the Treatment of Ulcerative Colitis; Organization type: Domestic For-Profits
| Aug 5, 2026 | NIH RePORTER 5R44DK145292-02 |
| Perlara PBC | NIH awarded $692K (SBIR Phase II 5R44GM161192-02, continuation, notice Aug 20, 2026).Evidence (1 event)- Aug 20, 2026 · NIH RePORTER 5R44GM161192-02
Organization: PERLARA, PBC; City/State: Alameda, CA; Project number: 5R44GM161192-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 692113; Administering IC: National Institute of General Medical Sciences; Project title: REMIT (Rescue Mitochondrial Therapeutics): Unlocking Broad-Spectrum Mitochondrial Rescuers; Organization type: Domestic For-Profits
| Aug 20, 2026 | NIH RePORTER 5R44GM161192-02 |
| Armida Labs, Inc. | NIH awarded $1.09M (SBIR Phase II 5R44CA277917-03, continuation, notice Sep 2, 2026).Evidence (1 event)- Sep 2, 2026 · NIH RePORTER 5R44CA277917-03
Organization: ARMIDA LABS, INC.; City/State: SAN DIEGO, CA; Project number: 5R44CA277917-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 1088000; Administering IC: National Cancer Institute; Project title: Targeting pancreatic cancer metastases with Targefrin; Organization type: Domestic For-Profits
| Sep 2, 2026 | NIH RePORTER 5R44CA277917-03 |
| Atsena Therapeutics, Inc. | NIH awarded $731K (SBIR Phase II 5R44EY037156-02, continuation, notice Sep 1, 2026); 1 role open.Evidence (1 event)- Sep 1, 2026 · NIH RePORTER 5R44EY037156-02
Organization: ATSENA THERAPEUTICS, INC.; City/State: DURHAM, NC; Project number: 5R44EY037156-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 731026; Administering IC: National Eye Institute; Project title: Manufacturing Development and Commercial Readiness of an Adeno-Associated Virus-Based Gene Therapy for the Treatment of Leber Congenital Amaurosis Type 1; Organization type: Domestic For-Profits
| Sep 1, 2026 | NIH RePORTER 5R44EY037156-02 |
| Vesteck, Inc. | NIH awarded $624K (SBIR Phase II 5R44HL178318-02, continuation, notice Sep 11, 2026).Evidence (1 event)- Sep 11, 2026 · NIH RePORTER 5R44HL178318-02
Organization: VESTECK, INC; City/State: Malvern, PA; Project number: 5R44HL178318-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 624389; Administering IC: National Heart Lung and Blood Institute; Project title: Endovascular Suturing Device for Augmentation of Endograft Fixation During Endovascular Repair of Abdominal Aortic Aneurysm to Reduce Reinterventions Due to Endograft Migration or Type 1a Endoleak; Organization type: Domestic For-Profits
| Sep 11, 2026 | NIH RePORTER 5R44HL178318-02 |
| neuro42 | NIH awarded $1.47M (SBIR Phase II 5U44NS136026-03, continuation, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 5U44NS136026-03
Organization: NEURO42, INC.; City/State: SAN FRANCISCO, CA; Project number: 5U44NS136026-03; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1465731; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Portable Intraoperative MRI for Neurosurgery; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5U44NS136026-03 |
| Orlance | NIH awarded $1M (SBIR Phase II 4R44AI186932-02, extension, notice Aug 31, 2026); 2 NIH awards totaling $1.3M in the last 12 months.Evidence (2 events)- Aug 31, 2026 · NIH RePORTER 4R44AI186932-02
Organization: ORLANCE, INC.; City/State: SEATTLE, WA; Project number: 4R44AI186932-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Enhanced Seasonal Influenza Vaccine Targeting Variable and Conserved Antigens; Organization type: Domestic For-Profits - Aug 14, 2026 · NIH RePORTER 5R41AI195068-02
Organization: ORLANCE, INC.; City/State: SEATTLE, WA; Project number: 5R41AI195068-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 298837; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Therapeutic nucleic acid vaccine for chronic hepatitis B in HIV/HBV co-infected individuals; Organization type: Domestic For-Profits
| Aug 31, 2026 | NIH RePORTER 4R44AI186932-02 |
| New Health Sciences, Inc. | NIH awarded $984K (SBIR Phase II 5R44HL178006-02, continuation, notice Sep 4, 2026).Evidence (1 event)- Sep 4, 2026 · NIH RePORTER 5R44HL178006-02
Organization: NEW HEALTH SCIENCES, INC.; City/State: Lexington, MA; Project number: 5R44HL178006-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 984232; Administering IC: National Heart Lung and Blood Institute; Project title: Efficacy of Hypoxic Red Blood Cells Processed with the Hemanext ONE® System in Patients with Sickle Cell Anemia; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 5R44HL178006-02 |
| Function Therapeutics | NIH awarded $200K (SBIR Phase I 5R43NS143450-02, continuation, notice Sep 18, 2026).Evidence (1 event)- Sep 18, 2026 · NIH RePORTER 5R43NS143450-02
Organization: FUNCTION THERAPEUTICS, INC.; City/State: MILWAUKEE, WI; Project number: 5R43NS143450-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 200070; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Parmodulins without Abuse Potential for the Treatment of Neuropathic Pain; Organization type: Domestic For-Profits
| Sep 18, 2026 | NIH RePORTER 5R43NS143450-02 |
| ImmunoBlue, LLC | NIH awarded $1.11M (STTR Phase II 5R42CA287488-03, continuation, notice Aug 18, 2026).Evidence (1 event)- Aug 18, 2026 · NIH RePORTER 5R42CA287488-03
Organization: IMMUNOBLUE, LLC; City/State: Baltimore, MD; Project number: 5R42CA287488-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 1106515; Administering IC: National Cancer Institute; Project title: Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 5R42CA287488-03 |
| Nest Health Tech Inc. | NIH awarded $791K (STTR Phase II 5R42HG013908-03, continuation, notice Aug 18, 2026).Evidence (1 event)- Aug 18, 2026 · NIH RePORTER 5R42HG013908-03
Organization: NEST GENOMICS; City/State: ALBANY, CA; Project number: 5R42HG013908-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 790626; Administering IC: National Human Genome Research Institute; Project title: Closing the GAPS: Guideline Adherence, Prevention and Surveillance in Hereditary Cancer; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 5R42HG013908-03 |
| Zylo Therapeutics | NIH awarded $300K (STTR Phase I 5R41AI188793-02, continuation, notice Sep 2, 2026).Evidence (1 event)- Sep 2, 2026 · NIH RePORTER 5R41AI188793-02
Organization: ZYLO THERAPEUTICS, INC.; City/State: GREENVILLE, SC; Project number: 5R41AI188793-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development and optimization of a nitric oxide releasing microparticle formulation for the topical treatment of chronic rhinosinusitis; Organization type: Domestic For-Profits
| Sep 2, 2026 | NIH RePORTER 5R41AI188793-02 |
| Baebies | NIH awarded $1M (SBIR Phase II 5R44AI188680-03, continuation, notice Sep 9, 2026).Evidence (1 event)- Sep 9, 2026 · NIH RePORTER 5R44AI188680-03
Organization: BAEBIES, INC.; City/State: DURHAM, NC; Project number: 5R44AI188680-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance; Organization type: Domestic For-Profits
| Sep 9, 2026 | NIH RePORTER 5R44AI188680-03 |
| TREKKA Therapeutics | NIH awarded $283K (STTR Phase I 5R41DE034604-02, continuation, notice Aug 14, 2026).Evidence (1 event)- Aug 14, 2026 · NIH RePORTER 5R41DE034604-02
Organization: TREKKA THERAPEUTICS, LLC; City/State: SAINT PAUL, MN; Project number: 5R41DE034604-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 283223; Administering IC: National Institute of Dental and Craniofacial Research; Project title: Nanodroplet Infused Analgesic-Wafer for Transmucosal Opioid-free Treatment of Subacute Oral Pain; Organization type: Domestic For-Profits
| Aug 14, 2026 | NIH RePORTER 5R41DE034604-02 |
| Rerx Therapeutics, Inc. | NIH awarded $1.31M (SBIR Phase II 5R44DK142483-02, continuation, notice Jul 6, 2026).Evidence (1 event)- Jul 6, 2026 · NIH RePORTER 5R44DK142483-02
Organization: RERX THERAPEUTICS, INC; City/State: BERKELEY, CA; Project number: 5R44DK142483-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-06; FY total cost (award amount): 1307195; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Evaluation of novel small molecule targeting lipid and energy homeostasis for treating obesity; Organization type: Domestic For-Profits
| Jul 6, 2026 | NIH RePORTER 5R44DK142483-02 |
| SPOC Biosciences | NIH awarded $815K (SBIR Phase II 5R44OD024970-04, continuation, notice Aug 25, 2026).Evidence (1 event)- Aug 25, 2026 · NIH RePORTER 5R44OD024970-04
Organization: SPOC PROTEOMICS INC.; City/State: SCOTTSDALE, AZ; Project number: 5R44OD024970-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 815054; Administering IC: NIH Office of the Director; Project title: Tools and Methods for Producing High Quality Functional Protein Microarrays for Biomarker Discovery; Organization type: Domestic For-Profits
| Aug 25, 2026 | NIH RePORTER 5R44OD024970-04 |
| Plurexa | NIH awarded $770K (STTR Phase II 5R42DK136452-03, continuation, notice Aug 20, 2026).Evidence (1 event)- Aug 20, 2026 · NIH RePORTER 5R42DK136452-03
Organization: PLUREXA LLC; City/State: Seattle, WA; Project number: 5R42DK136452-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 770372; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Targeting Myosin to Treat Polycystic Kidney Disease; Organization type: Domestic For-Profits
| Aug 20, 2026 | NIH RePORTER 5R42DK136452-03 |
| Gryphon Bio Inc. | NIH awarded $1.25M (SBIR Phase II 5R44NS130780-03, continuation, notice Aug 24, 2026).Evidence (1 event)- Aug 24, 2026 · NIH RePORTER 5R44NS130780-03
Organization: GRYPHON BIO, INC.; City/State: SOUTH SAN FRANCISCO, CA; Project number: 5R44NS130780-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 1246138; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of Novel sgp130-Fc Bioconjugates for TBI; Organization type: Domestic For-Profits
| Aug 24, 2026 | NIH RePORTER 5R44NS130780-03 |
| Integrated Micro-Chromatography Systems, Inc. | NIH awarded $699K (STTR Phase II 4R42GM163378-02, extension, notice Aug 28, 2026).Evidence (1 event)- Aug 28, 2026 · NIH RePORTER 4R42GM163378-02
Organization: INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, INC.; City/State: IRMO, SC; Project number: 4R42GM163378-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 698612; Administering IC: National Institute of General Medical Sciences; Project title: Chemoenzymatic methods and reagents to access affordable (iso)globo- and(neo)lacto-glycosphingolipids; Organization type: Domestic For-Profits
| Aug 28, 2026 | NIH RePORTER 4R42GM163378-02 |
| Eclipse Regenesis, Inc. | NIH awarded $861K (SBIR Phase II 5R44DK127658-05, continuation, notice Aug 21, 2026).Evidence (1 event)- Aug 21, 2026 · NIH RePORTER 5R44DK127658-05
Organization: ECLIPSE ENTEROGENESIS, INC.; City/State: MENLO PARK, CA; Project number: 5R44DK127658-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-21; FY total cost (award amount): 860948; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Outcomes study for the XL1 distraction enterogenesis device to improve nutrient absorption in short bowel syndrome patients; Organization type: Domestic For-Profits
| Aug 21, 2026 | NIH RePORTER 5R44DK127658-05 |
| Regenerative Medical Solutions Inc | NIH awarded $872K (SBIR Phase II 5R44DK133008-03, continuation, notice Aug 6, 2026).Evidence (1 event)- Aug 6, 2026 · NIH RePORTER 5R44DK133008-03
Organization: REGENERATIVE MEDICAL SOLUTIONS, INC.; City/State: CHICAGO, IL; Project number: 5R44DK133008-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 872115; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells; Organization type: Domestic For-Profits
| Aug 6, 2026 | NIH RePORTER 5R44DK133008-03 |
| Advanced Brain Monitoring | NIH awarded $365K (SBIR Phase I 5R43AG094486-02, continuation, notice Jun 25, 2026).Evidence (1 event)- Jun 25, 2026 · NIH RePORTER 5R43AG094486-02
Organization: ADVANCED BRAIN MONITORING, INC.; City/State: CARLSBAD, CA; Project number: 5R43AG094486-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 365227; Administering IC: National Institute on Aging; Project title: Characterizing neurocognitive deficits in post-acute sequelae of COVID-19; Organization type: Domestic For-Profits
| Jun 25, 2026 | NIH RePORTER 5R43AG094486-02 |
| Obatala Sciences | NIH awarded $150K (NIH grant 5R25AG078151-05, continuation, notice Aug 18, 2026).Evidence (1 event)- Aug 18, 2026 · NIH RePORTER 5R25AG078151-05
Organization: OBATALA SCIENCES, INC.; City/State: NEW ORLEANS, LA; Project number: 5R25AG078151-05; Activity code: R25; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 150234; Administering IC: National Institute on Aging; Project title: Getting Regenerative Medical Biotech REDI to Age; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 5R25AG078151-05 |
| Cryocrate LLC | NIH awarded $316K (NIH grant 5R33CA302632-02, continuation, notice Sep 4, 2026).Evidence (1 event)- Sep 4, 2026 · NIH RePORTER 5R33CA302632-02
Organization: CRYOCRATE, LLC; City/State: COLUMBIA, MO; Project number: 5R33CA302632-02; Activity code: R33; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 315827; Administering IC: National Cancer Institute; Project title: Novel Biocompatible, High-Throughput Cryopreservation Medium and Method for Enhanced Post-Thaw Migration and Cytotoxicity of NK Cells; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 5R33CA302632-02 |
| Novoron Bioscience Inc. | NIH awarded $1.25M (SBIR Phase II 5R44AG097355-02, continuation, notice Jun 3, 2026).Evidence (1 event)- Jun 3, 2026 · NIH RePORTER 5R44AG097355-02
Organization: NOVORON BIOSCIENCE, INC.; City/State: SAN DIEGO, CA; Project number: 5R44AG097355-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1245237; Administering IC: National Institute on Aging; Project title: Human iPSC neural spheroids to screen for compounds that block tau propagation; Organization type: Domestic For-Profits
| Jun 3, 2026 | NIH RePORTER 5R44AG097355-02 |
| Livivos Inc. | NIH awarded $786K (SBIR Phase II 5R44DK135225-03, continuation, notice Aug 5, 2026).Evidence (1 event)- Aug 5, 2026 · NIH RePORTER 5R44DK135225-03
Organization: LIVIVOS INC.; City/State: San Diego, CA; Project number: 5R44DK135225-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 785714; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Accurate Point of Care Liver Disease Diagnostics, Phase II; Organization type: Domestic For-Profits
| Aug 5, 2026 | NIH RePORTER 5R44DK135225-03 |
| Radiation Monitoring Devices, Inc. | NIH awarded $846K (SBIR Phase II 5R44MH135525-03, continuation, notice Aug 14, 2026).Evidence (1 event)- Aug 14, 2026 · NIH RePORTER 5R44MH135525-03
Organization: RADIATION MONITORING DEVICES, INC.; City/State: WATERTOWN, MA; Project number: 5R44MH135525-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 845777; Administering IC: National Institute of Mental Health; Project title: Ultra-dense ceramic scintillator for BrainPET scanner; Organization type: Domestic For-Profits
| Aug 14, 2026 | NIH RePORTER 5R44MH135525-03 |
| Navigation Sciences | NIH awarded $181K (STTR Phase I 5R41CA306611-02, continuation, notice Sep 16, 2026).Evidence (1 event)- Sep 16, 2026 · NIH RePORTER 5R41CA306611-02
Organization: NAVIGATION SCIENCES, INC.; City/State: BROOKLINE, MA; Project number: 5R41CA306611-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 181271; Administering IC: National Cancer Institute; Project title: Targeted Localization and Optimized Surgical Resection for Lung Cancer; Organization type: Domestic For-Profits
| Sep 16, 2026 | NIH RePORTER 5R41CA306611-02 |
| 5M Biomed, LLC | NIH awarded $811K (STTR Phase II 5R42AG078718-03, continuation, notice Jun 25, 2026).Evidence (1 event)- Jun 25, 2026 · NIH RePORTER 5R42AG078718-03
Organization: 5M BIOMED, LLC; City/State: JOHNS CREEK, GA; Project number: 5R42AG078718-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-06-25; FY total cost (award amount): 811413; Administering IC: National Institute on Aging; Project title: Development of "Imagnostix": A Liquid Biopsy System for Alzheimer's Disease; Organization type: Domestic For-Profits
| Jun 25, 2026 | NIH RePORTER 5R42AG078718-03 |
| Bioprovar Corporation | NIH awarded $349K (SBIR Phase II 5U44AG074105-03, continuation, notice Aug 14, 2026).Evidence (1 event)- Aug 14, 2026 · NIH RePORTER 5U44AG074105-03
Organization: BIOPROVAR CORPORATION; City/State: HOUSTON, TX; Project number: 5U44AG074105-03; Activity code: U44; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 349073; Administering IC: National Institute on Aging; Project title: An Innovative Immune Therapy with Antibiotics to Treat Deadly Excess Inflammation in Sepsis and ARDS Induced from Severe Bacterial Infection in Geriatric Patients; Organization type: Domestic For-Profits
| Aug 14, 2026 | NIH RePORTER 5U44AG074105-03 |
| LifeBio Inc. | NIH awarded $1.03M (SBIR Phase II 5R44AG069566-04, continuation, notice Jul 10, 2026).Evidence (1 event)- Jul 10, 2026 · NIH RePORTER 5R44AG069566-04
Organization: LIFEBIO INC; City/State: MARYSVILLE, OH; Project number: 5R44AG069566-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 1029947; Administering IC: National Institute on Aging; Project title: LifeBio Memory: Development of a reminiscence therapy online platform with machine learning to increase engagement; Organization type: Domestic For-Profits
| Jul 10, 2026 | NIH RePORTER 5R44AG069566-04 |
| Embiosys Inc. | NIH awarded $870K (SBIR Phase II 5R44CA310518-02, continuation, notice Sep 11, 2026).Evidence (1 event)- Sep 11, 2026 · NIH RePORTER 5R44CA310518-02
Organization: EMBIOSYS INC.; City/State: North Andover, MA; Project number: 5R44CA310518-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 870482; Administering IC: National Cancer Institute; Project title: CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer; Organization type: Domestic For-Profits
| Sep 11, 2026 | NIH RePORTER 5R44CA310518-02 |
| Cellsight Technologies, Inc. | NIH awarded $883K (SBIR Phase II 5R44AG094397-02, continuation, notice Aug 25, 2026).Evidence (1 event)- Aug 25, 2026 · NIH RePORTER 5R44AG094397-02
Organization: CELLSIGHT TECHNOLOGIES, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44AG094397-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 882921; Administering IC: National Institute on Aging; Project title: Imaging intracerebral and systemic T cell immunity in patients with Alzheimer's disease using 18F-F-AraG; Organization type: Domestic For-Profits
| Aug 25, 2026 | NIH RePORTER 5R44AG094397-02 |
| ADvantage Therapeutics | NIH awarded $1.25M (SBIR Phase II 5R44AG091827-02, continuation, notice Jun 3, 2026).Evidence (1 event)- Jun 3, 2026 · NIH RePORTER 5R44AG091827-02
Organization: ADVANTAGE THERAPEUTICS, INC; City/State: MIAMI, FL; Project number: 5R44AG091827-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-03; FY total cost (award amount): 1249368; Administering IC: National Institute on Aging; Project title: AD04 disease-modifying drug for Alzheimer's - preclinical and IND-enabling studies; Organization type: Domestic For-Profits
| Jun 3, 2026 | NIH RePORTER 5R44AG091827-02 |
| Reelin Therapeutics, Inc. | NIH awarded $241K (STTR Phase I 5R41AG094356-02, continuation, notice Aug 14, 2026).Evidence (1 event)- Aug 14, 2026 · NIH RePORTER 5R41AG094356-02
Organization: REELIN THERAPEUTICS, INC.; City/State: SAN DIEGO, CA; Project number: 5R41AG094356-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 241313; Administering IC: National Institute on Aging; Project title: Identification of next generation gamma-secretase modulators for Alzheimer's disease; Organization type: Domestic For-Profits
| Aug 14, 2026 | NIH RePORTER 5R41AG094356-02 |
| Glycyx MOR, Inc. | NIH awarded $1.05M (SBIR Phase II 5R44CA306565-02, continuation, notice Sep 14, 2026).Evidence (1 event)- Sep 14, 2026 · NIH RePORTER 5R44CA306565-02
Organization: GLYCYX MOR, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44CA306565-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1047803; Administering IC: National Cancer Institute; Project title: A Phase 2 Trial of Axelopran Plus Pembrolizumab for the First-Line Treatment of Recurrent/Metastatic HNSCC That Is PD-L1 Positive (PD-L1CPS >1); Organization type: Domestic For-Profits
| Sep 14, 2026 | NIH RePORTER 5R44CA306565-02 |
| QuantumBio | NIH awarded $684K (SBIR Phase II 4R44GM163476-02, extension, notice Aug 20, 2026).Evidence (1 event)- Aug 20, 2026 · NIH RePORTER 4R44GM163476-02
Organization: QUANTUMBIO, INC.; City/State: State College, PA; Project number: 4R44GM163476-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 684417; Administering IC: National Institute of General Medical Sciences; Project title: Addressing Structural Disorder and Conformational Heterogeneity in Modern Therapeutic Modalities: A Unified X-ray/Cryo-EM QM/MM Ensemble Refinement Toolkit with Enhanced Density-Driven MD; Organization type: Domestic For-Profits
| Aug 20, 2026 | NIH RePORTER 4R44GM163476-02 |
| Evoq Therapeutics, Inc. | NIH awarded $1M (SBIR Phase II 5R44AI192013-02, continuation, notice Aug 20, 2026).Evidence (1 event)- Aug 20, 2026 · NIH RePORTER 5R44AI192013-02
Organization: EVOQ THERAPEUTICS, INC.; City/State: ANN ARBOR, MI; Project number: 5R44AI192013-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-20; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: NanoDiscs for Immune Modulation in Celiac Disease; Organization type: Domestic For-Profits
| Aug 20, 2026 | NIH RePORTER 5R44AI192013-02 |
| Endomimetics | NIH awarded $665K (SBIR Phase II 5R44NS110114-04, continuation, notice Sep 14, 2026).Evidence (1 event)- Sep 14, 2026 · NIH RePORTER 5R44NS110114-04
Organization: ENDOMIMETICS, LLC; City/State: BIRMINGHAM, AL; Project number: 5R44NS110114-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 665292; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Enhanced endothelialization of nanomatrix coated flow diverter for intracranial aneurysms; Organization type: Domestic For-Profits
| Sep 14, 2026 | NIH RePORTER 5R44NS110114-04 |
| Cytoagents, Inc. | NIH awarded $936K (SBIR Phase II 5R44CA295189-02, continuation, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 5R44CA295189-02
Organization: CYTOAGENTS, INC.; City/State: PITTSBURGH, PA; Project number: 5R44CA295189-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 936370; Administering IC: National Cancer Institute; Project title: CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R44CA295189-02 |
| Jaan Biotherapeutics | NIH awarded $1.57M (SBIR Phase II 5R44HL180034-02, continuation, notice Aug 28, 2026).Evidence (1 event)- Aug 28, 2026 · NIH RePORTER 5R44HL180034-02
Organization: JAAN BIOTHERAPEUTICS, INC.; City/State: SAN DIEGO, CA; Project number: 5R44HL180034-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 1571571; Administering IC: National Heart Lung and Blood Institute; Project title: Heart Muscle Regeneration; Organization type: Domestic For-Profits
| Aug 28, 2026 | NIH RePORTER 5R44HL180034-02 |
| Translucence Biosystems, Inc. | NIH awarded $1.31M (SBIR Phase II 5R44AG090130-02, continuation, notice Aug 18, 2026).Evidence (1 event)- Aug 18, 2026 · NIH RePORTER 5R44AG090130-02
Organization: TRANSLUCENCE BIOSYSTEMS, INC.; City/State: Irvine, CA; Project number: 5R44AG090130-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 1307377; Administering IC: National Institute on Aging; Project title: Brain-Wide Quantification of Blood-Brain Barrier Penetrating Antibody Therapeutics; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 5R44AG090130-02 |
| Artiam Bio Inc. | NIH awarded $280K (STTR Phase I 5R41AG090138-02, continuation, notice Jun 19, 2026).Evidence (1 event)- Jun 19, 2026 · NIH RePORTER 5R41AG090138-02
Organization: ARTIAM BIO INC.; City/State: CARY, NC; Project number: 5R41AG090138-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 279513; Administering IC: National Institute on Aging; Project title: Validation of APT101 for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in an Aging Murine Model; Organization type: Domestic For-Profits
| Jun 19, 2026 | NIH RePORTER 5R41AG090138-02 |
| NovoMedix | NIH awarded $356K (SBIR Phase I 1R43HL182659-01A1, new, notice Aug 24, 2026).Evidence (1 event)- Aug 24, 2026 · NIH RePORTER 1R43HL182659-01A1
Organization: NOVOMEDIX, INC.; City/State: SAN DIEGO, CA; Project number: 1R43HL182659-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 355963; Administering IC: National Heart Lung and Blood Institute; Project title: Novel small molecule for the prevention and treatment of DMD cardiomyopathy; Organization type: Domestic For-Profits
| Aug 24, 2026 | NIH RePORTER 1R43HL182659-01A1 |
| Callahan-Young LLC | NIH awarded $962K (SBIR Phase II 5R44AG079736-03, continuation, notice Jul 10, 2026).Evidence (1 event)- Jul 10, 2026 · NIH RePORTER 5R44AG079736-03
Organization: CALLAHAN-YOUNG LLC; City/State: RALEIGH, NC; Project number: 5R44AG079736-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 962046; Administering IC: National Institute on Aging; Project title: Evaluating the Health Benefits of Jigsawdio: A Novel Multisensory Jigsaw Puzzle-based Intervention for Alzheimer's Disease and Related Dementias; Organization type: Domestic For-Profits
| Jul 10, 2026 | NIH RePORTER 5R44AG079736-03 |
| Matrisome Bio | NIH awarded $1.01M (SBIR Phase II 5R44CA298532-02, continuation, notice Aug 7, 2026).Evidence (1 event)- Aug 7, 2026 · NIH RePORTER 5R44CA298532-02
Organization: MATRISOME BIO, INC.; City/State: Cambridge, MA; Project number: 5R44CA298532-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-07; FY total cost (award amount): 1013647; Administering IC: National Cancer Institute; Project title: Development of an extracellular matrix-targeted theranostic radiopharmaceutical for metastatic lung cancer; Organization type: Domestic For-Profits
| Aug 7, 2026 | NIH RePORTER 5R44CA298532-02 |
| Rush River Research Corp. | NIH awarded $991K (SBIR Phase II 5R44MD018239-03, continuation, notice May 25, 2026).Evidence (1 event)- May 25, 2026 · NIH RePORTER 5R44MD018239-03
Organization: RUSH RIVER RESEARCH CORPORATION; City/State: ELLSWORTH, WI; Project number: 5R44MD018239-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-25; FY total cost (award amount): 991050; Administering IC: National Institute on Minority Health and Health Disparities; Project title: Modernized Culturally Sensitive Family Medical History Tool; Organization type: Domestic For-Profits
| May 25, 2026 | NIH RePORTER 5R44MD018239-03 |
| Natsar Pharmaceuticals, Inc. | NIH awarded $615K (SBIR Phase II 5R44CA295155-02, continuation, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 5R44CA295155-02
Organization: NATSAR PHARMACEUTICALS, INC.; City/State: ELLICOTT CITY, MD; Project number: 5R44CA295155-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 615189; Administering IC: National Cancer Institute; Project title: Drug development of RK-33 for breast cancer treatment; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 5R44CA295155-02 |
| Wavely Diagnostics | NIH awarded $992K (SBIR Phase II 5R44MD018225-04, continuation, notice Jun 9, 2026).Evidence (1 event)- Jun 9, 2026 · NIH RePORTER 5R44MD018225-04
Organization: WAVELY DIAGNOSTICS, INC.; City/State: SEATTLE, WA; Project number: 5R44MD018225-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-09; FY total cost (award amount): 991676; Administering IC: National Institute on Minority Health and Health Disparities; Project title: Improving Rural Access to Pediatric Health Care with Accurate Telehealth Diagnosis of Acute Otitis Media via Wide Scale Use of Smartphone Acoustic Reflectometry; Organization type: Domestic For-Profits
| Jun 9, 2026 | NIH RePORTER 5R44MD018225-04 |
| Indoor Biotechnologies | NIH awarded $717K (NIH grant 5R01AI077653-16, continuation, notice Sep 9, 2026).Evidence (1 event)- Sep 9, 2026 · NIH RePORTER 5R01AI077653-16
Organization: INDOOR BIOTECHNOLOGIES; City/State: CHARLOTTESVILLE, VA; Project number: 5R01AI077653-16; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 716893; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Antigenic determinants of asthma-associated allergens for design of immunotherapy; Organization type: Domestic For-Profits
| Sep 9, 2026 | NIH RePORTER 5R01AI077653-16 |
| Golden Helix | NIH awarded $945K (SBIR Phase II 5R44HG013456-03, continuation, notice Aug 6, 2026).Evidence (1 event)- Aug 6, 2026 · NIH RePORTER 5R44HG013456-03
Organization: GOLDEN HELIX, INC.; City/State: BOZEMAN, MT; Project number: 5R44HG013456-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 945358; Administering IC: National Human Genome Research Institute; Project title: Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options; Organization type: Domestic For-Profits
| Aug 6, 2026 | NIH RePORTER 5R44HG013456-03 |
| Anekabio LLC | NIH awarded $246K (STTR Phase I 5R41NS143585-02, continuation, notice Sep 4, 2026).Evidence (1 event)- Sep 4, 2026 · NIH RePORTER 5R41NS143585-02
Organization: ANEKABIO LLC; City/State: GAINESVILLE, FL; Project number: 5R41NS143585-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 245560; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development and Validation of Efficacy Biomarkers for QTE Therapy in Friedreich's Ataxia; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 5R41NS143585-02 |
| RespireRx Pharmaceuticals | NIH awarded $1.5M (SBIR Phase II 5R44NS143576-02, continuation, notice Sep 14, 2026).Evidence (1 event)- Sep 14, 2026 · NIH RePORTER 5R44NS143576-02
Organization: RESPIRERX PHARMACEUTICALS INC.; City/State: GLEN ROCK, NJ; Project number: 5R44NS143576-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1499869; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Development of a novel, preferring potentiator of GABAA receptor for treatment of epilepsy; Organization type: Domestic For-Profits
| Sep 14, 2026 | NIH RePORTER 5R44NS143576-02 |
| Nuvox Pharma, LLC | NIH awarded $1.06M (SBIR Phase II 5R44CA298498-02, continuation, notice Aug 27, 2026).Evidence (1 event)- Aug 27, 2026 · NIH RePORTER 5R44CA298498-02
Organization: NUVOX PHARMA, LLC; City/State: TUCSON, AZ; Project number: 5R44CA298498-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 1057531; Administering IC: National Cancer Institute; Project title: Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic; Organization type: Domestic For-Profits
| Aug 27, 2026 | NIH RePORTER 5R44CA298498-02 |
| NeOnc Technologies | NIH awarded $1.03M (STTR Phase II 5R42CA246902-04, continuation, notice Sep 14, 2026); 3 NIH awards totaling $2.44M in the last 12 months.Evidence (3 events)- Sep 14, 2026 · NIH RePORTER 5R42CA246902-04
Organization: NEONC TECHNOLOGIES HOLDINGS INC.; City/State: CALABASAS, CA; Project number: 5R42CA246902-04; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-14; FY total cost (award amount): 1033906; Administering IC: National Cancer Institute; Project title: Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant Gliomas; Organization type: Domestic For-Profits - Jul 16, 2026 · NIH RePORTER 6R41CA271879-02
Organization: NEONC TECHNOLOGIES HOLDINGS INC.; City/State: CALABASAS, CA; Project number: 6R41CA271879-02; Activity code: R41; Fiscal year: 2025; Award notice date: 2026-07-16; FY total cost (award amount): 399998; Administering IC: National Cancer Institute; Project title: Development of NEO212, A Novel Oral Drug for the Treatment of Acute Myeloid Leukemia; Organization type: Domestic For-Profits - Jul 15, 2026 · NIH RePORTER 6R42CA246902-03
Organization: NEONC TECHNOLOGIES HOLDINGS INC.; City/State: CALABASAS, CA; Project number: 6R42CA246902-03; Activity code: R42; Fiscal year: 2025; Award notice date: 2026-07-15; FY total cost (award amount): 1007612; Administering IC: National Cancer Institute; Project title: Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant Gliomas; Organization type: Domestic For-Profits
| Sep 14, 2026 | NIH RePORTER 5R42CA246902-04 |
| Shasqi | NIH awarded $1.14M (SBIR Phase II 5R44CA306491-02, continuation, notice Aug 18, 2026).Evidence (1 event)- Aug 18, 2026 · NIH RePORTER 5R44CA306491-02
Organization: SHASQI, INC.; City/State: SAN FRANCISCO, CA; Project number: 5R44CA306491-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 1142054; Administering IC: National Cancer Institute; Project title: CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 5R44CA306491-02 |
| Luminary Therapeutics | NIH awarded $587K (SBIR Phase II 5R44CA278021-03, continuation, notice Sep 10, 2026).Evidence (1 event)- Sep 10, 2026 · NIH RePORTER 5R44CA278021-03
Organization: LUMINARY THERAPEUTICS, INC.; City/State: MINNEAPOLIS, MN; Project number: 5R44CA278021-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 586799; Administering IC: National Cancer Institute; Project title: Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies; Organization type: Domestic For-Profits
| Sep 10, 2026 | NIH RePORTER 5R44CA278021-03 |
| Jericho Sciences, LLC | NIH awarded $314K (STTR Phase I 5R41AI195177-02, continuation, notice Aug 11, 2026).Evidence (1 event)- Aug 11, 2026 · NIH RePORTER 5R41AI195177-02
Organization: JERICHO SCIENCES, LLC; City/State: SPRINGFIELD, VA; Project number: 5R41AI195177-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 314363; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Translational Development of a Small Molecule for the Treatment of HBV Infection; Organization type: Domestic For-Profits
| Aug 11, 2026 | NIH RePORTER 5R41AI195177-02 |
| Seacoast Science, Inc. | NIH awarded $508K (SBIR Phase II 5R44OH012498-03, continuation, notice Aug 17, 2026).Evidence (1 event)- Aug 17, 2026 · NIH RePORTER 5R44OH012498-03
Organization: SEACOAST SCIENCE, INC.; City/State: CARLSBAD, CA; Project number: 5R44OH012498-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-17; FY total cost (award amount): 508352; Administering IC: National Institute for Occupational Safety and Health; Project title: Auto-calibrating, Air Quality Monitoring System; Organization type: Domestic For-Profits
| Aug 17, 2026 | NIH RePORTER 5R44OH012498-03 |
| Lo Biosciences, Inc | NIH awarded $1.02M (SBIR Phase II 5R44PS005271-03, continuation, notice Aug 13, 2026).Evidence (1 event)- Aug 13, 2026 · NIH RePORTER 5R44PS005271-03
Organization: LO BIOSCIENCES, INC.; City/State: ROCKVILLE, MD; Project number: 5R44PS005271-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-13; FY total cost (award amount): 1022051; Administering IC: National Center for HIVAIDS, Viral Hepatitis, STD, and TB Prevention; Project title: A novel remote blood separation device for at-home plasma collection for HIV-1 testing; Organization type: Domestic For-Profits
| Aug 13, 2026 | NIH RePORTER 5R44PS005271-03 |
| Mesa Science Associates, Inc. | NIH awarded $866K (SBIR Phase II 5R44AI191943-02, continuation, notice Aug 10, 2026).Evidence (1 event)- Aug 10, 2026 · NIH RePORTER 5R44AI191943-02
Organization: MESA SCIENCE ASSOCIATES, INC.; City/State: FREDERICK, MD; Project number: 5R44AI191943-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-10; FY total cost (award amount): 865895; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of Cobinamide as a Cyanide Antidote: Completion of pre-IND Studies; Organization type: Domestic For-Profits
| Aug 10, 2026 | NIH RePORTER 5R44AI191943-02 |
| Myogenica | NIH awarded $701K (STTR Phase II 5R42AR083779-03, continuation, notice Jul 8, 2026).Evidence (1 event)- Jul 8, 2026 · NIH RePORTER 5R42AR083779-03
Organization: MYOGENICA INC.; City/State: SAINT PAUL, MN; Project number: 5R42AR083779-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-07-08; FY total cost (award amount): 701471; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: Systemic Transplantation of MyoPAXon: IND Enabling Studies for the Treatment of DMD; Organization type: Domestic For-Profits
| Jul 8, 2026 | NIH RePORTER 5R42AR083779-03 |
| DFH Pharma, Inc | NIH awarded $965K (SBIR Phase II 5R44AI155312-05, continuation, notice Aug 26, 2026).Evidence (1 event)- Aug 26, 2026 · NIH RePORTER 5R44AI155312-05
Organization: DFH PHARMA, INC.; City/State: GAITHERSBURG, MD; Project number: 5R44AI155312-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 965000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: IND-Enabling Development of HIV Maturation Inhibitors Formulated for use as either Oral or Long-Acting Parenterally Administered Agents; Organization type: Domestic For-Profits
| Aug 26, 2026 | NIH RePORTER 5R44AI155312-05 |
| Eitr Biologics, Inc. | NIH awarded $1M (SBIR Phase II 5R44AI177179-03, continuation, notice Aug 27, 2026).Evidence (1 event)- Aug 27, 2026 · NIH RePORTER 5R44AI177179-03
Organization: EITR BIOLOGICS, INC.; City/State: SAN DIEGO, CA; Project number: 5R44AI177179-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-27; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure; Organization type: Domestic For-Profits
| Aug 27, 2026 | NIH RePORTER 5R44AI177179-03 |
| Eldec Pharmaceuticals | NIH awarded $908K (STTR Phase II 4R42DK145320-02, extension, notice Aug 11, 2026).Evidence (1 event)- Aug 11, 2026 · NIH RePORTER 4R42DK145320-02
Organization: ELDEC PHARMACEUTICALS, INC.; City/State: Durham, NC; Project number: 4R42DK145320-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 907989; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Novel peptide therapeutics to treat cystic fibrosis-related diabetes; Organization type: Domestic For-Profits
| Aug 11, 2026 | NIH RePORTER 4R42DK145320-02 |
| Amplified Sciences | NIH awarded $182K (NIH grant 1UH2CA318311-01, new, notice Sep 4, 2026).Evidence (1 event)- Sep 4, 2026 · NIH RePORTER 1UH2CA318311-01
Organization: AMPLIFIED SCIENCES INC; City/State: WEST LAFAYETTE, IN; Project number: 1UH2CA318311-01; Activity code: UH2; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 182018; Administering IC: National Cancer Institute; Project title: Validation of a Dysplasia Grading Assay for Precancerous Pancreatic Cystic Lesions; Organization type: Domestic For-Profits
| Sep 4, 2026 | NIH RePORTER 1UH2CA318311-01 |
| William D Shannon Consulting LLC | NIH awarded $220K (NIH grant 1R03DA064869-01A1, new, notice Aug 18, 2026).Evidence (1 event)- Aug 18, 2026 · NIH RePORTER 1R03DA064869-01A1
Organization: WILLIAM D SHANNON CONSULTING, LLC; City/State: St Louis, MO; Project number: 1R03DA064869-01A1; Activity code: R03; Fiscal year: 2026; Award notice date: 2026-08-18; FY total cost (award amount): 220000; Administering IC: National Institute on Drug Abuse; Project title: Novel Statistical Methods for Analyzing fcMRI Data for Substance Use and Addiction Research; Organization type: Domestic For-Profits
| Aug 18, 2026 | NIH RePORTER 1R03DA064869-01A1 |
| Glytr Therapeutics, Inc. | NIH awarded $1M (STTR Phase II 4R42CA302415-02, extension, notice Sep 16, 2026).Evidence (1 event)- Sep 16, 2026 · NIH RePORTER 4R42CA302415-02
Organization: GLYTR THERAPEUTICS, INC.; City/State: San Carlos, CA; Project number: 4R42CA302415-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 1002331; Administering IC: National Cancer Institute; Project title: Maximizing GlyTR pan-cancer immunotherapy by enhancing target density; Organization type: Domestic For-Profits
| Sep 16, 2026 | NIH RePORTER 4R42CA302415-02 |
| Onconaut Therapeutics | NIH awarded $760K (STTR Phase II 4R42CA306378-02, extension, notice Aug 31, 2026).Evidence (1 event)- Aug 31, 2026 · NIH RePORTER 4R42CA306378-02
Organization: ONCONAUT THERAPEUTICS INC.; City/State: AURORA, CO; Project number: 4R42CA306378-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-08-31; FY total cost (award amount): 760110; Administering IC: National Cancer Institute; Project title: CHD1Li Targeted Combinations with Chemotherapy to Address Unmet Needs in Colorectal Cancer Treatment; Organization type: Domestic For-Profits
| Aug 31, 2026 | NIH RePORTER 4R42CA306378-02 |
| Ioncologi Inc. | NIH awarded $1.01M (STTR Phase II 4R42CA302331-02, extension, notice Sep 17, 2026).Evidence (1 event)- Sep 17, 2026 · NIH RePORTER 4R42CA302331-02
Organization: IONCOLOGI INC; City/State: GAINESVILLE, FL; Project number: 4R42CA302331-02; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1006593; Administering IC: National Cancer Institute; Project title: Overcoming Immune Checkpoint Blockade Resistance in Glioblastoma with a Novel Stem Cell Biotherapeutic; Organization type: Domestic For-Profits
| Sep 17, 2026 | NIH RePORTER 4R42CA302331-02 |
| Gigamune, Inc. | NIH awarded $1M (SBIR Phase II 4R44CA310160-02, extension, notice Sep 9, 2026).Evidence (1 event)- Sep 9, 2026 · NIH RePORTER 4R44CA310160-02
Organization: GIGAMUNE, INC.; City/State: SAN FRANCISCO, CA; Project number: 4R44CA310160-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 1000000; Administering IC: National Cancer Institute; Project title: A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma; Organization type: Domestic For-Profits
| Sep 9, 2026 | NIH RePORTER 4R44CA310160-02 |
| VeraMorph LLC | NIH awarded $935K (SBIR Phase II 4R44CA306533-02, extension, notice Sep 11, 2026).Evidence (1 event)- Sep 11, 2026 · NIH RePORTER 4R44CA306533-02
Organization: VERAMORPH, LLC; City/State: NORWOOD, MA; Project number: 4R44CA306533-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-11; FY total cost (award amount): 935236; Administering IC: National Cancer Institute; Project title: Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer; Organization type: Domestic For-Profits
| Sep 11, 2026 | NIH RePORTER 4R44CA306533-02 |
| Mapp Biopharmaceutical | NIH awarded $993K (SBIR commercialization 5SB1AI191871-02, continuation, notice Aug 25, 2026).Evidence (1 event)- Aug 25, 2026 · NIH RePORTER 5SB1AI191871-02
Organization: MAPP BIOPHARMACEUTICAL, INC.; City/State: SAN DIEGO, CA; Project number: 5SB1AI191871-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-08-25; FY total cost (award amount): 993435; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of highly potent human monoclonal for RSV immunoprophylaxis; Organization type: Domestic For-Profits
| Aug 25, 2026 | NIH RePORTER 5SB1AI191871-02 |
| Lectenz Bio | NIH awarded $1.04M (SBIR Phase II 4R44GM159548-02, extension, notice Aug 24, 2026).Evidence (1 event)- Aug 24, 2026 · NIH RePORTER 4R44GM159548-02
Organization: LECTENZ BIO, INC.; City/State: ATHENS, GA; Project number: 4R44GM159548-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 1044652; Administering IC: National Institute of General Medical Sciences; Project title: Innovative glycan-specific reagents to accelerate the detection of disease biomarkers; Organization type: Domestic For-Profits
| Aug 24, 2026 | NIH RePORTER 4R44GM159548-02 |
| Gilgamesh Pharma | NIH awarded $1.85M (NIH grant 6UG3DA060053-03, change of grantee, notice May 13, 2026).Evidence (1 event)- May 13, 2026 · NIH RePORTER 6UG3DA060053-03
Organization: GILGAMESH PHARMA INC; City/State: NEW YORK, NY; Project number: 6UG3DA060053-03; Activity code: UG3; Fiscal year: 2025; Award notice date: 2026-05-13; FY total cost (award amount): 1851123; Administering IC: National Institute on Drug Abuse; Project title: Development of a Safer and More Effective Ibogaine Analog for the Treatment of Opioid Use Disorder; Organization type: Domestic For-Profits
| May 13, 2026 | NIH RePORTER 6UG3DA060053-03 |
| NeuroLux | NIH awarded $249K (SBIR Phase I 5R43MH143569-02, continuation, notice Sep 2, 2026).Evidence (1 event)- Sep 2, 2026 · NIH RePORTER 5R43MH143569-02
Organization: NEUROLUX, INC.; City/State: CHAMPAIGN, IL; Project number: 5R43MH143569-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-02; FY total cost (award amount): 248550; Administering IC: National Institute of Mental Health; Project title: Development and Validation of a Compliant Reversible Actuator and Detector Leveraging Electrophysiology for Organoids (Organoid-CRADLE); Organization type: Domestic For-Profits
| Sep 2, 2026 | NIH RePORTER 5R43MH143569-02 |
| Oligomerix, Inc | NIH awarded $1.5M (SBIR Phase II 4R44AG091987-02, extension, notice Jun 16, 2026).Evidence (1 event)- Jun 16, 2026 · NIH RePORTER 4R44AG091987-02
Organization: OLIGOMERIX, INC; City/State: Bronx, NY; Project number: 4R44AG091987-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 1499525; Administering IC: National Institute on Aging; Project title: A 13-Week Oral Gavage Toxicity Study of OLX-07010 in Beagle Dogs Followed by a 4-Week Recovery Period; Organization type: Domestic For-Profits
| Jun 16, 2026 | NIH RePORTER 4R44AG091987-02 |
| Nuravax, Inc. | NIH awarded $1.26M (SBIR Phase II 4R44AG091903-02, extension, notice Jul 21, 2026).Evidence (1 event)- Jul 21, 2026 · NIH RePORTER 4R44AG091903-02
Organization: NURAVAX, INC.; City/State: IRVINE, CA; Project number: 4R44AG091903-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-21; FY total cost (award amount): 1257282; Administering IC: National Institute on Aging; Project title: Evaluate the Safety, Tolerability, and Immunogenicity of Adjuvanted Preventive Dual Aβ/tau Vaccine, Duvax in Healthy Volunteers; Organization type: Domestic For-Profits
| Jul 21, 2026 | NIH RePORTER 4R44AG091903-02 |
| Verily Life Sciences | NIH awarded $150K (NIH grant 3OT2OD037975-01S2, supplement, notice Jul 27, 2026); 83 roles open.Evidence (1 event)- Jul 27, 2026 · NIH RePORTER 3OT2OD037975-01S2
Organization: VERILY LIFE SCIENCES LLC; City/State: SOUTH SAN FRANCISCO, CA; Project number: 3OT2OD037975-01S2; Activity code: OT2; Fiscal year: 2026; Award notice date: 2026-07-27; FY total cost (award amount): 150359; Administering IC: NIH Office of the Director; Project title: SysBio FAIRplex: a FAIR PLatform for EXploration of Systems Biology; Organization type: Domestic For-Profits
| Jul 27, 2026 | NIH RePORTER 3OT2OD037975-01S2 |
| Oui Therapeutics, Inc. | NIH awarded $967K (SBIR Phase II 4R44MH136888-03, extension, notice Jul 28, 2026).Evidence (1 event)- Jul 28, 2026 · NIH RePORTER 4R44MH136888-03
Organization: OUI THERAPEUTICS, INC; City/State: NEW HAVEN, CT; Project number: 4R44MH136888-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-28; FY total cost (award amount): 966804; Administering IC: National Institute of Mental Health; Project title: Development and Evaluation of a Novel Digital Therapeutic for Adults with Post-Traumatic Stress Disorder; Organization type: Domestic For-Profits
| Jul 28, 2026 | NIH RePORTER 4R44MH136888-03 |
| Oleolive, Inc. | NIH awarded $7K (STTR Phase I 3R41HL180136-01S1, supplement, notice Jul 22, 2026).Evidence (1 event)- Jul 22, 2026 · NIH RePORTER 3R41HL180136-01S1
Organization: OLEOLIVE, INC.; City/State: SHREVEPORT, LA; Project number: 3R41HL180136-01S1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 6500; Administering IC: National Heart Lung and Blood Institute; Project title: Repurposing Pyrvinium as an Inhalation Therapy for Idiopathic Pulmonary Fibrosis; Organization type: Domestic For-Profits
| Jul 22, 2026 | NIH RePORTER 3R41HL180136-01S1 |
| Resilient Lifescience, Inc. | NIH awarded $1.02M (SBIR Phase II 4R44DA060643-02, extension, notice Aug 3, 2026).Evidence (1 event)- Aug 3, 2026 · NIH RePORTER 4R44DA060643-02
Organization: RESILIENT LIFESCIENCE, INC.; City/State: Pittsburgh, PA; Project number: 4R44DA060643-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-03; FY total cost (award amount): 1018701; Administering IC: National Institute on Drug Abuse; Project title: Developing a wearable medical device to detect opioid overdose; Organization type: Domestic For-Profits
| Aug 3, 2026 | NIH RePORTER 4R44DA060643-02 |
| PyrAmes | NIH awarded $247K (NIH grant 4R33HL168741-03, extension, notice Aug 28, 2026).Evidence (1 event)- Aug 28, 2026 · NIH RePORTER 4R33HL168741-03
Organization: PYRAMES, INC.; City/State: CUPERTINO, CA; Project number: 4R33HL168741-03; Activity code: R33; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 246530; Administering IC: National Heart Lung and Blood Institute; Project title: Non-invasive, continuous blood pressure monitoring for prenatal maternal health; Organization type: Domestic For-Profits
| Aug 28, 2026 | NIH RePORTER 4R33HL168741-03 |